Unnamed: 0 stringlengths 3 8 | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher stringclasses 1 value | Author stringclasses 1 value | Article stringlengths 1 343k | Lsa_summary stringlengths 3 53.9k | Luhn_summary stringlengths 1 53.9k | Textrank_summary stringlengths 1 53.9k | Lexrank_summary stringlengths 1 53.9k |
|---|---|---|---|---|---|---|---|---|---|---|---|
25100.0 | 2019-02-04 00:00:00 UTC | Health Care Sector Update for 02/04/2019: ABMD,OMCL,BLRX,ABBV,BLK | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-02042019-abmdomclblrxabbvblk-2019-02-04 | nan | nan | Top Health Care Stocks
JNJ -1.24%
PFE -1.43%
ABT +0.23%
MRK +0.27%
AMGN -0.84%
Health care stocks trimmed some of their prior declines Monday, including a nearly 0.4% decline for the NYSE Health Care Index in afternoon trade. Shares of health care companies in the S&P 500 also were down over 0.6% as a group while the Nasdaq Biotechnology index was down nearly 0.4%.
Among health care stocks moving on news:
(-) Abiomed ( ABMD ) declined over 7% after the US Food and Drug Administration Monday issued a letter warning health care providers it was evaluating new data suggesting a higher mortality rate for certain patients who received the company's Impella RP heart-assist pump implant compared with prior studies. But the agency also said while it was concerned by interim results from the post-approval study, it still believes the benefits of the heart-assist implant outweight the potential risk for patients experiencing severe heart problems.
In other sector news:
(+) BioLineRx ( BLRX ) soared as much as 21% on Monday after its BL-8040 lead oncology candidate to treat pancreatic cancer was designated as an Orphan Drug by the FDA.
(+) Omnicell ( OMCL ) was 3% higher on Monday after its automated drug dispensing device won a Best in KLAS award for the 13th year in a row from independent health care research firm KLAS based on ratings by industry professionals.
(-) AbbVie ( ABBV ) dropped over 3% on Monday after a new regulatory filing showed Blackrock ( BLK ) recently sold over 5.5 million shares of the drugmaker's stock, paring its passive stake to nearly 95.8 million AbbVie shares, or about 6.4% of its outstanding stock.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (-) AbbVie ( ABBV ) dropped over 3% on Monday after a new regulatory filing showed Blackrock ( BLK ) recently sold over 5.5 million shares of the drugmaker's stock, paring its passive stake to nearly 95.8 million AbbVie shares, or about 6.4% of its outstanding stock. Among health care stocks moving on news: (-) Abiomed ( ABMD ) declined over 7% after the US Food and Drug Administration Monday issued a letter warning health care providers it was evaluating new data suggesting a higher mortality rate for certain patients who received the company's Impella RP heart-assist pump implant compared with prior studies. But the agency also said while it was concerned by interim results from the post-approval study, it still believes the benefits of the heart-assist implant outweight the potential risk for patients experiencing severe heart problems. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (-) AbbVie ( ABBV ) dropped over 3% on Monday after a new regulatory filing showed Blackrock ( BLK ) recently sold over 5.5 million shares of the drugmaker's stock, paring its passive stake to nearly 95.8 million AbbVie shares, or about 6.4% of its outstanding stock. Health care stocks trimmed some of their prior declines Monday, including a nearly 0.4% decline for the NYSE Health Care Index in afternoon trade. | (-) AbbVie ( ABBV ) dropped over 3% on Monday after a new regulatory filing showed Blackrock ( BLK ) recently sold over 5.5 million shares of the drugmaker's stock, paring its passive stake to nearly 95.8 million AbbVie shares, or about 6.4% of its outstanding stock. Health care stocks trimmed some of their prior declines Monday, including a nearly 0.4% decline for the NYSE Health Care Index in afternoon trade. Among health care stocks moving on news: (-) Abiomed ( ABMD ) declined over 7% after the US Food and Drug Administration Monday issued a letter warning health care providers it was evaluating new data suggesting a higher mortality rate for certain patients who received the company's Impella RP heart-assist pump implant compared with prior studies. | (-) AbbVie ( ABBV ) dropped over 3% on Monday after a new regulatory filing showed Blackrock ( BLK ) recently sold over 5.5 million shares of the drugmaker's stock, paring its passive stake to nearly 95.8 million AbbVie shares, or about 6.4% of its outstanding stock. Shares of health care companies in the S&P 500 also were down over 0.6% as a group while the Nasdaq Biotechnology index was down nearly 0.4%. Among health care stocks moving on news: (-) Abiomed ( ABMD ) declined over 7% after the US Food and Drug Administration Monday issued a letter warning health care providers it was evaluating new data suggesting a higher mortality rate for certain patients who received the company's Impella RP heart-assist pump implant compared with prior studies. |
25101.0 | 2019-02-03 00:00:00 UTC | Is AbbVie a Buy? | ABBV | https://www.nasdaq.com/articles/abbvie-buy-2019-02-03 | nan | nan | I'm biased. I wanted to mention that right out of the gate before discussing whether AbbVie (NYSE: ABBV) is a buy. I've owned AbbVie for a while and have a favorable view of the big drugmaker's long-term prospects. However, I'm not oblivious to the challenges AbbVie faces.
For investors trying to make a decision about buying AbbVie stock, it's important to consider the arguments both for and against it. Here are those arguments -- presented in what I hope is an unbiased way.
Against AbbVie
The biggest knock against AbbVie, by far, is that the company depends heavily on sales for a drug that's already under pressure and faces more threats in the not-too-distant future. I'm referring, of course, to Humira. The immunology drug generates close to 60% of AbbVie's total revenue.
Biosimilars to Humira hit the market in Europe beginning in October 2018. They're already taking a toll. AbbVie reported that international sales for the drug fell nearly 15% in the fourth quarter . The company predicts that international sales will plunge by 30% in 2019.
But the real problems for AbbVie begin in 2023. That's when Humira faces biosimilar competition in the U.S., where nearly three-quarters of total sales for the drug are made.
What about AbbVie's other products? Some industry observers have been skeptical about the company's projections for blood cancer drug Imbruvica since AbbVie acquired Pharmacyclics in 2015. Hepatitis C virus (HCV) drug Mavyret has been a big winner, but its growth has probably peaked. Other drugs, including Venclexta and Orilissa, as well as AbbVie's top pipeline candidates, have a long way to go to deliver on the company's predictions.
AbbVie has already demonstrated that it was overly optimistic about one candidate. The company acquired Stemcentrx in 2016 for $5.8 billion, adding cancer drug Rova-T to its pipeline. However, clinical flops for Rova-T left AbbVie writing off much of its investment related to the Stemcentrx acquisition in the fourth quarter.
For AbbVie
Perhaps the most important argument to note in AbbVie's defense is that Humira isn't disappearing overnight. Market research company EvaluatePharma even predicts that Humira will remain the top-selling drug in the world for several more years , with expected sales of $15.2 billion in 2024.
AbbVie is shooting for peak sales for Imbruvica of around $7 billion. It's already more than halfway to that level, with 2018 sales for Imbruvica totaling nearly $3.6 billion. Sales also continue to soar: AbbVie reported that Imbruvica's revenue jumped 42% year over year in Q4. And the drug recently won its 10th FDA approval, this time as a first-line treatment in combination with Gazyva for chronic lymphocytic leukemia/small lymphocytic lymphoma.
HCV drug Mavyret isn't likely to be a growth driver for AbbVie. However, no one should dismiss the financial impact of a drug that should contribute $3.5 billion or more annually for years to come.
The launches for newer drugs, including Venclexta and Orilissa, are also going well. AbbVie plans to file for approval later this year for another indication for Orilissa, treating uterine fibroids. The company's chances of winning this additional approval appear to be pretty good.
AbbVie's prospects of success also look great for two new immunology drugs, risankizumab and upadacitinib. Both drugs are considered best in class and are expected to become blockbusters. Upadacitinib even beat Humira in a head-to-head phase 3 study targeting treatment of rheumatoid arthritis.
At the J.P. Morgan Healthcare Conference in January , AbbVie President Mike Severino said the company projects at least $35 billion in annual risk-adjusted sales from drugs other than Humira by 2025. It's important to note that this is a risk-adjusted amount, which means that AbbVie has attempted to factor in the potential for pipeline and commercial setbacks.
The more critical thing to know, though, is that $35 billion is more than AbbVie made in 2018 with Humira. And, as mentioned previously, Humira won't disappear overnight even after it faces U.S. biosimilar competition.
To buy or not to buy?
AbbVie's challenge with offsetting the inevitable sales decline for Humira is a big one. But it's not an insurmountable one. Can AbbVie meet the challenge? I think the facts indicate that it will.
Granted, investors have to take a calculated risk that AbbVie's other drugs, including Imbruvica, Venclexta, and Orilissa, and its top pipeline candidates, such as upadacitinib and risankizumab, will deliver on their potential. Even if these drugs don't fully meet expectations, though, AbbVie should be able to generate solid revenue and earnings growth in the future without Humira.
There are also two other things to remember with AbbVie. First, the market already has priced a significant level of risk into AbbVie's share price, with the stock trading at a little over 8 times expected earnings. This makes AbbVie a bargain if the company can execute on its strategy to replace Humira. Second, AbbVie's dividend yield of 5.3% enables investors to enjoy a pretty good total return even if the stock doesn't rise very much.
I think AbbVie is a slam-dunk buy right now. Fears about the company's prospects after Humira are overblown, in my view. AbbVie looks like a great growth stock, value stock, and dividend stock.
Yes, I'm biased. But biases can often be right.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of November 14, 2018
Keith Speights owns shares of AbbVie. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | At the J.P. Morgan Healthcare Conference in January , AbbVie President Mike Severino said the company projects at least $35 billion in annual risk-adjusted sales from drugs other than Humira by 2025. Granted, investors have to take a calculated risk that AbbVie's other drugs, including Imbruvica, Venclexta, and Orilissa, and its top pipeline candidates, such as upadacitinib and risankizumab, will deliver on their potential. I wanted to mention that right out of the gate before discussing whether AbbVie (NYSE: ABBV) is a buy. | Other drugs, including Venclexta and Orilissa, as well as AbbVie's top pipeline candidates, have a long way to go to deliver on the company's predictions. Granted, investors have to take a calculated risk that AbbVie's other drugs, including Imbruvica, Venclexta, and Orilissa, and its top pipeline candidates, such as upadacitinib and risankizumab, will deliver on their potential. I wanted to mention that right out of the gate before discussing whether AbbVie (NYSE: ABBV) is a buy. | Against AbbVie The biggest knock against AbbVie, by far, is that the company depends heavily on sales for a drug that's already under pressure and faces more threats in the not-too-distant future. For AbbVie Perhaps the most important argument to note in AbbVie's defense is that Humira isn't disappearing overnight. At the J.P. Morgan Healthcare Conference in January , AbbVie President Mike Severino said the company projects at least $35 billion in annual risk-adjusted sales from drugs other than Humira by 2025. | For investors trying to make a decision about buying AbbVie stock, it's important to consider the arguments both for and against it. The more critical thing to know, though, is that $35 billion is more than AbbVie made in 2018 with Humira. I wanted to mention that right out of the gate before discussing whether AbbVie (NYSE: ABBV) is a buy. |
25102.0 | 2019-02-01 00:00:00 UTC | Notable ETF Inflow Detected - XLV, AMGN, ABBV, LLY | ABBV | https://www.nasdaq.com/articles/notable-etf-inflow-detected-xlv-amgn-abbv-lly-2019-02-01 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $113.3 million dollar inflow -- that's a 0.6% increase week over week in outstanding units (from 209,320,000 to 210,570,000). Among the largest underlying components of XLV, in trading today Amgen Inc (Symbol: AMGN) is down about 0.1%, AbbVie Inc (Symbol: ABBV) is down about 0.6%, and Lilly (Eli) & Co (Symbol: LLY) is higher by about 0.3%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average:
Looking at the chart above, XLV's low point in its 52 week range is $78.74 per share, with $96.06 as the 52 week high point - that compares with a last trade of $90.68. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of XLV, in trading today Amgen Inc (Symbol: AMGN) is down about 0.1%, AbbVie Inc (Symbol: ABBV) is down about 0.6%, and Lilly (Eli) & Co (Symbol: LLY) is higher by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $113.3 million dollar inflow -- that's a 0.6% increase week over week in outstanding units (from 209,320,000 to 210,570,000). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of XLV, in trading today Amgen Inc (Symbol: AMGN) is down about 0.1%, AbbVie Inc (Symbol: ABBV) is down about 0.6%, and Lilly (Eli) & Co (Symbol: LLY) is higher by about 0.3%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $78.74 per share, with $96.06 as the 52 week high point - that compares with a last trade of $90.68. Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. | Among the largest underlying components of XLV, in trading today Amgen Inc (Symbol: AMGN) is down about 0.1%, AbbVie Inc (Symbol: ABBV) is down about 0.6%, and Lilly (Eli) & Co (Symbol: LLY) is higher by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $113.3 million dollar inflow -- that's a 0.6% increase week over week in outstanding units (from 209,320,000 to 210,570,000). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $78.74 per share, with $96.06 as the 52 week high point - that compares with a last trade of $90.68. | Among the largest underlying components of XLV, in trading today Amgen Inc (Symbol: AMGN) is down about 0.1%, AbbVie Inc (Symbol: ABBV) is down about 0.6%, and Lilly (Eli) & Co (Symbol: LLY) is higher by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $113.3 million dollar inflow -- that's a 0.6% increase week over week in outstanding units (from 209,320,000 to 210,570,000). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $78.74 per share, with $96.06 as the 52 week high point - that compares with a last trade of $90.68. |
25103.0 | 2019-02-01 00:00:00 UTC | The Zacks Analyst Blog Highlights: Union Pacific, AbbVie and General Dynamics | ABBV | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-union-pacific-abbvie-and-general-dynamics-2019-02-01 | nan | nan | For Immediate Release
Chicago, IL - February 1, 2019 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include:Union Pacific UNP , AbbVie ABBV and General Dynamics GD .
Here are highlights from Thursday's Analyst Blog:
Top Research Reports for Union Pacific, AbbVie and General Dynamics
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Union Pacific, AbbVie and General Dynamics. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Buy-ranked Union Pacific 's shares have outperformed the Zacks Rail industry (+20.4% vs. +12%) in the past year. Union Pacific reported better-than-expected earnings per share and revenues in the fourth quarter of 2018. Both the metrics also increased year over year. Higher freight revenues on the back of volume growth aided top-line growth.
For 2019, the company anticipates volumes to increase in the low single-digit range. The Zacks analyst thinks Union Pacific's efforts to reward its shareholders are encouraging. Notably, the company has hiked dividends thrice since November 2017.
Improvement in operating ratio and low tax rates are added positives. Its efforts to promote safety are noteworthy as well. However, high debt levels and operating expenses are concerns. Escalated capital expenditures are contributing to rise in costs.
Shares of AbbVie have lost -29.6% in the past year, underperforming the Zacks Large-Cap Pharmaceuticals industry's decline of -1.2%. AbbVie missed estimates for earnings and sales in the fourth quarter. The Zacks analyst thinks AbbVie's key drug, Humira has been performing well in the United States based on strong demand trends despite new competition.
Moreover, Imbruvica has multibillion dollar potential. Mavyret saw a stronger-than-expected launch and has become a significant contributor to sales. AbbVie has also been successful in expanding approvals for its cancer drugs, Imbruvica and Venclexta.
AbbVie has an impressive late-stage pipeline comprising several products with multibillion-dollar potential expected to be launched in the near term. Sales erosion due to direct biosimilar competition to Humira in international markets will be a big headwind in 2019. Also costs to support expected new product/line extension launches are likely to hurt profits in 2019.
General Dynamics ' shares have lost -23.2% in the past year, underperforming the Zacks Aerospace & Defense industry's decrease of -6.3%. General Dynamics ended fourth-quarter 2018 with both earnings and revenues surpassing expectations.
The Zacks analyst thinks the company enjoys solid demand for its varied defense products leading to organic growth, whereas a notable acquisition strategy adds to inorganic growth. The company is on track to achieve FAA type certification for its G600 aircraft later this year, which is expected to enter service in 2019.
These new jets are likely to be significantly accretive in terms of revenues as well as earnings for the company, once they become available to global customers. Moreover, a comparative analysis of the company's historical EV/EBITDA ratio reflects a relatively gloomy picture that might be a cause for investors' concern.
Other noteworthy reports we are featuring today include Total System Services (TSS) and C.H. Robinson (CHRW).
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss . This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Union Pacific Corporation (UNP): Free Stock Analysis Report
AbbVie Inc. (ABBV): Get Free Report
General Dynamics Corporation (GD): Get Free Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks recently featured in the blog include:Union Pacific UNP , AbbVie ABBV and General Dynamics GD . The Zacks analyst thinks AbbVie's key drug, Humira has been performing well in the United States based on strong demand trends despite new competition. Here are highlights from Thursday's Analyst Blog: Top Research Reports for Union Pacific, AbbVie and General Dynamics The Zacks Research Daily presents the best research output of our analyst team. | Stocks recently featured in the blog include:Union Pacific UNP , AbbVie ABBV and General Dynamics GD . Today's Research Daily features new research reports on 16 major stocks, including Union Pacific, AbbVie and General Dynamics. Click to get this free report Union Pacific Corporation (UNP): Free Stock Analysis Report AbbVie Inc. (ABBV): Get Free Report General Dynamics Corporation (GD): Get Free Report To read this article on Zacks.com click here. | Here are highlights from Thursday's Analyst Blog: Top Research Reports for Union Pacific, AbbVie and General Dynamics The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Union Pacific, AbbVie and General Dynamics. Click to get this free report Union Pacific Corporation (UNP): Free Stock Analysis Report AbbVie Inc. (ABBV): Get Free Report General Dynamics Corporation (GD): Get Free Report To read this article on Zacks.com click here. | Today's Research Daily features new research reports on 16 major stocks, including Union Pacific, AbbVie and General Dynamics. Stocks recently featured in the blog include:Union Pacific UNP , AbbVie ABBV and General Dynamics GD . Here are highlights from Thursday's Analyst Blog: Top Research Reports for Union Pacific, AbbVie and General Dynamics The Zacks Research Daily presents the best research output of our analyst team. |
25104.0 | 2019-02-01 00:00:00 UTC | Pharma Stock Roundup: Q4 Earnings, Pipeline Updates at PFE, RHHBY | ABBV | https://www.nasdaq.com/articles/pharma-stock-roundup%3A-q4-earnings-pipeline-updates-at-pfe-rhhby-2019-02-01 | nan | nan | The earnings season was in full swing this week. Pfizer, Inc. PFE and Allergan plc's AGN strong fourth-quarter results were overshadowed by weak outlook for 2019. Others like AbbVie, Inc. ABBV and Novartis NVS also reported their fourth-quarter results. In other news, Roche RHHBY halted two studies on an Alzheimer's candidate while Pfizer/Eli Lilly's LLY investigational candidate, tanezumab succeeded in the second osteoarthritis pain study.
Recap of the Week's Most Important Headlines
Earnings in Full Swing: Pfizer and Allergan beat estimates for fourth-quarter earnings as well as sales. However, both the companies' 2019 forecast disappointed investors.
Loss of exclusivity of some drugs including its key drug Lyrica in the United States in June 2019 as well as currency headwinds is expected to significantly pull down Pfizer's 2019 revenues.
Similarly, Allergan's revenues are also expected to be hurt by loss of exclusivity of many key products. While generic version of Alzheimer's treatment, Namenda XR and Estrace cream have been launched, that of blockbuster dry-eye drug, Restasis, is expected to be launched in 2019.
AbbVie missed estimates for both earnings and sales and gave a weak revenue guidance for 2019. Sales rose 7.3% as higher sales of Humira in the United States and hematological/oncology products, Imbruvica and Venclexta offset weak Humira sales in international. Launch of several direct biosimilar drugs in Europe and other markets hurt Humira's international sales.
Novartis also missed estimates for both earnings and sales. The Innovative Medicines division recorded sales growth of 9%. Oncology franchise grew 11% while sales at the Sandoz division declined 5% due to price erosion in the United States. The company said that net sales in 2019 should grow in a mid-single digit range.
Roche Discontinues Studies on Alzheimer's Candidate: Roche announced its decision to discontinue mid-stage studies evaluating its anti-beta-amyloid molecule crenezumab for the treatment of early (prodromal to mild) sporadic Alzheimer's disease (AD). Data from a pre-planned interim analysis conducted by Independent Data Monitoring Committee indicated that the study was unlikely to meet the primary goal. Roche is developing crenezumab in partnership with AC Immune SA , which declined sharply on the news.
Roche, however, will continue with other Alzheimer's studies including late-stage GRADUATE studies with gantenerumab and mid-stage TAURIEL study with the anti-tau molecule RG6100. Also, Alzheimer's Prevention Initiative (API) study evaluating crenezumab in familial AD patient population will continue
Pfizer/Lilly's Tanezumab Succeeds in 2nd Osteoarthritis Pain Study: Pfizer and partner Lilly announced top-line data from the second phase III study evaluating tanezumab (2.5 mg or 5 mg) for the treatment of osteoarthritis (OA) pain.
Top-line data from the study showed that treatment with tanezumab 5 mg led to statistically significant improvement in pain, physical function and the patients' overall assessment of their OA - the three primary endpoints - compared to placebo at 24 weeks. The 2.5 mg dose demonstrated a statistically significant improvement in pain and physical function. However for the third primary endpoint, overall assessment of their OA, a statistical difference was not observed. Tanezumab is also being evaluated for chronic low back pain (CLBP) and cancer pain (due to bone metastases).
AbbVie Gets FDA Nod for Imbruvica+Gazyva in First-Line CLL/SLL: AbbVie announced FDA approval for Imbruvica plus Roche's Gazyva ( obinutuzumab) for the first-line treatment of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). With the FDA approval, Imbruvica plus obinutuzumab becomes the first chemotherapy-free CD20 combination in first-line CLL treatment.
J&J's Label Expansion Study onErleada Meets Endpoints : J&J's JNJ late-stage label expansion study on prostate cancer drug, Erleada was unblinded following the achievement of the dual primary endpoints, of significant improvement in radiographic progression-free survival (rPFS) and overall survival (OS). The decision was based on the recommendation of Independent Data Monitoring Committee. The phase III TITAN study was evaluating Erleada plus androgen deprivation therapy (ADT) in patients with newly-diagnosed metastatic castration-sensitive prostate cancer (mCSPC). Erleada is presently marketed for the treatment of men with non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease. Regulatory applications looking for FDA approval to treat this expanded patient population are expected to be filed this year.
J&J also signed a collaboration and license agreement with MeiraGTx to develop gene therapy programs for inherited retinal diseases (IRD) for an upfront payment of $100 million. Per the deal, J&J will co-develop MeiraGTx's leading IRD gene therapy programs while the latter will also explore new potential targets for these diseases. J&J also gets an exclusive option to license programs coming out of this research collaboration at the time of clearance of an Investigational New Drug (IND) application.
Merck's Pneumonia Vaccine Gets FDA's Breakthrough Status : Merck announced that the FDA has granted Breakthrough Therapy designation to V114 , its investigational 15-valent polyvalent conjugate vaccine for the prevention of invasive pneumococcal disease (IPD) in infants, children, and adolescents. V114is being developed in late-stage studies for prevention of IPD in children while also being studied in another study for the same indication in adults.
The NYSE ARCA Pharmaceutical Index rose 2.1% in the last five trading sessions.
Large Cap Pharmaceuticals Industry 5YR % Return
Large Cap Pharmaceuticals Industry 5YR % Return
Here is how the seven major stocks performed in the last five trading sessions:
In the past six months, Lilly (LLY) has been the biggest gainer (19.6%) while Bristol-Myers declined the most (16.7%).
(See the last pharma stock roundup here: JNJ & BMY's Q4 Earnings, Study Failures at LLY & ABBV )
What's Next in the Pharma World?
Watch out for fourth-quarter and full year 2018 earnings results by Lilly, Glaxo, Sanofi and others and pipeline and regulatory updates next week.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Get Free Report
Novartis AG (NVS): Get Free Report
Roche Holding AG (RHHBY): Free Stock Analysis Report
Eli Lilly and Company (LLY): Free Stock Analysis Report
Allergan plc (AGN): Free Stock Analysis Report
Pfizer Inc. (PFE): Free Stock Analysis Report
Johnson & Johnson (JNJ): Get Free Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Others like AbbVie, Inc. ABBV and Novartis NVS also reported their fourth-quarter results. AbbVie missed estimates for both earnings and sales and gave a weak revenue guidance for 2019. AbbVie Gets FDA Nod for Imbruvica+Gazyva in First-Line CLL/SLL: AbbVie announced FDA approval for Imbruvica plus Roche's Gazyva ( obinutuzumab) for the first-line treatment of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). | Click to get this free report AbbVie Inc. (ABBV): Get Free Report Novartis AG (NVS): Get Free Report Roche Holding AG (RHHBY): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Allergan plc (AGN): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Get Free Report To read this article on Zacks.com click here. Others like AbbVie, Inc. ABBV and Novartis NVS also reported their fourth-quarter results. AbbVie missed estimates for both earnings and sales and gave a weak revenue guidance for 2019. | Click to get this free report AbbVie Inc. (ABBV): Get Free Report Novartis AG (NVS): Get Free Report Roche Holding AG (RHHBY): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Allergan plc (AGN): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Get Free Report To read this article on Zacks.com click here. Others like AbbVie, Inc. ABBV and Novartis NVS also reported their fourth-quarter results. AbbVie missed estimates for both earnings and sales and gave a weak revenue guidance for 2019. | Others like AbbVie, Inc. ABBV and Novartis NVS also reported their fourth-quarter results. AbbVie missed estimates for both earnings and sales and gave a weak revenue guidance for 2019. AbbVie Gets FDA Nod for Imbruvica+Gazyva in First-Line CLL/SLL: AbbVie announced FDA approval for Imbruvica plus Roche's Gazyva ( obinutuzumab) for the first-line treatment of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). |
25105.0 | 2019-02-01 00:00:00 UTC | Roche (RHHBY) 2018 Sales Up on Solid New Drugs Performance | ABBV | https://www.nasdaq.com/articles/roche-rhhby-2018-sales-up-on-solid-new-drugs-performance-2019-02-01 | nan | nan | Shares of Swiss pharma giant Roche Holding AGRHHBY have gained 3.2% after the company reported solid sales growth in the fourth quarter and 2018, propelled by strong performance of new drugs. The company also provided an encouraging annual guidance for 2019.
Roche's stock has gained 8.9% in the last six months, against the industry 's growth of 2.0%.
The company reported sales of CHF 14.7 billion in the fourth quarter of 2018, up 9% from the year-ago quarter. Sales for 2018 came in at CHF 56.8 billion, up 7% from the year-ago period. Earnings per share came in at CHF 18.1 in 2018, up from CHF 15.3 in 2017.
The company reports results under two divisions - Pharmaceuticals and Diagnostics. All growth rates mentioned below are on a year-over-year basis and at constant exchange rates.
Sales at the Pharmaceuticals division increased 7%, driven by strong growth in Ocrevus, Perjeta, Tecentriq, Alecensa and Hemlibra. Growth in the United States offset the decline in sales in Europe stemming from biosimilar competition. Diagnostics division sales climbed 7%, primarily on the back of strong immunodiagnostic business.
Results in Detail
Herceptin sales grew 1% on demand in the United States and China, which more than offset the decline in Europe owing to biosimilar competition since mid-2018. Perjeta sales grew 27%, following increased demand in adjuvant early breast cancer therapy in the United States and neoadjuvant metastatic usage in Europe. Sales also got a boost from recent approvals in Japan and China. In total, the HER2-franchise (Herceptin, Perjeta and Kadcyla) was up 7%.
Strong Ocrevus sales further boosted the top line. The drug, used to treat two forms of multiple sclerosis (MS), continued to gain traction worldwide with sales of $2.4 billion. Approximately 80,000 patients were being treated globally as of December 2018.
Immuno-oncology drug, Tecentriq (for advanced bladder cancer and advanced lung cancer) recorded 59% growth in sales. Sales growth was driven by post-launch uptake in Europe, particularly in Germany, and launch in Japan. Sales of lung cancer drug, Alcenesa surged 76% and witnessed solid growth across all regions. Oncology drug Avastin recorded 3% growth.
Performance of the immunology franchise was driven by increased sales of Actemra/RoActemra (12%) and Xolair (11%). Gazyva/Gazyvaro sales soared 40%, due to growth in the United States and Europe.
Sales of ophthalmology drug, Lucentis grew 18%. Growth was driven by the launch of prefilled syringes and increased sales in all approved indications. Sales of Xolair (up 11%) was driven by demand in chronic idiopathic urticaria and allergic asthma.
However, sales of Rituxan/MabThera slumped 8%, due to entry of biosimilars in Europe. Sales of Tarceva declined 36%, due to growing use of other therapeutic options. Sales of Xeloda (down 6%) continue to be hit by generic competition.
Revenues at the Diagnostics division climbed 7% on the back of solid performance of the Centralised and Point of Care Solutions (up 8%) unit, which was, in turn, propelled by Immunodiagnostics (up 11%). Tissue Diagnostics (up 10%) and Molecular Diagnostics (up 5%) also performed impressively. Diabetes Care sales increased 2%.
2019 Outlook Raised
Sales in 2019 are expected to grow low to mid-single digits. The company expects core earnings to grow in line with sales. Roche anticipates to increase its dividend further.
Pipeline Progress
In December 2018, the FDA approved Tecentriq in combination with Avastin, paclitaxel and carboplatin for the initial treatment of people with metastatic nonsquamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumour aberrations. The FDA granted priority review to Tecentriq in combination with carboplatin and etoposide (chemotherapy) for the initial treatment of people with extensive-stage small cell lung cancer (ES-SCLC).
The FDA granted accelerated approval to Venclexta in combination with azacitidine or decitabine, or low dose cytarabine for the treatment of people with newly-diagnosed acute myeloid leukaemia (AML). The drug has been developed in collaboration with AbbVie, Inc. ABBV .
In October, the FDA approved Xofluza (baloxavir marboxil) for the treatment of acute, uncomplicated influenza in people aged 12 years and older.
The FDA granted priority review to Tecentriq plus Abraxane (albumin-bound paclitaxel; nab-paclitaxel) for the initial treatment of unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) in people whose disease expresses the PD-L1 protein, as determined by PD-L1 biomarker testing.
Polatuzumab vedotin in combination with MabThera/Rituxan plus bendamustine has been granted Breakthrough Therapy designation and Orphan Drug status by the FDA for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma who are not candidates for haematopoietic stem cell transplantation. The combination also secured PRIME designation and Orphan Drug status from the European Medical Agency (EMA) for the same indication.
Our Take
Roche's performance was impressive in 2018 as it combatted biosimilar competition in Europe. Strong growth from Ocrevus, Perjeta, Tecentriq, Alecensa and Hemlibra has been more than offset by lower sales of MabThera/Rituxan and Tarceva. In particular, MS drug Ocrevus witnessed strong growth, driven by increased demand.
Meanwhile, the company continues to progress with its pipeline as it looks to restructure the portfolio beyond oncology into MS and haemophilia, among others. Approval of new drugs and a potential label expansion of existing drugs bode well for Roche, as its legacy drugs like Herceptin and MabThera are facing competition from biosimilars. Novartis NVS has already launched its biosimilar version of Rituxan/ MabThera in Europe. Amgen AMGN also obtained the FDA approval for a biosimilar version of Avastin for treatment of five types of cancers.
Zacks Rank
Roche carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 (Strong Buy) Rank stocks here .
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here to see the 5 stocks >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Get Free Report
Novartis AG (NVS): Get Free Report
Roche Holding AG (RHHBY): Free Stock Analysis Report
Amgen Inc. (AMGN): Get Free Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The drug has been developed in collaboration with AbbVie, Inc. ABBV . Click to get this free report AbbVie Inc. (ABBV): Get Free Report Novartis AG (NVS): Get Free Report Roche Holding AG (RHHBY): Free Stock Analysis Report Amgen Inc. (AMGN): Get Free Report To read this article on Zacks.com click here. Pipeline Progress In December 2018, the FDA approved Tecentriq in combination with Avastin, paclitaxel and carboplatin for the initial treatment of people with metastatic nonsquamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumour aberrations. | Click to get this free report AbbVie Inc. (ABBV): Get Free Report Novartis AG (NVS): Get Free Report Roche Holding AG (RHHBY): Free Stock Analysis Report Amgen Inc. (AMGN): Get Free Report To read this article on Zacks.com click here. The drug has been developed in collaboration with AbbVie, Inc. ABBV . Sales at the Pharmaceuticals division increased 7%, driven by strong growth in Ocrevus, Perjeta, Tecentriq, Alecensa and Hemlibra. | Click to get this free report AbbVie Inc. (ABBV): Get Free Report Novartis AG (NVS): Get Free Report Roche Holding AG (RHHBY): Free Stock Analysis Report Amgen Inc. (AMGN): Get Free Report To read this article on Zacks.com click here. The drug has been developed in collaboration with AbbVie, Inc. ABBV . Shares of Swiss pharma giant Roche Holding AGRHHBY have gained 3.2% after the company reported solid sales growth in the fourth quarter and 2018, propelled by strong performance of new drugs. | The drug has been developed in collaboration with AbbVie, Inc. ABBV . Click to get this free report AbbVie Inc. (ABBV): Get Free Report Novartis AG (NVS): Get Free Report Roche Holding AG (RHHBY): Free Stock Analysis Report Amgen Inc. (AMGN): Get Free Report To read this article on Zacks.com click here. The company reports results under two divisions - Pharmaceuticals and Diagnostics. |
25106.0 | 2019-01-31 00:00:00 UTC | 3 Top Large-Cap Stocks to Buy in February | ABBV | https://www.nasdaq.com/articles/3-top-large-cap-stocks-buy-february-2019-01-31 | nan | nan | After the shocking volatility of December, stocks regained some of their balance in January. Investors, obviously, prefer things kept on an even keel, and that's why many of them turn to large-cap stocks, because they offer a measure of stability.
Not that they can't get beaten up too -- all three stocks below have suffered big swings of their own -- but time has a way of smoothing out the hills and valleys for large caps. Following shifts in fortune, check out why Gilead Sciences (NASDAQ: GILD) , Eaton (NYSE: ETN) , and British American Tobacco (NYSE: BTI) are three top large-cap stocks to consider buying in February.
A light at the end of the tunnel
George Budwell (Gilead Sciences): After a tumultuous three-year period, Gilead Sciences finally appears to be nearing an inflection point from a business standpoint. So its shares could be a nice addition to a large cap-oriented portfolio this year.
What's the backstory? Gilead's shares have been severely punished over the last three years due to the company's inability to ward off competitors like AbbVie 's Mavyret for treating hepatitis C. However, Gilead seems to be moving past the worst of these hepatitis C headwinds and into a far brighter period characterized by new drug launches. These include the game-changing HIV medication Biktarvy, as well as a host of high-value clinical readouts in cancer, nonalcoholic steatohepatitis (NASH), and rheumatoid arthritis.
As an added bonus, Gilead's novel cancer cell therapy Yescarta is also beginning to contribute in a meaningful way to the biotech's top line after a slower-than-expected debut. Now, Yescarta still has a long way to go to live up to its multibillion-dollar peak sales projection . But the therapy is at least gaining traction in the marketplace, and it might even be a key reason Gilead ends 2019 in positive territory from a top-line perspective.
In all, Gilead has a number of commercial and clinical catalysts on the near-term horizon that could boost its shares in a big way this year. And Wall Street, for its part, seems to agree with this positive outlook. A handful of analysts, after all, have already issued noteworthy upgrades and price target hikes for the biotech early in the new year.
This stock's recent price drop is an opportunity
Neha Chamaria(Eaton): Eaton is an industrial conglomerate, and that itself should give you an idea why the stock is down nearly 20% since October 2018. It's been a really rough few months for the industrials sector, what with geopolitical concerns and the ongoing trade tensions between the U.S. and China, in particular, triggering fears of decelerating growth among industrial manufacturers.
Yet Eaton, which calls itself a "power management company," has weathered many a storm in the past and looks well poised to do so in the future. As my colleague and fellow Fool Reuben Gregg Brewer aptly illustrated in this article , Eaton's earnings remained in the black even during the 2007 recession, evidencing the company's resilience. Since then, Eaton has diversified further and become bigger, positioning itself better for any downturn. Today, Eaton operates six divisions -- including the newly formed high-potential eMobility business targeted at the electric vehicle market -- that serve several key sectors such as oil and gas, utilities, healthcare, mining, aerospace, food, and transportation.
In October, Eaton upgraded its full-year adjusted earnings guidance to $5.30 to $5.40 per share, representing 15% growth over 2017 at the midpoint. More importantly, Eaton continues to generate solid cash flows: It generated nearly $2.7 billion in cash from operations (CFO) in the trailing 12 months, which is considerably higher than its five-year average CFO. Now consider that the stock is trading at only around 11 times price to CFO, which is well below its five-year average P/CFO. With Eaton shares also doling out a good 3.7% in dividend yield and the company most likely to reward shareholders with a dividend increase in coming weeks, this is one large-cap stock you might want to get your hands on now.
A beaten down stock with potential
Rich Duprey(British American Tobacco): Although there's little question about the declining fortunes of cigarette manufacturers, shares of British American Tobacco, which have lost more than half their value over the past year, still represent a great opportunity for investors. The company is profitable, has strong pricing power, and is investing considerable sums of money in next-generation cigarette alternatives that promise to carry the tobacco giant well into the future.
Industry cigarette volumes continue to fall as people either give up the smoking habit or turn to alternatives. British American Tobacco has spent more than $3 billion on alternatives to traditional cigarettes and arguably has the most diverse range of products. Whether it's smokeless tobacco, electronic cigarettes, or heated tobacco products, there seems to be something for everyone.
Although the Juul e-cig has captured a better-than-70% market share in the U.S., it is under scrutiny from the FDA and may see sales restricted because of its unusual popularity among teens. As a result, there could be a wide opening for heated tobacco products like British Tobacco's iFuse glo and Philip Morris International 's IQOS device.
Obviously there are a lot of risks still, and the FDA moved to ban menthol cigarettes, the market for which British American owns 50% with its Newport and Camel brands. The prospect for some middle path seems likely.
Because the tobacco giant's stock has been beaten down, its dividend currently yields an eye-popping 8.2%. Although dividend growth is likely to slow, the payout still appears to be safe, which ought to make British American Tobacco a buy at this discounted level.
10 stocks we like better than Gilead Sciences
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Gilead Sciences wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of November 14, 2018
George Budwell has no position in any of the stocks mentioned. Neha Chamaria has no position in any of the stocks mentioned. Rich Duprey has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Gilead's shares have been severely punished over the last three years due to the company's inability to ward off competitors like AbbVie 's Mavyret for treating hepatitis C. However, Gilead seems to be moving past the worst of these hepatitis C headwinds and into a far brighter period characterized by new drug launches. As my colleague and fellow Fool Reuben Gregg Brewer aptly illustrated in this article , Eaton's earnings remained in the black even during the 2007 recession, evidencing the company's resilience. Today, Eaton operates six divisions -- including the newly formed high-potential eMobility business targeted at the electric vehicle market -- that serve several key sectors such as oil and gas, utilities, healthcare, mining, aerospace, food, and transportation. | Gilead's shares have been severely punished over the last three years due to the company's inability to ward off competitors like AbbVie 's Mavyret for treating hepatitis C. However, Gilead seems to be moving past the worst of these hepatitis C headwinds and into a far brighter period characterized by new drug launches. Following shifts in fortune, check out why Gilead Sciences (NASDAQ: GILD) , Eaton (NYSE: ETN) , and British American Tobacco (NYSE: BTI) are three top large-cap stocks to consider buying in February. More importantly, Eaton continues to generate solid cash flows: It generated nearly $2.7 billion in cash from operations (CFO) in the trailing 12 months, which is considerably higher than its five-year average CFO. | Gilead's shares have been severely punished over the last three years due to the company's inability to ward off competitors like AbbVie 's Mavyret for treating hepatitis C. However, Gilead seems to be moving past the worst of these hepatitis C headwinds and into a far brighter period characterized by new drug launches. Following shifts in fortune, check out why Gilead Sciences (NASDAQ: GILD) , Eaton (NYSE: ETN) , and British American Tobacco (NYSE: BTI) are three top large-cap stocks to consider buying in February. This stock's recent price drop is an opportunity Neha Chamaria(Eaton): Eaton is an industrial conglomerate, and that itself should give you an idea why the stock is down nearly 20% since October 2018. | Gilead's shares have been severely punished over the last three years due to the company's inability to ward off competitors like AbbVie 's Mavyret for treating hepatitis C. However, Gilead seems to be moving past the worst of these hepatitis C headwinds and into a far brighter period characterized by new drug launches. A beaten down stock with potential Rich Duprey(British American Tobacco): Although there's little question about the declining fortunes of cigarette manufacturers, shares of British American Tobacco, which have lost more than half their value over the past year, still represent a great opportunity for investors. * David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Gilead Sciences wasn't one of them! |
25107.0 | 2019-01-30 00:00:00 UTC | ABBV Stock Is Worth a Look at Multi-Year Lows | ABBV | https://www.nasdaq.com/articles/abbv-stock-worth-look-multi-year-lows-2019-01-30 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Shares of AbbVie (NYSE: ABBV ) have been hammered lately following a disappointing earnings report and slowing European sales of their bestselling drug, Humira. ABBV stock is now trading at the lowest levels since September of 2017 after falling another 4% yesterday.
Certainly some of the selling was warranted due to slowing growth concerns and tepid guidance. But it has now gotten overdone given the fundamental and technical backdrop. Look for ABBV stock to find support and grind higher from current levels.
Source: Shutterstock
Earnings were released Friday with the company reporting $1.90 in EPS and $8.31 billion in revenue for Q4. Both of these were just shy of consensus estimates of $1.93 in EPS and $8.36 billion in revenues. The company also guided slightly lower for full year 2019 with expectations now of $8.65 to $8.75 per share falling mostly below analysts estimates for $8.74 per share. Sales of Humira, the company's blockbuster arthritis drug, also was a drag. Overseas sales are expected to be down 30%, but sales in the U.S. are still protected from competition until 2023.
While both earnings and revenues were just a slight miss, ABBV stock is down 10% over the past 2 days on the news. This makes the forward P/E less than 9. Important to remember that the company did still maintain solid guidance of $8.70 in earnings for 2019, so ABBV stock is definitely looking more attractive on a valuation basis.
ABBV stock is getting extremely oversold from a technical perspective. MACD is now at readings that has marked significant lows in the past. AbbVie is trading at a huge discount to the 20 day moving average, another indication that the selling has gotten to an extreme. This combination of extremes in MACD to the downside and large discounts to the 20-day moving average has coincided with major buying opportunities in the past.
Click to Enlarge
AbbVie stock now sports a very attractive dividend yield of 5.5% and a payout ratio of just 54.5%. This should help serve to buffer any additional downside damage from current levels.
10 Stocks to Sell in February
Implied volatility remains high in ABBV options due to the recent sharp sell off. This means option prices are still comparatively expensive, so selling a covered call makes sense. Selling the January 2020 $80 call at $6.50 cushions the downside by 8.4% while still leaving some upside price appreciation. Buying ABBV stock around $77 and selling the call around $6.50 puts the net cost at $70.50.
Tim Biggam may hold some of the aforementioned securities in one or more of his newsletters. Anyone interested in finding out more about Tim and his strategies can go to https://marketfy.com/item/options-and-volatility .
More From InvestorPlace
2 Toxic Pot Stocks You Should Avoid
10 Smart Money Stocks to Buy for the Rest of the Year
10 Best Consumer Stocks to Buy in 2019
10 Triple-A Stocks to Buy in February
Compare Brokers
The post ABBV Stock Is Worth a Look at Multi-Year Lows appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Important to remember that the company did still maintain solid guidance of $8.70 in earnings for 2019, so ABBV stock is definitely looking more attractive on a valuation basis. Click to Enlarge AbbVie stock now sports a very attractive dividend yield of 5.5% and a payout ratio of just 54.5%. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Shares of AbbVie (NYSE: ABBV ) have been hammered lately following a disappointing earnings report and slowing European sales of their bestselling drug, Humira. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips Shares of AbbVie (NYSE: ABBV ) have been hammered lately following a disappointing earnings report and slowing European sales of their bestselling drug, Humira. More From InvestorPlace 2 Toxic Pot Stocks You Should Avoid 10 Smart Money Stocks to Buy for the Rest of the Year 10 Best Consumer Stocks to Buy in 2019 10 Triple-A Stocks to Buy in February Compare Brokers The post ABBV Stock Is Worth a Look at Multi-Year Lows appeared first on InvestorPlace . ABBV stock is now trading at the lowest levels since September of 2017 after falling another 4% yesterday. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips Shares of AbbVie (NYSE: ABBV ) have been hammered lately following a disappointing earnings report and slowing European sales of their bestselling drug, Humira. 10 Stocks to Sell in February Implied volatility remains high in ABBV options due to the recent sharp sell off. More From InvestorPlace 2 Toxic Pot Stocks You Should Avoid 10 Smart Money Stocks to Buy for the Rest of the Year 10 Best Consumer Stocks to Buy in 2019 10 Triple-A Stocks to Buy in February Compare Brokers The post ABBV Stock Is Worth a Look at Multi-Year Lows appeared first on InvestorPlace . | InvestorPlace - Stock Market News, Stock Advice & Trading Tips Shares of AbbVie (NYSE: ABBV ) have been hammered lately following a disappointing earnings report and slowing European sales of their bestselling drug, Humira. While both earnings and revenues were just a slight miss, ABBV stock is down 10% over the past 2 days on the news. ABBV stock is now trading at the lowest levels since September of 2017 after falling another 4% yesterday. |
25108.0 | 2019-01-30 00:00:00 UTC | 3 Big Pharmas Expecting a Softer 2019 | ABBV | https://www.nasdaq.com/articles/3-big-pharmas-expecting-softer-2019-2019-01-30 | nan | nan | Johnson & Johnson (NYSE: JNJ) kicked off this earnings season with a grim outlook for its pharmaceutical business, and it looks like the trouble has spread to its big pharma peers. More recently, AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) told investors not to expect a great deal of sales growth in 2019.
Are these isolated incidents or is the entire pharmaceutical industry in for a year of disappointment? To answer that we need to understand why they're predicting slower sales growth in the first place. Here's what you need to know about the soft-guidance bug that's spreading throughout the biopharmaceutical industry.
1. Johnson & Johnson: Payer pushback
The world's largest healthcare conglomerate kicked of f earnings season by telling investors its U.S. pharmaceutical segment is trying to walk up an escalator that's going down. Johnson & Johnson made regular price hikes for successful drugs in 2018, but the net price it actually received after insurers applied discounts and rebates fell between 6% and 8% last year.
Overall, 2018 was a pretty good year for Johnson & Johnson's U.S. pharma division. Despite lower net pricing, higher volume drove U.S. pharmaceutical sales 8.4% higher.
In 2019, though, Johnson & Johnson expects total annual sales to fall 1% to $80.8 billion at the midpoint of its guided range. Net prices sliding across the pharmaceutical segment isn't the only headwind Johnson & Johnson faces right now. A rising dollar is expected to knock about $1.2 billion from reported sales this year.
Sales of the company's top-selling product, Remicade, slid 15.7% to $5.3 billion last year, due to biosimilar competition that probably won't subside soon. Zytiga sales reached $1.8 billion last year in the U.S., but generic versions of the prostate cancer tablet launched late last year. Unlike biosimilars, sales of small-molecule drugs often fall by more than half during their first year of generic competition.
2. AbbVie: Biosimilar pressure
AbbVie hasn't complained much about pushy U.S. insurers demanding higher rebates, although it probably could. Instead, AbbVie's softer-than-expected outlook for 2019 is the result of stingy end payers throughout Europe.
Biosimilar versions of AbbVie's top-selling anti-inflammatory injection, Humira, went on sale throughout the EU in the middle of the fourth quarter. Compared with the previous-year period, international Humira sales fell 17.5%, to $1.3 billion.
At around 15% of total revenue, sagging international Humira sales will create a headwind that AbbVie can probably overcome. In 2018, U.S. Humira sales rose 10.7% to $13.7 billion, and this huge revenue stream will probably continue growing until 2023.
AbbVie thinks biosimilar competition will reduce total sales by around $2 billion this year, which will probably be offset by a couple of blood cancer drugs that recently received some important label expansions . AbbVie could also launch two potential blockbusters before the end of the year and, if approved, total sales could rise by single digits in 2019.
3. Pfizer: Lyrica pain
Pfizer's top line rose just 2% in 2018, and in 2019 the company expects total revenue to remain flat. Altogether, generic competition for older drugs is expected to reduce total sales by $2.6 billion this year.
One of Pfizer's top sellers, Lyrica, loses U.S. market exclusivity in June, and it's going to sting. Sales of the nerve-pain drug reached $4.9 billion last year, which was about 9% of Pfizer's total revenue for the period.
Pfizer really isn't exposed to much biosimilar competition -- in fact, it's one of the companies applying pressure. Some of Johnson & Johnson's Remicade losses are a result of competition from Pfizer's Inflectra, a biosimilar version of the popular injection priced at a significant discount.
Don't let go now
Although competition for drugs that lose market exclusivity is a common theme here, these are company-specific events. When it comes to rebate pressure, we really can't say much about AbbVie and Pfizer because they haven't unveiled their gross-to-net-price differences the way Johnson & Johnson has.
Data source: Yahoo! Finance.
Johnson & Johnson, AbbVie, and Pfizer may be heading into a rough patch caused by patent expirations and other threats, but that doesn't mean you should let go of their shares right now. All three big pharma stocks are trading at below-average multiples of their earnings expectations for the year ahead, and their dividend programs are well funded.
It isn't easy watching your stocks flounder for a year or longer, but you can count on these three to raise their quarterly payouts going forward. Johnson & Johnson hasn't gone a year without raising its payout since JFK was in office, and it's hardly against the wall now.
Johnson & Johnson used just 51% of free cash flow to make dividend payments over the past year, which means it can keep raising the payout even if total revenue goes nowhere for years on end. AbbVie and Pfizer offer even higher yields right now that could contribute to market-beating returns over the long run.
10 stocks we like better than Pfizer
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Pfizer wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of November 14, 2018
Cory Renauer owns shares of Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie thinks biosimilar competition will reduce total sales by around $2 billion this year, which will probably be offset by a couple of blood cancer drugs that recently received some important label expansions . More recently, AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) told investors not to expect a great deal of sales growth in 2019. AbbVie: Biosimilar pressure AbbVie hasn't complained much about pushy U.S. insurers demanding higher rebates, although it probably could. | More recently, AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) told investors not to expect a great deal of sales growth in 2019. AbbVie: Biosimilar pressure AbbVie hasn't complained much about pushy U.S. insurers demanding higher rebates, although it probably could. Instead, AbbVie's softer-than-expected outlook for 2019 is the result of stingy end payers throughout Europe. | When it comes to rebate pressure, we really can't say much about AbbVie and Pfizer because they haven't unveiled their gross-to-net-price differences the way Johnson & Johnson has. More recently, AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) told investors not to expect a great deal of sales growth in 2019. AbbVie: Biosimilar pressure AbbVie hasn't complained much about pushy U.S. insurers demanding higher rebates, although it probably could. | More recently, AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) told investors not to expect a great deal of sales growth in 2019. AbbVie: Biosimilar pressure AbbVie hasn't complained much about pushy U.S. insurers demanding higher rebates, although it probably could. Instead, AbbVie's softer-than-expected outlook for 2019 is the result of stingy end payers throughout Europe. |
25109.0 | 2019-01-29 00:00:00 UTC | Health Care Sector Update for 01/29/2019: ARAY, TRVN, ABBV, JNJ, PFE, ABT, MRK, AMGN | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-01292019-aray-trvn-abbv-jnj-pfe-abt-mrk-amgn-2019-01-29 | nan | nan | Top Health Care Stocks:
JNJ: +0.02%
PFE: -3.36%
ABT: Flat
MRK: +0.10%
AMGN: Flat
Most health care stocks are seeing a dip pre-market Tuesday, including an 0.8% decline in the NYSE Health Care Index in recent trading. The Nasdaq Biotechnology Index was up 0.05% .
Early movers include:
(+) Accuray ( ARAY ) is up nearly 5% after its Accuray Asia subsidiary and CNNC High Energy Equipment (Tianjin), a subsidiary of China Isotope and Radiation formed of a joint venture to manufacture and sell radiation oncology systems in China.
In other sector news:
(-) Trevena ( TRVN ) shares are down 0.83% pre-market Tuesday after skyrocketing by 119.96% on market close Monday following the company saying it is "encouraged" to resubmit its new drug application for oliceridine as a result of a "productive discussion with FDA" concerning the complete response letter ( CRL ) received for oliceridine from the US Food and Drug Administration.
(+) AbbVie ( ABBV ) has recovered from a 4.22% drop on market close Monday, seeing its shares rise marginally pre-market Tuesday following the company's announcement that the US Food and Drug Administration (FDA) has approved the use of Imbruvica (ibrutinib) in combination with obinutuzumab (Gazyva) for adult patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (+) AbbVie ( ABBV ) has recovered from a 4.22% drop on market close Monday, seeing its shares rise marginally pre-market Tuesday following the company's announcement that the US Food and Drug Administration (FDA) has approved the use of Imbruvica (ibrutinib) in combination with obinutuzumab (Gazyva) for adult patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Early movers include: (+) Accuray ( ARAY ) is up nearly 5% after its Accuray Asia subsidiary and CNNC High Energy Equipment (Tianjin), a subsidiary of China Isotope and Radiation formed of a joint venture to manufacture and sell radiation oncology systems in China. In other sector news: (-) Trevena ( TRVN ) shares are down 0.83% pre-market Tuesday after skyrocketing by 119.96% on market close Monday following the company saying it is "encouraged" to resubmit its new drug application for oliceridine as a result of a "productive discussion with FDA" concerning the complete response letter ( CRL ) received for oliceridine from the US Food and Drug Administration. | (+) AbbVie ( ABBV ) has recovered from a 4.22% drop on market close Monday, seeing its shares rise marginally pre-market Tuesday following the company's announcement that the US Food and Drug Administration (FDA) has approved the use of Imbruvica (ibrutinib) in combination with obinutuzumab (Gazyva) for adult patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (+) AbbVie ( ABBV ) has recovered from a 4.22% drop on market close Monday, seeing its shares rise marginally pre-market Tuesday following the company's announcement that the US Food and Drug Administration (FDA) has approved the use of Imbruvica (ibrutinib) in combination with obinutuzumab (Gazyva) for adult patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). AMGN: Flat Most health care stocks are seeing a dip pre-market Tuesday, including an 0.8% decline in the NYSE Health Care Index in recent trading. | (+) AbbVie ( ABBV ) has recovered from a 4.22% drop on market close Monday, seeing its shares rise marginally pre-market Tuesday following the company's announcement that the US Food and Drug Administration (FDA) has approved the use of Imbruvica (ibrutinib) in combination with obinutuzumab (Gazyva) for adult patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). AMGN: Flat Most health care stocks are seeing a dip pre-market Tuesday, including an 0.8% decline in the NYSE Health Care Index in recent trading. Early movers include: (+) Accuray ( ARAY ) is up nearly 5% after its Accuray Asia subsidiary and CNNC High Energy Equipment (Tianjin), a subsidiary of China Isotope and Radiation formed of a joint venture to manufacture and sell radiation oncology systems in China. |
25110.0 | 2019-01-29 00:00:00 UTC | AbbVie (ABBV) Gains As Market Dips: What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-gains-as-market-dips%3A-what-you-should-know-2019-01-29 | nan | nan | AbbVie (ABBV) closed at $77.47 in the latest trading session, marking a +0.43% move from the prior day. This move outpaced the S&P 500's daily loss of 0.15%. Elsewhere, the Dow gained 0.21%, while the tech-heavy Nasdaq lost 0.81%.
Heading into today, shares of the drugmaker had lost 16.33% over the past month, lagging the Medical sector's gain of 2.7% and the S&P 500's gain of 6.55% in that time.
ABBV will be looking to display strength as it nears its nex t earnings release, which is expected to be April 25, 2019. On that day, ABBV is projected to report earnings of $2.02 per share, which would represent year-over-year growth of 8.02%. Meanwhile, our latest consensus estimate is calling for revenue of $7.77 billion, down 2.1% from the prior-year quarter.
ABBV's full-year Zacks Consensus Estimates are calling for earnings of $8.67 per share and revenue of $33.13 billion. These results would represent year-over-year changes of +9.61% and +1.15%, respectively.
Any recent changes to analyst estimates for ABBV should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.03% lower. ABBV is currently a Zacks Rank #3 (Hold).
Investors should also note ABBV's current valuation metrics, including its Forward P/E ratio of 8.9. This represents a discount compared to its industry's average Forward P/E of 14.05.
It is also worth noting that ABBV currently has a PEG ratio of 0.81. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Large Cap Pharmaceuticals stocks are, on average, holding a PEG ratio of 1.93 based on yesterday's closing prices.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 73, putting it in the top 29% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABBV's full-year Zacks Consensus Estimates are calling for earnings of $8.67 per share and revenue of $33.13 billion. AbbVie (ABBV) closed at $77.47 in the latest trading session, marking a +0.43% move from the prior day. ABBV will be looking to display strength as it nears its nex t earnings release, which is expected to be April 25, 2019. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie (ABBV) closed at $77.47 in the latest trading session, marking a +0.43% move from the prior day. ABBV will be looking to display strength as it nears its nex t earnings release, which is expected to be April 25, 2019. | ABBV's full-year Zacks Consensus Estimates are calling for earnings of $8.67 per share and revenue of $33.13 billion. AbbVie (ABBV) closed at $77.47 in the latest trading session, marking a +0.43% move from the prior day. ABBV will be looking to display strength as it nears its nex t earnings release, which is expected to be April 25, 2019. | On that day, ABBV is projected to report earnings of $2.02 per share, which would represent year-over-year growth of 8.02%. ABBV is currently a Zacks Rank #3 (Hold). AbbVie (ABBV) closed at $77.47 in the latest trading session, marking a +0.43% move from the prior day. |
25111.0 | 2019-01-29 00:00:00 UTC | 10 Value Stocks to Buy for 2019 and Beyond | ABBV | https://www.nasdaq.com/articles/10-value-stocks-buy-2019-and-beyond-2019-01-29 | nan | nan | Not that 2018 was a stellar year for growth companies, but it was downright miserable for value stocks. Using a pair of popular funds as proxies, growth stocks finished last year 4.5% in the hole ... but value equities lost nearly 8%.
The coming year could look quite different, however.
Yes, growth has led for a couple years now, but 2019 might well be the year value stocks take back the lead. While a full-blown bear market has faded as a fear, we do appear to be in the latter stages of an economic expansion phase. That is when growth-oriented companies begin to lose their luster and the value of underappreciated stocks starts to shine through. Qualities such as reliability and consistent income can start to matter in a big way when growth stories are threatened. This all has led some experts to predict a comeback for bargains in the year ahead .
Here are the 10 best value stocks to buy for 2019 ... and potentially for many more years to come.
SEE ALSO: 19 Best Stocks to Buy for 2019 (And 5 to Sell)
Market value: $10.0 billion
Forward P/E: 5.9
What happens when the economy is strong enough to spur the usage of industrial equipment but confidence in that economic strength's longevity is shaky? Do construction outfits and industrial-oriented companies rent rather than buy?
Actually, many organizations that use equipment ranging from scissor lifts to excavators to skid steer loaders prefer to lease that equipment rather than purchase it anyway. But when the future is less than clear, that environment turns United Rentals ( URI , $124.79) from a good prospect into a great one.
United Rentals hasn't appeared to be either, given the stock's performance since early 2018. URI shares are presently trading 34% below their March peak. Most of the damage was done since September on fears that the construction slowdown could be a prelude to a more widespread headwind prompted by an escalating trade war with China.
The sellers have arguably overshot their target, though. The pros still see revenue growth of 16% this year that should generate a 17% pop in profits. Sales growth is expected to slow to 4% in 2020, bu t earnings still should advance another 12%. And newcomers can plug into that projected profit growth at just about six times next year's estimated earnings.
SEE ALSO: 7 Cheap Stocks to Buy on the Dip
Market value: $30.5 billion
Forward P/E: 12.1
Eaton ( ETN , $69.11) isn't exactly a household name. But considering it's priced at less than 15 times trailing profits and roughly 12 times next year's projected earnings, it arguably has a place in more households' portfolios.
Eaton makes a variety of power-management products that meet the needs of the transportation, building management, utilities and mining industries, just to name a few. Motion controllers, hydraulic pumps, valves, clutches and air handling hardware are just some of the goods found in its extensive catalog. It always has something to sell to someone, and odds are good every consumer and every investor in North America benefits from Eaton's portfolio in one way or another.
That doesn't outright guarantee year-over-year revenue growth each and every quarter. Given enough time, though, Eaton grows the top line more often than it doesn't, and operating income makes forward progress even more reliably.
The track record - and Eaton's growth rate, for that matter - might be on the cusp of even more improvement. ETN has been upgraded by analysts twice since August, and three more research outfits have initiated coverage of the stock with a bullish stance. There have been no downgrades in that time.
SEE ALSO: 10 Small-Cap Stocks to Buy for 2019 and Beyond
Market value: $45.2 billion
Forward P/E: 9.7
FedEx ( FDX , $173.96) isn't a growth stock. There's simply a limited amount of delivery business that needs to be done, here and abroad, and most of it's being done more than well enough. Established competitors like DHL and United Parcel Service ( UPS ) help keep prices in check for all of these players in the meantime.
Even by value stock standards, however, a 35% year-over-year decline leaves FDX shares undervalued at a forward-looking P/E of less than 10.
There's no single reason for the stock's deterioration. Amazon.com's ( AMZN ) interest in handling more of its own shipping duties is certainly one concern, and the possibility of a global economic slowdown prompted by trade wars has likely weighed on investors. Last quarter's earnings miss and lowered earnings guidance for 2019 also spurred more profit-taking of a stock that admittedly started 2018 out in an overbought condition.
But as the dust starts to settle on all these matters, it's increasingly clear FedEx still is the company it was a year ago, three years ago, even five years ago. It has reported revenue growth in every quarter since 2010, and earnings growth - while not as persistent - still has been impressive. There's a lot to be said about reliability, never even mind how FedEx managed to push through the last recession with only minor cuts and bruises.
One last possibility to chew over: Loop Capital Markets analyst Anthony Chukumba reiterated recently his thought that if Amazon wants to enter the shipping arena, FedEx shares could be a relatively cheap way to do it.
SEE ALSO: The 9 Best Stocks of America's Last Bear Market
Market value: $222.1 billion
Forward P/E: 8.6
Shares of telecom outfit AT&T ( T , $30.67) have been treated like anything but a blue chip of late. The stock's is down roughly 30% from its mid-2016 peak, reaching fresh multiyear lows in December before bouncing back to still-depressed levels.
The curious part of the setback is, there's no clear reason for it - at least not for the depths that it has made. While last year's top line shrank, it was being compared to very healthy growth from 2016 that was largely spurred by the acquisition of DirecTV. Ditto for operating income, which was pressured in 2017 as the entire industry entered a price war that left all key players battered and bruised.
While the impact of the cutthroat price war is abating, investors are now worried AT&T's expensive acquisition of Time Warner may also fail to bear enough fruit. But those investors seem to have priced in an apocalypse that just isn't going to happen. T shares now trade at just six times the company's trailing-12-month earnings and less than nine times next year's estimated bottom line. Meanwhile, sales growth actually is expected to accelerate, from 6.4% this year to 8.1% in 2019.
The kicker: Not only is AT&T a deep-value stock, but it's now delivering a whopping 6.7% yield on a dividend that has been paid (and grown) like clockwork for years. In fact, AT&T is a member of the Dividend Aristocrats - the select group of S&P 500 stocks that have grown their payouts every year for at least a quarter-century.
SEE ALSO: Dogs of the Dow 2019: 10 Dividend Stocks to Watch
Market value: $29.9 billion
Forward P/E: 9.6
The last three months of 2018 were tough on insurer Allstate ( ALL , $86.49), and by extension its shareholders. The stock lost almost a quarter of its value between late September and Christmas, prompted in large part by Hurricane Florence battering the East Coast and Hurricane Michael hitting the Gulf Coast.
Both storms did more damage than the nation had reason to expect, and that meant heavy payouts from insurers. Allstate was no exception, with the company reporting $202 million in losses in October, most of that coming from Michael. September's reimbursements were on the order of $177 million. Then there are the California wildfires, which cost Allstate about $529 million after taxes.
But investors may have unduly punished Allstate, forgetting that hurricane and wildfires aren't exactly unusual any longer. The premiums it collects largely factor in these stunningly large payouts, even if the actuarial math isn't laser-precise.
Greg Oray, President of Michigan-based Oray King Wealth Advisors, explains the stock is "off the highs since September, due to the recent U.S. market correction and missing earnings in October." Oray adds, however, that "this year's catastrophe losses have been priced in ... I think this stock has the potential to get back to its 52-week high with strong revenue growth over the next two quarters."
SEE ALSO: 19 Best Retirement Stocks to Buy in 2019
Market value: $7.2 billion
Forward P/E: 16.3
The spinoff of nVent ( NVT ) from Pentair ( PNR , $40.54) in the first half of 2018 has made it tough to evaluate the newly shrunken company. But, even before the divestiture was complete, investors (professional and amateur alike) were more stoked about nVent than they were about the now-former parent. PNR shares broadly continued the downward trek they began shortly before the spinoff was even announced.
But the market might not be giving the slimmed-down Pentair its due respect. This isn't necessarily the same company that was holding nVent down.
Pentair used the cash infusion reaped from the spinoff to whittle down the company's former debt of $1.4 billion to only $800 million now. More than anything, though, Pentair already has alluded to new products and bolt-on acquisitions that will embellish its existing water-management portfolio. Its new automated/smart pool management solution already has won awards, and its connected internet-of-things platform for Beer Membrane Filtration (BMF) systems could become a must-have for breweries.
Next year's projected sales growth is a modest 3%, but analysts believe that should be enough to push the bottom line from $2.33 per share this year to $2.55 in 2019. With an overhauled portfolio in the works, the current lull might be a buying opportunity.
SEE ALSO: 20 Top Stock Picks the Analysts Love for 2019
Market value: $26.6 billion
Forward P/E: 17.3
Electronic Arts ( EA , $90.47) shares have lost nearly 40% of their value since July 2018, as investors have been forced to digest two rounds of disappointing revenue and earnings guidance.
The cause for the surprising weakness is both complicated and simple. The simple explanation is, it's not selling enough video games. The more complicated explanation is, Electronic Arts didn't foresee competing games like Fortnite proving so disruptive, and it didn't fully embrace the way gamers now like to purchase (digital downloads) and play games (on a subscription basis).
The stock's meltdown has caught the attention of Daniel Lugasi, Portfolio Manager with Winter Park, Florida-based VL Capital Management. He notes "We have recently become increasingly bullish on Electronic Arts Inc. (EA). The stock is currently trading at ... a significant discount from a few months back when it was trading well over 26x earnings."
Moreover, Lugasi feels the game publisher has addressed its recent miscues, adding, "A significant near-term catalyst for the stock is the release of the highly anticipated first-person shooter title Battlefield 5, which saw a delay and impacted the stock quite significantly. Longer term, we view the transition of disc-based game distribution to 100% downloadable games as a significant driver of margins for EA as distribution costs drop to zero."
The portfolio manager concludes, "EA is expected to launch a cloud gaming service in the next few years, which will be somewhat like the Netflix ( NFLX ) of gaming. Early impressions from those that have tested the service are overwhelmingly positive."
SEE ALSO: The 12 Best Tech Stocks for a 2019 Recovery
Market value: $75.2 billion
Forward P/E: 10.1
Caterpillar ( CAT , $124.37) - as well as several analysts and investors - have said that the imposition of trade tariffs on steel imported from China will be devastating. Indeed, after CAT shares soared over the course of 2017 when it finally looked like the machinery maker was back to its former full stride, fears of a trade war shaved roughly a third of Caterpillar's value reached at the beginning of 2018. The stock still is down 25% from that peak.
The company has since sent a couple of very mixed messages.
Caterpillar's third-quarter report indicated that the added cost of steel stemming from these tariffs would only cost the company an extra $100 million to $200 million in 2018. Not chump change, but a palatable expense for an organization that earned $3.8 billion over its previous four quarters at that point.
However, Caterpillar recently followed that up with its biggest earnings miss in a decade in its fourth-quarter report, with analysts perhaps too encouraged by that Q3 result. Caterpillar also disappointed with its 2019 outlook, now seeing "a modest sales increase" because of several pressures, China growth and tariff issues foremost among them.
Both of these issues will continue to be pivotal in determining Caterpillar's direction from here. That said, if you're convinced that the U.S. eventually will end its tariff spat with China, CAT is trading at an attractive speculation price of just 10 times forward earnings estimates.
SEE ALSO: The 27 Best Mutual Funds in 401(k) Retirement Plans
Market value: $285.7 billion
Forward P/E: 9.2
Rising interest rates are a two-edged sword for banks. On the one hand, higher rates make lending a more profitable venture for the lender, usually in a strong economic environment. On the other, higher interest rates makes borrowing more expensive, and therefore less attractive.
Investors haven't been sure if the glass has been half-full or half-empty since interest rates have been edging higher. But the 10% pullback Bank of America ( BAC , $29.63) has been through - including a much larger dip to below $23 per share by December - suggests investors are moreso leaning toward the latter.
Perhaps some optimism is warranted, however. Last quarter, Bank of America's loans were up 1.9%, helping the consumer banking business grow by 52%. That was part of a record-breaking fourth quarter that saw the company deliver $7.3 billion in profits. Once investors realize the economy isn't going to implode and that rates are rising because the economy is firm, they'll likely realize Bank of America's forward-looking P/E of 9.2 is simply too low.
BofA also is laying a long-term foundation that reflects the way the nation's demographic breakdown is maturing. Bill Smead, CEO of Seattle-based Smead Capital Management, explains, "The multiplier effect of millennial household formation should be a bonanza to the nation's largest depository bank, Bank of America. They have the technology the under-40 crowd likes and already uses for banking."
SEE ALSO: The 7 Best Bank ETFs for American Bulls
Market value: $116.8 billion
Forward P/E: 8.1
AbbVie ( ABBV , $77.14) had a downright lousy 2018. Even with a November bounce, ABBV shares are down 38% from their January 2018 peak. And some Wall Street analysts are in fact souring on the stock .
The prod for the pullback has mostly been fears surrounding its Humira franchise. Its primary patent has already expired, though the company has done an admirable job of introducing related patents that protect its blockbuster status; the multi-purposed anti-inflammatory drug still drove roughly $20 billion in sales last year.
The defensive maneuvering is only buying small bits of time, however. Rival pharmaceutical companies are going to introduce alternatives to Humira sooner than later. In the meantime, the federal government continues to threaten AbbVie's bottom line with reform that will ultimately make prescription drugs cheaper to purchase.
The doubters might have overdone it, though. While Humira's best days are almost behind it, investors are largely ignoring the pharmaceutical giant's pipeline, which is well-positioned to offset the eventual end of Humira's dominance. In January 2018, AbbVie's chiefs suggested that sales of drugs other than Humira - led by the likes of cancer drug Imbruvica - could grow from 2017's $10 billion to $35 billion by 2025. Indeed, the company already has started down a growth path that doesn't rely on Humira.
ABBV's weakness over the past year is an opportunity. Shares trade at almost eight times next year's projected profits and yield a fat 5.3%.
James Brumley was long T at the time of this writing.
SEE ALSO: The Best Health-Care Stocks to Buy for 2019
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | SEE ALSO: The 7 Best Bank ETFs for American Bulls Market value: $116.8 billion Forward P/E: 8.1 AbbVie ( ABBV , $77.14) had a downright lousy 2018. Even with a November bounce, ABBV shares are down 38% from their January 2018 peak. In the meantime, the federal government continues to threaten AbbVie's bottom line with reform that will ultimately make prescription drugs cheaper to purchase. | SEE ALSO: The 7 Best Bank ETFs for American Bulls Market value: $116.8 billion Forward P/E: 8.1 AbbVie ( ABBV , $77.14) had a downright lousy 2018. Even with a November bounce, ABBV shares are down 38% from their January 2018 peak. In the meantime, the federal government continues to threaten AbbVie's bottom line with reform that will ultimately make prescription drugs cheaper to purchase. | SEE ALSO: The 7 Best Bank ETFs for American Bulls Market value: $116.8 billion Forward P/E: 8.1 AbbVie ( ABBV , $77.14) had a downright lousy 2018. Even with a November bounce, ABBV shares are down 38% from their January 2018 peak. In the meantime, the federal government continues to threaten AbbVie's bottom line with reform that will ultimately make prescription drugs cheaper to purchase. | SEE ALSO: The 7 Best Bank ETFs for American Bulls Market value: $116.8 billion Forward P/E: 8.1 AbbVie ( ABBV , $77.14) had a downright lousy 2018. Even with a November bounce, ABBV shares are down 38% from their January 2018 peak. In the meantime, the federal government continues to threaten AbbVie's bottom line with reform that will ultimately make prescription drugs cheaper to purchase. |
25112.0 | 2019-01-29 00:00:00 UTC | 3 Top Dividend Stocks to Buy Right Now | ABBV | https://www.nasdaq.com/articles/3-top-dividend-stocks-buy-right-now-2019-01-29 | nan | nan | Dividend stocks are an essential part of any well-rounded portfolio. However, the fact that top dividend stocks are highly coveted items among blue-chip and institutional investors alike means that most of these equities garner stately premiums. Put simply, there aren't many bargains to be had when it comes to elite dividend plays.
With this theme in mind, we turned to three of our Motley Fool contributors to get their thoughts on which top dividend stocks offer retail investors a compelling mix of stable income and value. They picked Hanesbrands (NYSE: HBI) , Ford (NYSE: F) , and AbbVie (NYSE: ABBV) . Here's why.
Rebound potential and big yield at clearance prices
Keith Noonan (Hanesbrands): Hanesbrands has struggled amid slowdown for some of its key product categories and the threat that private-label retail brands will continue to eat away at its business. The stock has lost nearly 40% of its value over the last year, and shares now trade at just 7.5 times this year's expected earnings and yield 4.3%. Momentum for private-label retail brands presents a meaningful threat to Hanesbrands, and the stock's big sell-off over the last year isn't entirely unwarranted, but shares look cheap at current prices.
The company's socks and underwear sales have slowed in 2018, but the business is expected to stabilize this year -- which would alleviate sales and earnings pressure. Investors probably shouldn't look to the segment to power the clothing giant's rebound, but that doesn't mean that Hanesbrands is without growth engines. The company has been on an acquisitions push over the last few years, and it also has homegrown product lines that are showing strong momentum -- most notably its Champion brand. Champion clothing sales grew 30% year over year last quarter, and the brand is spearheading the company's international expansion and direct-to-consumer sales push.
Hanesbrands' dividend yield has never been higher than its levels over the last couple months, and the company's growth prospects do not appear to be as dim as the recent stock sell-offs suggest. There's an attractive value and returned-income profile here, and for patient investors, I think Hanesbrands is a dividend stock worth buying today.
A generous automaker
Jeremy Bowman(Ford): One top dividend stock I have been taking a closer look at lately is Ford. The legacy automaker has struggled of late with China sales down and losses in Europe piling up, but the stock has already paid the price for it as shares are down nearly 50% over the last five years.
That's made the stock dirt cheap at a P/E ratio of 6.6 based on its preliminary adjusted earnings per share forecast of $1.30 for 2018, and its dividend yield has risen to an enticing 7%. Management has also pledged not to cut the payout.
Indeed, Ford's challenges aren't about to disappear. The company was vague about 2019 guidance, saying only that it saw potential for improvement in revenue, EBIT, and operating cash flow growth. Investors sold off the stock in response to that unclear forecast, but considering its dividend, Ford doesn't look like a bad buy today even as its profit growth is uncertain as the low price and high yield offers its own return even without price appreciation.
But Ford is cutting costs , with plans to eliminate as much as $25.5 billion in expenses through 2022, and its pivot away from sedans to higher-margin trucks and SUVs should help with profitability. After all, Ford is still the maker of the F-series, the best-selling vehicle in the U.S. for the last 36 years, and it's refreshing 75% of its lineup over the next two years, which should also boost the brand and sales.
Those initiatives could help the stock finally start moving in the right direction. In the meantime, investors can sit back and collect 7% off the top.
A falling knife worth catching
George Budwell (AbbVie): Dividend Aristocrats rarely lose over a third of their value in a year's time, but that's exactly what has happened to biopharma heavyweight AbbVie. Due to Humira's shrinking market share in Europe following the introduction of copycat drugs known as biosimilars last year, investors began to view this once high-flying drugmaker as a potential value trap right around the end of the first quarter of 2018.
Unfortunately, AbbVie's recent fourth-quarter and full-year earnings release failed to tamp down this growing concern, and it even triggered another round of heavy selling in the first few weeks of 2019. The latest touch point for investors was management's lower-than-expected revenue guidance for the year. This anemic full-year guidance, which calls for revenue growth of approximately 1% on an operational basis in 2019, added even more steam to the narrative that the company simply hasn't done enough to prepare for Humira's patent expiration.
AbbVie, though, is being punished arguably for the sins of its peers and not for facts on the ground. Unlike several big pharmas that failed to get out in front of key patent expires, AbbVie has been super aggressive on this front. For instance, the company has built a top-notch hematology franchise with Imbruvica and Venclexta and it's also steaming toward major regulatory decisions in immunology with the next-generation therapies risankizumab and upadacitinib later this year. As a result, Wall Street thinks that AbbVie's top line will more or less return to form as soon as 2020.
Bottom line: There's no telling when the fear-based selling in AbbVie's stock will exhaust itself and a rebound will take shape. But the biotech's juicy yield of 5.31% and promising long-term outlook strongly suggest that investors may want to take advantage of this irrational downturn.
10 stocks we like better than Ford
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Ford wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of November 14, 2018
George Budwell owns shares of AbbVie. Jeremy Bowman has no position in any of the stocks mentioned. Keith Noonan owns shares of Hanesbrands. The Motley Fool recommends Ford. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | They picked Hanesbrands (NYSE: HBI) , Ford (NYSE: F) , and AbbVie (NYSE: ABBV) . A falling knife worth catching George Budwell (AbbVie): Dividend Aristocrats rarely lose over a third of their value in a year's time, but that's exactly what has happened to biopharma heavyweight AbbVie. Unfortunately, AbbVie's recent fourth-quarter and full-year earnings release failed to tamp down this growing concern, and it even triggered another round of heavy selling in the first few weeks of 2019. | They picked Hanesbrands (NYSE: HBI) , Ford (NYSE: F) , and AbbVie (NYSE: ABBV) . A falling knife worth catching George Budwell (AbbVie): Dividend Aristocrats rarely lose over a third of their value in a year's time, but that's exactly what has happened to biopharma heavyweight AbbVie. Unfortunately, AbbVie's recent fourth-quarter and full-year earnings release failed to tamp down this growing concern, and it even triggered another round of heavy selling in the first few weeks of 2019. | They picked Hanesbrands (NYSE: HBI) , Ford (NYSE: F) , and AbbVie (NYSE: ABBV) . A falling knife worth catching George Budwell (AbbVie): Dividend Aristocrats rarely lose over a third of their value in a year's time, but that's exactly what has happened to biopharma heavyweight AbbVie. Unfortunately, AbbVie's recent fourth-quarter and full-year earnings release failed to tamp down this growing concern, and it even triggered another round of heavy selling in the first few weeks of 2019. | They picked Hanesbrands (NYSE: HBI) , Ford (NYSE: F) , and AbbVie (NYSE: ABBV) . A falling knife worth catching George Budwell (AbbVie): Dividend Aristocrats rarely lose over a third of their value in a year's time, but that's exactly what has happened to biopharma heavyweight AbbVie. Unfortunately, AbbVie's recent fourth-quarter and full-year earnings release failed to tamp down this growing concern, and it even triggered another round of heavy selling in the first few weeks of 2019. |
25113.0 | 2019-01-29 00:00:00 UTC | AbbVie's Imbruvica Combo Gets FDA Nod in First-Line Setting | ABBV | https://www.nasdaq.com/articles/abbvies-imbruvica-combo-gets-fda-nod-in-first-line-setting-2019-01-29 | nan | nan | AbbVieABBV and J&J JNJ announced that the FDA has approved a label expansion of their key cancer drug, Imbruvica (ibrutinib) in combination with Roche's RHHBY Gazyva (obinutuzumab). The drug, in combination with gazyva, is now approved for first-line treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
With the FDA approval, Imbruvica plus obinutuzumab becomes the first chemotherapy-free CD20 combination in first-line CLL treatment.
Imbruvica is now approved in 10 different settings in six cancer indications. Imbruvica is already approved as monotherapy or in combination with Teva's TEVA Treanda (bendamustine) and Biogen/Roche's Rituxan (rituximab) for CLL/SLL.
AbbVie's shares have declined 15.7% in the past six months compared with the industry 's decrease of 1%.
The approval was based on data from the phase III study - iLLUMINATE - evaluating the Imbruvica combination therapy in previously untreated CLL/SLL patients 65 years or older or in patients below 65 years with coexisting conditions. Data from the study showed that the combination significantly improved progression-free survival (PFS) (77%) compared to chlorambucil plus Gazyva. The combination also reduced risk of progression or death by 85% in patients with high-risk disease.
The chlorambucil plus Gazyva therapy is the National Comprehensive Cancer Network ("NCCN") recommended treatment for CLL/SLL patients.
The FDA also approved an update to Imbruvica's label to include additional long-term efficacy data from phase III studies, RESONATE and RESONATE-2, evaluating the drug as monotherapy in CLL/SLL patients.
Imbruvica, a key drug in AbbVie's oncology portfolio, generated $3.6 billion in sales in 2018, growing almost 40% compared to 2017. Sales of another important cancer drug in AbbVie's oncology portfolio, Venclexta more than doubled to $344 million in 2018.
However, AbbVie's major revenue generator, Humira, started to face biosimilar competition in European markets during the fourth quarter of 2018, which resulted in international revenue, decline of 17.5% on a reported basis. The unfavorable impact is likely to increase in the future quarters. Although Humira is protected in the United States till 2023, a biosimilar launch following that will have significant unfavorable impact on the company's top line.
AbbVie's focus on developing its oncology portfolio along with the HCV treatment, Mavyret, and a few other new drugs is encouraging as growth in the sales of these drugs will partially offset the decline in Humira sales.
AbbVie Inc. Price
AbbVie Inc. Price | AbbVie Inc. Quote
Zacks Rank
AbbVie currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Wall Street's Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It's a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Roche Holding AG (RHHBY): Free Stock Analysis Report
Johnson & Johnson (JNJ): Get Free Report
Teva Pharmaceutical Industries Ltd. (TEVA): Get Free Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVieABBV and J&J JNJ announced that the FDA has approved a label expansion of their key cancer drug, Imbruvica (ibrutinib) in combination with Roche's RHHBY Gazyva (obinutuzumab). AbbVie's shares have declined 15.7% in the past six months compared with the industry 's decrease of 1%. Imbruvica, a key drug in AbbVie's oncology portfolio, generated $3.6 billion in sales in 2018, growing almost 40% compared to 2017. | AbbVieABBV and J&J JNJ announced that the FDA has approved a label expansion of their key cancer drug, Imbruvica (ibrutinib) in combination with Roche's RHHBY Gazyva (obinutuzumab). AbbVie Inc. Price AbbVie Inc. Price | AbbVie Inc. Quote Zacks Rank AbbVie currently carries a Zacks Rank #3 (Hold). Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Johnson & Johnson (JNJ): Get Free Report Teva Pharmaceutical Industries Ltd. (TEVA): Get Free Report To read this article on Zacks.com click here. | AbbVie Inc. Price AbbVie Inc. Price | AbbVie Inc. Quote Zacks Rank AbbVie currently carries a Zacks Rank #3 (Hold). Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Johnson & Johnson (JNJ): Get Free Report Teva Pharmaceutical Industries Ltd. (TEVA): Get Free Report To read this article on Zacks.com click here. AbbVieABBV and J&J JNJ announced that the FDA has approved a label expansion of their key cancer drug, Imbruvica (ibrutinib) in combination with Roche's RHHBY Gazyva (obinutuzumab). | Imbruvica, a key drug in AbbVie's oncology portfolio, generated $3.6 billion in sales in 2018, growing almost 40% compared to 2017. AbbVieABBV and J&J JNJ announced that the FDA has approved a label expansion of their key cancer drug, Imbruvica (ibrutinib) in combination with Roche's RHHBY Gazyva (obinutuzumab). AbbVie's shares have declined 15.7% in the past six months compared with the industry 's decrease of 1%. |
25114.0 | 2019-01-28 00:00:00 UTC | What's Making News In These Pharma And Cannabis Stocks Today? | ABBV | https://www.nasdaq.com/articles/whats-making-news-these-pharma-and-cannabis-stocks-today-2019-01-28 | nan | nan | (RTTNews.com) - AbbVie ( ABBV ) announced that the FDA has approved the use of IMBRUVICA in combination with Roche's Gazyva for adult patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma.
Today's approval marks the 10th FDA approval for IMBRUVICA in six different disease areas since 2013.
The drug is approved for the treatment of mantle cell lymphoma, chronic lymphocytic leukemia, Waldenström's macroglobulinemia, small lymphocytic lymphoma, marginal zone lymphoma, and chronic graft versus host disease.
Imbruvica generated sales of $2.58 billion in the first nine months of 2018, up 38.5% over the comparable year-ago period.
ABBV closed Friday's trading at $80.54, down 6.22%. In pre-market trading on Monday, the stock is up 0.96% to $81.31.
Cellect Biotechnology Ltd. (APOP), a regenerative and cell therapy company, has concluded the scale-up development and manufacturing of clinical grade FasL in collaboration with its outsourced supplier.
The FasL protein is central to Cellect's technology of cell separation and functional selection of stem cells and is the key active ingredient in Cellect's ApoGraft and Apotainer product lines.
APOP closed Friday's trading at $2.70, down 6.74%.
OrganiGram Holdings Inc. (OGI.V), a licensed producer of cannabis, has reported encouraging results for the first quarter of fiscal 2019.
The net sales from continuing operations for the three months ended November 30, 2018 (Q1'2019) is $12.4 million, up 419% from $2.4 million in Q1'2018, and up 287% from $3.2 million in Q4'2018.
The net income from continuing operations is $29.5 million or $0.195 per share on a diluted basis, for Q1'2019, up from a net loss of $1.2 million, or $0.012 per share in Q1'2018, and net income of $18.0 million or $0.152 per share in Q4'2018.
OGI.V closed Friday's trading at C$5.95, down 2.94%.
Pivot Pharmaceuticals Inc. (PVOT.CN) (PVOTF.OB) has entered into a strategic Contract Manufacturing Agreement with Growpacker Inc., a fully-licensed cannabis co-packing and bottling company, to produce Pivot's differentiated and patented topical gels, creams, and beverages for the California cannabis market.
According to Pivot, the agreement will enable it to launch its patented line of bio-cannabis products immediately and cost-effectively while complementing its existing production capacity at its licensed facility in Costa Mesa, California.
PVOT.CN closed Friday's trading at $0.23, down 4.17%.
Protalix BioTherapeutics Inc. (PLX) announced that it will be presenting preliminary pharmacokinetic data from its phase III study of Pegunigalsidase alfa for the treatment of Fabry disease, dubbed BRIGHT, at the 15th Annual WORLDSymposium 2019 on February 7.
Fabry disease is an inherited disorder that results from the buildup of a particular type of fat, called globotriaosylceramide, in the body's cells due to deficiency of the enzyme, alpha-galactosidase A (AGA).
PLX closed Friday's trading at $0.43, up 0.96%.
Trevena Inc. (TRVN), whose pain drug candidate Oliceridine, was turned down by the FDA last November on the grounds of inadequate size of safety database for the proposed dosing and inadequate clinical data on QT prolongation has good news for investors.
Now, the FDA has agreed that the current safety database will support labeling at a maximum daily dose of 27 mg. The regulatory agency also has agreed that the Company can conduct a study in healthy volunteers to collect the requested QT interval data and that the study should include placebo- and positive-control arms.
The Company is not required to provide any additional efficacy data to resubmit the Oliceridine NDA.
TRVN closed Friday's trading at $0.54, up 1.56%. In pre-market trading on Monday, the stock is up 27.54% to $0.69.
Read the original article on RTTNews (http://www.rttnews.com/2973157/what-s-making-news-in-these-pharma-and-cannabis-stocks-today.aspx)
For comments and feedback: contact editorial@rttnews.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews.com) - AbbVie ( ABBV ) announced that the FDA has approved the use of IMBRUVICA in combination with Roche's Gazyva for adult patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma. ABBV closed Friday's trading at $80.54, down 6.22%. Cellect Biotechnology Ltd. (APOP), a regenerative and cell therapy company, has concluded the scale-up development and manufacturing of clinical grade FasL in collaboration with its outsourced supplier. | (RTTNews.com) - AbbVie ( ABBV ) announced that the FDA has approved the use of IMBRUVICA in combination with Roche's Gazyva for adult patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma. ABBV closed Friday's trading at $80.54, down 6.22%. The drug is approved for the treatment of mantle cell lymphoma, chronic lymphocytic leukemia, Waldenström's macroglobulinemia, small lymphocytic lymphoma, marginal zone lymphoma, and chronic graft versus host disease. | (RTTNews.com) - AbbVie ( ABBV ) announced that the FDA has approved the use of IMBRUVICA in combination with Roche's Gazyva for adult patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma. ABBV closed Friday's trading at $80.54, down 6.22%. The drug is approved for the treatment of mantle cell lymphoma, chronic lymphocytic leukemia, Waldenström's macroglobulinemia, small lymphocytic lymphoma, marginal zone lymphoma, and chronic graft versus host disease. | (RTTNews.com) - AbbVie ( ABBV ) announced that the FDA has approved the use of IMBRUVICA in combination with Roche's Gazyva for adult patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma. ABBV closed Friday's trading at $80.54, down 6.22%. The net sales from continuing operations for the three months ended November 30, 2018 (Q1'2019) is $12.4 million, up 419% from $2.4 million in Q1'2018, and up 287% from $3.2 million in Q4'2018. |
25115.0 | 2019-01-28 00:00:00 UTC | Drug/Biotech Stock Earnings on Jan 29: PFE, AMGN, BIIB & AGN | ABBV | https://www.nasdaq.com/articles/drug-biotech-stock-earnings-on-jan-29%3A-pfe-amgn-biib-agn-2019-01-28 | nan | nan | The earnings season for the quarter ending December has been unimpressive from the start except for a few companies. As expected, the momentum has decelerated compared to the first three quarter of 2018. Although more than 75% of the S&P 500 companies are yet to report, the weakening earnings trend is expected to continue.
Per the Earnings Trends report, Energy, Transportation, Construction, Finance, and the Retail sectors are expected to drive earnings growth in Q4. The Zacks Medical sector's companies, comprising pharma biotech as well as medical device companies, which have reported so far and constituting almost a third of the sector's market capitalization recorded 18.5% earnings growth and 8.5% sales growth year over year. Overall, fourth-quarter earnings and sales growth of this sector is expected to be 8.1% and 6.1%, respectively.
Although pharma bigwig Johnson & Johnson JNJ reported better-than-expected results, it provided a softer outlook for 2019, which had an unfavorable effect on the sector. Among the other two big pharma companies, which reported earnings last week, Bristol-Myers BMY bea t earnings while AbbVie ABBV missed the same. Both the companies missed the revenue expectations.
Several of the companies from the pharma/drug/biotech sectors have been facing rising generic/biosimilar competition for their key drugs and issues related to high drug prices. However, consistent innovation has brought several new drugs, which helped offset declining sales of many legacy drugs so far.
Let's take a look at four pharma/biotech companies that are set to report fourth-quarter 2018 results on Jan 29.
Pfizer Inc.PFE
Pfizer, which is scheduled to release earnings before the opening bell, delivered positive earnings surprise of 2.63% last quarter. The company's earnings beat expectations in all the last four quarters with the average positive surprise being 6.35%.
For this quarter, Pfizer's Earnings ESP of is 0.00% as the Most Accurate Estimate as well as the Zacks Consensus Estimate is pegged at 63 cents. The company currently holds a Zacks Rank #3 (Hold). You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter .
The company's top line has been driven by strong growth in the sales of new drugs including Eliquis and Prevnar, which have successfully offset the loss due to declining sales of legacy drugs. These drugs along with Xeljanz are likely to contribute to the top line in the fourth quarter. Pfizer also has a strong biosimilar portfolio, which is set to contribute to sales growth. The company is also poised to get a boost from its expansion into emerging markets.
Ibrance U.S. sales declined in the third quarter due to increased rebates and rising competition. The sales trend for the drug in the fourth quarter remains unclear. Meanwhile, during the quarter Pfizer announced the merger of its consumer healthcare unit with Glaxo's unit, creating the world's largest consumer healthcare business. (Read more: Pfizer to Report Q4 Earnings: What's in the Cards? )
Pfizer Inc. Price and EPS Surprise
Pfizer Inc. Price and EPS Surprise | Pfizer Inc. Quote
Amgen Inc.AMGN
Amgen is scheduled to announce results after the closing bell. The company beat estimates in three of the past four quarters while missing the same once. Amgen delivered a positive earnings surprise of 7.89% last quarter. The company delivered four-quarter average positive earnings surprise of 4.80%. The Zacks Consensus Estimate for earnings per share is pegged at $3.26.
The company has an Earnings ESP of +0.23% and a Zacks Rank #3. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Amgen's revenues are likely to be driven by the encouraging performance of its newer drugs like Prolia, Kyprolis, Xgeva and Blincyto. Patient population for the leukemia drug, Blincyto, was expanded in the third quarter with its approval in Japan and U.S. label expansion into pediatric patients. These factors are likely to boost sales of the drug in the soon-to-be-reported quarter. Cholesterol drug, Repatha, is expected to see lower revenues on the back of a 60% price cut and payer restrictions. However, investors will remain focused on the performance of the newly approved migraine drug, Aimovig. (Read more: Amgen to Report Q4 Earnings: What's in the Cards? )
Amgen Inc. Price and EPS Surprise
Amgen Inc. Price and EPS Surprise | Amgen Inc. Quote
Biogen Inc.BIIB
The company is expected to report before market open. Biogen beat estimates in three of the past four quarters while missing the same once, with a positive earnings surprise of 8.82% in the las t report ed quarter. The company delivered average positive earnings surprise of 4.66%.
The company has an Earnings ESP of -0.45% and a Zacks Rank #3. The Zacks Consensus Estimate for earnings per share is pegged at $6.72.
Biogen's sales are mainly driven by its strong portfolio of multiple sclerosis ("MS") drugs. Tecfidera sales improved in the third quarter especially driven by European and Japanese markets which is likely to continue in the fourth quarter. The new drug, Spinraza, approved for spinal muscular atrophy performed well on the back of strong uptake. The trend is expected to continue in the soon-to-be reported quarter. The company on its third-quarter earnings call had stated that year-over-year comparison in revenues will be difficult in the soon-to-be reported quarter due to favorable timing of contract manufacturing in the fourth quarter of 2017. (Read more: Biogen Q4 Earnings Coming Up: What's in the Cards? )
Biogen Inc. Price and EPS Surprise
Biogen Inc. Price and EPS Surprise | Biogen Inc. Quote
Allergan plcAGN
The company is expected to report before market open. Allergan delivered an earnings surprise of 5.99% last quarter. Allergan's performance has been encouraging with the company reporting positive surprise in all the last four quarters. The avera ge earnings beat over the last four quarters is 6.66%.
The company has an Earnings ESP of +2.8% and a Zacks Rank #3.The Zacks Consensus Estimate is pegged at $4.15.
The company's key products like Botox, Juvéderm collection of fillers, Vraylar, Alloderm, Linzess and Lo Loestrin are likely to support sales growth in the quarter. Demand for Botox has been strong despite facing rising competition with the recent launch of Amgen's CGRP antibody, Aimovig. However, sales of several drugs like Namenda XR and Estrace cream are likely to be hurt by generic competition. Delay in the launch of a generic version of Restasis was a relief for the company in the fourth quarter. (Read more: Can Allergan Keep the Earnings Streak Alive in Q4?)
Allergan plc Price and EPS Surprise
Allergan plc Price and EPS Surprise | Allergan plc Quote
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year?
Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.
See Latest Stocks Today >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Johnson & Johnson (JNJ): Free Stock Analysis Report
Allergan plc (AGN): Get Free Report
Bristol-Myers Squibb Company (BMY): Get Free Report
Pfizer Inc. (PFE): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Biogen Inc. (BIIB): Get Free Report
Amgen Inc. (AMGN): Get Free Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the other two big pharma companies, which reported earnings last week, Bristol-Myers BMY bea t earnings while AbbVie ABBV missed the same. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Allergan plc (AGN): Get Free Report Bristol-Myers Squibb Company (BMY): Get Free Report Pfizer Inc. (PFE): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Biogen Inc. (BIIB): Get Free Report Amgen Inc. (AMGN): Get Free Report To read this article on Zacks.com click here. Cholesterol drug, Repatha, is expected to see lower revenues on the back of a 60% price cut and payer restrictions. | Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Allergan plc (AGN): Get Free Report Bristol-Myers Squibb Company (BMY): Get Free Report Pfizer Inc. (PFE): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Biogen Inc. (BIIB): Get Free Report Amgen Inc. (AMGN): Get Free Report To read this article on Zacks.com click here. Among the other two big pharma companies, which reported earnings last week, Bristol-Myers BMY bea t earnings while AbbVie ABBV missed the same. Amgen Inc. Price and EPS Surprise Amgen Inc. Price and EPS Surprise | Amgen Inc. Quote Biogen Inc.BIIB The company is expected to report before market open. | Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Allergan plc (AGN): Get Free Report Bristol-Myers Squibb Company (BMY): Get Free Report Pfizer Inc. (PFE): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Biogen Inc. (BIIB): Get Free Report Amgen Inc. (AMGN): Get Free Report To read this article on Zacks.com click here. Among the other two big pharma companies, which reported earnings last week, Bristol-Myers BMY bea t earnings while AbbVie ABBV missed the same. The Zacks Medical sector's companies, comprising pharma biotech as well as medical device companies, which have reported so far and constituting almost a third of the sector's market capitalization recorded 18.5% earnings growth and 8.5% sales growth year over year. | Among the other two big pharma companies, which reported earnings last week, Bristol-Myers BMY bea t earnings while AbbVie ABBV missed the same. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Allergan plc (AGN): Get Free Report Bristol-Myers Squibb Company (BMY): Get Free Report Pfizer Inc. (PFE): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Biogen Inc. (BIIB): Get Free Report Amgen Inc. (AMGN): Get Free Report To read this article on Zacks.com click here. Overall, fourth-quarter earnings and sales growth of this sector is expected to be 8.1% and 6.1%, respectively. |
25116.0 | 2019-01-28 00:00:00 UTC | Health Care Sector Update for 01/28/2019: TRVN, ARAY, ABBV, JNJ, PFE, ABT, MRK, AMGN | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-01282019-trvn-aray-abbv-jnj-pfe-abt-mrk-amgn-2019-01-28 | nan | nan | Top Health Care Stocks:
JNJ: -0.68%
PFE: -0.10%
ABT: Flat
MRK: +0.01%
AMGN: -1.39%
Most health care stocks were retreating in pre-market Monday.
Early movers include:
(+) Trevena ( TRVN ), which was surging by more than 27% after the company received the official type A meeting minutes from the US Food and Drug Administration concerning the complete response letter received for the oliceridine new drug application, with the FDA agreeing that Trevena's current safety database will support labeling at a maximum daily dose of 27 mg.
(+) Accuray was more than 8% higher after its Accuray Asia unit and China Isotope and Radiation's CNNC High Energy Equipment (Tianjin) subsidiary said they formed of a joint venture to manufacture and sell radiation oncology systems in China.
In other sector news:
(+) AbbVie ( ABBV ) was slightly higher as it said the US Food and Drug Administration (FDA) has approved the use of Imbruvica (ibrutinib) in combination with obinutuzumab (Gazyva) for adult patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In other sector news: (+) AbbVie ( ABBV ) was slightly higher as it said the US Food and Drug Administration (FDA) has approved the use of Imbruvica (ibrutinib) in combination with obinutuzumab (Gazyva) for adult patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Most health care stocks were retreating in pre-market Monday. Early movers include: (+) Trevena ( TRVN ), which was surging by more than 27% after the company received the official type A meeting minutes from the US Food and Drug Administration concerning the complete response letter received for the oliceridine new drug application, with the FDA agreeing that Trevena's current safety database will support labeling at a maximum daily dose of 27 mg. (+) Accuray was more than 8% higher after its Accuray Asia unit and China Isotope and Radiation's CNNC High Energy Equipment (Tianjin) subsidiary said they formed of a joint venture to manufacture and sell radiation oncology systems in China. | In other sector news: (+) AbbVie ( ABBV ) was slightly higher as it said the US Food and Drug Administration (FDA) has approved the use of Imbruvica (ibrutinib) in combination with obinutuzumab (Gazyva) for adult patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In other sector news: (+) AbbVie ( ABBV ) was slightly higher as it said the US Food and Drug Administration (FDA) has approved the use of Imbruvica (ibrutinib) in combination with obinutuzumab (Gazyva) for adult patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Most health care stocks were retreating in pre-market Monday. Early movers include: (+) Trevena ( TRVN ), which was surging by more than 27% after the company received the official type A meeting minutes from the US Food and Drug Administration concerning the complete response letter received for the oliceridine new drug application, with the FDA agreeing that Trevena's current safety database will support labeling at a maximum daily dose of 27 mg. (+) Accuray was more than 8% higher after its Accuray Asia unit and China Isotope and Radiation's CNNC High Energy Equipment (Tianjin) subsidiary said they formed of a joint venture to manufacture and sell radiation oncology systems in China. | In other sector news: (+) AbbVie ( ABBV ) was slightly higher as it said the US Food and Drug Administration (FDA) has approved the use of Imbruvica (ibrutinib) in combination with obinutuzumab (Gazyva) for adult patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Top Health Care Stocks: ABT: Flat |
25117.0 | 2019-01-28 00:00:00 UTC | The Zacks Analyst Blog Highlights: J&J, Bristol-Myers, Lilly, AbbVie and Merck | ABBV | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-jj-bristol-myers-lilly-abbvie-and-merck-2019-01-28 | nan | nan | For Immediate Release
Chicago, IL -January 28, 2019 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: J&JJNJ , Bristol-MyersBMY , LillyLLYAbbVieABBV and MerckMRK .
Here are highlights from Friday's Analyst Blog:
Pharma Stock Roundup: JNJ, BMY, LLY & More
J&J and Bristol-Myers set the earnings season in motion for the pharma space. Meanwhile, Lilly and AbbVie faced pipeline setbacks with failure of their late-stage studies. Lilly's confirmatory study to convert soft tissue sarcoma drug Lartruvo's conditional approval to full approval and AbbVie's Imbruvica combination study in metastatic pancreatic cancer failed to meet their respective primary endpoints.
Recap of the Week's Most Important Headlines
Inside J&J & Bristol-Myers' Q4 Earnings: J&J beat estimates for both earnings and sales in the fourth quarter of 2018. Sales increased 1% from the year-ago quarter to $20.4 billion while earnings per share rose 13.2% to $1.95 per share. Pharmaceutical segment sales rose 5.3% year over year. However, J&J's sales guidance for 2019 was below expectation.
Bristol-Myers beat estimates for earnings while missing the same for sales. Revenues were up 10% year over year to $6 billion while earnings rose 38% to $94 per share. However, the company announced the voluntary withdrawal of a label expansion application for Opdivo + low-dose Yervoy combination in first-line ling cancer, which pushed its share price down. Opdivo sales were up 33% in the fourth quarter. Bristol-Myers confirmed its 2019 earnings guidance range of $4.10 to $4.20.
Lilly's Confirmatory Study on Lartruvo Fails : Lilly's drug Lartruvo, which had won conditional approval two years back, failed to improve survival for patients with advanced soft tissue sarcoma in a late-stage confirmatory study, ANNOUNCE.
The ANNOUNCE study evaluated Lartruvo in combination with doxorubicin, a standard of care chemotherapy compared with doxorubicin alone. The study did not meet the primary endpoints of overall survival (OS) in the full study population or in the leiomyosarcoma (LMS) sub-population. It was noticed that there was no difference in survival between the study arms for either population. The study thus did not confirm the clinical benefit of Lartruvo in combination with doxorubicin as shown earlier in a phase II study. The clinical benefit achieved earlier had led to an accelerated approval of Lartruvo+doxorubicin by the FDA and conditional marketing authorization by the European Medicines Agency in 2016.
Continued approval was contingent on verification of clinical benefit in a confirmatory study. With ANNOUNCE failing to confirm clinical benefit, Lilly said it will stop promoting Lartruvo while remaining in discussion with global regulators to determine the next steps for the drug.
AbbVie's Imbruvica Fails in Pancreatic Cancer Study: AbbVie's late-stage study evaluating its cancer drug, Imbruvica in combination with chemotherapy for metastatic pancreatic cancer failed to meet the primary endpoint of statistically-significant progression-free or overall survival benefit.
The RESOLVE study evaluated Imbruvica plus chemotherapy agents nab-paclitaxel and gemcitabine versus placebo in combination with these chemotherapy agents for the treatment of first-line metastatic pancreatic cancer, one of the most aggressive and deadliest forms of cancer. Imbruvica, currently approved for nine cancer indications, has multi-billion dollar potential and AbbVie is exploring the potential to expand Imbruvica's label into solid tumors and autoimmune diseases.
FDA Accepts Merck's sNDAs for HIV Medicines: Merck's supplemental new drug applications (sNDAs) looking for label expansion of its two new HIV drugs - Pifeltro and Delstrigo - was accepted by the FDA. Pifeltro and Delstrigo were approved by the FDA in August for the treatment of adults with no prior antiretroviral treatment experience. The sNDAs are looking to get the HIV drugs approved for use in treatment-experienced adults living with HIV-1 whose virus is suppressed to switch to Pifeltro (in combination with other antiretrovirals) or Delstrigo. The FDA is expected to give its decision on Sep 20. The sNDAs were based on data from the phase III DRIVE-SHIFT study. Data from the study, presented in the past, has shown non-inferior efficacy for those who switched to Delstrigo compared to those who continued on their baseline regimen.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss . This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Johnson & Johnson (JNJ): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Eli Lilly and Company (LLY): Free Stock Analysis Report
Merck & Co., Inc. (MRK): Free Stock Analysis Report
Bristol-Myers Squibb Company (BMY): Get Free Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks recently featured in the blog include: J&JJNJ , Bristol-MyersBMY , LillyLLYAbbVieABBV and MerckMRK . Meanwhile, Lilly and AbbVie faced pipeline setbacks with failure of their late-stage studies. Lilly's confirmatory study to convert soft tissue sarcoma drug Lartruvo's conditional approval to full approval and AbbVie's Imbruvica combination study in metastatic pancreatic cancer failed to meet their respective primary endpoints. | Lilly's confirmatory study to convert soft tissue sarcoma drug Lartruvo's conditional approval to full approval and AbbVie's Imbruvica combination study in metastatic pancreatic cancer failed to meet their respective primary endpoints. AbbVie's Imbruvica Fails in Pancreatic Cancer Study: AbbVie's late-stage study evaluating its cancer drug, Imbruvica in combination with chemotherapy for metastatic pancreatic cancer failed to meet the primary endpoint of statistically-significant progression-free or overall survival benefit. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Get Free Report To read this article on Zacks.com click here. | Lilly's confirmatory study to convert soft tissue sarcoma drug Lartruvo's conditional approval to full approval and AbbVie's Imbruvica combination study in metastatic pancreatic cancer failed to meet their respective primary endpoints. AbbVie's Imbruvica Fails in Pancreatic Cancer Study: AbbVie's late-stage study evaluating its cancer drug, Imbruvica in combination with chemotherapy for metastatic pancreatic cancer failed to meet the primary endpoint of statistically-significant progression-free or overall survival benefit. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Get Free Report To read this article on Zacks.com click here. | Lilly's confirmatory study to convert soft tissue sarcoma drug Lartruvo's conditional approval to full approval and AbbVie's Imbruvica combination study in metastatic pancreatic cancer failed to meet their respective primary endpoints. Stocks recently featured in the blog include: J&JJNJ , Bristol-MyersBMY , LillyLLYAbbVieABBV and MerckMRK . Meanwhile, Lilly and AbbVie faced pipeline setbacks with failure of their late-stage studies. |
25118.0 | 2019-01-28 00:00:00 UTC | Health Care Sector Update for 01/28/2019: ABBV,ALXN,TRVN,ARAY | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-01282019-abbvalxntrvnaray-2019-01-28 | nan | nan | Top Health Care Stocks
JNJ +0.26%
PFE -2.65%
ABT -3.00%
MRK -0.11%
AMGN -3.53%
Health care stocks were mostly lower, including a 0.9% decline for the NYSE Health Care Index in recent trade. Shares of health care companies in the S&P 500 also were down nearly 1.3% as a group while the Nasdaq Biotechnology index was falling over 2.1%.
Among health care stocks moving on news:
(+) AbbVie ( ABBV ) slipped more than 4% during Monday trading after the US Food and Drug Administration approved the use of a combination of its Imbruvica cancer medication in combination with Genentech's Gazyva monoclonal antibody in adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
In other sector news:
(+) Trevena ( TRVN ) surged about 100% higher after the US Food and Drug Administration agreed the current safety database for the company's oliceridine intravenous drug candidate will support labeling for the prospective opioid pain treatment at a maximum daily dose of 27 milligrams.
(-) Accuray ( ARAY ) was down over 4% on Monday. The company's Accuray Asia unit said it formed a joint venture with a China Isotope and Radiation subsidiary to build and sell radiation oncology systems in China.
(-) Alexion Pharmaceuticals ( ALXN ) fell almost 2% this afternoon. The company Monday said its Ultomiris drug candidate met its primary endpoint during phase III testing, with 53.6% of patients with atypical hemolytic uremic syndrome demonstrating complete thrombotic microangiopathy response defined by hematologic normalization and improved kidney function.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among health care stocks moving on news: (+) AbbVie ( ABBV ) slipped more than 4% during Monday trading after the US Food and Drug Administration approved the use of a combination of its Imbruvica cancer medication in combination with Genentech's Gazyva monoclonal antibody in adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. In other sector news: (+) Trevena ( TRVN ) surged about 100% higher after the US Food and Drug Administration agreed the current safety database for the company's oliceridine intravenous drug candidate will support labeling for the prospective opioid pain treatment at a maximum daily dose of 27 milligrams. The company Monday said its Ultomiris drug candidate met its primary endpoint during phase III testing, with 53.6% of patients with atypical hemolytic uremic syndrome demonstrating complete thrombotic microangiopathy response defined by hematologic normalization and improved kidney function. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Among health care stocks moving on news: (+) AbbVie ( ABBV ) slipped more than 4% during Monday trading after the US Food and Drug Administration approved the use of a combination of its Imbruvica cancer medication in combination with Genentech's Gazyva monoclonal antibody in adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. Top Health Care Stocks | Among health care stocks moving on news: (+) AbbVie ( ABBV ) slipped more than 4% during Monday trading after the US Food and Drug Administration approved the use of a combination of its Imbruvica cancer medication in combination with Genentech's Gazyva monoclonal antibody in adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. Health care stocks were mostly lower, including a 0.9% decline for the NYSE Health Care Index in recent trade. In other sector news: (+) Trevena ( TRVN ) surged about 100% higher after the US Food and Drug Administration agreed the current safety database for the company's oliceridine intravenous drug candidate will support labeling for the prospective opioid pain treatment at a maximum daily dose of 27 milligrams. | Among health care stocks moving on news: (+) AbbVie ( ABBV ) slipped more than 4% during Monday trading after the US Food and Drug Administration approved the use of a combination of its Imbruvica cancer medication in combination with Genentech's Gazyva monoclonal antibody in adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. Top Health Care Stocks Health care stocks were mostly lower, including a 0.9% decline for the NYSE Health Care Index in recent trade. |
25119.0 | 2019-01-28 00:00:00 UTC | U.S. STOCKS ON THE MOVE-Caterpillar, Novavax, GrubHub | ABBV | https://www.nasdaq.com/articles/us-stocks-move-caterpillar-novavax-grubhub-2019-01-28 | nan | nan | The Day Ahead newsletter:
The Morning News Call newsletter:
U.S. stock index futures dipped on Monday, as weak forecast from Caterpillar added to nerves about Chinese economy, while optimism over the end to the longest U.S. government shutdown in history faded
The top three NYSE percentage gainers premarket:
** Babcock & Wilcox Enterprises Inc, up 6.2 pct
** Jernigan Capital Inc, up 5.9 pct
** Azure Power Global Ltd, up 6.2 pct
The top three NYSE percentage losers premarket:
** Nordic American Offshore Ltd, down 40.6 pct
** Dynagas LNG Partners LP, down 35.3 pct
** Vale SA, down 11.6 pct
The top three Nasdaq percentage gainers premarket:
** Trevena Inc, up 25.7 pct
** Organogenesis Holdings Inc, up 12.3 pct
** Stellar Biotechnologies Inc, up 11.1 pct
The top three Nasdaq percentage losers premarket:
** iFresh Inc, down 12.9 pct
** Golden Ocean Group Ltd, down 9.1 pct
** Internet Gold-Golden Lines Ltd, down 7.1 pct
** Caterpillar: down 6.2 pct premarket
Caterpillar profit, forecast fall short of estimates; shares tumble
Reverses course to trade lower on Q4 miss, weak outlook
** Novavax Inc: up 4.1 pct premarket
H.C. Wainwright sees RSV vaccine making history, says "buy"
** GrubHub Inc : up 2.3 pct premarket
Gains after Credit Suisse upgrades to "outperform"
** Audio Codes Ltd : up 3.2 pct premarket
Rises on higher Q4 revenue
** Wayfair Inc : up 4.5 pct premarket
Gains as CS upgrades to 'outperform'
** Tempur Sealy International Inc: up 0.4 pct premarket
Barclays says macro drivers in bedding subsector attractive vs rest of retail
** Fiserv Inc: up 1.1 pct premarket
RBC upgrades rating after First Data acquisition
** Zynga Corp: up 1.6 pct premarket
KeyBanc ups to 'overweight' on confidence in its pipeline and execution
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The Day Ahead newsletter: The Morning News Call newsletter: U.S. stock index futures dipped on Monday, as weak forecast from Caterpillar added to nerves about Chinese economy, while optimism over the end to the longest U.S. government shutdown in history faded The top three NYSE percentage gainers premarket: ** Babcock & Wilcox Enterprises Inc, up 6.2 pct ** Jernigan Capital Inc, up 5.9 pct ** Azure Power Global Ltd, up 6.2 pct The top three NYSE percentage losers premarket: ** Nordic American Offshore Ltd, down 40.6 pct ** Dynagas LNG Partners LP, down 35.3 pct ** Vale SA, down 11.6 pct The top three Nasdaq percentage gainers premarket: ** Trevena Inc, up 25.7 pct ** Organogenesis Holdings Inc, up 12.3 pct ** Stellar Biotechnologies Inc, up 11.1 pct The top three Nasdaq percentage losers premarket: ** iFresh Inc, down 12.9 pct ** Golden Ocean Group Ltd, down 9.1 pct ** Internet Gold-Golden Lines Ltd, down 7.1 pct ** Caterpillar: down 6.2 pct premarket Caterpillar profit, forecast fall short of estimates; shares tumble Reverses course to trade lower on Q4 miss, weak outlook ** Novavax Inc: up 4.1 pct premarket H.C. Wainwright sees RSV vaccine making history, says "buy" ** GrubHub Inc : up 2.3 pct premarket Gains after Credit Suisse upgrades to "outperform" ** Audio Codes Ltd : up 3.2 pct premarket Rises on higher Q4 revenue ** Wayfair Inc : up 4.5 pct premarket Gains as CS upgrades to 'outperform' ** Tempur Sealy International Inc: up 0.4 pct premarket Barclays says macro drivers in bedding subsector attractive vs rest of retail ** Fiserv Inc: up 1.1 pct premarket RBC upgrades rating after First Data acquisition ** Zynga Corp: up 1.6 pct premarket KeyBanc ups to 'overweight' on confidence in its pipeline and execution The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The Day Ahead newsletter: The Morning News Call newsletter: U.S. stock index futures dipped on Monday, as weak forecast from Caterpillar added to nerves about Chinese economy, while optimism over the end to the longest U.S. government shutdown in history faded The top three NYSE percentage gainers premarket: ** Babcock & Wilcox Enterprises Inc, up 6.2 pct ** Jernigan Capital Inc, up 5.9 pct ** Azure Power Global Ltd, up 6.2 pct The top three NYSE percentage losers premarket: ** Nordic American Offshore Ltd, down 40.6 pct ** Dynagas LNG Partners LP, down 35.3 pct ** Vale SA, down 11.6 pct The top three Nasdaq percentage gainers premarket: ** Trevena Inc, up 25.7 pct ** Organogenesis Holdings Inc, up 12.3 pct ** Stellar Biotechnologies Inc, up 11.1 pct The top three Nasdaq percentage losers premarket: ** iFresh Inc, down 12.9 pct ** Golden Ocean Group Ltd, down 9.1 pct ** Internet Gold-Golden Lines Ltd, down 7.1 pct ** Caterpillar: down 6.2 pct premarket Caterpillar profit, forecast fall short of estimates; shares tumble Reverses course to trade lower on Q4 miss, weak outlook ** Novavax Inc: up 4.1 pct premarket H.C. Wainwright sees RSV vaccine making history, says "buy" ** GrubHub Inc : up 2.3 pct premarket Gains after Credit Suisse upgrades to "outperform" ** Audio Codes Ltd : up 3.2 pct premarket Rises on higher Q4 revenue ** Wayfair Inc : up 4.5 pct premarket Gains as CS upgrades to 'outperform' ** Tempur Sealy International Inc: up 0.4 pct premarket Barclays says macro drivers in bedding subsector attractive vs rest of retail ** Fiserv Inc: up 1.1 pct premarket RBC upgrades rating after First Data acquisition ** Zynga Corp: up 1.6 pct premarket KeyBanc ups to 'overweight' on confidence in its pipeline and execution The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The Day Ahead newsletter: The Morning News Call newsletter: U.S. stock index futures dipped on Monday, as weak forecast from Caterpillar added to nerves about Chinese economy, while optimism over the end to the longest U.S. government shutdown in history faded The top three NYSE percentage gainers premarket: ** Babcock & Wilcox Enterprises Inc, up 6.2 pct ** Jernigan Capital Inc, up 5.9 pct ** Azure Power Global Ltd, up 6.2 pct The top three NYSE percentage losers premarket: ** Nordic American Offshore Ltd, down 40.6 pct ** Dynagas LNG Partners LP, down 35.3 pct ** Vale SA, down 11.6 pct The top three Nasdaq percentage gainers premarket: ** Trevena Inc, up 25.7 pct ** Organogenesis Holdings Inc, up 12.3 pct ** Stellar Biotechnologies Inc, up 11.1 pct The top three Nasdaq percentage losers premarket: ** iFresh Inc, down 12.9 pct ** Golden Ocean Group Ltd, down 9.1 pct ** Internet Gold-Golden Lines Ltd, down 7.1 pct ** Caterpillar: down 6.2 pct premarket Caterpillar profit, forecast fall short of estimates; shares tumble Reverses course to trade lower on Q4 miss, weak outlook ** Novavax Inc: up 4.1 pct premarket H.C. Wainwright sees RSV vaccine making history, says "buy" ** GrubHub Inc : up 2.3 pct premarket Gains after Credit Suisse upgrades to "outperform" ** Audio Codes Ltd : up 3.2 pct premarket Rises on higher Q4 revenue ** Wayfair Inc : up 4.5 pct premarket Gains as CS upgrades to 'outperform' ** Tempur Sealy International Inc: up 0.4 pct premarket Barclays says macro drivers in bedding subsector attractive vs rest of retail ** Fiserv Inc: up 1.1 pct premarket RBC upgrades rating after First Data acquisition ** Zynga Corp: up 1.6 pct premarket KeyBanc ups to 'overweight' on confidence in its pipeline and execution The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The Day Ahead newsletter: The Morning News Call newsletter: U.S. stock index futures dipped on Monday, as weak forecast from Caterpillar added to nerves about Chinese economy, while optimism over the end to the longest U.S. government shutdown in history faded The top three NYSE percentage gainers premarket: ** Babcock & Wilcox Enterprises Inc, up 6.2 pct ** Jernigan Capital Inc, up 5.9 pct ** Azure Power Global Ltd, up 6.2 pct The top three NYSE percentage losers premarket: ** Nordic American Offshore Ltd, down 40.6 pct ** Dynagas LNG Partners LP, down 35.3 pct ** Vale SA, down 11.6 pct The top three Nasdaq percentage gainers premarket: ** Trevena Inc, up 25.7 pct ** Organogenesis Holdings Inc, up 12.3 pct ** Stellar Biotechnologies Inc, up 11.1 pct The top three Nasdaq percentage losers premarket: ** iFresh Inc, down 12.9 pct ** Golden Ocean Group Ltd, down 9.1 pct ** Internet Gold-Golden Lines Ltd, down 7.1 pct ** Caterpillar: down 6.2 pct premarket Caterpillar profit, forecast fall short of estimates; shares tumble Reverses course to trade lower on Q4 miss, weak outlook ** Novavax Inc: up 4.1 pct premarket H.C. Wainwright sees RSV vaccine making history, says "buy" ** GrubHub Inc : up 2.3 pct premarket Gains after Credit Suisse upgrades to "outperform" ** Audio Codes Ltd : up 3.2 pct premarket Rises on higher Q4 revenue ** Wayfair Inc : up 4.5 pct premarket Gains as CS upgrades to 'outperform' ** Tempur Sealy International Inc: up 0.4 pct premarket Barclays says macro drivers in bedding subsector attractive vs rest of retail ** Fiserv Inc: up 1.1 pct premarket RBC upgrades rating after First Data acquisition ** Zynga Corp: up 1.6 pct premarket KeyBanc ups to 'overweight' on confidence in its pipeline and execution The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
25120.0 | 2019-01-28 00:00:00 UTC | Monday Sector Laggards: Energy, Healthcare | ABBV | https://www.nasdaq.com/articles/monday-sector-laggards-energy-healthcare-2019-01-28 | nan | nan | In afternoon trading on Monday, Energy stocks are the worst performing sector, showing a 1.5% loss. Within that group, Halliburton Company (Symbol: HAL) and Baker Hughes, A GE Company (Symbol: BHGE) are two large stocks that are lagging, showing a loss of 3.2% and 2.6%, respectively. Among energy ETFs , one ETF following the sector is the Energy Select Sector SPDR ETF (Symbol: XLE), which is down 1.3% on the day, and up 8.27% year-to-date. Halliburton Company, meanwhile, is up 16.90% year-to-date, and Baker Hughes, A GE Company is up 6.42% year-to-date. Combined, HAL and BHGE make up approximately 3.3% of the underlying holdings of XLE.
The next worst performing sector is the Healthcare sector, showing a 1.4% loss. Among large Healthcare stocks, AbbVie Inc (Symbol: ABBV) and Amgen Inc (Symbol: AMGN) are the most notable, showing a loss of 4.4% and 4.0%, respectively. One ETF closely tracking Healthcare stocks is the Health Care Select Sector SPDR ETF ( XLV ), which is down 1.3% in midday trading, and up 1.43% on a year-to-date basis. AbbVie Inc, meanwhile, is down 15.33% year-to-date, and Amgen Inc, is down 1.97% year-to-date. Combined, ABBV and AMGN make up approximately 7.2% of the underlying holdings of XLV.
Comparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom:
Here's a snapshot of how the S&P 500 components within the various sectors are faring in afternoon trading on Monday. As you can see, none of the sectors are up on the day, while eight sectors are down.
25 Dividend Giants Widely Held By ETFs »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among large Healthcare stocks, AbbVie Inc (Symbol: ABBV) and Amgen Inc (Symbol: AMGN) are the most notable, showing a loss of 4.4% and 4.0%, respectively. AbbVie Inc, meanwhile, is down 15.33% year-to-date, and Amgen Inc, is down 1.97% year-to-date. Combined, ABBV and AMGN make up approximately 7.2% of the underlying holdings of XLV. | Among large Healthcare stocks, AbbVie Inc (Symbol: ABBV) and Amgen Inc (Symbol: AMGN) are the most notable, showing a loss of 4.4% and 4.0%, respectively. AbbVie Inc, meanwhile, is down 15.33% year-to-date, and Amgen Inc, is down 1.97% year-to-date. Combined, ABBV and AMGN make up approximately 7.2% of the underlying holdings of XLV. | Among large Healthcare stocks, AbbVie Inc (Symbol: ABBV) and Amgen Inc (Symbol: AMGN) are the most notable, showing a loss of 4.4% and 4.0%, respectively. AbbVie Inc, meanwhile, is down 15.33% year-to-date, and Amgen Inc, is down 1.97% year-to-date. Combined, ABBV and AMGN make up approximately 7.2% of the underlying holdings of XLV. | Among large Healthcare stocks, AbbVie Inc (Symbol: ABBV) and Amgen Inc (Symbol: AMGN) are the most notable, showing a loss of 4.4% and 4.0%, respectively. AbbVie Inc, meanwhile, is down 15.33% year-to-date, and Amgen Inc, is down 1.97% year-to-date. Combined, ABBV and AMGN make up approximately 7.2% of the underlying holdings of XLV. |
25121.0 | 2019-01-28 00:00:00 UTC | 5 Dividend Growth Stocks With Upside To Analyst Targets | ABBV | https://www.nasdaq.com/articles/5-dividend-growth-stocks-upside-analyst-targets-2019-01-28 | nan | nan | To become a "Dividend Aristocrat," a dividend paying company must accomplish an incredible feat: consistently increase shareholder dividends every year for at least 20 consecutive years. Companies with this kind of track record tend to attract a lot of investor attention - and furthermore, "tracking" funds that follow the Dividend Aristocrats Index must own them. With all of this demand for shares, dividend growth stocks can sometimes become "fully priced," where there isn't much upside to analyst targets.
But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. Which means, if the analysts are correct, these are five dividend growth stocks that could produce capital gains in addition to their growing dividend payments.
In the first table below, we present the five stocks. The recent share price, average analyst 12-month target price, and percentage upside to reach the analyst target are presented.
The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period - so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. To ballpark that total return potential, we have added the current yield to the analyst target price upside, in order to arrive at the 12-month total return potential:
Another consideration with dividend growth stocks is just how much the dividend is growing . We looked up the trailing twelve months worth o f dividends shareholders of each of the above five companies have collected, and then also looked up the same number for the prior trailing twelve months. This gives us a rough yardstick to see how much the dividend has grown, from one trailing twelve month period to another.
These five stocks are part of our full Dividend Aristocrats List . The average analyst target price data upon which this article was based, is courtesy of data provided by Zacks Investment Research via Quandl.com .
Get the latest Zacks research report on PII - FREE
Get the latest Zacks research report on WTR - FREE
Dividend Growth Stocks: 25 Aristocrats »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | With all of this demand for shares, dividend growth stocks can sometimes become "fully priced," where there isn't much upside to analyst targets. To ballpark that total return potential, we have added the current yield to the analyst target price upside, in order to arrive at the 12-month total return potential: Another consideration with dividend growth stocks is just how much the dividend is growing . Get the latest Zacks research report on PII - FREE Get the latest Zacks research report on WTR - FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The recent share price, average analyst 12-month target price, and percentage upside to reach the analyst target are presented. The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period - so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. Get the latest Zacks research report on PII - FREE Get the latest Zacks research report on WTR - FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period - so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. To ballpark that total return potential, we have added the current yield to the analyst target price upside, in order to arrive at the 12-month total return potential: Another consideration with dividend growth stocks is just how much the dividend is growing . | But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. The recent share price, average analyst 12-month target price, and percentage upside to reach the analyst target are presented. Get the latest Zacks research report on PII - FREE Get the latest Zacks research report on WTR - FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
25122.0 | 2019-01-27 00:00:00 UTC | 3 Reasons AbbVie Investors Aren't Too Worried About Humira Anymore | ABBV | https://www.nasdaq.com/articles/3-reasons-abbvie-investors-arent-too-worried-about-humira-anymore-2019-01-27 | nan | nan | AbbVie (NYSE: ABBV) investors have been dreading this moment since the company's inception in 2013. International Humira sales tumbled during the fourth quarter, following the loss of patent-protected market exclusivity.
Sales of the world's top-selling drug probably peaked 2018, but AbbVie investors have plenty to look forward to in the years to come. Here are four good reasons not to be afraid of holding those AbbVie shares for the long run.
Four more years
During the fourth quarter, international Humira sales fell 14.8% from the previous year because low-cost biosimilar versions launched throughout the EU in October. In the U.S., though, annual Humira sales rose 10.7% in 2018 to $13.7 billion, and they'll probably continue rising for at least a few more years.
AbbVie's already signed seven settlement agreements, with potential competitors trying to launch biosimilar versions of Humira in its domestic market. The thicket of patents surrounding the rheumatoid arthritis drug should allow U.S. sales to nearly offset biosimilar competition in the EU through most of 2023.
A strong lineup of more recently launched drugs and a couple more near the finish line make the upcoming losses a lot less terrifying. In fact, Humira losses might not seem like such a big deal four years from now, for these four reasons.
1. Imbruvica isn't finished growing yet
Imbruvica sales have surged since easy-to-swallow tablets became the first chemo-free option for adults newly diagnosed with the most common form of leukemia. AbbVie's share of annual Imbruvica sales surged 39% in 2018 to $3.6 billion, and there won't be much to prevent it from going a lot further.
Although Imbruvica beat standard chemo on its own, many first-line chronic lymphocytic leukemia (CLL) patients have been receiving combinations of standard chemo plus a drug from Roche (NASDAQOTH: RHHBY) called Gazyva. Investors worried this treatment option would be hard for Imbruvica to compete with can rest easy.
Right now, the FDA is reviewing an application that will probably make Imbruvica plus Gazyva the new standard before the year is finished. During the pivotal Illuminate trial, Imbruvica plus Gazyva wiped the floor with the chemo-containing combination. Patients given the Gazyva-plus-Imbruvica combination were 77% less likely to show signs of disease progression than those given chemo plus Gazyva.
2. Venclexta's next
In 2016, AbbVie launched Venclexta in partnership with Roche, and sales got off to a slow start but they're about to pick up the pace. During the fourth quarter, the FDA approved a combination of low-dose chemotherapy plus Venclexta for the front-line treatment of acute myeloid leukemia (AML), a malignancy more common among older adults.
Venclexta's AML approval is somewhat limited to patients over 75, or too frail to survive an intense round of chemotherapy. This description fits most of the AML population, which is the second most commonly diagnosed form of leukemia. That means we can expect annual Venclexta sales to reach over $2 billion from this population by 2023.
Venclexta will probably earn another several billion annually as part of a combination therapy for CLL patients who relapse after their first round of treatment. A combination of Venclexta plus Roche's Rituxan that the partners call VenR is already approved to treat this group, and results from the Murano study that AbbVie presented in December are already boosting its popularity.
After 36 months, 71.4% of patients who received Venclexta plus Rituxan still hadn't shown any signs of disease progression. Progression-free survival was just 15.2% among patients treated with Rituxan plus chemo.
As this combination therapy gives more CLL patients who fail their first round of treatment a second chance at long-term survival, Venclexta sales will surge. Second-line CLL sales could begin adding another $2 billion to AbbVie's top line each year by the time U.S. Humira sales start sliding.
3. Another big step for Orilissa
By 2025, AbbVie expects at least $2 billion annually from the first new treatment to reduce pain from abnormal growths found on the outside of the uterus. This condition, called endometriosis, affects around one in 10 women of reproductive age. Last year the FDA approved Orilissa to treat those who experience endometriosis pain by preventing the release of a hormone responsible for the disorder.
Orilissa also helps reduce the size of abnormal growths on the inside of the uterus called uterine fibroids. This condition affects roughly three-quarters of women by age 50, and it's the leading reason to seek a hysterectomy. AbbVie's new tablet significantly reduced bleeding for 87.9% of women with uterine fibroids, and AbbVie will probably send an application to the FDA for this population in the first half of 2019.
4. Late-stage hopefuls
AbbVie has a couple of immunology drugs near the finish line that might have what it takes to offset Humira losses. The FDA began reviewing an application for an experimental psoriasis treatment called risankizumab last April, which means an approval decision is expected before the end of February. The injection beat the competition in head-to-head trials supporting its application and could outperform in the commercial setting as well.
More recently, the FDA began reviewing an application for upadacitinib, an oral rheumatoid arthritis treatment that scored high marks for efficacy during clinical trials. Humira's a popular treatment for psoriasis and rheumatoid arthritis. With a bit of luck, AbbVie will be able to transition many of these patients to new and improved options before 2023 rolls around.
Time to buy?
Combined, upadacitinib, risankizumab, Venclexta, Imbruvica, and Orilissa probably have a chance to offset Humira losses for investors who plan on holding this stock for the long term.
If you don't already own shares of AbbVie, now might be a good time to pick some up. The stock offers a 5.3% yield at recent prices that might not soar in the years ahead, but AbbVie should be able to push it forward much faster than the rate of inflation.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of November 14, 2018
Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie (NYSE: ABBV) investors have been dreading this moment since the company's inception in 2013. International Humira sales tumbled during the fourth quarter, following the loss of patent-protected market exclusivity. A combination of Venclexta plus Roche's Rituxan that the partners call VenR is already approved to treat this group, and results from the Murano study that AbbVie presented in December are already boosting its popularity. Sales of the world's top-selling drug probably peaked 2018, but AbbVie investors have plenty to look forward to in the years to come. | AbbVie (NYSE: ABBV) investors have been dreading this moment since the company's inception in 2013. International Humira sales tumbled during the fourth quarter, following the loss of patent-protected market exclusivity. Sales of the world's top-selling drug probably peaked 2018, but AbbVie investors have plenty to look forward to in the years to come. Here are four good reasons not to be afraid of holding those AbbVie shares for the long run. | Venclexta's next In 2016, AbbVie launched Venclexta in partnership with Roche, and sales got off to a slow start but they're about to pick up the pace. Second-line CLL sales could begin adding another $2 billion to AbbVie's top line each year by the time U.S. Humira sales start sliding. AbbVie (NYSE: ABBV) investors have been dreading this moment since the company's inception in 2013. International Humira sales tumbled during the fourth quarter, following the loss of patent-protected market exclusivity. | AbbVie's share of annual Imbruvica sales surged 39% in 2018 to $3.6 billion, and there won't be much to prevent it from going a lot further. AbbVie (NYSE: ABBV) investors have been dreading this moment since the company's inception in 2013. International Humira sales tumbled during the fourth quarter, following the loss of patent-protected market exclusivity. Sales of the world's top-selling drug probably peaked 2018, but AbbVie investors have plenty to look forward to in the years to come. |
25123.0 | 2019-01-25 00:00:00 UTC | AbbVie (ABBV) Misses Q4 Earnings and Revenues, Shares Down | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-misses-q4-earnings-and-revenues-shares-down-2019-01-25 | nan | nan | North Chicago, IL-based AbbVie Inc.ABBV is best known for its autoimmune disease drug, Humira. AbbVie's flagship product Humira is approved for several indications like rheumatoid arthritis (moderate to severe), moderately to severely active polyarticular juvenile idiopathic arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease (moderate to severe), ulcerative colitis (moderate to severe), axial spondyloarthritis, pediatric Crohn's disease, chronic plaque psoriasis (moderate to severe), and hidradenitis suppurativa (moderate to severe. Other key products include Imbruvica (cancer) and Mavyret (hepatitis C virus (HCV) treatment).
Performance of other drugs, namely Duodopa and Creon, are also encouraging. Leukemia drug, Venclexta, has also shown rapid growth
Humira, is a major contributor to AbbVie's top line. While Humira will remain the key growth driver at AbbVie, Imbruvica and Mavyret are fast becoming important revenue generators.
AbbVie's performance has been impressive, with the pharmaceuticals company delivering positive surprises in all of the past four quarter. The avera ge earnings beat over the last four quarters is 3.54%.
Currently, AbbVie has a Zacks Rank #3 (Hold), but that could definitely change following the company's earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: AbbVie's fourth-quarter earnings came in at $1.90 per share, missing the Zacks Consensus Estimate of $1.92.
Revenues: AbbVie posted revenues of $8.31 billion, which also missed the Zacks Consensus Estimate of $8.36 billion.
Key Stats: Humira sales came in at $4.9 billion, a slow growth of 1.4% year over year excluding currency impact due to biosimilar impact in international market. Fourth-quarter Imbruvica net revenues were $1 billion, up 42% year over year. HCV sales more than doubled year-over year to $862 million on strong sales of Mavyret.
2019 Outlook: AbbVie provided its outlook for 2019. The company expects its adjusted EPS in the range of $8.65 to $8.75. The Zacks Consensus Estimate is currently pegged at $8.68 per share.
Share Price Impact: Shares fell more than 2.2% in pre-market trading .
Check back later for our full write up on this AbbVie earnings report.
AbbVie Inc. Price and Consensus
AbbVie Inc. Price and Consensus | AbbVie Inc. Quote
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Get Free Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Leukemia drug, Venclexta, has also shown rapid growth Humira, is a major contributor to AbbVie's top line. While Humira will remain the key growth driver at AbbVie, Imbruvica and Mavyret are fast becoming important revenue generators. AbbVie's performance has been impressive, with the pharmaceuticals company delivering positive surprises in all of the past four quarter. | AbbVie's flagship product Humira is approved for several indications like rheumatoid arthritis (moderate to severe), moderately to severely active polyarticular juvenile idiopathic arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease (moderate to severe), ulcerative colitis (moderate to severe), axial spondyloarthritis, pediatric Crohn's disease, chronic plaque psoriasis (moderate to severe), and hidradenitis suppurativa (moderate to severe. Revenues: AbbVie posted revenues of $8.31 billion, which also missed the Zacks Consensus Estimate of $8.36 billion. AbbVie Inc. Price and Consensus AbbVie Inc. Price and Consensus | AbbVie Inc. Quote The Hottest Tech Mega-Trend of All Last year, it generated $8 billion in global revenues. | AbbVie's flagship product Humira is approved for several indications like rheumatoid arthritis (moderate to severe), moderately to severely active polyarticular juvenile idiopathic arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease (moderate to severe), ulcerative colitis (moderate to severe), axial spondyloarthritis, pediatric Crohn's disease, chronic plaque psoriasis (moderate to severe), and hidradenitis suppurativa (moderate to severe. Revenues: AbbVie posted revenues of $8.31 billion, which also missed the Zacks Consensus Estimate of $8.36 billion. AbbVie Inc. Price and Consensus AbbVie Inc. Price and Consensus | AbbVie Inc. Quote The Hottest Tech Mega-Trend of All Last year, it generated $8 billion in global revenues. | While Humira will remain the key growth driver at AbbVie, Imbruvica and Mavyret are fast becoming important revenue generators. Currently, AbbVie has a Zacks Rank #3 (Hold), but that could definitely change following the company's earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below: Earnings: AbbVie's fourth-quarter earnings came in at $1.90 per share, missing the Zacks Consensus Estimate of $1.92. |
25124.0 | 2019-01-25 00:00:00 UTC | Health Care Sector Update for 01/25/2019: IDXG, RMD, ABBV, JNJ, PFE, MRK, ABT, AMGN | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-01252019-idxg-rmd-abbv-jnj-pfe-mrk-abt-amgn-2019-01-25 | nan | nan | Top Health Care Stocks:
JNJ: +0.22%
PFE: +0.10%
ABT: +0.25%
MRK: +0.59%
AMGN: Flat
Most health care stocks were gaining in Friday's pre-bell trading.
Stocks moving on news include:
(-) Interpace Diagnostics Group ( IDXG ), which was declining by more than 14% after it priced its previously
announced public offering of 9.3 million common shares at $0.75 apiece, for gross proceeds of $7 million.
(-) ResMed's ( RMD ) was down 12% as its adjusted EPS was flat at $1.00 in Q2 from a year earlier, exceeding analysts' estimates of $0.95 in a Capital IQ poll.
(-) AbbVie ( ABBV ) was more than 3% lower after it posted $1.90 earnings per share on a non-GAAP basis, higher than $1.48 in the year-ago period, but missing the $1.93 consensus EPS estimate provided by Capital IQ.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (-) AbbVie ( ABBV ) was more than 3% lower after it posted $1.90 earnings per share on a non-GAAP basis, higher than $1.48 in the year-ago period, but missing the $1.93 consensus EPS estimate provided by Capital IQ. AMGN: Flat Most health care stocks were gaining in Friday's pre-bell trading. (-) ResMed's ( RMD ) was down 12% as its adjusted EPS was flat at $1.00 in Q2 from a year earlier, exceeding analysts' estimates of $0.95 in a Capital IQ poll. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (-) AbbVie ( ABBV ) was more than 3% lower after it posted $1.90 earnings per share on a non-GAAP basis, higher than $1.48 in the year-ago period, but missing the $1.93 consensus EPS estimate provided by Capital IQ. AMGN: Flat Most health care stocks were gaining in Friday's pre-bell trading. | (-) AbbVie ( ABBV ) was more than 3% lower after it posted $1.90 earnings per share on a non-GAAP basis, higher than $1.48 in the year-ago period, but missing the $1.93 consensus EPS estimate provided by Capital IQ. AMGN: Flat Most health care stocks were gaining in Friday's pre-bell trading. Stocks moving on news include: (-) Interpace Diagnostics Group ( IDXG ), which was declining by more than 14% after it priced its previously announced public offering of 9.3 million common shares at $0.75 apiece, for gross proceeds of $7 million. | (-) AbbVie ( ABBV ) was more than 3% lower after it posted $1.90 earnings per share on a non-GAAP basis, higher than $1.48 in the year-ago period, but missing the $1.93 consensus EPS estimate provided by Capital IQ. Top Health Care Stocks: AMGN: Flat Most health care stocks were gaining in Friday's pre-bell trading. |
25125.0 | 2019-01-25 00:00:00 UTC | U.S. STOCKS ON THE MOVE-Intel, AbbVie, Ford, PG&E, Amazon, Starbucks | ABBV | https://www.nasdaq.com/articles/us-stocks-move-intel-abbvie-ford-pge-amazon-starbucks-2019-01-25 | nan | nan | The Day Ahead newsletter:
The Morning News Call newsletter:
U.S. stocks rose on Friday, with technology and consumer discretionary sectors leading a rally, as upbeat earnings reports helped investors overlook trade and growth worries.
The top three S&P 500 percentage gainers:
** Western Digital Corp, up 5.8 pct
** Coty Inc, up 5.6 pct
** Freeportmcmoran, up 5.3 pct
The top three S&P 500 percentage losers:
** Resmed Inc, down 17.1 pct
** Intel Corp, down 6.5 pct
** Abbvie Inc, down 6.2 pct
The top NYSE percentage gainers:
** Bristow Group, up 24.4 pct
** Centrus Energy C, up 12.7 pct
The top NYSE percentage losers:
** Resmed Inc, down 17.1 pct
** Pg&E Corp, down 11.4 pct
The top three Nasdaq percentage gainers:
** Organogenisis Holdings Inc, up 42.3 pct
** Rand Cap Corp, up 33.6 pct
** Clearone Inc, up 24 pct
The top three Nasdaq percentage losers:
** Toughbuilt Industries Inc, down 15.9 pct
** Titan Medical Inc, down 11.6 pct
** Helius Medical Technologies Inc, down 10.6 pct
** Intel Corp: down 6.5 pct
Weak forecast drags chipmaker in the red; Eyes worst day in 6 months
** AbbVie Inc: down 6.1 pct
Falls on forecast of steeper decline in ex-U.S. Humira sales
** Ford Motor Co: up 3.1 pct
Jumps on plan to double FY oper profit
** NuCana Plc: up 7.4 pct
Rises after company scraps stock deal
** Resmed Inc: down 16.4 pct
Q2 revenue lags estimates; JPM downgrade deepens misery
** e.l.f. Beauty Inc: up 4.2 pct
Marathon Partners urges company to conduct review, shares up
** Aptose Biosciences Inc: up 3.4 pct
Rises as Oppenheimer starts with outperform rating
** Rand Capital Corp: up 29.3 pct
Soars on $25 mln investment, plans to declare special dividend
** Midatech Pharma Plc: down 25.0 pct
Slips as company raises going concern doubts
** Canopy Growth Corp: up 7.6 pct
Higher as Piper hikes price target by 50 pct
** PG&E Corp: down 11.6 pct
Drops as 2017 fire relief does not alter bankruptcy plan
** Intuitive Surgical Inc: down 2.2 pct
Falls on steep increase in 2019 operating expenses
** Amazon.com Inc: up 1.5 pct
Amazon's upbeat Q4 led by AWS, advertising - Cowen
** Interpace Diagnostics Group Inc: down 5.6 pct
Falls on $7 mln stock deal
** Western Digital Corp: up 6.9 pct
Street View: Western Digital to inflect higher H2 onward
** Union Pacific Corp: up 0.1 pct
Street View: Union Pacific 2019 outlook positive, to build operating momentum
** Starbucks Corp: up 4.1 pct
Street View: Starbucks likely to continue growing in U.S., China
** Overstock.com Inc: up 11.8 pct
Overstock.com: Rises after tZERO security trading platform begins trading
The 11 major S&P 500 sectors:
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 percentage gainers: ** Western Digital Corp, up 5.8 pct ** Coty Inc, up 5.6 pct ** Freeportmcmoran, up 5.3 pct The top three S&P 500 percentage losers: ** Resmed Inc, down 17.1 pct ** Intel Corp, down 6.5 pct ** Abbvie Inc, down 6.2 pct The top NYSE percentage gainers: ** Bristow Group, up 24.4 pct ** Centrus Energy C, up 12.7 pct The top NYSE percentage losers: ** Resmed Inc, down 17.1 pct ** Pg&E Corp, down 11.4 pct The top three Nasdaq percentage gainers: ** Organogenisis Holdings Inc, up 42.3 pct ** Rand Cap Corp, up 33.6 pct ** Clearone Inc, up 24 pct The top three Nasdaq percentage losers: ** Toughbuilt Industries Inc, down 15.9 pct ** Titan Medical Inc, down 11.6 pct ** Helius Medical Technologies Inc, down 10.6 pct ** Intel Corp: down 6.5 pct Weak forecast drags chipmaker in the red; Eyes worst day in 6 months ** AbbVie Inc: down 6.1 pct Falls on forecast of steeper decline in ex-U.S. Humira sales ** Ford Motor Co: up 3.1 pct Jumps on plan to double FY oper profit ** NuCana Plc: up 7.4 pct Rises after company scraps stock deal ** Resmed Inc: down 16.4 pct Q2 revenue lags estimates; JPM downgrade deepens misery ** e.l.f. The Day Ahead newsletter: The Morning News Call newsletter: U.S. stocks rose on Friday, with technology and consumer discretionary sectors leading a rally, as upbeat earnings reports helped investors overlook trade and growth worries. Beauty Inc: up 4.2 pct Marathon Partners urges company to conduct review, shares up ** Aptose Biosciences Inc: up 3.4 pct Rises as Oppenheimer starts with outperform rating ** Rand Capital Corp: up 29.3 pct Soars on $25 mln investment, plans to declare special dividend ** Midatech Pharma Plc: down 25.0 pct Slips as company raises going concern doubts ** Canopy Growth Corp: up 7.6 pct Higher as Piper hikes price target by 50 pct ** PG&E Corp: down 11.6 pct Drops as 2017 fire relief does not alter bankruptcy plan ** Intuitive Surgical Inc: down 2.2 pct Falls on steep increase in 2019 operating expenses ** Amazon.com Inc: up 1.5 pct Amazon's upbeat Q4 led by AWS, advertising - Cowen ** Interpace Diagnostics Group Inc: down 5.6 pct Falls on $7 mln stock deal ** Western Digital Corp: up 6.9 pct Street View: Western Digital to inflect higher H2 onward ** Union Pacific Corp: up 0.1 pct Street View: Union Pacific 2019 outlook positive, to build operating momentum ** Starbucks Corp: up 4.1 pct Street View: Starbucks likely to continue growing in U.S., China ** Overstock.com Inc: up 11.8 pct Overstock.com: Rises after tZERO security trading platform begins trading The 11 major S&P 500 sectors: The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 percentage gainers: ** Western Digital Corp, up 5.8 pct ** Coty Inc, up 5.6 pct ** Freeportmcmoran, up 5.3 pct The top three S&P 500 percentage losers: ** Resmed Inc, down 17.1 pct ** Intel Corp, down 6.5 pct ** Abbvie Inc, down 6.2 pct The top NYSE percentage gainers: ** Bristow Group, up 24.4 pct ** Centrus Energy C, up 12.7 pct The top NYSE percentage losers: ** Resmed Inc, down 17.1 pct ** Pg&E Corp, down 11.4 pct The top three Nasdaq percentage gainers: ** Organogenisis Holdings Inc, up 42.3 pct ** Rand Cap Corp, up 33.6 pct ** Clearone Inc, up 24 pct The top three Nasdaq percentage losers: ** Toughbuilt Industries Inc, down 15.9 pct ** Titan Medical Inc, down 11.6 pct ** Helius Medical Technologies Inc, down 10.6 pct ** Intel Corp: down 6.5 pct Weak forecast drags chipmaker in the red; Eyes worst day in 6 months ** AbbVie Inc: down 6.1 pct Falls on forecast of steeper decline in ex-U.S. Humira sales ** Ford Motor Co: up 3.1 pct Jumps on plan to double FY oper profit ** NuCana Plc: up 7.4 pct Rises after company scraps stock deal ** Resmed Inc: down 16.4 pct Q2 revenue lags estimates; JPM downgrade deepens misery ** e.l.f. The Day Ahead newsletter: The Morning News Call newsletter: U.S. stocks rose on Friday, with technology and consumer discretionary sectors leading a rally, as upbeat earnings reports helped investors overlook trade and growth worries. Beauty Inc: up 4.2 pct Marathon Partners urges company to conduct review, shares up ** Aptose Biosciences Inc: up 3.4 pct Rises as Oppenheimer starts with outperform rating ** Rand Capital Corp: up 29.3 pct Soars on $25 mln investment, plans to declare special dividend ** Midatech Pharma Plc: down 25.0 pct Slips as company raises going concern doubts ** Canopy Growth Corp: up 7.6 pct Higher as Piper hikes price target by 50 pct ** PG&E Corp: down 11.6 pct Drops as 2017 fire relief does not alter bankruptcy plan ** Intuitive Surgical Inc: down 2.2 pct Falls on steep increase in 2019 operating expenses ** Amazon.com Inc: up 1.5 pct Amazon's upbeat Q4 led by AWS, advertising - Cowen ** Interpace Diagnostics Group Inc: down 5.6 pct Falls on $7 mln stock deal ** Western Digital Corp: up 6.9 pct Street View: Western Digital to inflect higher H2 onward ** Union Pacific Corp: up 0.1 pct Street View: Union Pacific 2019 outlook positive, to build operating momentum ** Starbucks Corp: up 4.1 pct Street View: Starbucks likely to continue growing in U.S., China ** Overstock.com Inc: up 11.8 pct Overstock.com: Rises after tZERO security trading platform begins trading The 11 major S&P 500 sectors: The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 percentage gainers: ** Western Digital Corp, up 5.8 pct ** Coty Inc, up 5.6 pct ** Freeportmcmoran, up 5.3 pct The top three S&P 500 percentage losers: ** Resmed Inc, down 17.1 pct ** Intel Corp, down 6.5 pct ** Abbvie Inc, down 6.2 pct The top NYSE percentage gainers: ** Bristow Group, up 24.4 pct ** Centrus Energy C, up 12.7 pct The top NYSE percentage losers: ** Resmed Inc, down 17.1 pct ** Pg&E Corp, down 11.4 pct The top three Nasdaq percentage gainers: ** Organogenisis Holdings Inc, up 42.3 pct ** Rand Cap Corp, up 33.6 pct ** Clearone Inc, up 24 pct The top three Nasdaq percentage losers: ** Toughbuilt Industries Inc, down 15.9 pct ** Titan Medical Inc, down 11.6 pct ** Helius Medical Technologies Inc, down 10.6 pct ** Intel Corp: down 6.5 pct Weak forecast drags chipmaker in the red; Eyes worst day in 6 months ** AbbVie Inc: down 6.1 pct Falls on forecast of steeper decline in ex-U.S. Humira sales ** Ford Motor Co: up 3.1 pct Jumps on plan to double FY oper profit ** NuCana Plc: up 7.4 pct Rises after company scraps stock deal ** Resmed Inc: down 16.4 pct Q2 revenue lags estimates; JPM downgrade deepens misery ** e.l.f. The Day Ahead newsletter: The Morning News Call newsletter: U.S. stocks rose on Friday, with technology and consumer discretionary sectors leading a rally, as upbeat earnings reports helped investors overlook trade and growth worries. Beauty Inc: up 4.2 pct Marathon Partners urges company to conduct review, shares up ** Aptose Biosciences Inc: up 3.4 pct Rises as Oppenheimer starts with outperform rating ** Rand Capital Corp: up 29.3 pct Soars on $25 mln investment, plans to declare special dividend ** Midatech Pharma Plc: down 25.0 pct Slips as company raises going concern doubts ** Canopy Growth Corp: up 7.6 pct Higher as Piper hikes price target by 50 pct ** PG&E Corp: down 11.6 pct Drops as 2017 fire relief does not alter bankruptcy plan ** Intuitive Surgical Inc: down 2.2 pct Falls on steep increase in 2019 operating expenses ** Amazon.com Inc: up 1.5 pct Amazon's upbeat Q4 led by AWS, advertising - Cowen ** Interpace Diagnostics Group Inc: down 5.6 pct Falls on $7 mln stock deal ** Western Digital Corp: up 6.9 pct Street View: Western Digital to inflect higher H2 onward ** Union Pacific Corp: up 0.1 pct Street View: Union Pacific 2019 outlook positive, to build operating momentum ** Starbucks Corp: up 4.1 pct Street View: Starbucks likely to continue growing in U.S., China ** Overstock.com Inc: up 11.8 pct Overstock.com: Rises after tZERO security trading platform begins trading The 11 major S&P 500 sectors: The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The top three S&P 500 percentage gainers: ** Western Digital Corp, up 5.8 pct ** Coty Inc, up 5.6 pct ** Freeportmcmoran, up 5.3 pct The top three S&P 500 percentage losers: ** Resmed Inc, down 17.1 pct ** Intel Corp, down 6.5 pct ** Abbvie Inc, down 6.2 pct The top NYSE percentage gainers: ** Bristow Group, up 24.4 pct ** Centrus Energy C, up 12.7 pct The top NYSE percentage losers: ** Resmed Inc, down 17.1 pct ** Pg&E Corp, down 11.4 pct The top three Nasdaq percentage gainers: ** Organogenisis Holdings Inc, up 42.3 pct ** Rand Cap Corp, up 33.6 pct ** Clearone Inc, up 24 pct The top three Nasdaq percentage losers: ** Toughbuilt Industries Inc, down 15.9 pct ** Titan Medical Inc, down 11.6 pct ** Helius Medical Technologies Inc, down 10.6 pct ** Intel Corp: down 6.5 pct Weak forecast drags chipmaker in the red; Eyes worst day in 6 months ** AbbVie Inc: down 6.1 pct Falls on forecast of steeper decline in ex-U.S. Humira sales ** Ford Motor Co: up 3.1 pct Jumps on plan to double FY oper profit ** NuCana Plc: up 7.4 pct Rises after company scraps stock deal ** Resmed Inc: down 16.4 pct Q2 revenue lags estimates; JPM downgrade deepens misery ** e.l.f. The Day Ahead newsletter: The Morning News Call newsletter: U.S. stocks rose on Friday, with technology and consumer discretionary sectors leading a rally, as upbeat earnings reports helped investors overlook trade and growth worries. Beauty Inc: up 4.2 pct Marathon Partners urges company to conduct review, shares up ** Aptose Biosciences Inc: up 3.4 pct Rises as Oppenheimer starts with outperform rating ** Rand Capital Corp: up 29.3 pct Soars on $25 mln investment, plans to declare special dividend ** Midatech Pharma Plc: down 25.0 pct Slips as company raises going concern doubts ** Canopy Growth Corp: up 7.6 pct Higher as Piper hikes price target by 50 pct ** PG&E Corp: down 11.6 pct Drops as 2017 fire relief does not alter bankruptcy plan ** Intuitive Surgical Inc: down 2.2 pct Falls on steep increase in 2019 operating expenses ** Amazon.com Inc: up 1.5 pct Amazon's upbeat Q4 led by AWS, advertising - Cowen ** Interpace Diagnostics Group Inc: down 5.6 pct Falls on $7 mln stock deal ** Western Digital Corp: up 6.9 pct Street View: Western Digital to inflect higher H2 onward ** Union Pacific Corp: up 0.1 pct Street View: Union Pacific 2019 outlook positive, to build operating momentum ** Starbucks Corp: up 4.1 pct Street View: Starbucks likely to continue growing in U.S., China ** Overstock.com Inc: up 11.8 pct Overstock.com: Rises after tZERO security trading platform begins trading The 11 major S&P 500 sectors: The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
25126.0 | 2019-01-25 00:00:00 UTC | AbbVie Earnings: ABBV Stock Falters on Q4 Miss | ABBV | https://www.nasdaq.com/articles/abbvie-earnings-abbv-stock-falters-q4-miss-2019-01-25 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
AbbVie earnings for the fourth quarter of 2018 saw ABBV stock falling today.
Source: Shutterstock
AbbVie (NYSE: ABBV ) reported earnings per share of $1.90 for the fourth quarter of the year. This is an increase over the company's earnings per share of $1.48 from the same period of the year prior. However, it was bad news for ABBV stock by missing Wall Street's earnings per share estimate of $1.94 for the quarter.
The most recent AbbVie earnings report also includes a net loss of $1.83 billion. This is a drop from the company's net income of $52 million reported in the fourth quarter of 2017.
Operating loss reported in AbbVie earnings for the fourth quarter of 2018 came in at $2.44 billion. The biopharmaceutical company reported operating income of $1.78 billion during the same time last year.
The AbbVie earnings report for the fourth quarter of the year also has it bringing in revenue of $8.31 billion . This is up from the company's revenue of $7.74 billion reported in the fourth quarter of the previous year. Despite this increase, it was still a blow to ABBV stock by coming in below analysts' revenue estimate of $8.38 billion for the period.
5 Best Stocks to Buy and Hold for the Long Term
The AbbVie earnings report for the fourth quarter of 2018 also includes its outlook for 2019. The company is expecting earnings per share for the year to range from $8.65 to $8.75. Wall Street is looking for earnings per share of $8.71 for the full year of 2019.
ABBV stock was down 6% as of Friday morning.
More From InvestorPlace
2 Toxic Pot Stocks You Should Avoid
7 Semiconductor Stocks to Buy Now
10 of the Best Stocks to Invest In for February
5 Top Stocks for a FOMO Rally
As of this writing, William White did not hold a position in any of the aforementioned securities.
Compare Brokers
The post AbbVie Earnings: ABBV Stock Falters on Q4 Miss appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | However, it was bad news for ABBV stock by missing Wall Street's earnings per share estimate of $1.94 for the quarter. 5 Best Stocks to Buy and Hold for the Long Term The AbbVie earnings report for the fourth quarter of 2018 also includes its outlook for 2019. Compare Brokers The post AbbVie Earnings: ABBV Stock Falters on Q4 Miss appeared first on InvestorPlace . | InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie earnings for the fourth quarter of 2018 saw ABBV stock falling today. However, it was bad news for ABBV stock by missing Wall Street's earnings per share estimate of $1.94 for the quarter. The most recent AbbVie earnings report also includes a net loss of $1.83 billion. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie earnings for the fourth quarter of 2018 saw ABBV stock falling today. Source: Shutterstock AbbVie (NYSE: ABBV ) reported earnings per share of $1.90 for the fourth quarter of the year. The AbbVie earnings report for the fourth quarter of the year also has it bringing in revenue of $8.31 billion . | InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie earnings for the fourth quarter of 2018 saw ABBV stock falling today. Source: Shutterstock AbbVie (NYSE: ABBV ) reported earnings per share of $1.90 for the fourth quarter of the year. However, it was bad news for ABBV stock by missing Wall Street's earnings per share estimate of $1.94 for the quarter. |
25127.0 | 2019-01-25 00:00:00 UTC | Congressional Activities on Shutdown in Focus | ABBV | https://www.nasdaq.com/articles/congressional-activities-on-shutdown-in-focus-2019-01-25 | nan | nan | By now, it's become a familiar refrain: no economic data is currently available due to the partial U.S. government shutdown. Now completing its fifth straight week - already an all-time record by a country mile - an estimated 800K U.S. federal workers will see their second payday come and go without compensation. Today, it's Durable Goods Orders, including data on Core Capital Equipment, and New Home Sales that will be left wanting.
The shutdown, should it continue through next Friday (or longer), will not affect the release of non-farm payrolls from the Bureau of Labor Statistics (BLS) due next week. These numbers include a fresh look at the Unemployment Rate, Average Wage Growth and Labor Force Participation. For December, these BLS numbers were far beyond expectations: 312K new jobs created, with Wage Growth up 40 basis points month over month.
Market indexes are up in today's pre-market - the Dow in the green a healthy triple digits - despite a disappointing earnings call from Intel INTC yesterday afternoon, and a comment from U.S. Commerce Secretary Wilbur Ross that we are "miles and miles" from a trade agreement with China. Beyond this, analysts are now predicting a drag on the Q1 economy due to the prolonged government shutdown.
We're seeing green futures this morning partly on a nice rally in Asia overnight, led by a +1.65% close in the Hang Seng (Hong Kong index). These rallies appear to have stemmed from the People's Bank of China (PBOC) beginning steps to bring stimulus to the Chinese market, using bill swaps to help offset shrinking growth to the country's lowest levels in nearly 30 years.
That the U.S. Senate has also begun to bring votes to the floor to re-open the government, even though they have so far initially failed, can also be seen as a positive development for the markets. At this point, following several weeks of more or less total inaction, any activity in Congress in this regard has got to be a welcoming sign. Whether or not the body can pull together a deal, however, is another matter.
Q4 Earnings Roundup
Real quick, we are seeing pre-market Friday earnings reports that are decidedly mixed: Colgate-Palmolive CL beat by a penny to 75 cents per share on sales +1% from estimates to $3.81 billion. But D.R. Horton DHI came in light of expectations by 2 cents to 76 cents per share, on $3.50 billion in revenues that also topped consensus by 1%. NextEra Energy (NEE and AbbVie ABBV both missed on their top and bottom lines, however, both by 2 cents per share and roughly -1% on revenues.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
NextEra Energy, Inc. (NEE): Free Stock Analysis Report
AbbVie Inc. (ABBV): Get Free Report
D.R. Horton, Inc. (DHI): Free Stock Analysis Report
Colgate-Palmolive Company (CL): Get Free Report
Intel Corporation (INTC): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | NextEra Energy (NEE and AbbVie ABBV both missed on their top and bottom lines, however, both by 2 cents per share and roughly -1% on revenues. Click to get this free report NextEra Energy, Inc. (NEE): Free Stock Analysis Report AbbVie Inc. (ABBV): Get Free Report D.R. The shutdown, should it continue through next Friday (or longer), will not affect the release of non-farm payrolls from the Bureau of Labor Statistics (BLS) due next week. | Click to get this free report NextEra Energy, Inc. (NEE): Free Stock Analysis Report AbbVie Inc. (ABBV): Get Free Report D.R. NextEra Energy (NEE and AbbVie ABBV both missed on their top and bottom lines, however, both by 2 cents per share and roughly -1% on revenues. Horton, Inc. (DHI): Free Stock Analysis Report Colgate-Palmolive Company (CL): Get Free Report Intel Corporation (INTC): Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report NextEra Energy, Inc. (NEE): Free Stock Analysis Report AbbVie Inc. (ABBV): Get Free Report D.R. NextEra Energy (NEE and AbbVie ABBV both missed on their top and bottom lines, however, both by 2 cents per share and roughly -1% on revenues. Horton, Inc. (DHI): Free Stock Analysis Report Colgate-Palmolive Company (CL): Get Free Report Intel Corporation (INTC): Free Stock Analysis Report To read this article on Zacks.com click here. | NextEra Energy (NEE and AbbVie ABBV both missed on their top and bottom lines, however, both by 2 cents per share and roughly -1% on revenues. Click to get this free report NextEra Energy, Inc. (NEE): Free Stock Analysis Report AbbVie Inc. (ABBV): Get Free Report D.R. Q4 Earnings Roundup Real quick, we are seeing pre-market Friday earnings reports that are decidedly mixed: Colgate-Palmolive CL beat by a penny to 75 cents per share on sales +1% from estimates to $3.81 billion. |
25128.0 | 2019-01-25 00:00:00 UTC | AbbVie (ABBV) Misses on Q4 Earnings & Revenues, Shares Down | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-misses-on-q4-earnings-revenues-shares-down-2019-01-25 | nan | nan | AbbVie Inc.ABBV posted lower-than-expected fourth-quarter 2018 earnings and revenues. Moreover, Humira sales growth slowed as biosimilar launch in Europe pulled down sales of the drug. Shares fell almost 5% in pre-market trading .
Shares of AbbVie have declined 30.3% in a year's time against the industry 's 6.8% rise.
The biopharmaceutical company reported earnings of $1.90 per share in the fourth quarter, missing the Zacks Consensus Estimate of $1.92. However, the figure surged 28.4% year over year. Earnings per share were within the guided range of $1.89 and $1.91.
The company posted revenues of $8.31 billion in the quarter under review, missing the Zacks Consensus Estimate of $8.36 billion. However, the top line increased 7.3% year over year. Excluding a 1% unfavorable impact from foreign exchange rate fluctuations, operational revenues rose 8.3%. Revenue growth was higher than the projection of approximately 7% on an operational basis.
Quarter in Detail
Key drug Humira recorded sales growth of 1.4% on an operational basis with revenues from the same coming in at $4.9 billion. The Zacks Consensus Estimate for Humira sales was $5 billion. Sales in the United States increased 9.1% to $3.6 billion. Humira sales in ex-U.S. markets were down 14.8% on an operational basis and 17.5% on a reported basis to $1.3 billion. International sales were severely impacted by the launch of several direct biosimilar drugs in Europe by other pharma companies including Amgen AMGN , Sandoz and Biogen.
Fourth-quarter net revenues from Imbruvica were $1 billion, up 42% year over year. U.S. sales of Imbruvica grossed $839 million, up 43.2% from the year-ago figure. AbbVie logged $167 million of international profit sharing with Johnson & Johnson JNJ .
The company's leukemia drug, Venclexta, brought in revenues of $124 million, up more than 100% year over year.
Other products that delivered an impressive performance include Duodopa. It recorded revenue growth of 16.7% on operational basis and 14% on reported basis. Another product, Creon witnessed an increase of 11.4% in revenues on both operational and reported basis.
HCV (chronic hepatitis C virus) products recorded sales of $862 million, up 71.4% operationally year over year, on the back of strong demand for Mavyret, which was launched in the second half of 2017. Mavyret sales more than doubled to $819 million.
Other drugs that recorded sales decline include Androgel, Kaletra and Sevoflurane, which fell 45.8%, 23.1% and 10.6%, respectively, operationally, during the quarter.
Adjusted SG&A expenses increased 9.2% to $1.8 billion while R&D expenses rose 3.1% to $1.37 billion in the fourth quarter. Adjusted operating margin was 41.7% of sales.
Other Updates
In January, data from the phase III RESOLVE study showed that the Imbruvica combination failed to bring statistically-significant improvement in progression-free-survival ("PFS") and overall survival in patients with metastatic pancreatic adenocarcinoma. The study was evaluating Imbruvica in combination with chemotherapy agents nab-paclitaxel and gemcitabine.
In December, AbbVie stopped enrolling patients in the phase III study, TAHOE, evaluating Rova-T in second-line small cell lung cancer ("SCLC") on recommendation from an Independent Data Monitoring Committee.
Last month, the company submitted regulatory applications in the United States and EU for seeking approval for upadacitinib for treating adults with moderate-to-severe rheumatoid arthritis.
In October, a label expansion of cancer drug, Venclyxto (Venclexta), in combination with Roche's RHHBY Rituxan (rituximab) for the treatment of patients with chronic lymphocytic leukemia ("CLL"), in second or later-line setting was approved in Europe. A label expansion for the drug was approved in the United States for treating acute myeloid leukemia in first-line setting during the quarter.
During the quarter, the company's board approved an increase of $5 billion in its present share repurchase program.
2019 Guidance
AbbVie expects adjusted EPS to be in the range of $8.65-$8.75 for 2019. The earnings guidance indicates a year-over-year increase of 10% at the mid-point. The Zacks Consensus Estimate for current-year earnings per share is pegged at $8.68.
AbbVie Inc. Price, Consensus and EPS Surprise
AbbVie Inc. Price, Consensus and EPS Surprise | AbbVie Inc. Quote
Zacks Rank
AbbVie currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Get Free Report
Roche Holding AG (RHHBY): Free Stock Analysis Report
Johnson & Johnson (JNJ): Get Free Report
Amgen Inc. (AMGN): Get Free Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In December, AbbVie stopped enrolling patients in the phase III study, TAHOE, evaluating Rova-T in second-line small cell lung cancer ("SCLC") on recommendation from an Independent Data Monitoring Committee. AbbVie Inc.ABBV posted lower-than-expected fourth-quarter 2018 earnings and revenues. Shares of AbbVie have declined 30.3% in a year's time against the industry 's 6.8% rise. | AbbVie Inc. Price, Consensus and EPS Surprise AbbVie Inc. Price, Consensus and EPS Surprise | AbbVie Inc. Quote Zacks Rank AbbVie currently carries a Zacks Rank #3 (Hold). Click to get this free report AbbVie Inc. (ABBV): Get Free Report Roche Holding AG (RHHBY): Free Stock Analysis Report Johnson & Johnson (JNJ): Get Free Report Amgen Inc. (AMGN): Get Free Report To read this article on Zacks.com click here. AbbVie Inc.ABBV posted lower-than-expected fourth-quarter 2018 earnings and revenues. | AbbVie Inc. Price, Consensus and EPS Surprise AbbVie Inc. Price, Consensus and EPS Surprise | AbbVie Inc. Quote Zacks Rank AbbVie currently carries a Zacks Rank #3 (Hold). Click to get this free report AbbVie Inc. (ABBV): Get Free Report Roche Holding AG (RHHBY): Free Stock Analysis Report Johnson & Johnson (JNJ): Get Free Report Amgen Inc. (AMGN): Get Free Report To read this article on Zacks.com click here. AbbVie Inc.ABBV posted lower-than-expected fourth-quarter 2018 earnings and revenues. | AbbVie Inc.ABBV posted lower-than-expected fourth-quarter 2018 earnings and revenues. Shares of AbbVie have declined 30.3% in a year's time against the industry 's 6.8% rise. AbbVie logged $167 million of international profit sharing with Johnson & Johnson JNJ . |
25129.0 | 2019-01-25 00:00:00 UTC | Asia, Congress Activity, Put Futures in the Green | ABBV | https://www.nasdaq.com/articles/asia-congress-activity-put-futures-green-2019-01-25 | nan | nan | Friday, January 25, 2019
By now, it's become a familiar refrain: no economic data is currently available due to the partial U.S. government shutdown. Now completing its fifth straight week - already an all-time record by a country mile - an estimated 800K U.S. federal workers will see their second payday come and go without compensation. Today, it's Durable Goods Orders, including data on Core Capital Equipment, and New Home Sales that will be left wanting.
The shutdown, should it continue through next Friday (or longer), will not affect the release of non-farm payrolls from the Bureau of Labor Statistics (BLS) due next week. These numbers include a fresh look at the Unemployment Rate, Average Wage Growth and Labor Force Participation. For December, these BLS numbers were far beyond expectations: 312K new jobs created, with Wage Growth up 40 basis points month over month.
Market indexes are up in today's pre-market - the Dow in the green a healthy triple digits - despite a disappointing earnings call from Intel INTC yesterday afternoon, and a comment from U.S. Commerce Secretary Wilbur Ross that we are "miles and miles" from a trade agreement with China. Beyond this, analysts are now predicting a drag on the Q1 economy due to the prolonged government shutdown.
We're seeing green futures this morning partly on a nice rally in Asia overnight, led by a +1.65% close in the Hang Seng (Hong Kong index). These rallies appear to have stemmed from the People's Bank of China (PBOC) beginning steps to bring stimulus to the Chinese market, using bill swaps to help offset shrinking growth to the country's lowest levels in nearly 30 years.
That the U.S. Senate has also begun to bring votes to the floor to re-open the government, even though they have so far initially failed, can also be seen as a positive development for the markets. At this point, following several weeks of more or less total inaction, any activity in Congress in this regard has got to be a welcoming sign. Whether or not the body can pull together a deal, however, is another matter.
Q4 Earnings Roundup
Real quick, we are seeing pre-market Friday earnings reports that are decidedly mixed: Colgate-Palmolive CL beat by a penny to 75 cents per share on sales +1% from estimates to $3.81 billion. But D.R. Horton DHI came in light of expectations by 2 cents to 76 cents per share, on $3.50 billion in revenues that also topped consensus by 1%. NextEra Energy NEE and AbbVie ABBV both missed on their top and bottom lines, however, both by 2 cents per share and roughly -1% on revenues.
Mark Vickery
Senior Editor
Questions or comments about this article and/or its author? Click here>>
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
NextEra Energy, Inc. (NEE): Free Stock Analysis Report
AbbVie Inc. (ABBV): Get Free Report
D.R. Horton, Inc. (DHI): Get Free Report
Colgate-Palmolive Company (CL): Free Stock Analysis Report
Intel Corporation (INTC): Get Free Report
To read this article on Zacks.com click here.
Zacks Investment Research
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | NextEra Energy NEE and AbbVie ABBV both missed on their top and bottom lines, however, both by 2 cents per share and roughly -1% on revenues. Click to get this free report NextEra Energy, Inc. (NEE): Free Stock Analysis Report AbbVie Inc. (ABBV): Get Free Report D.R. The shutdown, should it continue through next Friday (or longer), will not affect the release of non-farm payrolls from the Bureau of Labor Statistics (BLS) due next week. | Click to get this free report NextEra Energy, Inc. (NEE): Free Stock Analysis Report AbbVie Inc. (ABBV): Get Free Report D.R. NextEra Energy NEE and AbbVie ABBV both missed on their top and bottom lines, however, both by 2 cents per share and roughly -1% on revenues. Horton, Inc. (DHI): Get Free Report Colgate-Palmolive Company (CL): Free Stock Analysis Report Intel Corporation (INTC): Get Free Report To read this article on Zacks.com click here. | Click to get this free report NextEra Energy, Inc. (NEE): Free Stock Analysis Report AbbVie Inc. (ABBV): Get Free Report D.R. NextEra Energy NEE and AbbVie ABBV both missed on their top and bottom lines, however, both by 2 cents per share and roughly -1% on revenues. Horton, Inc. (DHI): Get Free Report Colgate-Palmolive Company (CL): Free Stock Analysis Report Intel Corporation (INTC): Get Free Report To read this article on Zacks.com click here. | Click to get this free report NextEra Energy, Inc. (NEE): Free Stock Analysis Report AbbVie Inc. (ABBV): Get Free Report D.R. NextEra Energy NEE and AbbVie ABBV both missed on their top and bottom lines, however, both by 2 cents per share and roughly -1% on revenues. Horton DHI came in light of expectations by 2 cents to 76 cents per share, on $3.50 billion in revenues that also topped consensus by 1%. |
25130.0 | 2019-01-25 00:00:00 UTC | Pharma Stock Roundup: JNJ & BMY's Q4 Earnings, Study Failures at LLY & ABBV | ABBV | https://www.nasdaq.com/articles/pharma-stock-roundup%3A-jnj-bmys-q4-earnings-study-failures-at-lly-abbv-2019-01-25 | nan | nan | J&J JNJ and Bristol-Myers BMY set the earnings season in motion for the pharma space. Meanwhile, Lilly LLY and AbbVie ABBV faced pipeline setbacks with failure of their late-stage studies. Lilly's confirmatory study to convert soft tissue sarcoma drug Lartruvo's conditional approval to full approval and AbbVie's Imbruvica combination study in metastatic pancreatic cancer failed to meet their respective primary endpoints.
Recap of the Week's Most Important Headlines
Inside J&J & Bristol-Myers' Q4 Earnings: J&J beat estimates for both earnings and sales in the fourth quarter of 2018. Sales increased 1% from the year-ago quarter to $20.4 billion while earnings per share rose 13.2% to $1.95 per share. Pharmaceutical segment sales rose 5.3% year over year. However, J&J's sales guidance for 2019 was below expectation.
Bristol-Myers beat estimates for earnings while missing the same for sales. Revenues were up 10% year over year to $6 billion while earnings rose 38% to $94 per share. However, the company announced the voluntary withdrawal of a label expansion application for Opdivo + low-dose Yervoy combination in first-line ling cancer, which pushed its share price down. Opdivo sales were up 33% in the fourth quarter. Bristol-Myers confirmed its 2019 earnings guidance range of $4.10 to $4.20.
Lilly's Confirmatory Study on Lartruvo Fails : Lilly's drug Lartruvo, which had won conditional approval two years back, failed to improve survival for patients with advanced soft tissue sarcoma in a late-stage confirmatory study, ANNOUNCE.
The ANNOUNCE study evaluated Lartruvo in combination with doxorubicin, a standard of care chemotherapy compared with doxorubicin alone. The study did not meet the primary endpoints of overall survival (OS) in the full study population or in the leiomyosarcoma (LMS) sub-population. It was noticed that there was no difference in survival between the study arms for either population. The study thus did not confirm the clinical benefit of Lartruvo in combination with doxorubicin as shown earlier in a phase II study. The clinical benefit achieved earlier had led to an accelerated approval of Lartruvo+doxorubicin by the FDA and conditional marketing authorization by the European Medicines Agency in 2016.
Continued approval was contingent on verification of clinical benefit in a confirmatory study. With ANNOUNCE failing to confirm clinical benefit, Lilly said it will stop promoting Lartruvo while remaining in discussion with global regulators to determine the next steps for the drug.
AbbVie's Imbruvica Fails in Pancreatic Cancer Study: AbbVie's late-stage study evaluating its cancer drug, Imbruvica in combination with chemotherapy for metastatic pancreatic cancer failed to meet the primary endpoint of statistically-significant progression-free or overall survival benefit.
The RESOLVE study evaluated Imbruvica plus chemotherapy agents nab-paclitaxel and gemcitabine versus placebo in combination with these chemotherapy agents for the treatment of first-line metastatic pancreatic cancer, one of the most aggressive and deadliest forms of cancer. Imbruvica, currently approved for nine cancer indications, has multi-billion dollar potential and AbbVie is exploring the potential to expand Imbruvica's label into solid tumors and autoimmune diseases.
FDA Accepts Merck's sNDAs for HIV Medicines: Merck's MRK supplemental new drug applications (sNDAs) looking for label expansion of its two new HIV drugs - Pifeltro and Delstrigo - was accepted by the FDA. Pifeltro and Delstrigo were approved by the FDA in August for the treatment of adults with no prior antiretroviral treatment experience. The sNDAs are looking to get the HIV drugs approved for use in treatment-experienced adults living with HIV-1 whose virus is suppressed to switch to Pifeltro (in combination with other antiretrovirals) or Delstrigo. The FDA is expected to give its decision on Sep 20. The sNDAs were based on data from the phase III DRIVE-SHIFT study. Data from the study, presented in the past, has shown non-inferior efficacy for those who switched to Delstrigo compared to those who continued on their baseline regimen.
Sanofi's Influenza Vaccine Gets FDA Nod for Kids: Sanofi SNY announced FDA approval of 0.5 mL dose of its influenza vaccine, Fluzone Quadrivalent for use in children 6 months through 35 months of age. The 0.5 mL dose is already approved for use in patients 3 years and above. The FDA approval was based on clinical data from a phase IV safety and immunogenicity study conducted in nearly 2,000 children. Fluzone Quadrivalent's lower 0.25 mL dose is already approved for use in this age group.
The NYSE ARCA Pharmaceutical Index declined 1.9% in the last four trading sessions.
Large Cap Pharmaceuticals Industry 5YR % Return
Large Cap Pharmaceuticals Industry 5YR % Return
Here is how the seven major stocks performed in the last four trading sessions:
All the seven stocks recorded a decline of more than 1% in the last four trading sessions with Pfizer PFE declining the most (3.6%).
In the past six months, Lilly has been the biggest gainer (20.8%) while Bristol-Myers declined the most (15.4%).
(See the last pharma stock roundup here: Regulatory Updates in Focus at PFE, BMY, RHHBY, SNY )
What's Next in the Pharma World?
Watch out for fourth-quarter and full year 2018 earnings results by Merck, Pfizer, Allergan and others and pipeline and regulatory updates next week.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce ""the world's first trillionaires,"" but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report
Merck & Co., Inc. (MRK): Free Stock Analysis Report
AbbVie Inc. (ABBV): Get Free Report
Eli Lilly and Company (LLY): Free Stock Analysis Report
Sanofi (SNY): Free Stock Analysis Report
Pfizer Inc. (PFE): Free Stock Analysis Report
Johnson & Johnson (JNJ): Get Free Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Meanwhile, Lilly LLY and AbbVie ABBV faced pipeline setbacks with failure of their late-stage studies. Lilly's confirmatory study to convert soft tissue sarcoma drug Lartruvo's conditional approval to full approval and AbbVie's Imbruvica combination study in metastatic pancreatic cancer failed to meet their respective primary endpoints. AbbVie's Imbruvica Fails in Pancreatic Cancer Study: AbbVie's late-stage study evaluating its cancer drug, Imbruvica in combination with chemotherapy for metastatic pancreatic cancer failed to meet the primary endpoint of statistically-significant progression-free or overall survival benefit. | Lilly's confirmatory study to convert soft tissue sarcoma drug Lartruvo's conditional approval to full approval and AbbVie's Imbruvica combination study in metastatic pancreatic cancer failed to meet their respective primary endpoints. AbbVie's Imbruvica Fails in Pancreatic Cancer Study: AbbVie's late-stage study evaluating its cancer drug, Imbruvica in combination with chemotherapy for metastatic pancreatic cancer failed to meet the primary endpoint of statistically-significant progression-free or overall survival benefit. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Get Free Report Eli Lilly and Company (LLY): Free Stock Analysis Report Sanofi (SNY): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Get Free Report To read this article on Zacks.com click here. | Lilly's confirmatory study to convert soft tissue sarcoma drug Lartruvo's conditional approval to full approval and AbbVie's Imbruvica combination study in metastatic pancreatic cancer failed to meet their respective primary endpoints. AbbVie's Imbruvica Fails in Pancreatic Cancer Study: AbbVie's late-stage study evaluating its cancer drug, Imbruvica in combination with chemotherapy for metastatic pancreatic cancer failed to meet the primary endpoint of statistically-significant progression-free or overall survival benefit. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Get Free Report Eli Lilly and Company (LLY): Free Stock Analysis Report Sanofi (SNY): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Get Free Report To read this article on Zacks.com click here. | AbbVie's Imbruvica Fails in Pancreatic Cancer Study: AbbVie's late-stage study evaluating its cancer drug, Imbruvica in combination with chemotherapy for metastatic pancreatic cancer failed to meet the primary endpoint of statistically-significant progression-free or overall survival benefit. Meanwhile, Lilly LLY and AbbVie ABBV faced pipeline setbacks with failure of their late-stage studies. Lilly's confirmatory study to convert soft tissue sarcoma drug Lartruvo's conditional approval to full approval and AbbVie's Imbruvica combination study in metastatic pancreatic cancer failed to meet their respective primary endpoints. |
25131.0 | 2019-01-25 00:00:00 UTC | AbbVie warns of steeper decline in Humira's international sales | ABBV | https://www.nasdaq.com/articles/abbvie-warns-steeper-decline-humiras-international-sales-2019-01-25 | nan | nan | By Tamara Mathias
Jan 25 () - AbbVie Inc said on Friday it expects a steeper decline in overseas sales of its top-selling drug, Humira, due to intense competition from cheaper versions in Europe, driving its shares down nearly 7 percent.
Humira is the world's best-selling prescription medicine and in the six years since AbbVie spun out from device maker Abbott Labs the rheumatoid arthritis drug has remained by far the company's top earner, accounting for about 60 percent of net revenue.
In November, the company forecast a 26 to 27 percent decline in 2019 Humira sales outside the United States due to stiff competition in Europe from companies such as Mylan NV and Biogen Inc.
"What we're giving you is our best estimate of what will happen," Chief Executive Richard Gonzalez said on a conference call with analysts.
"Obviously, this is driven by not us, it's driven by competitors and their behavior and so ultimately it's not like we have a crystal ball that we can predict exactly what they do."
AbbVie said international sales of Humira fell 17.5 percent on a reported basis to $1.30 billion in the fourth quarter ended Dec.31.
Overall, the drug brought in sales of $4.92 billion in the quarter, falling short of the $5.02 billion forecast by six analysts polled by Refinitiv IBES.
"When they first started talking about outside U.S. biosimilar competition it was that it would be in the mid-teens over a two-year period," Piper Jaffray & Co analyst Christopher Raymond told .
"And now they've said they'll be down 30 percent so I think that's the issue. It's a concern that if they got it wrong once, how do we know that the current guidance is accurate?"
In the United States, AbbVie's largest market, Humira is not expected to face biosimilar competition until 2023.
The drugmaker has signed a series of deals with rivals, including Mylan NV and Amgen Inc, which prevent their biosimilars from entering the U.S. market before then.
The company forecast 2019 adjusted earnings of between $8.65 and $8.75 per share, largely below the average analyst forecast of $8.74 per share.
In the fourth quarter, AbbVie's adjusted earnings were $1.90 per share and revenue $8.31 billion, both missing Wall Street estimates.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | By Tamara Mathias Jan 25 () - AbbVie Inc said on Friday it expects a steeper decline in overseas sales of its top-selling drug, Humira, due to intense competition from cheaper versions in Europe, driving its shares down nearly 7 percent. Humira is the world's best-selling prescription medicine and in the six years since AbbVie spun out from device maker Abbott Labs the rheumatoid arthritis drug has remained by far the company's top earner, accounting for about 60 percent of net revenue. AbbVie said international sales of Humira fell 17.5 percent on a reported basis to $1.30 billion in the fourth quarter ended Dec.31. | In the United States, AbbVie's largest market, Humira is not expected to face biosimilar competition until 2023. In the fourth quarter, AbbVie's adjusted earnings were $1.90 per share and revenue $8.31 billion, both missing Wall Street estimates. By Tamara Mathias Jan 25 () - AbbVie Inc said on Friday it expects a steeper decline in overseas sales of its top-selling drug, Humira, due to intense competition from cheaper versions in Europe, driving its shares down nearly 7 percent. | By Tamara Mathias Jan 25 () - AbbVie Inc said on Friday it expects a steeper decline in overseas sales of its top-selling drug, Humira, due to intense competition from cheaper versions in Europe, driving its shares down nearly 7 percent. Humira is the world's best-selling prescription medicine and in the six years since AbbVie spun out from device maker Abbott Labs the rheumatoid arthritis drug has remained by far the company's top earner, accounting for about 60 percent of net revenue. AbbVie said international sales of Humira fell 17.5 percent on a reported basis to $1.30 billion in the fourth quarter ended Dec.31. | In the United States, AbbVie's largest market, Humira is not expected to face biosimilar competition until 2023. By Tamara Mathias Jan 25 () - AbbVie Inc said on Friday it expects a steeper decline in overseas sales of its top-selling drug, Humira, due to intense competition from cheaper versions in Europe, driving its shares down nearly 7 percent. Humira is the world's best-selling prescription medicine and in the six years since AbbVie spun out from device maker Abbott Labs the rheumatoid arthritis drug has remained by far the company's top earner, accounting for about 60 percent of net revenue. |
25132.0 | 2019-01-25 00:00:00 UTC | AbbVie Q4 Results Miss View; Stock Down | ABBV | https://www.nasdaq.com/articles/abbvie-q4-results-miss-view-stock-down-2019-01-25 | nan | nan | (RTTNews.com) - AbbVie ( ABBV ) reported that its net loss for the fourth quarter was $1.83 billion or $1.23 per share, compared to net income of $52 million or $0.03 per share in the prior year.
The latest-quarter result included the recent partial impairment charge related to intangible assets acquired as part of the 2016 acquisition of Stemcentrx Inc.
Adjusted earnings per share, excluding specified items, was $1.90, up 28.4 percent. Analysts polled by Thomson Reuters expected the company to report earnings of $1.94 per share for the quarter. Analysts' estimates typically exclude special items.
In Friday pre-market trade, ABBV is trading at $83.50, down $2.38 or 2.77 percent.
Worldwide GAAP net revenues were $8.305 billion in the fourth quarter, up 7.3 percent year-over-year. Worldwide adjusted net revenues of $8.305 billion increased 8.3 percent on an operational basis, excluding a 1.0 percent unfavorable impact from foreign exchange. Analysts expected revenue of $8.38 billion for the quarter.
AbbVie expects GAAP earnings per share for the full-year 2019 to be in the range $7.39 to $7.49. The company's 2019 GAAP guidance does not reflect non-cash charges for contingent consideration adjustments related to the expected approval of risankizumab in the first half of the year.
AbbVie expects to deliver adjusted earnings per share for the full-year 2019 of $8.65 to $8.75, representing growth of 10.0 percent at the mid-point. The company's 2019 adjusted earnings per share guidance excludes $1.26 per share of intangible asset amortization expense, non-cash charges for contingent consideration adjustments, and other specified items. Analysts expect annual earnings of $8.71 per share.
Read the original article on RTTNews (http://www.rttnews.com/2972762/abbvie-q4-results-miss-view-stock-down.aspx)
For comments and feedback: contact editorial@rttnews.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie expects to deliver adjusted earnings per share for the full-year 2019 of $8.65 to $8.75, representing growth of 10.0 percent at the mid-point. (RTTNews.com) - AbbVie ( ABBV ) reported that its net loss for the fourth quarter was $1.83 billion or $1.23 per share, compared to net income of $52 million or $0.03 per share in the prior year. In Friday pre-market trade, ABBV is trading at $83.50, down $2.38 or 2.77 percent. | (RTTNews.com) - AbbVie ( ABBV ) reported that its net loss for the fourth quarter was $1.83 billion or $1.23 per share, compared to net income of $52 million or $0.03 per share in the prior year. In Friday pre-market trade, ABBV is trading at $83.50, down $2.38 or 2.77 percent. AbbVie expects GAAP earnings per share for the full-year 2019 to be in the range $7.39 to $7.49. | (RTTNews.com) - AbbVie ( ABBV ) reported that its net loss for the fourth quarter was $1.83 billion or $1.23 per share, compared to net income of $52 million or $0.03 per share in the prior year. AbbVie expects to deliver adjusted earnings per share for the full-year 2019 of $8.65 to $8.75, representing growth of 10.0 percent at the mid-point. In Friday pre-market trade, ABBV is trading at $83.50, down $2.38 or 2.77 percent. | AbbVie expects GAAP earnings per share for the full-year 2019 to be in the range $7.39 to $7.49. (RTTNews.com) - AbbVie ( ABBV ) reported that its net loss for the fourth quarter was $1.83 billion or $1.23 per share, compared to net income of $52 million or $0.03 per share in the prior year. In Friday pre-market trade, ABBV is trading at $83.50, down $2.38 or 2.77 percent. |
25133.0 | 2019-01-25 00:00:00 UTC | Wall Street's Risk Appetite Improves on Upcoming Trade Talks, Tech Sector Gains | ABBV | https://www.nasdaq.com/articles/wall-streets-risk-appetite-improves-upcoming-trade-talks-tech-sector-gains-2019-01-25 | nan | nan | US stock futures were gaining ground into Friday's open as positive developments in the US-China trade front helped overshadow bearish German economic data and disappointing results from chipmaker Intel ( INTC ). Led by gains in technology shares, the Dow Jones Industrial Average was indicated to open more than 100 points higher.
Asian shares were launched higher after news circulated that a Chinese delegation was headed to Washington, led by Vice Premier Liu He, indicating Beijing's commitment to resolving the trade issue with the US. Gains spilled into Europe with earnings underpinning the technology sector, and dovish remarks from members of the European Central Bank driving Germany's DAX 1.6% higher despite a big miss on the Ifo business climate index.
On the earnings front, Intel beat adjusted earnings estimates, but missed revenue expectations and issued Q1 guidance that fell short of Wall Street's expectations. Starbucks (SBX) fiscal Q1 results came in above estimates while the company's outlook for this year was above analysts' estimates.
Before the open, AbbVie ( ABBV ) profit and sales increased from a year ago, but was shy of estimates, while Colgate-Palmolive's ( CL ) adjusted earnings beat estimates, thought its GAAP earnings missed them, as revenue fell by less than what was forecast.
Oil futures were higher for a second day as the political crisis in Venezuela offset increased supply; demand for risk pushed Treasury yields higher with the 10-year note at 2.726%; while gold was bucking the trend by trading up more than $8 per ounce on the weaker dollar.
Economic data scheduled for Friday -- durable goods orders and new home sales -- have been postponed due to the partial government shutdown.
-Dow Jones Industrial up 0.98%
-S&P 500 futures up/down 0.96%
-Nasdaq 100 futures up/down 1.3%
SENTIMENT
Nikkei up 0.97%
Hang Seng up 1.65%
Shanghai Composite up 0.39%
FTSE-100 up 0.20%
DAX-30 up 1.63%
PRE-MARKET SECTOR WATCH
(+) Large cap tech: Higher
(-) Chip stocks: Lower
(+) Software stocks: Higher
(+) Hardware stocks: Higher
(+) Internet stocks: Higher
(+) Oil stocks: Higher
(+) Biotech stocks: Higher
(+) Drug stocks: Higher
(+) Financial stocks: Higher
(+) Retail stocks: Higher
(+) Industrial stocks: Higher
(+) Airlines: Higher
(+) Autos: Higher
UPSIDE MOVERS:
(+) WDC (+10.49%) Missed Q2 expectations but forecasted higher revenue in second half of 2019
(+) OSIS (+9.11%) Beat Q2 estimates and raised FY19 guidance
(+) ALB (+3.22%) Reached a deal with Corfo, no arbitration filed
DOWNSIDE MOVERS:
(-) RMD (-15.60%) Missed Q2 revenue estimates, downgraded at JP Morgan
(-) INTC (-6.69%) Missed revenue estimates, issued soft guidance
(-) CRBP (-5.92%) Announced stock offering
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Before the open, AbbVie ( ABBV ) profit and sales increased from a year ago, but was shy of estimates, while Colgate-Palmolive's ( CL ) adjusted earnings beat estimates, thought its GAAP earnings missed them, as revenue fell by less than what was forecast. US stock futures were gaining ground into Friday's open as positive developments in the US-China trade front helped overshadow bearish German economic data and disappointing results from chipmaker Intel ( INTC ). Asian shares were launched higher after news circulated that a Chinese delegation was headed to Washington, led by Vice Premier Liu He, indicating Beijing's commitment to resolving the trade issue with the US. | Before the open, AbbVie ( ABBV ) profit and sales increased from a year ago, but was shy of estimates, while Colgate-Palmolive's ( CL ) adjusted earnings beat estimates, thought its GAAP earnings missed them, as revenue fell by less than what was forecast. On the earnings front, Intel beat adjusted earnings estimates, but missed revenue expectations and issued Q1 guidance that fell short of Wall Street's expectations. (+) Large cap tech: Higher (-) Chip stocks: Lower (+) Software stocks: Higher (+) Hardware stocks: Higher (+) Internet stocks: Higher (+) Oil stocks: Higher (+) Biotech stocks: Higher (+) Drug stocks: Higher (+) Financial stocks: Higher (+) Retail stocks: Higher (+) Industrial stocks: Higher (+) Airlines: Higher (+) Autos: Higher | Before the open, AbbVie ( ABBV ) profit and sales increased from a year ago, but was shy of estimates, while Colgate-Palmolive's ( CL ) adjusted earnings beat estimates, thought its GAAP earnings missed them, as revenue fell by less than what was forecast. (+) Large cap tech: Higher (-) Chip stocks: Lower (+) Software stocks: Higher (+) Hardware stocks: Higher (+) Internet stocks: Higher (+) Oil stocks: Higher (+) Biotech stocks: Higher (+) Drug stocks: Higher (+) Financial stocks: Higher (+) Retail stocks: Higher (+) Industrial stocks: Higher (+) Airlines: Higher (+) Autos: Higher (-) RMD (-15.60%) Missed Q2 revenue estimates, downgraded at JP Morgan (-) INTC (-6.69%) Missed revenue estimates, issued soft guidance (-) CRBP (-5.92%) Announced stock offering The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Before the open, AbbVie ( ABBV ) profit and sales increased from a year ago, but was shy of estimates, while Colgate-Palmolive's ( CL ) adjusted earnings beat estimates, thought its GAAP earnings missed them, as revenue fell by less than what was forecast. Led by gains in technology shares, the Dow Jones Industrial Average was indicated to open more than 100 points higher. (-) RMD (-15.60%) Missed Q2 revenue estimates, downgraded at JP Morgan (-) INTC (-6.69%) Missed revenue estimates, issued soft guidance (-) CRBP (-5.92%) Announced stock offering The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
25134.0 | 2019-01-25 00:00:00 UTC | AbbVie profit misses as Humira faces biosimilar challenge in Europe | ABBV | https://www.nasdaq.com/articles/abbvie-profit-misses-humira-faces-biosimilar-challenge-europe-2019-01-25 | nan | nan | By Tamara Mathias
Jan 25 () - AbbVie Inc on Friday posted a lower-than-expected quarterly profit and forecast weak earnings for 2019, as the drugmaker's top-selling drug, Humira, faces competition from cheaper versions in Europe.
Shares of the Chicago-based company fell 3.4 percent before the opening bell.
However, in November, AbbVie lowered its forecast for overseas sales of Humira, citing stiff competition in Europe from companies such as Mylan NV and Biogen Inc.
AbbVie said international sales of Humira fell 17.5 percent on a reported basis to $1.30 billion in the fourth quarter.
Overall, the drug brought in sales of $4.92 billion in the quarter, falling short of the $5.02 billion forecast by six analysts polled by Refinitiv IBES.
The drugmaker said it expects 2019 adjusted earnings of between $8.65 and $8.75 per share, largely below the average analyst forecast of $8.74 per share.
In the United States, AbbVie's largest market, Humira is not expected to face biosimilar competition until 2023.
The drugmaker has signed a series of deals with rivals, including Mylan NV and Amgen Inc, which prevent their biosimilars from entering the U.S. market before then.
On Friday, the company settled with Coherus BioSciences Inc to allow Coherus to launch its Humira biosimilar in Europe only in December 2023.
AbbVie posted a loss of $1.83 billion, or $1.23 per share, for the quarter ended Dec. 31, compared with a profit of $52 million, or 3 cents per share, last year, when it took a tax-related charge.
In the latest quarter, the drugmaker recorded $4.12 billion in impairment charges related to the scrapping of its development program for cancer drug Rova-T, acquired as part of its $5.8 billion purchase of Stemcentrx in 2016.
Excluding items, AbbVie earned $1.90 per share, falling short of the Wall Street target of $1.94 per share.
Net revenue rose 7.3 percent to $8.31 billion in the quarter, but came below the average analyst estimate of $8.38 billion.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | By Tamara Mathias Jan 25 () - AbbVie Inc on Friday posted a lower-than-expected quarterly profit and forecast weak earnings for 2019, as the drugmaker's top-selling drug, Humira, faces competition from cheaper versions in Europe. However, in November, AbbVie lowered its forecast for overseas sales of Humira, citing stiff competition in Europe from companies such as Mylan NV and Biogen Inc. AbbVie said international sales of Humira fell 17.5 percent on a reported basis to $1.30 billion in the fourth quarter. In the United States, AbbVie's largest market, Humira is not expected to face biosimilar competition until 2023. | By Tamara Mathias Jan 25 () - AbbVie Inc on Friday posted a lower-than-expected quarterly profit and forecast weak earnings for 2019, as the drugmaker's top-selling drug, Humira, faces competition from cheaper versions in Europe. However, in November, AbbVie lowered its forecast for overseas sales of Humira, citing stiff competition in Europe from companies such as Mylan NV and Biogen Inc. AbbVie said international sales of Humira fell 17.5 percent on a reported basis to $1.30 billion in the fourth quarter. In the United States, AbbVie's largest market, Humira is not expected to face biosimilar competition until 2023. | By Tamara Mathias Jan 25 () - AbbVie Inc on Friday posted a lower-than-expected quarterly profit and forecast weak earnings for 2019, as the drugmaker's top-selling drug, Humira, faces competition from cheaper versions in Europe. However, in November, AbbVie lowered its forecast for overseas sales of Humira, citing stiff competition in Europe from companies such as Mylan NV and Biogen Inc. AbbVie said international sales of Humira fell 17.5 percent on a reported basis to $1.30 billion in the fourth quarter. AbbVie posted a loss of $1.83 billion, or $1.23 per share, for the quarter ended Dec. 31, compared with a profit of $52 million, or 3 cents per share, last year, when it took a tax-related charge. | By Tamara Mathias Jan 25 () - AbbVie Inc on Friday posted a lower-than-expected quarterly profit and forecast weak earnings for 2019, as the drugmaker's top-selling drug, Humira, faces competition from cheaper versions in Europe. However, in November, AbbVie lowered its forecast for overseas sales of Humira, citing stiff competition in Europe from companies such as Mylan NV and Biogen Inc. AbbVie said international sales of Humira fell 17.5 percent on a reported basis to $1.30 billion in the fourth quarter. In the United States, AbbVie's largest market, Humira is not expected to face biosimilar competition until 2023. |
25135.0 | 2019-01-25 00:00:00 UTC | Why Intel, AbbVie, and Vale Slumped Today | ABBV | https://www.nasdaq.com/articles/why-intel-abbvie-and-vale-slumped-today-2019-01-25 | nan | nan | The stock market was strong on Friday, as the Dow Jones Industrial Average posted a triple-digit gain and other major indexes saw even larger rises on a percentage basis. Generally good earnings from significant companies and optimism about the future course of U.S. monetary policy prompted the move upward, and news late in the day that the government shutdown might come to an end was also generally positive. Yet some companies had bad news that caused their shares to decline. Intel (NASDAQ: INTC) , AbbVie (NYSE: ABBV) , and Vale (NYSE: VALE) were among the worst performers. Here's why they did so poorly.
Intel can't live up to its promise
Shares of Intel fell more than 5% after the semiconductor gian t report ed its fourth-quarter financial results. The chipmaker managed to grow revenue, but not as quickly as most had hoped, and key growth drivers like the data center segment failed to produce the results that investors were looking to see. Intel also warned that demand for servers could remain weak into the beginning of 2019 as well. With competition growing fiercer, even the hint of a slowdown was enough to put Intel shareholders on edge, especially after having endured years of underperformance throughout the 2000s and early 2010s.
AbbVie disappoints
Pharmaceutical company AbbVie saw its stock drop 6% in the wake of the release of its results for the fourth quarter. The drugmaker's growth in sales and profit failed to match what shareholders expected, and many investors seemed troubled by the extent to which biosimilar competition for its blockbuster drug Humira ate into sales. The company also warned tha t earnings growth in 2019 would slow dramatically from 2018's pace. AbbVie has plenty of prospects in its pipeline that could help it make up for the eventual decline of Humira's success, but investors want proof before they'll be entirely comfortable with the pharma giant's future.
Dam collapse hits Vale hard
Finally, shares of Vale finished lower by 8%. A dam for containing mine tailings at one of Vale's iron ore mines in the southeastern Brazilian state of Minas Gerais burst, sending sludge and other material into surrounding areas. Early reports said that more than 200 people were missing following the collapse, and many residents had to be evacuated. The tragedy comes as Vale has tried to rebound from poor conditions in the mining industry in recent years, and investors are concerned about the potential consequences for Vale from the dam collapse.
Offer from The Motley Fool: The 10 best stocks to buy now
Motley Fool co-founders Tom and David Gardner have spent more than a decade beating the market. In fact, the newsletter they run, Motley Fool Stock Advisor , has tripled the S&P 500!*
Tom and David just revealed their ten top stock picks for investors to buy right now.
Click here to get access to the full list!
* Stock Advisor returns as of Nov. 14, 2018.
Dan Caplinger has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie has plenty of prospects in its pipeline that could help it make up for the eventual decline of Humira's success, but investors want proof before they'll be entirely comfortable with the pharma giant's future. Intel (NASDAQ: INTC) , AbbVie (NYSE: ABBV) , and Vale (NYSE: VALE) were among the worst performers. AbbVie disappoints Pharmaceutical company AbbVie saw its stock drop 6% in the wake of the release of its results for the fourth quarter. | Intel (NASDAQ: INTC) , AbbVie (NYSE: ABBV) , and Vale (NYSE: VALE) were among the worst performers. AbbVie disappoints Pharmaceutical company AbbVie saw its stock drop 6% in the wake of the release of its results for the fourth quarter. AbbVie has plenty of prospects in its pipeline that could help it make up for the eventual decline of Humira's success, but investors want proof before they'll be entirely comfortable with the pharma giant's future. | Intel (NASDAQ: INTC) , AbbVie (NYSE: ABBV) , and Vale (NYSE: VALE) were among the worst performers. AbbVie disappoints Pharmaceutical company AbbVie saw its stock drop 6% in the wake of the release of its results for the fourth quarter. AbbVie has plenty of prospects in its pipeline that could help it make up for the eventual decline of Humira's success, but investors want proof before they'll be entirely comfortable with the pharma giant's future. | Intel (NASDAQ: INTC) , AbbVie (NYSE: ABBV) , and Vale (NYSE: VALE) were among the worst performers. AbbVie disappoints Pharmaceutical company AbbVie saw its stock drop 6% in the wake of the release of its results for the fourth quarter. AbbVie has plenty of prospects in its pipeline that could help it make up for the eventual decline of Humira's success, but investors want proof before they'll be entirely comfortable with the pharma giant's future. |
25136.0 | 2019-01-25 00:00:00 UTC | Health Care Sector Update for 01/25/2019: CHRS,AMGN,RMD,AZN,IDXG,ABBV | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-01252019-chrsamgnrmdaznidxgabbv-2019-01-25 | nan | nan | Top Health Care Stocks
JNJ +0.84%
PFE -0.68%
ABT +0.23%
MRK -0.18%
AMGN -1.25%
Health care stocks were finishing slightly higher this afternoon, including a more than 0.1% gain for the NYSE Health Care Index in late trade. Shares of health care companies in the S&P 500 also were up 0.1% as a group while the Nasdaq Biotechnology index was climbing almost 1.3%.
Among health care stocks moving on news:
(+) Coherus BioSciences ( CHRS ) rose more than 6.5% this afternoon after the specialty drugmaker Friday said it has reached a settlement with AbbVie ( ABBV ) providing it with global rights to develop its CHS-1420 biosimilar for Humira. Coherus Friday also said it was suing Amgen ( AMGN ) in Delaware federal court, alleging Amgen's Humira biosimilar product infringes on three of its U.S. patents.
In other sector news:
(-) Astrazeneca ( AZN ) was fractionally lower during Friday trading after the drugmaker completed the $1.6 billion sale of US rights for the Synagis antibody used to prevent severe respiratory syncytial virus infections in infants and young children to Swedish Orphan Biovitrumm, receiving $1 billion in cash and an 8% equity stake in the smaller drugmaker.
(-) Interpace Diagnostics Group ( IDXG ) tumbled nearly 7% to a record low on Friday after the cancer diagnostics company priced a $7 million public offering of 9.3 million common shares at 75 cents apiece, representing a 16.7% discount to Thursday's closing price.
(-) ResMed (RMD) retreated Friday, sinking almost 19%, after the medical device company reported an 8% year-over-year increase in revenue to $651.1 million, lagging the $676.77 million analyst mean and prompting analysts at least two brokerages to downgrade their investment recommendations for the company's stock.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among health care stocks moving on news: (+) Coherus BioSciences ( CHRS ) rose more than 6.5% this afternoon after the specialty drugmaker Friday said it has reached a settlement with AbbVie ( ABBV ) providing it with global rights to develop its CHS-1420 biosimilar for Humira. In other sector news: (-) Astrazeneca ( AZN ) was fractionally lower during Friday trading after the drugmaker completed the $1.6 billion sale of US rights for the Synagis antibody used to prevent severe respiratory syncytial virus infections in infants and young children to Swedish Orphan Biovitrumm, receiving $1 billion in cash and an 8% equity stake in the smaller drugmaker. (-) Interpace Diagnostics Group ( IDXG ) tumbled nearly 7% to a record low on Friday after the cancer diagnostics company priced a $7 million public offering of 9.3 million common shares at 75 cents apiece, representing a 16.7% discount to Thursday's closing price. | Among health care stocks moving on news: (+) Coherus BioSciences ( CHRS ) rose more than 6.5% this afternoon after the specialty drugmaker Friday said it has reached a settlement with AbbVie ( ABBV ) providing it with global rights to develop its CHS-1420 biosimilar for Humira. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among health care stocks moving on news: (+) Coherus BioSciences ( CHRS ) rose more than 6.5% this afternoon after the specialty drugmaker Friday said it has reached a settlement with AbbVie ( ABBV ) providing it with global rights to develop its CHS-1420 biosimilar for Humira. Health care stocks were finishing slightly higher this afternoon, including a more than 0.1% gain for the NYSE Health Care Index in late trade. In other sector news: (-) Astrazeneca ( AZN ) was fractionally lower during Friday trading after the drugmaker completed the $1.6 billion sale of US rights for the Synagis antibody used to prevent severe respiratory syncytial virus infections in infants and young children to Swedish Orphan Biovitrumm, receiving $1 billion in cash and an 8% equity stake in the smaller drugmaker. | Among health care stocks moving on news: (+) Coherus BioSciences ( CHRS ) rose more than 6.5% this afternoon after the specialty drugmaker Friday said it has reached a settlement with AbbVie ( ABBV ) providing it with global rights to develop its CHS-1420 biosimilar for Humira. Shares of health care companies in the S&P 500 also were up 0.1% as a group while the Nasdaq Biotechnology index was climbing almost 1.3%. (-) Interpace Diagnostics Group ( IDXG ) tumbled nearly 7% to a record low on Friday after the cancer diagnostics company priced a $7 million public offering of 9.3 million common shares at 75 cents apiece, representing a 16.7% discount to Thursday's closing price. |
25137.0 | 2019-01-25 00:00:00 UTC | AbbVie Inc (ABBV) Q4 2018 Earnings Conference Call Transcript | ABBV | https://www.nasdaq.com/articles/abbvie-inc-abbv-q4-2018-earnings-conference-call-transcript-2019-01-25 | nan | nan | AbbVie Inc. (NYSE: ABBV)
Q4 2018 Earnings Conference Call
Jan. 25, 2019, 9:00 a.m. ET
Contents:
Prepared Remarks
Questions and Answers
Call Participants
Prepared Remarks:
Operator
Good morning and thank you for standing by. Welcome to the AbbVie fourth quarter 2018 earnings conference call . All participants will be able to listen only until the question and answer portion of this call. You may ask a question by pressing *1 on your phone. And I would now like to introduce Ms. Liz Shea, Vice President of Investor Relations.
Elizabeth Shea-- Vice President of Investor Relations
Good morning and thanks for joining us. Also, on the call with me, today are Rick Gonzalez, Chairman of the Board and Chief Executive Officer. Michael Severino, Vice Chairman, and President. Bill Chase, Executive Vice President of Finance and Administration. And Rob Michael, Senior Vice President, and Chief Financial Officer. Before we get started, I would like to remind you that some statements we make today are or may be considered forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements.
Additional information about the factors that may affect AbbVie's operations is included in our 2017 annual report on Form 10K and in our other SEC filings. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent [inaudible] except as required by law. On today's conference call as in the past, non-GAAP financial measures will be used to help investors understand AbbVie's ongoing business performance. These non-GAAP financial measures are reconciled with comparable GAAP financial measures in our earnings release and regulatory filings from today, which can be found on our website. Following our prepared remarks, we'll take your questions. So, with that, I'll now turn the call over to Rick.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of November 14, 2018
Richard Gonzalez-- Chief Executive Officer
Thank you, Liz. Good morning, everyone, and thank you for joining us today. This morning I'll discuss our fourth quarter in full-year 2018 performance as well as our expectations for 2019. Mike will then provide an update on recent advancements across the R&D pipeline and Bill will discuss the quarter and our 2019 guidance in more detail. Following our remarks, we'll take your questions. We delivered another impressive year with results well above initial expectations. Adjusted earnings per share in the fourth quarter were $1.90 representing growth of more than 28% versus last year and once again achieving our guidance for the quarter.
Total adjusted operational sales growth of 8.3% exceeded our guidance for the quarter. This growth was driven by a number of products, including our hematological oncology portfolio with global operational sales growth of more than 50% and US Humira which grew more than 9% versus last year. Our international Humira sales were down nearly 15% reflecting the impact of direct biosimilar competition in Europe and other international markets. We also saw a continued strong performance from several other products including Mavyret, Creon, and Duodopa.
AbbVie has demonstrated an exceptional track record of consistently delivering top tier financial performance despite any market or competitive challenges. And 2018 was another clear example of that performance. We continue to drive strong commercial and operational execution resulting in full-year 2018 global operational sales growth of more than 15% and adjusted earnings-per-share growth of more than 41%. As we look at the evolution of our business and of our strategy, we're pleased with the progress that we're making. AbbVie strategy has contemplated biosimilar competition since day one of the launch of this company. Our focus has been on building a pipeline that would allow us to absorb the impact of biosimilar competition and maintain a strong and growing business.
Although our work is never done, we have made tremendous progress building what we believe is one of the industry's most attractive pipelines. In hematological oncology, we have built a powerhouse franchise with Imbruvica and Venclexta. Today, this franchise is roughly $4 billion with more than $1 billion of growth expected in 2019 and significant growth anticipated over our long-range plan. In immunology, Humira in the US will continue to generate strong revenue driving roughly $1 billion of growth in 2019. Since we became an independent company, our research and development efforts in immunology have focused on identifying and advancing new assets that could deliver efficacy superior to Humira and other new agents. Given the importance of this growth platform, we understood that in order to maintain and expand our leadership position, the development of highly differentiated assets was absolutely critical.
We are now confident that with Risankizumab and Upadacitinib we have accomplished our objective. Both of our next generation immunology therapies have demonstrated across multiple clinical trials superiority versus Humira and other competitive offerings. This efficacy was shown across the broad spectrum of patients, including bio-naïve patients at one end of the treatment paradigm and very difficult to treat patients who would fail one or more therapies at the other end of the spectrum. In our hands, these assets have the ability to become the new standards of care in immunology. We expect to launch both Risankizumab and Upadacitinib in 2019 and based on their profiles anticipate broad formulary access.
Beyond our new therapies in hem/onc and immunology, we've also developed other assets that represented attractive, multi-billion-dollar revenue opportunities such as Mavyret and Orilissa. And we have a base business that includes therapies like Creon, Duodopa, Synthroid, and MuPrime. All products we expect will remain durable for many years to come. The event that has for many years concerned investors most has been the loss of exclusivity for Humira. Certainly, the most frequently asked question that we get is what impact will biosimilars have on AbbVie's business? We have long been planning and preparing for the event that is now upon us. We are now facing direct biosimilar competition in Europe and other countries, which represent approximately 75% of our international Humira business or approximately 25% of total global Humira revenues.
As we described on our third quarter call, biosimilar competitors have been more aggressive with Humira than previous anti-TNF biosimilar analogs. But despite the more aggressive discounting, our strategy is working as we had intended. 2019 is a year that should clearly demonstrate to all investors that AbbVie is once again delivering on its commitments. In 2019, we will absorb roughly $2 billion of erosion related to biosimilar competition and roughly $400 million of additional impact following the entry of generic competition brand for Androgel 1.62. We're also facing an extremely difficult comparison period due to the outstanding growth we drove in 2018. And in 2019, we'll also be funding five major product or indicational launches.
Yet despite all of these challenges, AbbVie expects to deliver positive revenue growth and double-digit EPS growth this year. This level of performance demonstrates that the strategy we have in place is working as we planned. And it should reassure all investors of our ability to absorb the impact of direct biosimilar competition while maintaining a strong, growing and vibrant business. Further to that point, our ability to deliver industry-leading EPS growth in 2019 despite the challenges I just outlined, is particularly notable given that this year many of our key pipeline assets will be at the very early stages of their launch trajectory, and therefore providing minimal offset to the biosimilar impact. Given their product profiles, we expect these pipeline assets will grow substantially over the next several years and provide significant offset to the 2023 US biosimilar event.
So, as I said, we're pleased with the progress, with our strategy, and investors should view 2019 as a real test of that strategy. In summary, this is an important time for AbbVie. The continued momentum of our US business and our hematological oncology franchise combined with the launch and ramp of several new products will allow us to grow through biosimilar impact in 2019 just as we had predicted. We've demonstrated a strong track record of managing and overcoming challenges and our expected performance in 2019 is another clear example of that. And while we're certainly proud of what we've accomplished in the first six years as an independent company, I can tell you we remain focused and committed to delivering on our long-term vision for the company. Sustain top tier performance. With that, I'll turn the call over to Mike for additional comments on our R&D programs.
Michael Severino -- Vice Chairman and President
Thank you. 2018 was a very productive year with significant pipeline advancement, including numerous development and regulatory achievements and successful data readouts across our pipeline. We secured regulatory approvals for several programs, including Venclexta in the broad relapse refractory CLL population and conditional approval for Venclexta in newly diagnosed AML patients ineligible for intensive chemotherapy. Approval for Imbruvica in combination with Rituxan as the first chemotherapy-free combination treatment for Waldenstrom's. The ninth FDA approval for Imbruvica overall. And for Orilissa, for the management of moderate to severe pain associated with endometriosis. We completed registrational studies and submitted regulatory applications for our two next-generation immunology therapies. Risankizumab in its initial indication, psoriasis, and Upadacitinib in its first indication, rheumatoid arthritis. Across each of the four phase three studies in the pivotal program for psoriasis, Risankizumab showed consistent, high, durable rates of skin clearance.
Based on these results, we believe Risankizumab has the potential to significantly improve upon current treatment options for both bio-naïve and TNF inadequate responder patients with moderate to severe psoriasis while offering the convenience of quarterly dosing. Our regulatory reviews are well under way with approval decisions expected in the second quarter. With Upadacitinib, our goal is to deliver a differentiated patient to RA patients. We designed a broad and comprehensive set of six pivotal studies in RA, enrolling nearly 5,000 patients across multiple populations, including two studies with biologic comparators. We evaluated Upadacitinib head-to-head against the standards of care in RA, including Methotrexate and Humira. And in a broad range of patient types within the moderate to severe RA segment.
This includes immunotherapy treatment in patients who are naïve to methotrexate as well as studies in very difficult to treat patients who have failed one or more biologic therapies. Across the select clinical program, both doses of Upadacitinib performed extremely well and demonstrated a strong benefit-risk profile. Based on our analysis of the data generated across the registrational program, we believe that 15-milligram dose represents the best dose for the RA indication as it delivered maximal efficacy across a wide range of studies, drove strong results on important structural endpoints, and demonstrated superiority to Humira in our head-to-head study. Thus, this dose provides the differentiation we were seeking when we designed our program.
Our regulatory submissions are currently under review and we expect to approve all decisions in the second half of this year. In addition to the successful trial readouts for Upadacitinib and Risankizumab, we also reported positive data from several phase three studies in other areas of our pipeline, including Elagolix and uterine fibroids, Venclexta in frontline CLL. And data from several important phase three studies in our frontline CLL program from Imbruvica, including results from the ECOG alliance and ILLUMINATE trials. Data from these three studies show treatment with Imbruvica alone or in combination significantly prolonged progression-free survival compared to therapy, such as FCR, BR, and Gazyva plus Chlorambucil and previously untreated CLL patients. We also initiated several phase three programs, including studies for Upadacitinib in atopic dermatitis and ulcerative colitis.
In addition to the progress we made across our late-stage programs, we also advanced a number of early stage assets in the mid-stage development, including our jack BTK program in RA and our CD40 program in ulcerative colitis. And, we transitioned several pre-clinical programs into human trials, including our novel PNF steroid conjugate and our ROR gamma T programs. Clearly, we made tremendous progress advancing our pipeline in 2018. And, we look forward to many important pipeline milestones in 2019 as well. In hematologic oncology, we'll see data from several phase three studies for Venclexta this year, including results from the Bellini trial in relapsed refractory multiple myeloma and from our two frontline AML studies. As well as the detailed data from CLL14. Our phase three study for Venclexta in frontline CLL.
These data and subsequent label augmentations will build upon the body of evidence demonstrating Venclexta's potential as a foundational treatment option across a number of hematologic malignancies. Earlier this month, the Venclexta CLL14 data were selected for FDA's real-time oncology review program. This program is aimed at expediting the review and approval process for supplemental drug applications. Results from CLL14 have already been shared with the FDA, which was part of the agency's evaluation process leading to the decision to offer the real-time review. Very soon, we will begin submitting data as part of the review process and expect an approval decision later this year.
We look forward to bringing this new treatment to market in the frontline CLL population. In the area of solid tumors, we'll see data this year from our phase three study for Depatux-M in newly diagnosed glioblastoma multiforme. This is an extremely difficult to treat form of brain cancer with a very high unmet need and limited treatment options. We have seen encouraging trends in overall survival in our phase two study and second line GBM and look forward to the results of our frontline phase three study to define the future regulatory path for the program. We also expect several assets from our early stage solid tumor programs to transition to proof of concept studies this year. And we'll share data from these programs as they mature.
In the area of immunology, as I previously mentioned, we expect regulatory decisions later this year for Upadacitinib in RA and Risankizumab in psoriasis. In addition to their leave indications, we continue to make great progress with Upadacitinib and Risankizumab in a number of other immune-mediated conditions. This year, we'll report mid-stage data for Upadacitinib and Axial SpA and we plan to begin phase three development in giant cell arteritis. Overall, this year we'll have ten active ongoing registration enabling programs for Upadacitinib and Risankizumab.
We're also making good progress with our early stage immunology pipeline, which includes programs aimed at redefining the standard of care in autoimmune diseases. We have several promising assets, including ABBV-323, our CD40 antagonist. ABBV-3373, our PNF steroid conjugate, and ABBV-599, our combination jack BTK inhibitor. And in the area of women's health, following completion of the pivotal trials for Elagolix and uterine fibroids, we plan to submit our regulatory application around the middle of the year.
So, in summary, in 2018 we made tremendous progress advancing our pipeline, achieving a number of key clinical and regulatory milestones across all of our therapeutic areas. And we expect 2019 to be another very productive year for our R&D organization. We look forward to updating you on our pipeline progress throughout the year. With that, I'll turn the call over to Bill for additional comments on our 2018 performance and our 2019 guidance.
Bill Chase -- Executive Vice President of Finance and Administration
Thanks, Mike. Today, I'll review the highlights of our performance for the fourth quarter and full-year 2018 and then walk through our 2019 outlook. As Rick mentioned, we have completed another year of outstanding performance delivering top and bottom line growth that ranks AbbVie among the very top of our industry peers. We reported adjusted earnings per share of $7.91 up more than 40% compared to 2017 and one $1.44 above the midpoint of our initial expectations for the year. For the year, adjusted revenues were $32.7 billion, up 15.2% on an operational basis excluding a nearly 1% favorable impact from foreign exchange.
For the fourth quarter, total revenues were $8.3 billion, an increase of 8.3% on an operational basis excluding a 1% unfavorable impact from foreign exchange. This performance reflects double-digit underlying volume growth offset by approximately 2.5 points of negative price. Global sales of Humira were $4.9 billion in the quarter up 1.4% operationally. In the US, Humira sales increased 9.1% compared to the prior year, reflecting high single-digit volume growth plus price. Wholesale or inventory levels remain below half a month in the quarter. International Humira sales were $1.3 billion in the quarter down 14.8% operationally, reflecting the introduction of biosimilar competition across Europe and other international markets.
Global Humira sales for the full year 2018 were $19.9 billion reflecting operational sales growth of 7.4%. Full-year sales of Humira in the US grew more than 10% and international Humira sales approached $6.3 billion performing in line with our expectations. Hematologic oncology global sales were $1.1 billion in the quarter up 50.3% on an operational basis driven by the continued strong growth of both Imbruvica and Venclexta. In the quarter, Imbruvica net revenues were $1 billion primarily driven by continued uptake in the frontline CLL segment. Venclexta revenues were $124 million in the quarter driven by continued uptake in the second line plus setting as a result of our mid-year approval in the broad relapse refractory CLL segment. For the full year, our hem/onc global revenues were $3.9 billion up 45.8% on an operational basis.
Global HCV sales for the fourth quarter were $862 million. Mavyret continues to perform well, holding roughly 50% market share globally. For the full year, HCV sales exceeded $3.6 billion and was above our previously communicated guidance. We also saw continued double-digit operational sales growth for both Duodopa and Creon. Turning now to the P&L profile for the fourth quarter, adjusted gross margin was 79.8% of sales, up 80 basis points compared to the prior year. This was inclusive of the year-over-year benefit related to the termination of certain royalties with Humira, partially offset by the dilute of impact of partnership accounting. Adjusted R&D was 16.5% of sales supporting our pipeline programs in oncology, immunology, and other areas.
Adjusted SGNA was 21.6% of sales, an increase of 30 basis points versus the prior year, reflecting continued investment in our on-market products, as well as investment in advance of several upcoming product launches. The adjusted operating margin was 41.7% of sales in the fourth quarter, an improvement of over 100 basis points versus the prior year. Net interest expense was $319 million, and the adjusted tax rate was 9.1% in the quarter. Fourth quarter adjusted earnings per share, excluding specified items, were $1.90 up 28.4% year-over-year. In the quarter, we recorded a net charge of $2.75 per share related to the partial impairment of intangible assets acquired as part of the Stemcentrx acquisition. The net after-tax impact of this impairment and the related adjustment to contingent consideration liabilities was $4.1 billion. This one-time net charge has been excluded from our adjusted EPS results.
As we look ahead to 2019, our full-year adjusted EPS range is $8.65 to $8.75 reflecting growth of 10% at the midpoint. Excluded from this guidance is $1.26 of known intangible amortization and specified items as well as non-cash charges for contingent consideration adjustments related to the expected approval of Risankizumab in the first half of the year. On the top line in 2019, we expect revenue growth of approximately 1% on an operational basis. At current rates, we would expect foreign exchange to have just less than 1% unfavorable impact on reported sales growth. Included in our revenue guidance are the following assumptions for our key products. In 2019, we expect US Humira to once again be an important contributor to our performance with revenue growth of approximately 7%. We expect 2019 international Humira to be down approximately 30% on an operational basis reflecting the impact of biosimilar competition outside of the US.
For our hem/onc franchise, we expect global revenues of approximately $5.1 billion contributing more than $1 billion of growth. This includes Imbruvica global revenues to AbbVie approaching $4.4 billion with US sales growth of approximately 21%. For Venclexta, we expect sales of approximately $725 million. We expect global HCV sales of approximately $3.3 billion in 2019 with a roughly flat performance in the US and international sales of approximately $1.7 billion. For Orilissa, we expect sales of approximately $200 million. We are pleased with the early stages of the launch and expect demand to ramp given recently increased formulary access which now stands at approximately 70%. For Creon, we expect approximately 10% sales growth.
For Duodopa, we expect revenues approaching $500 million. For Lupron, Synthroid, and Synagis, we expect sales to be roughly flat year-over-year. And for Androgel, we are forecasting sales of approximately $100 million following the entry of generic competition for Androgel 1.62. Finally, we are expecting a regulatory decision for both Risankizumab and Upadacitinib later this year. We will provide specific guidance for these assets following their respective approvals.
Looking at the P&L for 2019, we are forecasting an adjusted gross margin ratio of above 82.5%. This profile reflects a year-over-year benefit of the [inaudible] [00:29:20] royalty reduction as well as the impacts of partnership accounting. We are forecasting R&D expense of approximately 15.5% of sales reflecting funding actions supporting all stages of our pipeline. We are forecasting SGNA to be approximately 20.5% of sales in support of five major product or indication launches. For 2019, we are forecasting an operating margin ratio of just above 46.5% roughly 200 basis points above prior year inclusive of the required investment on our new product launches. We expect net interest expense approaching $1.3 billion and we model a non-GAAP tax rate just above our full-year rates in 2018.
Regarding our first quarter outlook, we expect adjusted earnings per share between $2.05 and $2.07, excluding approximately $0.31 of specified items. We anticipate first quarter revenue of approximately $7.7 billion. At current rates, we would expect foreign exchange to have an unfavorable impact on reported sales growth of approximately 2% in the first quarter. For US Humira, we expect sales of approaching $3.2 billion. We expect international Humira sales of approximately $1.2 billion assuming current exchange rates. And for Imbruvica, we expect sales of approximately $1 billion. Moving now to the P&L for the first quarter. We are forecasting adjusted gross margin ratio in line with full-year guidance and spending levels slightly favorable relative to the full-year profile due to investment timing.
We expect an adjusted tax rate just below 8% on the first quarter, lower than our expected full-year rate reflecting the fact that the tax impact of equity compensation is most pronounced in the first quarter of each year. In summary, AbbVie has once again delivered an excellent quarter and full-year results. We've driven top tier revenue in EPS growth while also advancing our strategic priorities and our pipeline. And our strong growth prospects have enabled us to position the business for yet another year of double-digi t earnings growth in 2019 despite biosimilar dynamics and the required investments to support several major product and indication launches. We are very pleased with AbbVie's strong performance. And with that, I'll turn the call back over to Liz.
Questions and Answers:
Liz Shea-- Vice President of Investor Relations
Thanks, Bill. We'll now open the call for questions. Operator, first question, please.
Operator
Thank you. And as a reminder, to ask a question, please press *1. Our first question today is from Steve Scala from Cowen.
Steve Scala-- Cowen -- Analyst
Thank you very much. In 2019, if Humira grows one billion in the US but declines two billion OUS, it would have to grow 11% in 2020 to hit the $21 billion guidance figure. Is that still your expectation?
Secondly, do you anticipate an FDA ADCOM for Upadacitinib? And then lastly, perhaps in part due to AbbVie's openness to do a deal and its desire to have another therapeutic vertical, there's been some speculation that AbbVie might pursue a big deal even in an unfriendly way. Considering the many moving parts at AbbVie, what is your appetite right now for a big deal and would you consider an unfriendly one? Thank you.
Richard Gonzalez-- Chief Executive Officer
Steve, this is Rick. I'll cover one and three and then Mike can cover number two. So, first of all, if you look at Humira, obviously, we continue to see strong growth in the US. We're continuing to see the biosimilar effect play out. We've assumed within our planning period of 2019 that we'll see some continued erosion from a price standpoint across the time period that is greater than what we currently have as currently in place. So obviously, we'll have to see how that plays out. In the end, if we look at the long-term targets that we put in place, we still feel confident in the overall long-term targets, whether or not one product is slightly different than another. I mean, we'll see how that plays out, but we obviously feel confident in what we have committed to and we maintain that commitment.
As far as the appetite for a big deal, I can tell you that is not something that we contemplating.
Michael Severino -- Vice Chairman and President
This is Mike, I'll take number two. With respect to UPA and the potential for an ADCOM, I think it's important to keep in mind that we're in the very early stages of our regulatory review. But if you look at the practice of this review division, it's common for filings like this, for new molecular entities in RA to go to an ADCOM. So, it's certainly possible. But we'll have a much better idea once we're further along in the review process.
Operator
Thank you. Our next question is from Andrew Baum from Citi.
Andrew Baum-- Citi -- Analyst
Thank you. Apologies if I missed the early parts of the call, but just in terms of what's embedded in your 2019 adjusted earnings guidance for Humira in international markets, if you could give us additional color on that that would be great. Second, you recently had a management reorg. Could you talk to that in relation to also planning and the organization? And then finally, you disclosed a couple of negative headlines in Q phase three, the leuprolide trials over a year ago. I haven't seen the data for that. Its border interest is what it's for -- when might we see that data being presented? Many thanks.
Bill Chase -- Executive Vice President of Finance and Administration
Hi, Andrew. I'll start with your first question. It's Bill Chase. Our guidance around Humira for 2019 is in the US strong growth 7% is what we are recommending that you model. Outside of the US, obviously, with the advent of biosimilars we are forecasting a decline and currently, we view that as about 30% on an operational basis.
Richard Gonzalez-- Chief Executive Officer
Andrew, this is Rick. I'll cover number two. We did announce a change in our organizational structure at the executive level. The purpose of that change -- we've operated now for six years with a fairly broad management structure reporting into me. The purpose of the change really was to narrow the focus of the direc t report s that I had that ultimately would allow us to focus and execute even at a higher level around where our strategy is going forward.
In addition, we have a very talented executive leadership team and we wanted to get those people some additional experience in other areas and this will allow us to be able to do that. I've heard all the rumors about potentially me retiring. I can tell you they are not true. As many of you probably know, I retired once, and I can tell you I'm a heck of a lot better at running AbbVie than I was at retirement. Hopefully, that clarifies it.
Michael Severino -- Vice Chairman and President
This is Mike. With respect to the leuprolide data. So, we announced those top climbers, ultimately, we had them. We're committed to publishing all results and making the data available. I don't have a specific meeting or specific timeframe to point to here on the call today. But we will be making those data publicly available.
Operator
Thank you. Our next question is from Geoff Meacham from Barclays.
Geoff Meacham-- Barclays -- Analyst
Hey, guys. Thanks for the question. Just had a few on Humira. For OUS, are there countries that still need to be contractually locked in for '19 and with your new guidance bill, are there resets at year-end looking to 2020 and beyond? And then, when you guys talk about the US, the strategy seems to be moving Humira to later in the paradigm across different markets. And then, you patent Risa upstream. As you guys get closer to launch, are you thinking about -- how is the contracting gonna make this happen? Is it just about discounts or rebates or are there more novel strategies under discussion? Thanks, guys.
Richard Gonzalez-- Chief Executive Officer
This is Rick. I'll cover those first two. There are still some countries where obviously it is still evolving. The southern European countries are probably the most significant and to some extent, Germany. I'd say we've haven't seen a lot of movement in place over the last 60 days or so, but we are anticipating -- and as I've said, we built into our forecast some incremental decline in place just to make sure that we felt comfortable with where potentially could go. As far as other countries in 2020, the majority of the volume doesn't come under additional biosimilar exposure in 2020. The more significant countries are in 2021. There is some but the majority of it occurs in 2021, not in '20.
As far as what you described as contracting dynamics, I think if you talk about our go-to-market strategy for these products, we're not in a position nor from a competitive standpoint do I think we would want to talk about it at this point where our go-to-market strategy is. But I think in general, the way you can think about these assets -- and it's certainly the way we're thinking about it is -- now that we've produced the data on Upa and Risa across the broad range of indications. It has validated for us that these assets ultimately are superior to what's out there today.
And clearly, as I indicated, we've now had enough data across a broad range of clinical trials and across a broad range of patient population from naïve patients to TNF inadequate responding patients. That we know these assets will ultimately be able to deliver significantly superior results through both Humira as well as other assets that are out there, other medicines that are out there. And therefore, the logical strategy with these assets is to position them to be lead products in the marketplace. We would obviously put a contracting strategy in place that would be consistent with that approach and obviously, we will fund those launches in a way to be able to drive that approach in the marketplace both in the US as well as outside of the US. And we expect the uptake to be consistent with the profile of those assets.
Operator
Thank you. Our next question is from Tim Anderson from Wolfe Research.
Tim Anderson-- Wolfe Research -- Analyst
Thanks so much for the questions. I have a question on spending infrastructure over the long-term. So naturally, the big concern is Humira biosimilars and how that impacts with P&L and what other levers you could potentially pull is cutting cost. At some point in the future, and I know you've given long-term operating margin guidance, but can you give us kinda more detail on how you see SGNA and R&D evolving over time. I'm wondering if you can cull large amounts of spending out of these line items. It seems like that could be challenging in the context of still investing heavily in the I&I space with your other assets. So how much is spending a major lever that can be pulled in the future?
And then the second question just goes back to Humira international. In October, you revised down your erosion guidance and now just three months later you've revised it down again in terms of international performance for 2019. Can we be confident that you won't have to revise it down yet again at another point in the current year? Thank you.
Richard Gonzalez-- Chief Executive Officer
Tim, this is Rick. I'll cover most of those questions and Bill can fill in with anything I haven't covered. So, let me start with what you described as the guidance. And let me go through the history of the guidance because I think it is important to lay out. We came out with the original guidance back in 2015 and that was based on what we saw in the marketplace primarily at the time, Remicade, and then followed it with Enbrel. And we updated it I think in 2017 specifically what we thought.
And then, from that point forward, we said we needed to see what it would look like going forward. On the third quarter call, from the best of my recollection, we were three weeks into biosimilars, right? And we made it fairly clear, and I think if you go back and you read the transcript, it's fairly clear. What we were giving the market was a snapshot of what we saw at that time. And in fact, I think I said at the time, you should not assume this as guidance. It's likely to get worse. So, hopefully, we were clear at that point. As far as specifically to your question. As I indicated, we have built in further erosion that we haven't seen yet.
So, in the number that Bill described, the 30-31%, which is roughly five points above where it was before, that has some assumed erosion that has not occurred. Look, what we're giving you is our best estimate of what will happen. Obviously, this is driven by not us, it's driven by competitors and their behavior. And so, ultimately, it's not like we have a crystal ball that we can predict exactly what they do. What I can tell you is this; we have a high level of confidence in delivering the bottom line performance that we described to the market and we have enough ability to be able to do that and we have a high level of confidence in double-digit EPS.
So, that's what you should rely upon. Whether or not things move around a little bit, they could. But to the best of our ability, we're forecasting what we believe, and I think I'd say, it's a reasonably high probability that those numbers should be accurate. As far as spending in infrastructure, obviously, as we look at what's going on in these various markets, just like we do with any product that experiences an LOE, we flex as quickly as possible the spending around those products to be reflective of what's appropriate in that particular market and under those circumstances.
And we're certainly doing that with Humira right now in the international markets. But obviously, one of the things that's important to remember here is we've either just launched or will launch over the course of the next 12 months four major products that have multi-billion-dollar potential. If you think about Venetoclax, it's in its very early stages now, it's just received the broad label in CLL and in AML, so it's essentially a relatively small product that's now growing rapidly. Orilissa, we just launched that product. We're gonna launch Upadacitinib. We're gonna launch Risankizumab. These are all multi-billion-dollar assets. We're gonna fund those to the extent that is appropriate to drive the potential because that is ultimately what will offset and absorb the biosimilar impact. And so, that's the strategy that we'll drive.
Bill Chase -- Executive Vice President of Finance and Administration
The only thing I'd add is, as you look at the 50% -- the big part of the story from here on out is gonna be obviously P&L leverage given the robust sales that we're expecting once these new products get up to into their ramps. So, 2020 should be a sales expansion year. But even then, we're always gonna be thoughtful about how we deploy our resources. You look at this year on an operational sales increase of 1%, we're still delivering 200 basis points of op margin progress.
I think that's pretty good. And we're appropriately funding those new product launches. The only way you can do that is being thoughtful about your overall book of SGNA and do some prudent reallocation and obviously, you could infer that that's happening in the numbers this year. So, look, we're always gonna be thoughtful on spend but the real way to get to an improved op margin is gonna be through sales leverage, P&L leverage and we're gonna remain focused on making sure that we appropriately fund new opportunities.
Richard Gonzalez-- Chief Executive Officer
The only other thing I'd add is; I think it's important to keep in perspective how this business is performing. You have a business here that for six years has delivered top tier performance. Last year they grew the bottom line 41%, through the top line 15%. If you look at 2019 and you look at that guidance range at the midpoint being 10%, you back out the share repurchase, which is about three or four points of it, it says that the underlying business despite taking almost a $2.5 billion hit, is growing at 6-7% from an EPS standpoint. If you adjusted for the $2.5 billion, the bottom line is growing at 23%.
There aren't many businesses around here that have that kinda performance. At the top line, the same thing. If I adjust the top line, which is roughly 1%, if I adjust it for the $2.5 billion, the rest of the business is growing high single digits. And so, you certainly want to make sure that you're in a position that you can continue to drive this business in a way that it can continue to perform because that is ultimately the way you're gonna absorb biosimilars. And I would tell you that despite the fact that these biosimilars have priced more aggressively than we thought, or the analogs would've suggested, the business is absorbing them effectively. And that's what the strategy was designed to do.
Operator
Thank you. Our next question is from Geoffrey Porges from SVB Leerink.
Geoffrey Porges-- SVB Leerink -- Analyst
Thank you very much for taking the questions. First, could you just talk a little bit about pricing, Rick? What assumptions about pricing have you baked into your guidance for particularly US revenue growth in 2019? And what do you think of the political risks that could affect that outlook?
And then secondly, could you talk a little bit about the launches of Upa and Ris in 2019? Could you help us understand what, if any ability you have, to prepare for those launches in your discussions with payers? Should we be expecting them to launch with the same sort of trajectories as their preceding products in that class or should we push those launches out to 2020 as you get into that payer cycle? Thanks.
Richard Gonzalez-- Chief Executive Officer
I think as you look at pricing, we have now -- we were one of the companies that made a commitment that we're gonna do one price increase per year a couple of years ago and it would be below double-digits. And we've obviously ironed that going forward. So, we've done the price increase for this year. You saw that it was lower, 6.2% roughly. So, I think you know what the pricing will be in 2019 because we have no intention of doing another price increase in 2019.
I think if you look overall, yes, the industry has adjusted to some extent. I believe to the environment as it relates to pricing. Our business is not a business that is driven to any great extent by pricing. We're fortunate that we have innovative products and volume is the vast majority of it. Bill, you're probably talking about -- well, in 2019, you're probably talking about overall negative price.
Bill Chase -- Executive Vice President of Finance and Administration
For the entire book, including the US, low single digit.
Richard Gonzalez-- Chief Executive Officer
So, it's not heavily reliant upon price nor last year was it heavily reliant upon price. So, I think we're comfortable with where we are from a pricing standpoint. We don't see any exposure related to that. As far as Upa and Risa, obviously, we will want to get these products on formulary as broadly and as quickly as possible. I would say that's an area that we have a team that is good at doing that, effective at doing that. And so obviously, based on the fact that we assume Ris is gonna be approved here in the not too distant future, we have to be in a position where we are in discussions.
Nothing that I'm gonna update you here on but I would say the operating assumption that is probably a good assumption is that we will end up with broad coverage of these assets. As far as the ramp is concerned, I think I understood your question and I'm gonna answer it in the backdrop of what I thought you asked. What I thought you asked is, how would I compare these -- the prior competitive launches.
I can tell you that we would expect, like other launches, they will take a little bit of time in order to ramp, but I'd say also with our expertise in this area and the portfolio of assets that we have and the profile of these particular drugs. From a clinical standpoint, I would expect that these assets will be able to drive significant share over time. And a significant capture of new patients and switching patients and that'll certainly be the strategy we have in place to drive a significant part of those available patients to these better assets.
Operator
Thank you. Our next question is from Chris Schott from JP Morgan.
Chris Schott-- JP Morgan -- Analyst
Great. Thanks very much for the questions. My first one is just following up on the longer-term international Humira business, so beyond 2019. Do you see 2019 as a peak rate of erosion for that business and then maybe a more moderate step downs beyond 2019? Or could we see several years of this more severe erosion level as we just think about kinda getting past this year and the outlook for that business?
My second question was on capital allocation. And I guess as the more challenging your Humira environment change or alter your priorities at all, specifically, the company's been very active on the sheer repo front over the past few years. How do you balance that repo with priority with diversification given some of these Humira dynamics that we're seeing playing out? Thank you.
Richard Gonzalez-- Chief Executive Officer
So, I think I would see that you have gotten the vast majority of the impact from a price erosion standpoint in 2019. But, remember what I described before. We have factored into our plan further erosion as you go throughout the year. So, there'll be some annualization impact that you would obviously see in 2020 if that is to kinda play out the way that we have planned for. And then, you will have some countries that will go biosimilar in '21 that have not gone biosimilar to date. And they would obviously have some impact, although I would say most of those countries it should be a lower impact but we're gonna have to see how that sorts itself out.
So, certainly, I don't think you'll see a step down that's as significant as we've seen in the first year because there have been very aggressive prices in certain countries and so you'll obviously get to the point at which the biosimilar players have gotten to what they believe is the floor where they wanna operate. And so, I think you should see it moderate, I guess is the best way to describe it. As far as capital allocation versus share repo, if you look at how we've operated this business since day one, we've obviously been very vocal about how we view the business and what our mission is and what our vision is for the business. And that is to drive long-term, sustainable top tier performance.
And in order to do that, you have to invest in the business appropriately. We've obviously invested significantly in R&D since we launched the company we grew R&D significantly. We've obviously been very active from a PD standpoint. At the same time, we have a business that generates a tremendous amount of cash flow and we generated enough cash flow that we had opportunities to be able to also do share repurchase and other methods of being able to return capital to shareholders such as a growing dividend. And so, we tried to balance those things in a way that is appropriate but never to not strategically invest in the business. That's always our first priority.
If you look at the share repo that we've done in 2018 as an example -- I think the thing you have to remember and the numbers I quoted, you a minute ago I think are reflective of that. Yes, share repo is driving some of the EPS growth if you look at the midpoint. But it's relatively modest, 3-4% of that. It wasn't driven for the purpose of doing that. Ultimately, we did the share repo and we announced it I believe in that first quarter call that we were gonna do a significant amount of share repo because of tax reform, and we thought that was fundamentally important to be able to return cash and capital back to shareholders.
So, we did it long before we ever knew what the biosimilar pricing would be. So, it wasn't driven for the purpose of driving the short-term versus the long-term. Having said all that, we continue to be active in looking at opportunities that are out there. We have a very active business development group. We look at things that are small, things that are medium, things that are large, and we certainly have the wherewithal to be able to do things. If we can find something that's strategically fit and we could get a good return on that, I can tell you we would act, and we would act swiftly in order to do that. I think you've seen us do that before.
If we could find another Imbruvica or we could find another Risankizumab out there, I can tell you we would aggressively pursue that. And so, we fundamentally have a pipeline that we believe has the ability to do what we strategically intended it to do, and that is to absorb the impact of biosimilars. Our focus is to ramp that pipeline as rapidly as we possibly can and make sure we're in a position to be able to continue to drive strong growth in the business.
Operator
Thank you. Our next question is from Jason Gerberry from Bank of America.
Jason Gerberry-- Bank of America -- Analyst
Hey, good morning, and thanks for taking my questions. First one, just coming back to US Humira, just curious -- the softening of the 2019 number. Just sort of curious; to what degree is that cannibalization from the next generation immunology brands? Just sort of curious if that's a factor of it really was just sort of maybe the moderation of pricing. And then my second question; I guess with Jamie no longer on these calls, I'll ask the question. Rick, how are you defining a large M&A deal? That's a question that we're getting from investors. So, if you can maybe put some parameters around it that'd be great. Thank you.
Richard Gonzalez-- Chief Executive Officer
Last time I defined a large bolt on it had an undesirable reaction in the marketplace. Look, the largest transaction that we've done so far has been Pharmacyclics. That's what I view as the size of a roughly bolt on kinds of transaction. When I say a large deal, I'm thinking about a very significant kind of deal. Merger type deals. We're not contemplating anything of that magnitude at all. US Humira, you wanna cover that, Bill?
Bill Chase -- Executive Vice President of Finance and Administration
Yeah, sure. So, if you look at US Humira, we're guiding 7% in 2019. That's coming off of a number in '18 of 10% and as I think you pointed out, a lighter price increase on the year. So, if you really factor out the change in pricing year-over-year, you'll see that the business is still performing very, very well. Volumes are still pretty much pegged right where they have been historically. You've got the law of large numbers here, a little bit. But I wouldn't read much into underlying dynamics on Humira other than continued strong performance in the US.
Liz Shea-- Vice President of Investor Relations
Thanks, Jason. Operator, we have time for one final question.
Operator
Thank you. Our final question today is from Katherine Xu from William Blair.
Katherine Xu-- William Blair -- Analyst
Good morning. I'm just curious about the hem/onc franchise strategy. Apparently, [inaudible] [01:00:51] and [inaudible] are doing well. What are you thinking about boosting over that? There is, of course, the pediatric taste that you used to have with other companies and returned and there's also the seller therapy that was a very big space. Just wondering about your general strategy there?
Michael Severino -- Vice Chairman and President
This is Mike, I'll take that. With respect to our hem/onc franchise. Both Imbruvica and Venclexta are performing very well. Both from a data perspective and from their trajectories in the marketplace. One of the things that I think is particularly attractive about those two with respect to our franchise is that they cover a broad range of heme malignancies. They work well together in areas like CLL and mantle cell lymphoma and CL. And then they also have some unique areas.
For example, like Venetoclax in AML. So that's gonna be an important area for us going forward. It's now annualizing over $4 billion. It's growing at a robust rate. So, I think you can expect to see us continue to work in this area. We're gonna look at how we not only continue to develop those mechanisms in areas like multiple myeloma for Venclexta. But also, how from our earlier pipeline we can add additional mechanisms so that'll further strengthen our position in hem/onc.
There are a lot of things in our early now approaching mid-stage pipeline, working apoptosis in other areas that could apply there. And of course, we're looking more broadly than that. You've seen us do early stage deals but early stage deals that give us access to interesting technologies. We have some very early plays that could be aimed toward cellular therapies. And to other mechanisms that could further develop that franchise.
Liz Shea-- Vice President of Investor Relations
Thanks, Katherine. That concludes today's conference call. If you'd like to listen to a replay of the call, please visit our website at investors.abbv.com. Thanks again for joining us.
Operator
Thank you. And this does conclude today's conference. You may disconnect at this time.
Duration:60 minutes
Call participants:
Liz Shea-- Vice President of Investor Relations
Richard Gonzalez-- Chief Executive Officer
Michael Severino -- Vice Chairman and President
Bill Chase -- Executive Vice President of Finance and Administration
Steve Scala-- Cowen -- Analyst
Andrew Baum-- Citi -- Analyst
Geoff Meacham-- Barclays -- Analyst
Tim Anderson-- Wolfe Research -- Analyst
Geoffrey Porges-- SVB Leerink -- Analyst
Chris Schott-- JP Morgan -- Analyst
Jason Gerberry-- Bank of America -- Analyst
Katherine Xu-- William Blair -- Analyst
More ABBV analysis
This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of November 14, 2018
Motley Fool Transcription has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | 10 stocks we like better than AbbVie When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. * David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! AbbVie Inc. (NYSE: ABBV) Q4 2018 Earnings Conference Call Jan. 25, 2019, 9:00 a.m. | 10 stocks we like better than AbbVie When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. * David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! Duration:60 minutes Call participants: Liz Shea-- Vice President of Investor Relations Richard Gonzalez-- Chief Executive Officer Michael Severino -- Vice Chairman and President Bill Chase -- Executive Vice President of Finance and Administration Steve Scala-- Cowen -- Analyst Andrew Baum-- Citi -- Analyst Geoff Meacham-- Barclays -- Analyst Tim Anderson-- Wolfe Research -- Analyst Geoffrey Porges-- SVB Leerink -- Analyst Chris Schott-- JP Morgan -- Analyst Jason Gerberry-- Bank of America -- Analyst Katherine Xu-- William Blair -- Analyst More ABBV analysis This article is a transcript of this conference call produced for The Motley Fool. | 10 stocks we like better than AbbVie When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. * David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! Duration:60 minutes Call participants: Liz Shea-- Vice President of Investor Relations Richard Gonzalez-- Chief Executive Officer Michael Severino -- Vice Chairman and President Bill Chase -- Executive Vice President of Finance and Administration Steve Scala-- Cowen -- Analyst Andrew Baum-- Citi -- Analyst Geoff Meacham-- Barclays -- Analyst Tim Anderson-- Wolfe Research -- Analyst Geoffrey Porges-- SVB Leerink -- Analyst Chris Schott-- JP Morgan -- Analyst Jason Gerberry-- Bank of America -- Analyst Katherine Xu-- William Blair -- Analyst More ABBV analysis This article is a transcript of this conference call produced for The Motley Fool. | 10 stocks we like better than AbbVie When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. * David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! Duration:60 minutes Call participants: Liz Shea-- Vice President of Investor Relations Richard Gonzalez-- Chief Executive Officer Michael Severino -- Vice Chairman and President Bill Chase -- Executive Vice President of Finance and Administration Steve Scala-- Cowen -- Analyst Andrew Baum-- Citi -- Analyst Geoff Meacham-- Barclays -- Analyst Tim Anderson-- Wolfe Research -- Analyst Geoffrey Porges-- SVB Leerink -- Analyst Chris Schott-- JP Morgan -- Analyst Jason Gerberry-- Bank of America -- Analyst Katherine Xu-- William Blair -- Analyst More ABBV analysis This article is a transcript of this conference call produced for The Motley Fool. |
25138.0 | 2019-01-25 00:00:00 UTC | AbbVie Q4 Earnings: 3 Key Things You Need to Know | ABBV | https://www.nasdaq.com/articles/abbvie-q4-earnings-3-key-things-you-need-know-2019-01-25 | nan | nan | It's obvious that AbbVie 's (NYSE: ABBV) fourth-quarter earnings update didn't please Wall Street. Shares of the big drugmaker fell nearly 7% in early trading on Friday morning following AbbVie's earnings release.
But what was AbbVie's bad news? Did the market overreact? What's next for AbbVie? Here are the three key things you need to know from the company's Q4 update.
1. Misses on revenue and earnings
Investors have become accustomed to AbbVie beating Wall Street estimates. It didn't happen this time around.
AbbVie reported Q4 revenue of $8.3 billion, up 7.3% year over year. Analysts were expecting revenue of $8.38 billion. The company posted adjusted earnings per share (EPS) of $1.90. This reflected strong year-over-year growth of 28.4%. However, the consensus Wall Street adjusted EPS estimate was $1.94.
The big pharma company's GAAP earnings numbers especially looked bad. AbbVie reported a loss of $1.23 per share. This loss resulted from a big write-off related to its Stemcentrx acquisition following clinical failures for experimental cancer drug Rova-T .
2. Challenging times for Humira
Going into AbbVie's Q4 update, all eyes were focused on how Humira would fare in its first quarter facing biosimilar competition in Europe. AbbVie CEO Rick Gonzalez had warned in the company's Q3 conference call that competitors were discounting their biosimilars more than expected.
AbbVie reported Q4 sales of Humira of $4.9 billion. This included U.S. sales of $3.6 billion and international sales of $1.3 billion. Although international sales fell nearly 15% year over year, the decline was pretty much in line with what I expected .
U.S. sales, though, were a little lower than what I thought they'd be. My view was that AbbVie would report U.S. sales of Humira of around $3.7 billion.
3. Relatively weak 2019 guidance
Another key story from AbbVie's Q4 update was the company's guidance for 2019. AbbVie projected adjusted diluted earnings per share (EPS) this year between $8.65 and $8.75. This reflects growth of 10% at the midpoint.
Achieving that level of growth might not sound too bad. But AbbVie has delivered adjusted EPS growth at a compound annual growth rate (CAGR) of 20% over the last five years. Falling to 10% growth is definitely a step backward for the drugmaker.
The big culprit for the relatively weak guidance is Humira. AbbVie expects international sales for its top-selling drug will plunge 30% in 2019. The company thinks that U.S. sales will continue to grow, but AbbVie will feel the impact of taking lower price increases than in the past.
Looking ahead
There's no question that AbbVie is at a turning point. The company has been planning for the day that it would face a serious threat to Humira. That day has arrived.
However, AbbVie's hematologic oncology drugs Imbruvica and Venclexta are going strong, with more growth likely on the way. New drug Orilissa should have blockbuster potential. The company is also on the cusp of potentially winning approvals for two other drugs that could be major blockbusters -- risankizumab and upadacitinib.
AbbVie disappointed Wall Street in the fourth quarter. But with its strong dividend and sustained growth potential despite the challenges for Humira, the pharma stock still looks like a smart pick for long-term investors.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of November 14, 2018
Keith Speights owns shares of AbbVie. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The company thinks that U.S. sales will continue to grow, but AbbVie will feel the impact of taking lower price increases than in the past. It's obvious that AbbVie 's (NYSE: ABBV) fourth-quarter earnings update didn't please Wall Street. Shares of the big drugmaker fell nearly 7% in early trading on Friday morning following AbbVie's earnings release. | AbbVie reported Q4 revenue of $8.3 billion, up 7.3% year over year. Relatively weak 2019 guidance Another key story from AbbVie's Q4 update was the company's guidance for 2019. It's obvious that AbbVie 's (NYSE: ABBV) fourth-quarter earnings update didn't please Wall Street. | AbbVie reported Q4 sales of Humira of $4.9 billion. My view was that AbbVie would report U.S. sales of Humira of around $3.7 billion. But AbbVie has delivered adjusted EPS growth at a compound annual growth rate (CAGR) of 20% over the last five years. | What's next for AbbVie? My view was that AbbVie would report U.S. sales of Humira of around $3.7 billion. It's obvious that AbbVie 's (NYSE: ABBV) fourth-quarter earnings update didn't please Wall Street. |
25139.0 | 2019-01-25 00:00:00 UTC | Health Care Sector Update for 01/25/2019: AZN,IDXG,ABBV | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-01252019-aznidxgabbv-2019-01-25 | nan | nan | Top Health Care Stocks
JNJ +0.74%
PFE -0.31%
ABT +0.19%
MRK -0.07%
AMGN -1.13%
Health care stocks have turned narrowly higher this afternoon, including a nearly 0.1% gain for the NYSE Health Care Index in recent trade. Shares of health care companies in the S&P 500 also were up almost 0.1% as a group while the Nasdaq Biotechnology index was climbing over 0.9%.
Among health care stocks moving on news:
(-) Astrazeneca ( AZN ) was fractionally lower during Friday trading after the drugmaker completed the $1.6 billion sale of US rights for the Synagis antibody used to prevent severe respiratory syncytial virus infections in infants and young children to Swedish Orphan Biovitrumm, receiving $1 billion in cash and an 8% equity stake in the smaller drugmaker.
In other sector news:
(-) Interpace Diagnostics Group ( IDXG ) tumbled over 16% to a record low on Friday after the cancer diagnostics company priced a $7 million public offering of 9.3 million common shares at 75 cents apiece, representing a 16.7% discount to Thursday's closing price.
(-) AbbVie ( ABBV ) dropped over 6% after posting adjusted Q4 net income of $1.90 per share, improving on its $1.48 per share non-GAAP profit during the same quarter last year but still missing the $1.93 consensus call.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (-) AbbVie ( ABBV ) dropped over 6% after posting adjusted Q4 net income of $1.90 per share, improving on its $1.48 per share non-GAAP profit during the same quarter last year but still missing the $1.93 consensus call. Shares of health care companies in the S&P 500 also were up almost 0.1% as a group while the Nasdaq Biotechnology index was climbing over 0.9%. Among health care stocks moving on news: (-) Astrazeneca ( AZN ) was fractionally lower during Friday trading after the drugmaker completed the $1.6 billion sale of US rights for the Synagis antibody used to prevent severe respiratory syncytial virus infections in infants and young children to Swedish Orphan Biovitrumm, receiving $1 billion in cash and an 8% equity stake in the smaller drugmaker. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (-) AbbVie ( ABBV ) dropped over 6% after posting adjusted Q4 net income of $1.90 per share, improving on its $1.48 per share non-GAAP profit during the same quarter last year but still missing the $1.93 consensus call. In other sector news: (-) Interpace Diagnostics Group ( IDXG ) tumbled over 16% to a record low on Friday after the cancer diagnostics company priced a $7 million public offering of 9.3 million common shares at 75 cents apiece, representing a 16.7% discount to Thursday's closing price. | (-) AbbVie ( ABBV ) dropped over 6% after posting adjusted Q4 net income of $1.90 per share, improving on its $1.48 per share non-GAAP profit during the same quarter last year but still missing the $1.93 consensus call. Health care stocks have turned narrowly higher this afternoon, including a nearly 0.1% gain for the NYSE Health Care Index in recent trade. Among health care stocks moving on news: (-) Astrazeneca ( AZN ) was fractionally lower during Friday trading after the drugmaker completed the $1.6 billion sale of US rights for the Synagis antibody used to prevent severe respiratory syncytial virus infections in infants and young children to Swedish Orphan Biovitrumm, receiving $1 billion in cash and an 8% equity stake in the smaller drugmaker. | (-) AbbVie ( ABBV ) dropped over 6% after posting adjusted Q4 net income of $1.90 per share, improving on its $1.48 per share non-GAAP profit during the same quarter last year but still missing the $1.93 consensus call. Shares of health care companies in the S&P 500 also were up almost 0.1% as a group while the Nasdaq Biotechnology index was climbing over 0.9%. Among health care stocks moving on news: (-) Astrazeneca ( AZN ) was fractionally lower during Friday trading after the drugmaker completed the $1.6 billion sale of US rights for the Synagis antibody used to prevent severe respiratory syncytial virus infections in infants and young children to Swedish Orphan Biovitrumm, receiving $1 billion in cash and an 8% equity stake in the smaller drugmaker. |
25140.0 | 2019-01-25 00:00:00 UTC | AbbVie (ABBV) Lags Q4 Earnings and Revenue Estimates | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-lags-q4-earnings-and-revenue-estimates-2019-01-25 | nan | nan | AbbVie (ABBV) came out with quarterly earnings of $1.90 per share, missing the Zacks Consensus Estimate of $1.92 per share. This compares to earnings of $1.48 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -1.04%. A quarter ago, it was expected that this drugmaker would pos t earnings of $2.01 per share when it actually produced earnings of $2.14, delivering a surprise of 6.47%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
AbbVie, which belongs to the Zacks Large Cap Pharmaceuticals industry, posted revenues of $8.31 billion for the quarter ended December 2018, missing the Zacks Consensus Estimate by 0.63%. This compares to year-ago revenues of $7.74 billion. The company has topped consensus revenue estimates two times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call .
AbbVie shares have lost about 6.8% since the beginning of the year versus the S&P 500's gain of 5.4%.
What's Next for AbbVie?
While AbbVie has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power o f earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for AbbVie was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $2.03 on $7.96 billion in revenues for the coming quarter and $8.68 on $33.51 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Large Cap Pharmaceuticals is currently in the top 37% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Get Free Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie (ABBV) came out with quarterly earnings of $1.90 per share, missing the Zacks Consensus Estimate of $1.92 per share. AbbVie, which belongs to the Zacks Large Cap Pharmaceuticals industry, posted revenues of $8.31 billion for the quarter ended December 2018, missing the Zacks Consensus Estimate by 0.63%. AbbVie shares have lost about 6.8% since the beginning of the year versus the S&P 500's gain of 5.4%. | AbbVie, which belongs to the Zacks Large Cap Pharmaceuticals industry, posted revenues of $8.31 billion for the quarter ended December 2018, missing the Zacks Consensus Estimate by 0.63%. AbbVie (ABBV) came out with quarterly earnings of $1.90 per share, missing the Zacks Consensus Estimate of $1.92 per share. AbbVie shares have lost about 6.8% since the beginning of the year versus the S&P 500's gain of 5.4%. | AbbVie (ABBV) came out with quarterly earnings of $1.90 per share, missing the Zacks Consensus Estimate of $1.92 per share. AbbVie, which belongs to the Zacks Large Cap Pharmaceuticals industry, posted revenues of $8.31 billion for the quarter ended December 2018, missing the Zacks Consensus Estimate by 0.63%. AbbVie shares have lost about 6.8% since the beginning of the year versus the S&P 500's gain of 5.4%. | AbbVie (ABBV) came out with quarterly earnings of $1.90 per share, missing the Zacks Consensus Estimate of $1.92 per share. AbbVie, which belongs to the Zacks Large Cap Pharmaceuticals industry, posted revenues of $8.31 billion for the quarter ended December 2018, missing the Zacks Consensus Estimate by 0.63%. AbbVie shares have lost about 6.8% since the beginning of the year versus the S&P 500's gain of 5.4%. |
25141.0 | 2019-01-25 00:00:00 UTC | Coherus Reaches Settlement With AbbVie Securing Rights To Commercialize CHS-1420 | ABBV | https://www.nasdaq.com/articles/coherus-reaches-settlement-abbvie-securing-rights-commercialize-chs-1420-2019-01-25 | nan | nan | (RTTNews.com) - Coherus BioSciences Inc. (CHRS) said it has executed settlement agreements with AbbVie Inc. that grant Coherus global, non-exclusive license rights under AbbVie's intellectual property to commercialize CHS-1420, Coherus' proposed adalimumab (HUMIRA) biosimilar.
The global settlements resolve all pending disputes between the parties related to Coherus' adalimumab biosimilar. Under the U.S. settlement, Coherus' license period in the U.S. commences on December 15, 2023. Coherus will pay royalties to AbbVie. Financial terms are not disclosed.
CHS-1420 is among a number of significant biosimilar candidates in Coherus' pipeline of high-value treatments for patients in need, which include the company's biosimilar candidates directed to Enbrel, Lucentis and Eylea.
The company is currently preparing its biologics license application for CHS-1420 for submission to the U.S. Food and Drug Administration, with anticipated filing in late 2019.
Upon the expected U.S. market launch of CHS-1420 in late 2023, the company believes it will be well-positioned to effectively leverage the commercial infrastructure it has already deployed for its recent U.S. launch of UDENYCA (pegfilgrastim-cbqv). Coherus continues to evaluate options and potential strategies for ex-U.S. commercialization of CHS-1420.
Read the original article on RTTNews (http://www.rttnews.com/2972767/coherus-reaches-settlement-with-abbvie-securing-rights-to-commercialize-chs-1420.aspx)
For comments and feedback: contact editorial@rttnews.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Read the original article on RTTNews (http://www.rttnews.com/2972767/coherus-reaches-settlement-with-abbvie-securing-rights-to-commercialize-chs-1420.aspx) For comments and feedback: contact editorial@rttnews.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews.com) - Coherus BioSciences Inc. (CHRS) said it has executed settlement agreements with AbbVie Inc. that grant Coherus global, non-exclusive license rights under AbbVie's intellectual property to commercialize CHS-1420, Coherus' proposed adalimumab (HUMIRA) biosimilar. Coherus will pay royalties to AbbVie. | (RTTNews.com) - Coherus BioSciences Inc. (CHRS) said it has executed settlement agreements with AbbVie Inc. that grant Coherus global, non-exclusive license rights under AbbVie's intellectual property to commercialize CHS-1420, Coherus' proposed adalimumab (HUMIRA) biosimilar. Coherus will pay royalties to AbbVie. Read the original article on RTTNews (http://www.rttnews.com/2972767/coherus-reaches-settlement-with-abbvie-securing-rights-to-commercialize-chs-1420.aspx) For comments and feedback: contact editorial@rttnews.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews.com) - Coherus BioSciences Inc. (CHRS) said it has executed settlement agreements with AbbVie Inc. that grant Coherus global, non-exclusive license rights under AbbVie's intellectual property to commercialize CHS-1420, Coherus' proposed adalimumab (HUMIRA) biosimilar. Read the original article on RTTNews (http://www.rttnews.com/2972767/coherus-reaches-settlement-with-abbvie-securing-rights-to-commercialize-chs-1420.aspx) For comments and feedback: contact editorial@rttnews.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Coherus will pay royalties to AbbVie. | (RTTNews.com) - Coherus BioSciences Inc. (CHRS) said it has executed settlement agreements with AbbVie Inc. that grant Coherus global, non-exclusive license rights under AbbVie's intellectual property to commercialize CHS-1420, Coherus' proposed adalimumab (HUMIRA) biosimilar. Coherus will pay royalties to AbbVie. Read the original article on RTTNews (http://www.rttnews.com/2972767/coherus-reaches-settlement-with-abbvie-securing-rights-to-commercialize-chs-1420.aspx) For comments and feedback: contact editorial@rttnews.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
25142.0 | 2019-01-24 00:00:00 UTC | Is a Surprise Coming for AbbVie (ABBV) This Earnings Season? | ABBV | https://www.nasdaq.com/articles/is-a-surprise-coming-for-abbvie-abbv-this-earnings-season-2019-01-24 | nan | nan | Investors are always looking for stocks that are poised to beat a t earnings season and AbbVie Inc. ABBV may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
That is because AbbVie is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings - with the most up-to-date information possible - is a pretty good indicator of some favorable trends underneath the surface for ABBV in this report.
In fact, the Most Accurate Estimate for the current quarter is currently at $1.93 per share for ABBV, compared to a broader Zacks Consensus Estimate of $1.91 cents per share. This suggests that analysts have very recently bumped up their estimates for ABBV, giving the stock a Zacks Earnings ESP of +1.07% heading into earnings season.
AbbVie Inc. Price and EPS Surprise
AbbVie Inc. Price and EPS Surprise | AbbVie Inc. Quote
Why is this Important?
A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10-year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here ).
Given that ABBV has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead o f earnings . You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Clearly, recent earnings estimate revisions suggest that good things are ahead for AbbVie, and that a beat might be in the cards for the upcoming report.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | After all, analysts raising estimates right before earnings - with the most up-to-date information possible - is a pretty good indicator of some favorable trends underneath the surface for ABBV in this report. Given that ABBV has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead o f earnings . Clearly, recent earnings estimate revisions suggest that good things are ahead for AbbVie, and that a beat might be in the cards for the upcoming report. | AbbVie Inc. Price and EPS Surprise AbbVie Inc. Price and EPS Surprise | AbbVie Inc. Quote Why is this Important? Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Investors are always looking for stocks that are poised to beat a t earnings season and AbbVie Inc. ABBV may be one such company. | This suggests that analysts have very recently bumped up their estimates for ABBV, giving the stock a Zacks Earnings ESP of +1.07% heading into earnings season. Given that ABBV has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead o f earnings . Investors are always looking for stocks that are poised to beat a t earnings season and AbbVie Inc. ABBV may be one such company. | Investors are always looking for stocks that are poised to beat a t earnings season and AbbVie Inc. ABBV may be one such company. Given that ABBV has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead o f earnings . That is because AbbVie is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. |
25143.0 | 2019-01-24 00:00:00 UTC | Healthcare ETFs in Focus Ahead of Q4 Earnings | ABBV | https://www.nasdaq.com/articles/healthcare-etfs-focus-ahead-q4-earnings-2019-01-24 | nan | nan | Healthcare has been gathering enough investors' interest driven by its non-cyclical nature, which provides a defensive tilt to the portfolio in a turbulent market.
The Health Care Select Sector SPDR Fund XLV hasgained 3.4% in the year-to-date timeframe, while Vanguard Health Care ETF VHT , iShares U.S. Healthcare ETF IYH and Fidelity MSCI Health Care Index ETF FHLC are up more than 4% each. The strength is likely to continue with some big names like Pfizer PFE , Merck MRK , Amgen AMGN , AbbVie ABBV , and Gilead Sciences GILD lined up to report this week and in the next. All these stocks collectively account for 23.3% share in XLV, 21.7% in IYH, 21.3% in VHT and 20.3% in FHLC (read: Top-Ranked Sector ETFs & Stocks to Buy for 2019 ).
Let's dig deeper into the earnings picture of these companies, which will drive the performance of the above-mentioned funds in the coming days:
According to the our methodology, a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), when combined with a positive Earnings ESP increases our chances of predicting an earnings beat, while Zacks Rank #4 or 5 (Sell rated) stocks are best avoided. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter .
Inside Our Surprise Prediction for These Stocks
Pfizer has a Zacks Rank #4 and an Earnings ESP of 0.00%. The stock saw negative earnings estimate revision of a penny for to-be-reported quarter over the past 30 days. It delivered an average positive earnings surprise of 6.35% for the past four quarters. It has a VGM Score of D. Pfizer is scheduled to repor t earnings on Jan 29, before the opening bell.
Merck is expected to report results on Feb 1 before market open. It has a Zacks Rank #3 and an Earnings ESP of 0.00%. The stock delivered a positive earnings surprise in the last four quarters, with the average beat being 3.96%. However, it has witnessed negative earnings estimate revision of a penny over the past 30 days for the to-be-reported quarter. Merck has a VGM Score of D.
Amgen carries a Zacks Rank #3 and has an Earnings ESP of -0.28%, indicating lower chance of beating estimates this quarter. The earnings surprise track over the past four quarters is strong, with the average positive surprise being 4.80%. Amgen has witnessed no earnings estimate revision over the past 30 days for the quarter to be reported. The stock has a solid VGM Score of B. Amgen will report earnings on Jan 29 after market close.
AbbVie has a Zacks Rank #3 and an Earnings ESP of +1.07%, indicating a reasonable chance of beating estimates this quarter. The company delivered a positive earnings surprise in the last four quarters, with the average beat being 3.54%. It has seen positive earnings estimate revision of a penny over the past month for the to-be-reported quarter. The stock has a solid VGM Score of B. The company is scheduled to report on Jan 25 before the opening bell (read: JNJ Beats, Offers Bleak Outlook: Health Care ETFs in Focus ).
Gilead is expected to release earnings on Feb 4 after market close. It has a Zacks Rank #4 and an Earnings ESP of -4.72%. Gilead delivered average positive earnings surprise of 6.99% over the last four quarters and saw no earnings estimate revision over the past month for the to-be-reported quarter. It has a VGM Score of D.
Summing Up
With lower negative earnings revisions, the healthcare sector is expected to witness earnings growth of 7.7% in the fourth quarter, suggesting continued outperformance for healthcare ETFs. In particular, all the four ETFs have a Zacks ETF Rank #1 (Strong Buy) or #2 (Buy) (see: all the Healthcare ETFs here ).
Want key ETF info delivered straight to your inbox?
Zacks' free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Merck & Co., Inc. (MRK): Free Stock Analysis Report
Pfizer Inc. (PFE): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
iShares U.S. Healthcare ETF (IYH): ETF Research Reports
Health Care Select Sector SPDR Fund (XLV): ETF Research Reports
Vanguard Health Care ETF (VHT): ETF Research Reports
Gilead Sciences, Inc. (GILD): Free Stock Analysis Report
Amgen Inc. (AMGN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The strength is likely to continue with some big names like Pfizer PFE , Merck MRK , Amgen AMGN , AbbVie ABBV , and Gilead Sciences GILD lined up to report this week and in the next. AbbVie has a Zacks Rank #3 and an Earnings ESP of +1.07%, indicating a reasonable chance of beating estimates this quarter. Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report iShares U.S. Healthcare ETF (IYH): ETF Research Reports Health Care Select Sector SPDR Fund (XLV): ETF Research Reports Vanguard Health Care ETF (VHT): ETF Research Reports Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. | The strength is likely to continue with some big names like Pfizer PFE , Merck MRK , Amgen AMGN , AbbVie ABBV , and Gilead Sciences GILD lined up to report this week and in the next. Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report iShares U.S. Healthcare ETF (IYH): ETF Research Reports Health Care Select Sector SPDR Fund (XLV): ETF Research Reports Vanguard Health Care ETF (VHT): ETF Research Reports Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie has a Zacks Rank #3 and an Earnings ESP of +1.07%, indicating a reasonable chance of beating estimates this quarter. | Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report iShares U.S. Healthcare ETF (IYH): ETF Research Reports Health Care Select Sector SPDR Fund (XLV): ETF Research Reports Vanguard Health Care ETF (VHT): ETF Research Reports Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. The strength is likely to continue with some big names like Pfizer PFE , Merck MRK , Amgen AMGN , AbbVie ABBV , and Gilead Sciences GILD lined up to report this week and in the next. AbbVie has a Zacks Rank #3 and an Earnings ESP of +1.07%, indicating a reasonable chance of beating estimates this quarter. | Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report iShares U.S. Healthcare ETF (IYH): ETF Research Reports Health Care Select Sector SPDR Fund (XLV): ETF Research Reports Vanguard Health Care ETF (VHT): ETF Research Reports Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. The strength is likely to continue with some big names like Pfizer PFE , Merck MRK , Amgen AMGN , AbbVie ABBV , and Gilead Sciences GILD lined up to report this week and in the next. AbbVie has a Zacks Rank #3 and an Earnings ESP of +1.07%, indicating a reasonable chance of beating estimates this quarter. |
25144.0 | 2019-01-24 00:00:00 UTC | The Zacks Analyst Blog Highlights: Amazon, Verizon, AbbVie, Lowe???s and Chubb | ABBV | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-amazon-verizon-abbvie-lowes-and-chubb-2019-01-24 | nan | nan | For Immediate Release
Chicago, IL - January 24, 2019 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Amazon AMZN , Verizon VZ , AbbVie ABBV , Lowe's LOW and Chubb CB .
Here are highlights from Wednesday's Analyst Blog:
Top Research Reports for Amazon, Verizon and AbbVie
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amazon, Verizon and AbbVie. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Buy-ranked Amazon 's shares have outperformed the broader market in the past year by a wide margin (the stock is up +20.3% vs. the -7.1% decline for the S&P 500 as a whole). The Zacks analyst thinks Amazon's strengthening retail position, riding on its growing global footprint and distribution strength remains its key growth driver.
Moreover, robust Prime and its benefits are aiding its retail business. Also, rapid expansion of Prime enabled grocery services and growing physical presence are tailwinds. Further, increasing AWS regions and its growing adoption will continue to aid Amazon's cloud momentum. Also, rising number of Alexa compatible devices are a major positive. Amazon's strong holiday initiatives have boosted its holiday performance.
Estimates have been going up ahead of the company's Q4 earnings release. The company has positive record o f earnings surprises in recent quarters. However, its sales outlook for holiday season is weak due to changes in Indian holiday timing. Also, rising cloud battle and heavy investment in fulfillment centers are headwinds.
Shares of Buy-ranked Verizon have gained +5.1% in the past year, outperforming the Zacks Wireless National industry's decline of -4.4% during the same period. The Zacks analyst thinks Verizon remains poised to benefit from the upcoming 5G boom, driven by healthy traction in the wireless business.
The company is further seeking a first mover advantage in the 5G race as it plans to launch commercial 5G smartphones in the market in the first half of 2019 in collaboration with Samsung. Focus on online content delivery, mobile video and online advertising should also drive future growth.
In the enterprise and the wholesale business, Verizon is changing its revenue mix toward newer growth services like cloud, security and professional services. Management is bullish on the industry's ability to grow revenues from smartphones, tablets and cloud computing and has reiterated its earlier guidance. However, Verizon continues to struggle in a competitive and saturated U.S. wireless market, where spectrum crunch has become a major issue, hurting its profitability.
AbbVie 's shares have gained +11.6% in the past three months, outperforming the Zacks Large-Cap Pharmaceuticals industry's increase of +2%. The Zacks analyst thinks AbbVie's key drug, Humira has been performing well based on strong demand trends despite new competition. Moreover, Imbruvica has multibillion dollar potential. Mavyret's launch has also been stronger than expected. AbbVie has also been successful in expanding approvals for its cancer drugs, Imbruvica and Venclexta.
AbbVie has a strong late-stage pipeline comprising several products with multibillion-dollar potential expected to be launched in the near term. AbbVie expects to launch more than 20 new products or line extensions of marketed drugs before Humira biosimilar competition begins in the United States in 2023. However, direct biosimilar competition to Humira in Europe from October can erode revenues in 2019. Nonetheless, estimates have gone up ahead of Q4 earnings. AbbVie has a positive record of earnings surprises in the recent quarters.
Other noteworthy reports we are featuring today include Lowe's and Chubb.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, wouldn't you like to know about our 10 finest buy-and-holds for the year?
From more than 4,000 companies covered by the Zacks Rank, these 10 were picked by a process that consistently beats the market. Even during 2018 while the market dropped -5.2%, our Top 10s were up well into double-digits. And during bullish 2012 - 2017, they soared far above the market's +126.3%, reaching +181.9%.
This year, the portfolio features a player that thrives on volatility, an AI comer, and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs.
See Stocks Today >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss . This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Amazon.com, Inc. (AMZN): Get Free Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Verizon Communications Inc. (VZ): Free Stock Analysis Report
Lowe's Companies, Inc. (LOW): Free Stock Analysis Report
Chubb Limited (CB): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks recently featured in the blog include: Amazon AMZN , Verizon VZ , AbbVie ABBV , Lowe's LOW and Chubb CB . Here are highlights from Wednesday's Analyst Blog: Top Research Reports for Amazon, Verizon and AbbVie The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amazon, Verizon and AbbVie. | Stocks recently featured in the blog include: Amazon AMZN , Verizon VZ , AbbVie ABBV , Lowe's LOW and Chubb CB . Today's Research Daily features new research reports on 16 major stocks, including Amazon, Verizon and AbbVie. Click to get this free report Amazon.com, Inc. (AMZN): Get Free Report AbbVie Inc. (ABBV): Free Stock Analysis Report Verizon Communications Inc. (VZ): Free Stock Analysis Report Lowe's Companies, Inc. (LOW): Free Stock Analysis Report Chubb Limited (CB): Free Stock Analysis Report To read this article on Zacks.com click here. | Here are highlights from Wednesday's Analyst Blog: Top Research Reports for Amazon, Verizon and AbbVie The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amazon, Verizon and AbbVie. Click to get this free report Amazon.com, Inc. (AMZN): Get Free Report AbbVie Inc. (ABBV): Free Stock Analysis Report Verizon Communications Inc. (VZ): Free Stock Analysis Report Lowe's Companies, Inc. (LOW): Free Stock Analysis Report Chubb Limited (CB): Free Stock Analysis Report To read this article on Zacks.com click here. | Here are highlights from Wednesday's Analyst Blog: Top Research Reports for Amazon, Verizon and AbbVie The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amazon, Verizon and AbbVie. The Zacks analyst thinks AbbVie's key drug, Humira has been performing well based on strong demand trends despite new competition. |
25145.0 | 2019-01-24 00:00:00 UTC | Zacks Investment Ideas feature highlights: International Business Machines, Procter and Gamble, Ford, Intel and Abbvie | ABBV | https://www.nasdaq.com/articles/zacks-investment-ideas-feature-highlights%3A-international-business-machines-procter-and | nan | nan | For Immediate Release
Chicago, IL - January 24, 2019 - Today, Zacks Investment Ideas feature highlights Features: International Business Machines IBM , Procter and Gamble PG , Ford F , Intel INTC and Abbvie ABBV .
Blue Chips IBM, Procter & Gamble Rally on Earnings
The broad markets turned positive on Wednesday morning after positive earnings reports at Dow components International Business Machines and Procter and Gamble. At mid-morning, IBM was trading up 7% and PG was up 5% after both companies delivered modest beats but also affirmed or raised important 2019 guidance figures.
The focus on future guidance starkly illustrates investors' cautious optimism about equity prices in 2019. With geopolitical issues still threatening global economic growth, the markets are understandably interested in forecasts from the largest industrial companies for an indication of the relative health of the economy.
The Numbers
IBM posted ne t earnings of $4.87/share on revenues of $21.8B, beating the Zacks Consensus Estimates of $4.81/share and $21.7B, respectively. Though the results were only modestly better than expectations, IBM shares enjoyed their biggest single day rally in almost a decade on both the diversity of revenues - which was spread across all business units - and the company's forecast for earnings of more than $13.90/share in 2019 earnings, an improvement over current estimates of $13.86/share.
The affirmation that IBM anticipates earnings growth in 2019 put investors at ease that the technology giant, with a global business that includes old-fashioned hardware and operating systems as well as cloud computing and AI, sees economic opportunity around the world.
Consumer Goods behemoth Procter and Gamble similarly beat estimates by a small amount, but also raised revenue guidance and affirmed earnings guidance which already called for per share earnings to grow between 3 and 8% in 2019.
PG had been expected to earn $1.21/share on revenues of $17.19B and surpassed both estimates with sales of $17.44B and net earnings of $1.21/share.
Procter and Gamble has a very stable business and a long history of results for analysts to base estimates upon. There is generally a tight consensus of estimates going into quarterly reports and PG tends to beat the Zacks Consensus Estimate by a small amount. The previous 4 quarters were beats of 4 cents, 2 cents, 4 cents and 3 cents.
That's solid performance to be sure, but it's also clear that the likelihood of a big surprise in either direction is quite low.
As we saw with IBM, the rally in PG shares seems mostly to be due to the raised/affirmed estimates for full year 2019.
Sales of Consumer Goods are often seen as a proxy for the health of the "main street" economy and the fact that PG sees continued increases bodes well for the US as a whole.
The Takeaway
Less than 20% of S&P 500 companies have reported so far this earnings season and so far, the results have been encouraging. Later this week, big cap stocks Ford, Intel and Abbvie will report.
As was the case with IBM and PG, investors will likely be paying close attention to any changes in guidance or forecasts as much as the posted sales and earnings. As the 2019 rally picks up steam, the confidence of the biggest companies that the growth picture remains intact will go a long way toward soothing nerves that were frayed by the volatile end to 2018.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early. See Zacks' 3 Best Stocks to Play This Trend >>
Follow us on Twitter: http://twitter.com/ZacksResearch
Join us on Facebook: http://www.facebook.com/ZacksInvestmentResearch
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss.This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
International Business Machines Corporation (IBM): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Ford Motor Company (F): Free Stock Analysis Report
Procter & Gamble Company (The) (PG): Free Stock Analysis Report
Intel Corporation (INTC): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | For Immediate Release Chicago, IL - January 24, 2019 - Today, Zacks Investment Ideas feature highlights Features: International Business Machines IBM , Procter and Gamble PG , Ford F , Intel INTC and Abbvie ABBV . Later this week, big cap stocks Ford, Intel and Abbvie will report. Click to get this free report International Business Machines Corporation (IBM): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Ford Motor Company (F): Free Stock Analysis Report Procter & Gamble Company (The) (PG): Free Stock Analysis Report Intel Corporation (INTC): Free Stock Analysis Report To read this article on Zacks.com click here. | For Immediate Release Chicago, IL - January 24, 2019 - Today, Zacks Investment Ideas feature highlights Features: International Business Machines IBM , Procter and Gamble PG , Ford F , Intel INTC and Abbvie ABBV . Click to get this free report International Business Machines Corporation (IBM): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Ford Motor Company (F): Free Stock Analysis Report Procter & Gamble Company (The) (PG): Free Stock Analysis Report Intel Corporation (INTC): Free Stock Analysis Report To read this article on Zacks.com click here. Later this week, big cap stocks Ford, Intel and Abbvie will report. | Click to get this free report International Business Machines Corporation (IBM): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Ford Motor Company (F): Free Stock Analysis Report Procter & Gamble Company (The) (PG): Free Stock Analysis Report Intel Corporation (INTC): Free Stock Analysis Report To read this article on Zacks.com click here. For Immediate Release Chicago, IL - January 24, 2019 - Today, Zacks Investment Ideas feature highlights Features: International Business Machines IBM , Procter and Gamble PG , Ford F , Intel INTC and Abbvie ABBV . Later this week, big cap stocks Ford, Intel and Abbvie will report. | Click to get this free report International Business Machines Corporation (IBM): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Ford Motor Company (F): Free Stock Analysis Report Procter & Gamble Company (The) (PG): Free Stock Analysis Report Intel Corporation (INTC): Free Stock Analysis Report To read this article on Zacks.com click here. For Immediate Release Chicago, IL - January 24, 2019 - Today, Zacks Investment Ideas feature highlights Features: International Business Machines IBM , Procter and Gamble PG , Ford F , Intel INTC and Abbvie ABBV . Later this week, big cap stocks Ford, Intel and Abbvie will report. |
25146.0 | 2019-01-24 00:00:00 UTC | 3 Things to Expect in AbbVie's Q4 Earnings Update | ABBV | https://www.nasdaq.com/articles/3-things-expect-abbvies-q4-earnings-update-2019-01-24 | nan | nan | AbbVie (NYSE: ABBV) beat expectations the first three quarters of 2018, turning in an exceptionally strong performance in Q3 . Those third-quarter results prompted the big drugmaker to boost its full-year 2018 adjusted earnings outlook.
The company reports its fourth-quarter results on Friday, Jan. 25. Will AbbVie continue its streak of outperforming expectations? Here are three things you can expect in its Q4 earnings update.
1. A turning point for Humira
As Humira goes, so goes AbbVie -- at least for now. The fourth quarter will be a significant turning point for AbbVie's top-selling drug, as it faced biosimilar competition in Europe for the first time ever.
CEO Rick Gonzalez said in the company's Q3 earnings call that discounting for biosimilars to Humira was "on the higher end of the planning scenarios that we had laid out." Instead of 18% to 20% discounts, AbbVie saw discounting of 26% to 27% in the first several weeks of biosimilar competition for Humira.
You can probably expect international sales for Humira to fall to around $1.3 billion from nearly $1.6 billion in the third quarter. Any decline significantly greater than that will cause concerns. On the other hand, Humira should continue to generate solid growth in the U.S. market, with sales probably increasing around 12% year over year to roughly $3.7 billion.
2. More strong growth in hematologic oncology
One area for AbbVie that continues to knock the ball out of the park is its hematologic oncology franchise, which uses a lot of syllables to refer to the company's two blood cancer drugs, Imbruvica and Venclexta. Imbruvica's sales soared more than 40% year over year in Q3, while sales for Venclexta nearly tripled from the prior-year period.
It won't be surprising for Imbruvica's growth to moderate a little in the fourth quarter of 2018. AbbVie's full-year 2018 guidance implies that Q4 sales could be around the same level as the drug made in the third quarter. However, that would still represent strong year-over-year growth of nearly 30%.
But Venclexta should pick up considerable momentum in Q4. Gonzalez noted in his comments during the Q3 conference call that AbbVie was "starting to hit the inflection point" with Venclexta thanks to the release of its great results from the Murano phase 3 study in acute myeloid leukemia (AML).
3. Moderating growth for Mavyret
Mavyret has been a resounding success for AbbVie. The hepatitis C virus (HCV) drug was launched in late 2017 and now claims roughly 50% of the global HCV market.
Expect Mavyret to make a solid contribution to AbbVie's top line in the fourth quarter. However, it's likely that the growth will begin to moderate, particularly in international markets.
AbbVie's full-year 2018 outlook for its HCV franchise called for sales of above $3.5 billion. During the first nine months of 2018, Mayvyret and older HCV drug Viekira generated revenue of $2.6 billion. Therefore, AbbVie expects total sales of around $900 million for the two drugs in Q4, nearly all of which will stem from Mayvyret. By comparison, AbbVie's HCV drugs made $839 million in Q3 and $510 million in the fourth quarter of 2017.
A changing story
The storyline is changing for AbbVie. Humira will definitely dominate the company's quarterly updates for several more years. However, AbbVie will soon be talking a lot more about its new immunology drugs, risankizumab and upadacitinib, both of which could win regulatory approval this year.
In addition, a couple of AbbVie's newer drugs could become much more important for the company in the not-too-distant future. Venclexta has a great opportunity in AML and could become a megablockbuster. Orilissa has already received approval for managing endometriosis pain. AbbVie expects to file for approval of the drug in treating uterine fibroids this year as well.
What doesn't seem likely to change with AbbVie's story, though, is its continued strong earnings growth. The company expects to wrap up 2018 with solid adjusted earnings per share and keep the momentum going in 2019. With promising new drugs and new indications for existing drugs potentially on the way, AbbVie just might be able to beat expectations for a long time to come.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of November 14, 2018
Keith Speights owns shares of AbbVie. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The fourth quarter will be a significant turning point for AbbVie's top-selling drug, as it faced biosimilar competition in Europe for the first time ever. Gonzalez noted in his comments during the Q3 conference call that AbbVie was "starting to hit the inflection point" with Venclexta thanks to the release of its great results from the Murano phase 3 study in acute myeloid leukemia (AML). AbbVie (NYSE: ABBV) beat expectations the first three quarters of 2018, turning in an exceptionally strong performance in Q3 . | AbbVie's full-year 2018 outlook for its HCV franchise called for sales of above $3.5 billion. By comparison, AbbVie's HCV drugs made $839 million in Q3 and $510 million in the fourth quarter of 2017. AbbVie (NYSE: ABBV) beat expectations the first three quarters of 2018, turning in an exceptionally strong performance in Q3 . | The fourth quarter will be a significant turning point for AbbVie's top-selling drug, as it faced biosimilar competition in Europe for the first time ever. More strong growth in hematologic oncology One area for AbbVie that continues to knock the ball out of the park is its hematologic oncology franchise, which uses a lot of syllables to refer to the company's two blood cancer drugs, Imbruvica and Venclexta. With promising new drugs and new indications for existing drugs potentially on the way, AbbVie just might be able to beat expectations for a long time to come. | The fourth quarter will be a significant turning point for AbbVie's top-selling drug, as it faced biosimilar competition in Europe for the first time ever. What doesn't seem likely to change with AbbVie's story, though, is its continued strong earnings growth. AbbVie (NYSE: ABBV) beat expectations the first three quarters of 2018, turning in an exceptionally strong performance in Q3 . |
25147.0 | 2019-01-24 00:00:00 UTC | Pfizer (PFE) to Report Q4 Earnings: What's in the Cards? | ABBV | https://www.nasdaq.com/articles/pfizer-pfe-to-report-q4-earnings%3A-whats-in-the-cards-2019-01-24 | nan | nan | Pfizer, Inc.PFE will report fourth-quarter and full-year 2018 results on Jan 29, before market open. In the las t report ed quarter, the company delivered a positive earnings surprise of 2.63%.
The pharma giant has a strong record o f earnings surprises. The company's earnings surpassed expectations in each of the last four quarters, leading to an average positive surprise of 6.35%.
Pfizer Inc. Price and EPS Surprise
Pfizer Inc. Price and EPS Surprise | Pfizer Inc. Quote
Pfizer's shares have risen 14.2% this year so far against a decline of 1% for the industry .
Factors at Play
Higher sales of Pfizer's key brands, Ibrance, Eliquis and Prevnar, are makingup for loss of exclusivity of some products, lower sales of legacy Established Products in developed markets and continued supply shortages in legacy Hospira products.
In the Innovative Health (IH) segment, products like Xeljanz (rheumatoid arthritis), Ibrance (breast cancer), Prevnar 13 (pneumonia vaccine) and Eliquis (blood thinner) should contribute to the top line meaningfully. In Essential Health (EH), biosimilars and emerging markets are expected to support sales.
Ibrance sales declined in the United States in the third quarter due to increased rebates and rising competition in the CDK inhibitor category. The category now includes Eli Lilly's Verzenio and Novartis' Kisqali. It is to be seen if the sales trend improves in the fourth quarter.
Xeljanz was approved for new indications - ulcerative colitis in both Europe and United States and active psoriatic arthritis in Europe in 2018 - which boosted sales of the drug in the third quarter. The trend is expected to continue.
The Zacks Consensus Estimate for sales of Ibrance (worldwide) and Xeljanz is $1.14 billion and $537 million, respectively.
Blockbuster drug Enbrel sales will continue to decline in the quarter due to biosimilar competition in key European markets. The Zacks Consensus Estimate for sales of Enbrel and Prevnar is $507 million and $1.49 billion, respectively.
Xtandi was approved for non-metastatic prostate cancer patient population in the United States in July and in the EU in October and is expected to add to alliance revenues from the drug. The Zacks Consensus Estimate for alliance revenues from Xtandi is $205 million.
However, the loss of exclusivity and associated generic competition for some products primarily Pristiq and Viagra in the United States and Lyrica in Europe, and lower revenues from sterile injectables portfolio due to continued legacy Hospira product shortages in the United States is expected to dampen top-line growth. Also, lower sales of legacy Established Products in developed markets driven by industry-wide pricing challenges will hurt EH segment sales.
The bottom line is expected to be driven by cost savings and share buybacks.
In 2018, Pfizer made significant progress with its biosimilar portfolio. In the United States, a biosimilar of Amgen's AMGN Neupogen was launched in late September 2018 while a biosimilar version of Epogen was approved in May and launched in November 2018. These should add to the company's top line in the fourth quarter. The Zacks Consensus Estimate for sales of biosimilars in the fourth quarter is $240 million.
In oncology, Pfizer gained FDA approval for four innovative medicines in third/fourth of 2018, which can boost its oncology sales. These include Daurismo (glasdegib) for previously untreated AML, Lorbrena (lorlatinib) for second line non-small-cell lung cancer, Vizimpro (dacomitinib) for advanced NSCLC with EGFR activating mutations and Talzenna (talazoparib), an orally-available PARP inhibitor for advanced breast cancer. Investors will be keen to know the sales plan for new cancer medicines on the conference call.
Last month, the company resolved a long pending issue by announcing an agreement to merge its consumer healthcare unit with Glaxo's unit. The new joint venture (JV) will be the world's largest consumer healthcare business. While Glaxo will own a controlling stake of 68% in the JV, Pfizer will own 32%. The separation of its consumer health unit will allow Pfizer to better concentrate on its core pharmaceutical unit in 2019. Investors are expected to question Pfizer on this development.
What Our Model Indicates
Our proven model does not conclusively show that Pfizer is likely to beat on earnings this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is not the case here, as you will see below.
Earnings ESP: Its Earnings ESP is 0.00% as the Most Accurate Estimate as well as the Zacks Consensus Estimate is pegged at 63 cents. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter .
Zacks Rank: Pfizer has a Zacks Rank #4 (Sell). We caution against Zacks Rank #4 or 5 (Strong Sell) stocks going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks to Consider
Here are some large drug stocks that have the right combination of elements to beat on earnings this time around:
Allergan plc. AGN has an Earnings ESP of +3.45% and a Zacks Rank #3. The company is slated to release results on Jan 29. You can see the complete list of today's Zacks #1 Rank stocks here .
AbbVie, Inc. ABBV has an Earnings ESP of +1.07% and a Zacks Rank #3. The company is slated to release results on Jan 25.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Allergan plc (AGN): Get Free Report
Pfizer Inc. (PFE): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Amgen Inc. (AMGN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie, Inc. ABBV has an Earnings ESP of +1.07% and a Zacks Rank #3. Click to get this free report Allergan plc (AGN): Get Free Report Pfizer Inc. (PFE): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. In the Innovative Health (IH) segment, products like Xeljanz (rheumatoid arthritis), Ibrance (breast cancer), Prevnar 13 (pneumonia vaccine) and Eliquis (blood thinner) should contribute to the top line meaningfully. | Click to get this free report Allergan plc (AGN): Get Free Report Pfizer Inc. (PFE): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie, Inc. ABBV has an Earnings ESP of +1.07% and a Zacks Rank #3. Factors at Play Higher sales of Pfizer's key brands, Ibrance, Eliquis and Prevnar, are makingup for loss of exclusivity of some products, lower sales of legacy Established Products in developed markets and continued supply shortages in legacy Hospira products. | Click to get this free report Allergan plc (AGN): Get Free Report Pfizer Inc. (PFE): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie, Inc. ABBV has an Earnings ESP of +1.07% and a Zacks Rank #3. Pfizer Inc. Price and EPS Surprise Pfizer Inc. Price and EPS Surprise | Pfizer Inc. Quote Pfizer's shares have risen 14.2% this year so far against a decline of 1% for the industry . | AbbVie, Inc. ABBV has an Earnings ESP of +1.07% and a Zacks Rank #3. Click to get this free report Allergan plc (AGN): Get Free Report Pfizer Inc. (PFE): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. These should add to the company's top line in the fourth quarter. |
25148.0 | 2019-01-24 00:00:00 UTC | Can Allergan (AGN) Keep the Earnings Streak Alive in Q4? | ABBV | https://www.nasdaq.com/articles/can-allergan-agn-keep-the-earnings-streak-alive-in-q4-2019-01-24 | nan | nan | We expect Allergan plcAGN to beat expectations when i t report s fourth-quarter and full-year 2018 results on Jan 29, before market open. In the last reported quarter, the company delivered a positive earnings surprise of 5.99%.
Allergan's share price has declined 13.8% in the past year compared with the industry 's decline of 21.8%.
Allergan's earnings performance has been strong, with the company beating expectations in each of the past four quarters. The average positive earnings surprise over the last four quarters is 6.66%.
Amgen Inc. Price and EPS Surprise
Amgen Inc. Price and EPS Surprise | Amgen Inc. Quote
Let's see how things are shaping up for this announcement.
Factors to Consider
We believe that Allergan's key products like Botox, Juvéderm collection of fillers, Vraylar, Alloderm, Linzess and Lo Loestrin are likely to support sales growth in the quarter. The Zacks Consensus Estimate for Botox is $937 million.
On the third-quarter call, the company had said that Botox demand was strong despite the launch of Amgen's CGRP antibody, Aimovig. However, the company did mention that it expects the growth rate for Botox Therapeutic to moderate due to competition from CGRPs. Other than Aimovig, Teva's and Lilly's CGRPs were also approved in September.
Botox's sales growth rate is expected to be in mid- to high-single digits. At the same time, the company said that that the introduction of the CGRPs should expand the migraine market and that Botox and the CGRPs can coexist in the larger market. An update is expected on the fourth-quarter conference call.
However, revenues in the fourth quarter are expected to be hurt by recall of Ozurdex in international markets in October, currency translation and lost revenues due to the sale of medical dermatology assets in September 2018.
Meanwhile, lower sales of Namenda XR and Estrace cream due to generic competition are expected to continue to hurt Allergan's revenues in the fourth quarter.
While a generic version of Alzheimer's treatment Namenda XR was launched by India based company, Lupin in February 2018 that of Estrace cream was launched by Mylan MYL in January 2018. A generic version of Delzicol is also expected to be launched soon.
However, no generic version of Restasis, Allergan's second best-selling drug, has been launched yet. On the third-quarter conference call, management had said that a generic version of Restasis is now expected to be launched between Nov 1, 2018 and Jan 1, 2019. The delay in launch of Restasis generics may add to the top line in the fourth quarter.
Gross margin is expected to be hurt by loss of exclusivity of high-margin products - Restasis, Estrace and Delzicol - and unfavorable product mix.
Regarding its plan to sell its Women's Health and Infectious Disease units, on the third-quarter call, Allergan had said that it has initiated processes to sell both the businesses. However, the bids that it has received for them were below management expectation. Investors will be keen to know the progress on these efforts on the fourth-quarter conference call.
Earnings Whispers
Our proven model shows that Allergan is likely to beat estimates this quarter because it has the right combination of two key ingredients. A stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for a likely positive surprise.
Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate ($4.28 per share) and the Zacks Consensus Estimate ($4.13 per share), is +3.45%. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter .
Zacks Rank: Allergan has a Zacks Rank #3. The combination of Allergan's Zacks Rank #3 and positive ESP makes us confident of an earnings beat in the upcoming release.
Sell-rated stocks (Zacks Rank #4 or 5) should never be considered going into an earnings announcement, especially when the company is seeing negative estimate revisions.
Other Stocks to Consider
Here are some large drug/biotech stocks that also have the right combination of elements to beat on earnings this time around:
AbbVie, Inc. ABBV has an Earnings ESP of +1.07% and a Zacks Rank #3. The company is slated to release results on Jan 25. You can see the complete list of today's Zacks #1 Rank stocks here .
Celgene Corp. CELG has an Earnings ESP of +2.31% and a Zacks Rank #1. The company is slated to release results on Jan 31.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Allergan plc (AGN): Get Free Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Celgene Corporation (CELG): Free Stock Analysis Report
Mylan N.V. (MYL): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Other Stocks to Consider Here are some large drug/biotech stocks that also have the right combination of elements to beat on earnings this time around: AbbVie, Inc. ABBV has an Earnings ESP of +1.07% and a Zacks Rank #3. Click to get this free report Allergan plc (AGN): Get Free Report AbbVie Inc. (ABBV): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. Factors to Consider We believe that Allergan's key products like Botox, Juvéderm collection of fillers, Vraylar, Alloderm, Linzess and Lo Loestrin are likely to support sales growth in the quarter. | Click to get this free report Allergan plc (AGN): Get Free Report AbbVie Inc. (ABBV): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. Other Stocks to Consider Here are some large drug/biotech stocks that also have the right combination of elements to beat on earnings this time around: AbbVie, Inc. ABBV has an Earnings ESP of +1.07% and a Zacks Rank #3. Amgen Inc. Price and EPS Surprise Amgen Inc. Price and EPS Surprise | Amgen Inc. Quote Let's see how things are shaping up for this announcement. | Other Stocks to Consider Here are some large drug/biotech stocks that also have the right combination of elements to beat on earnings this time around: AbbVie, Inc. ABBV has an Earnings ESP of +1.07% and a Zacks Rank #3. Click to get this free report Allergan plc (AGN): Get Free Report AbbVie Inc. (ABBV): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. A stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for a likely positive surprise. | Other Stocks to Consider Here are some large drug/biotech stocks that also have the right combination of elements to beat on earnings this time around: AbbVie, Inc. ABBV has an Earnings ESP of +1.07% and a Zacks Rank #3. Click to get this free report Allergan plc (AGN): Get Free Report AbbVie Inc. (ABBV): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. On the third-quarter conference call, management had said that a generic version of Restasis is now expected to be launched between Nov 1, 2018 and Jan 1, 2019. |
25149.0 | 2019-01-24 00:00:00 UTC | Is a Surprise in the Cards for Novartis (NVS) in Q4 Earnings? | ABBV | https://www.nasdaq.com/articles/is-a-surprise-in-the-cards-for-novartis-nvs-in-q4-earnings-2019-01-24 | nan | nan | Swiss pharma-giant Novartis AG NVS is scheduled to report fourth-quarter 2018 results on Jan 30.
Novartis has a mixed track record. In the las t report ed quarter, Novartis reported in-line results. The company posted average positive earnings surprise of 1.27% in the trailing four quarters. Let's see how things are shaping up for this announcement.
Factors at Play
Novartis did not provide any quarterly guidance. The company expects net sales in 2018 to grow mid-single digit. Innovative Medicines is projected to grow mid to high-single digit. Revenues from Sandoz are expected to decline low-single digit, while Alcon sales are estimated to grow mid-single digit.
The Innovative Medicines division maintains momentum on the back of strong oncology performance. Novartis has a strong oncology portfolio of drugs like Afinitor, Exjade, Jakavi, Zykadia, Tasigna, Jadenu and Kisqali. Oncology franchise continues to grow on the back of Promacta/Revolade, Tafinlar + Mekinist, Jakavi and recent launches. The Eurooean Commission recently approved a label expansion of Kisqali.
Psoriasis Cosentyx continues to gain traction on the back of strong growth in its three approved indications, while Entresto's sales benefited from continued access improvements and expansion of sales force in the United States. We expect the division to record similar growth in the fourth quarter and combat generic pressure for key drugs - Diovan, Gleevec and Exforge.
However, the generic division faces challenges in the form of price erosion in the United States due to competitive pressure. The trend might continue in the fourth quarter as well. Nevertheless, the launches of Rixathon, the biosimilar version of Rituxan (rituximab), and Erelzi, the biosimilar of Enbrel in EU, will partially offset the decline in the United States. In Europe, Sandoz also obtained approval for Zessly, a biosimilar version of Johnson & Johnson's Remicade. The FDA also approved Hyrimoz, the biosimilar of Humira.
Novartis intends to spin-off its ophthalmology division, Alcon, into a separately-traded standalone company in order to grow as a medicines company solely. The Alcon business wasn't performing according to management's expectations. While it did revive in between, the company decided to spin-off the same to focus better on its legacy drug business. Nevertheless, Alcon sales are estimated to grow in low-to-mid-single digits.
Apart from the top and bottom-line numbers, we expect investors to focus on the company's pipeline updates. Novartis recently acquired Endocyte to expand expertise in radiopharmaceuticals and transformational therapeutic platforms. The acquisition will add 177Lu-PSMA-617, a potential first-in-class radioligand therapy, to Novartis' diverse portfolio. The therapy is in phase III development for metastatic castration-resistant prostate cancer (mCRPC).
The FDA has accepted the company's Biologics License Application (BLA) for AVXS-101, now known as Zolgensma (onasemnogene abeparvovec-xxxx). The FDA also granted a Priority Review to Zolgensma and regulatory action is expected in May 2019.
The European Commission also approved Luxturna, a one-time gene therapy, for the treatment of patients suffering from vision loss due to a genetic mutation in both copies of the RPE65gene who have enough viable retinal cells. The EC granted marketing authorization to Ziextenzo, the biosimilar of Amgen's AMGN Neulasta. Management should also throw more light on its acquisition plans for 2019.
Share Price Performance
Novartis' stock has gained 4.7% in the last six months, same as the industry 's growth.
Earnings Whispers
Our proven model does not conclusively show that Novartis will beat on earnings this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to be able to beat estimates. Unfortunately, that is not the case here, as you will see below.
Earnings ESP : Earnings ESP for Novartis is 0.00%. This is because both the Most Accurate Estimate and the Zacks Consensus Estimate are pegged at $1.34. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter .
Zacks Rank : Novartis currently carries a Zacks Rank #2.
Although the rank is favorable, the company's 0.00% ESP makes surprise prediction difficult.
Note that we caution against stocks with a Zacks Rank #4 or 5 (Sell-rated) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stock to Consider
Here are some stocks you may want to consider as our model shows that these have the right combination of elements to post an earnings beat this quarter.
Celgene Corp. CELG is scheduled to release its results on Jan 31. The company has an Earnings ESP of +2.31% and a Zacks Rank #1. You can see the complete list of today's Zacks #1 Rank stocks here .
AbbVie Inc. ABBV is scheduled to release its results on Jan 25. The company has an Earnings ESP of +0.75% and a Zacks Rank #3.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Novartis AG (NVS): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Amgen Inc. (AMGN): Get Free Report
Celgene Corporation (CELG): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie Inc. ABBV is scheduled to release its results on Jan 25. Click to get this free report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Get Free Report Celgene Corporation (CELG): Free Stock Analysis Report To read this article on Zacks.com click here. Novartis has a strong oncology portfolio of drugs like Afinitor, Exjade, Jakavi, Zykadia, Tasigna, Jadenu and Kisqali. | Click to get this free report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Get Free Report Celgene Corporation (CELG): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc. ABBV is scheduled to release its results on Jan 25. Revenues from Sandoz are expected to decline low-single digit, while Alcon sales are estimated to grow mid-single digit. | Click to get this free report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Get Free Report Celgene Corporation (CELG): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc. ABBV is scheduled to release its results on Jan 25. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to be able to beat estimates. | AbbVie Inc. ABBV is scheduled to release its results on Jan 25. Click to get this free report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Get Free Report Celgene Corporation (CELG): Free Stock Analysis Report To read this article on Zacks.com click here. In the las t report ed quarter, Novartis reported in-line results. |
25150.0 | 2019-01-24 00:00:00 UTC | Notable Thursday Option Activity: SEAS, ABBV, TWLO | ABBV | https://www.nasdaq.com/articles/notable-thursday-option-activity-seas-abbv-twlo-2019-01-24 | nan | nan | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in SeaWorld Entertainment Inc. (Symbol: SEAS), where a total of 5,669 contracts have traded so far, representing approximately 566,900 underlying shares. That amounts to about 43.8% of SEAS's average daily trading volume over the past month of 1.3 million shares. Especially high volume was seen for the $23.50 strike put option expiring February 01, 2019 , with 2,006 contracts trading so far today, representing approximately 200,600 underlying shares of SEAS. Below is a chart showing SEAS's trailing twelve month trading history, with the $23.50 strike highlighted in orange:
AbbVie Inc (Symbol: ABBV) saw options trading volume of 28,289 contracts, representing approximately 2.8 million underlying shares or approximately 42.8% of ABBV's average daily trading volume over the past month, of 6.6 million shares. Especially high volume was seen for the $81.50 strike put option expiring January 25, 2019 , with 1,539 contracts trading so far today, representing approximately 153,900 underlying shares of ABBV. Below is a chart showing ABBV's trailing twelve month trading history, with the $81.50 strike highlighted in orange:
And Twilio Inc (Symbol: TWLO) saw options trading volume of 17,683 contracts, representing approximately 1.8 million underlying shares or approximately 41.8% of TWLO's average daily trading volume over the past month, of 4.2 million shares. Particularly high volume was seen for the $100 strike call option expiring February 01, 2019 , with 3,329 contracts trading so far today, representing approximately 332,900 underlying shares of TWLO. Below is a chart showing TWLO's trailing twelve month trading history, with the $100 strike highlighted in orange:
For the various different available expirations for SEAS options , ABBV options , or TWLO options , visit StockOptionsChannel.com.
Today's Most Active Call & Put Options of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Especially high volume was seen for the $81.50 strike put option expiring January 25, 2019 , with 1,539 contracts trading so far today, representing approximately 153,900 underlying shares of ABBV. Below is a chart showing SEAS's trailing twelve month trading history, with the $23.50 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) saw options trading volume of 28,289 contracts, representing approximately 2.8 million underlying shares or approximately 42.8% of ABBV's average daily trading volume over the past month, of 6.6 million shares. Below is a chart showing ABBV's trailing twelve month trading history, with the $81.50 strike highlighted in orange: And Twilio Inc (Symbol: TWLO) saw options trading volume of 17,683 contracts, representing approximately 1.8 million underlying shares or approximately 41.8% of TWLO's average daily trading volume over the past month, of 4.2 million shares. | Below is a chart showing SEAS's trailing twelve month trading history, with the $23.50 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) saw options trading volume of 28,289 contracts, representing approximately 2.8 million underlying shares or approximately 42.8% of ABBV's average daily trading volume over the past month, of 6.6 million shares. Below is a chart showing ABBV's trailing twelve month trading history, with the $81.50 strike highlighted in orange: And Twilio Inc (Symbol: TWLO) saw options trading volume of 17,683 contracts, representing approximately 1.8 million underlying shares or approximately 41.8% of TWLO's average daily trading volume over the past month, of 4.2 million shares. Especially high volume was seen for the $81.50 strike put option expiring January 25, 2019 , with 1,539 contracts trading so far today, representing approximately 153,900 underlying shares of ABBV. | Below is a chart showing SEAS's trailing twelve month trading history, with the $23.50 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) saw options trading volume of 28,289 contracts, representing approximately 2.8 million underlying shares or approximately 42.8% of ABBV's average daily trading volume over the past month, of 6.6 million shares. Below is a chart showing ABBV's trailing twelve month trading history, with the $81.50 strike highlighted in orange: And Twilio Inc (Symbol: TWLO) saw options trading volume of 17,683 contracts, representing approximately 1.8 million underlying shares or approximately 41.8% of TWLO's average daily trading volume over the past month, of 4.2 million shares. Especially high volume was seen for the $81.50 strike put option expiring January 25, 2019 , with 1,539 contracts trading so far today, representing approximately 153,900 underlying shares of ABBV. | Below is a chart showing SEAS's trailing twelve month trading history, with the $23.50 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) saw options trading volume of 28,289 contracts, representing approximately 2.8 million underlying shares or approximately 42.8% of ABBV's average daily trading volume over the past month, of 6.6 million shares. Below is a chart showing ABBV's trailing twelve month trading history, with the $81.50 strike highlighted in orange: And Twilio Inc (Symbol: TWLO) saw options trading volume of 17,683 contracts, representing approximately 1.8 million underlying shares or approximately 41.8% of TWLO's average daily trading volume over the past month, of 4.2 million shares. Especially high volume was seen for the $81.50 strike put option expiring January 25, 2019 , with 1,539 contracts trading so far today, representing approximately 153,900 underlying shares of ABBV. |
25151.0 | 2019-01-24 00:00:00 UTC | What's Behind the Biotech ETF Rally to Start 2019? | ABBV | https://www.nasdaq.com/articles/whats-behind-biotech-etf-rally-start-2019-2019-01-24 | nan | nan | This year, biotech stocks have seen their best-ever start to a year since 2012. A solid merger-and-acquisition momentum has been instrumental in this rally. The announcement of the mega-merger deal between Bristol-MyersBMY and CelgeneCELG at the beginning of 2019 has set the space on fire. Bristol-Myers has offered $74 billion to take over Celgene.
Also, Eli Lilly and CompanyLLY has announced that it will acquire Loxo Oncology for $8 billion to expand its oncology portfolio to precision medicines or targeted therapies. The winning momentum started from December 2018, when GlaxoGSK offered to acquire TESARO for almost $5.1 billion. With this deal, Glaxo will gain access to TESARO's PARP inhibitor, Zejula, which is approved for ovarian cancer.
More Deals Ahead?
Heightened speculation about increasing consolidation in the cancer space is doing rounds. Analysts have predicted a sizable increase in merger and acquisition activity in both drugmakers and medical device corners in 2019 .
Needless to say, all these acquisitions have acted as a cornerstone in the industry. A few of the novel drugs approved in 2018 for treating cancer are from smaller biotechs. This makes them lucrative acquisition targets. As a result, smaller biotech companies like Clovis OncologyCLVS , EpizymeEPZM and Blueprint MedicinesBPMC have been on a tear this year.
Eli Lilly's chief executive officer affirmed its desire to ink more deals in the areas of cancer, neuroscience and immunology . Investors should note that biotech giants are cash rich and can pay rich premium if they eye any specific company, per Bloomberg. Gilead SciencesGILD , Biogen BIIB , AbbVieABBV and AstraZenecaAZN can act as potential acquirers down the line.
Success Story Beyond Cancer
While researches and approvals have been solid in the oncology space, the other areas have also held strong. Some of the key approvals so far this year include that of Gilead Sciences' HIV regimen, Biktarvy; Vertex Pharmaceuticals' Symdeko (tezacaftor/ivacaftor and ivacaftor) for the treatment of cystic fibrosis (CF); Regeneron Pharmaceuticals' Libtayo and BioMarin's Palynziq for the treatment of phenylketonuria. Sage Therapeutics (SAGE) reported positive late-stage data on its treatment for postpartum depression .
Upbeat Zacks Rank
The Medical - Biomed/Genetics sub-industry currently comes from the top-ranked Zacks industry (top 21%). The index is up 11.54% this year compared with 6.54% gains in the iShares Core S&P 500 ETFIVV .
Any Roadblock Ahead?
While momentum is pretty strong and is likely to stay the same ahead, the ongoing U.S. government shutdown could play foul. There are products in the pipeline awaiting review at the U.S. Food and Drug Administration and the shutdown is not helping, as quoted on Bloombergquint. However, even if there is a short-term lull, the momentum should pick up once the impasse clears.
ETFs in Focus
Against this backdrop, investors may want to have a look at some of the wining biotech ETFs of this year.
Principal Healthcare Innovators Index ETF BTEC - Up 14.20%
Virtus LifeSci Biotech Products ETF BBP - Up 14.0%
VanEck Vectors Biotech ETF BBH - Up 13.4%
First Trust Amex Biotechnology Index FBT - Up 13.4%
iShares Nasdaq Biotechnology ETF IBB - Up 12.7%
Want key ETF info delivered straight to your inbox?
Zacks' free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AstraZeneca PLC (AZN): Free Stock Analysis Report
Eli Lilly and Company (LLY): Free Stock Analysis Report
GlaxoSmithKline plc (GSK): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report
VanEck Vectors Biotech ETF (BBH): ETF Research Reports
First Trust NYSE Arca Biotechnology Index Fund (FBT): ETF Research Reports
iShares Nasdaq Biotechnology ETF (IBB): ETF Research Reports
iShares Core S&P 500 ETF (IVV): ETF Research Reports
Biogen Inc. (BIIB): Get Free Report
Gilead Sciences, Inc. (GILD): Free Stock Analysis Report
Clovis Oncology, Inc. (CLVS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Gilead SciencesGILD , Biogen BIIB , AbbVieABBV and AstraZenecaAZN can act as potential acquirers down the line. Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report VanEck Vectors Biotech ETF (BBH): ETF Research Reports First Trust NYSE Arca Biotechnology Index Fund (FBT): ETF Research Reports iShares Nasdaq Biotechnology ETF (IBB): ETF Research Reports iShares Core S&P 500 ETF (IVV): ETF Research Reports Biogen Inc. (BIIB): Get Free Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Clovis Oncology, Inc. (CLVS): Free Stock Analysis Report To read this article on Zacks.com click here. Analysts have predicted a sizable increase in merger and acquisition activity in both drugmakers and medical device corners in 2019 . | Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report VanEck Vectors Biotech ETF (BBH): ETF Research Reports First Trust NYSE Arca Biotechnology Index Fund (FBT): ETF Research Reports iShares Nasdaq Biotechnology ETF (IBB): ETF Research Reports iShares Core S&P 500 ETF (IVV): ETF Research Reports Biogen Inc. (BIIB): Get Free Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Clovis Oncology, Inc. (CLVS): Free Stock Analysis Report To read this article on Zacks.com click here. Gilead SciencesGILD , Biogen BIIB , AbbVieABBV and AstraZenecaAZN can act as potential acquirers down the line. Principal Healthcare Innovators Index ETF BTEC - Up 14.20% Virtus LifeSci Biotech Products ETF BBP - Up 14.0% VanEck Vectors Biotech ETF BBH - Up 13.4% First Trust Amex Biotechnology Index FBT - Up 13.4% iShares Nasdaq Biotechnology ETF IBB - Up 12.7% Want key ETF info delivered straight to your inbox? | Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report VanEck Vectors Biotech ETF (BBH): ETF Research Reports First Trust NYSE Arca Biotechnology Index Fund (FBT): ETF Research Reports iShares Nasdaq Biotechnology ETF (IBB): ETF Research Reports iShares Core S&P 500 ETF (IVV): ETF Research Reports Biogen Inc. (BIIB): Get Free Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Clovis Oncology, Inc. (CLVS): Free Stock Analysis Report To read this article on Zacks.com click here. Gilead SciencesGILD , Biogen BIIB , AbbVieABBV and AstraZenecaAZN can act as potential acquirers down the line. Success Story Beyond Cancer While researches and approvals have been solid in the oncology space, the other areas have also held strong. | Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report VanEck Vectors Biotech ETF (BBH): ETF Research Reports First Trust NYSE Arca Biotechnology Index Fund (FBT): ETF Research Reports iShares Nasdaq Biotechnology ETF (IBB): ETF Research Reports iShares Core S&P 500 ETF (IVV): ETF Research Reports Biogen Inc. (BIIB): Get Free Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Clovis Oncology, Inc. (CLVS): Free Stock Analysis Report To read this article on Zacks.com click here. Gilead SciencesGILD , Biogen BIIB , AbbVieABBV and AstraZenecaAZN can act as potential acquirers down the line. More Deals Ahead? |
25152.0 | 2019-01-23 00:00:00 UTC | Is a Beat in Store for AbbVie (ABBV) This Earnings Season? | ABBV | https://www.nasdaq.com/articles/is-a-beat-in-store-for-abbvie-abbv-this-earnings-season-2019-01-23 | nan | nan | We expect AbbVie Inc.ABBV to beat expectations when i t report s fourth-quarter 2018 results on Jan 25, before market open. In the last reported quarter, the company delivered a positive earnings surprise of 6.47%.
Shares of AbbVie have declined 0.8% in the past six months against the industry 's increase of 5.8%.
Let's see how things are shaping up for the company this quarter.
Factors to Consider
AbbVie expects earnings per share for the quarter to be in the range of $1.89 and $1.91. Revenues are expected to be driven by operational growth of 7%. However, currency movement is likely to have an unfavorable impact of less than 1%. The Zacks Consensus Estimate for earnings and revenue stands at $1.91 per share and $8.38 billion, respectively.
AbbVie's flagship product, Humira, which is approved for several inflammatory indications, has witnessed strong demand trends despite the launch of drugs with new mechanisms of action and competition from indirect biosimilars. U.S. sales were above expectation in the third quarter and in the soon to-be reported quarter a similar performance is likely. However, international sales are likely to have an unfavorable impact as several biosimilar versions of the drug were launched in Europe in October. U.S. Humira sales are expected to be $13.7 billion in 2018 while the company reduced its guidance for international sales from $6.4 billion to $6.3 billion. The Zacks Consensus Estimate for fourth-quarter Humira sales is pegged at $5 billion.
The company also has a strong oncology portfolio. New drug Imbruvica has shown impressive adoption in the approved indications, especially front-line chronic lymphocytic leukemia. AbbVie continues to develop the drug in several indications. There were several positive data readouts during the quarter. Earlier this week, the company's partner, Johnson & Johnson JNJ reported earnings. Sales of Imbruvica confirm the growth trend in the fourth quarter.
Label expansion of Imbruvica in combination with Roche/Biogen's Rituxan for treating Waldenström's macroglobulinemia in August is likely to boost sales this quarter. In 2018, the company expects Imbruvica global revenues to exceed $3.5 billion with sales in the United States likely to cross $2.9 billion. The Zacks Consensus Estimate for the drug is pegged at $967 million in the soon-to-be reported quarter.
Other drugs, namely Duodopa and Creon, are also likely to continue their year-to-date strong performance in the soon-to-be-reported quarter. The Zacks Consensus Estimate for Duodopa and Creon sales is $113 million and $246 million, respectively.
Sales of another leukemia drug, Venclexta, is also growing rapidly on the back of label expansion in second-line plus setting for CLL patients and doubled year over year in the third quarter. In September, the drug's label was expanded to include CLL patients with minimal residual disease, broadening the eligible patient population in the fourth quarter. However, impact on sales remains to be seen.
In November, the drug received approval for newly-diagnosed acute myeloid leukaemia (AML) patients aged 75 years or older or those ineligible for intensive induction chemotherapy in the United States. In October, the drug was approved in combination with Roche's Rituxan for treating CLL in second or later-line setting in Europe.
AbbVie's hepatitis C virus ("HCV") segment also showed impressive growth on the back of better-than-expected uptake of Mavyret despite stiff competition. Mavyret has become a major growth driver for AbbVie within a short time of its launch and commanded roughly 50% market share globally at the end of the third quarter. We expect the positive trend to continue this quarter. However, Viekira may continue to see declining sales, affected by intense pricing and competitive pressure in the HCV market. Full year HCV global sales are estimated to be $3.5 billion, up nearly 2.7 times from 2017.
The company may continue to see higher operating expense due to ongoing clinical studies and launch of new drugs and label expansions.
Why a Likely Positive Surprise?
Our proven model indicates that AbbVie is likely to bea t earnings estimates this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen.
Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate ($1.97) and the Zacks Consensus Estimate ($1.91), stands at +2.65%. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter .
Zacks Rank: AbbVie has a Zacks Rank #3. The combination of a positive Earnings ESP and a favorable Zacks Rank makes us reasonably confident of an earnings beat.
Conversely, we caution against the Sell-rated stocks (#4 or 5) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
AbbVie Inc. Price and EPS Surprise
AbbVie Inc. Price and EPS Surprise | AbbVie Inc. Quote
Other Stocks That Warrant a Look
Here are some biotech stocks that you may also want to consider, as our model shows that these have the right combination of elements to post an earnings beat in their upcoming releases.
Exact Sciences Corporation EXAS has an Earnings ESP of +17.7% and a Zacks Rank #2. The company is expected to release fourth-quarter results on Feb 28. You can see the complete list of today's Zacks #1 Rank stocks here .
Regeneron Pharmaceuticals, Inc. REGN has an Earnings ESP of +6.12% and a Zacks Rank #3. The company is expected to release fourth-quarter results on Feb 14.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, wouldn't you like to know about our 10 finest buy-and-holds for the year?
From more than 4,000 companies covered by the Zacks Rank, these 10 were picked by a process that consistently beats the market. Even during 2018 while the market dropped -5.2%, our Top 10s were up well into double-digits. And during bullish 2012 - 2017, they soared far above the market's +126.3%, reaching +181.9%.
This year, the portfolio features a player that thrives on volatility, an AI comer, and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs.
See Stocks Today >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Johnson & Johnson (JNJ): Get Free Report
Exact Sciences Corporation (EXAS): Free Stock Analysis Report
Regeneron Pharmaceuticals, Inc. (REGN): Get Free Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie's flagship product, Humira, which is approved for several inflammatory indications, has witnessed strong demand trends despite the launch of drugs with new mechanisms of action and competition from indirect biosimilars. We expect AbbVie Inc.ABBV to beat expectations when i t report s fourth-quarter 2018 results on Jan 25, before market open. Shares of AbbVie have declined 0.8% in the past six months against the industry 's increase of 5.8%. | AbbVie Inc. Price and EPS Surprise AbbVie Inc. Price and EPS Surprise | AbbVie Inc. Quote Other Stocks That Warrant a Look Here are some biotech stocks that you may also want to consider, as our model shows that these have the right combination of elements to post an earnings beat in their upcoming releases. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Johnson & Johnson (JNJ): Get Free Report Exact Sciences Corporation (EXAS): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Get Free Report To read this article on Zacks.com click here. We expect AbbVie Inc.ABBV to beat expectations when i t report s fourth-quarter 2018 results on Jan 25, before market open. | AbbVie Inc. Price and EPS Surprise AbbVie Inc. Price and EPS Surprise | AbbVie Inc. Quote Other Stocks That Warrant a Look Here are some biotech stocks that you may also want to consider, as our model shows that these have the right combination of elements to post an earnings beat in their upcoming releases. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Johnson & Johnson (JNJ): Get Free Report Exact Sciences Corporation (EXAS): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Get Free Report To read this article on Zacks.com click here. We expect AbbVie Inc.ABBV to beat expectations when i t report s fourth-quarter 2018 results on Jan 25, before market open. | We expect AbbVie Inc.ABBV to beat expectations when i t report s fourth-quarter 2018 results on Jan 25, before market open. Shares of AbbVie have declined 0.8% in the past six months against the industry 's increase of 5.8%. Factors to Consider AbbVie expects earnings per share for the quarter to be in the range of $1.89 and $1.91. |
25153.0 | 2019-01-23 00:00:00 UTC | 3 Upcoming Readouts for Gilead Sciences You Don't Want to Miss | ABBV | https://www.nasdaq.com/articles/3-upcoming-readouts-gilead-sciences-you-dont-want-miss-2019-01-23 | nan | nan | Gilead Sciences (NASDAQ: GILD) stock has been sliding for years, but the biotech has the right ingredients to stage a comeback and provide market-thumping gains down the road. Gilead's new HIV pill is a hit, and it has a couple of drugs in late-stage trials that could do just as well.
Of course, this biotech stock isn't going anywhere if ongoing clinical trials don't produce the right results. Here's what you need to know about three clinical trial readouts on the horizon that could smooth out a path to growth for Gilead -- or put up barriers.
1. Glaxo's new two-drug HIV combo
Last February, Gilead introduced Biktarvy, a single-pill regimen for HIV that's already the company's lead growth driver. Biktarvy's approved to treat patients switching from another antiviral, and those new to treatment. A large patient population on the lifelong medication is expected to drive annual sales to $5 billion by 2022.
Gilead Sciences investors want to keep an eye on a two-drug combination from GlaxoSmithKline (NYSE: GSK) that's in a pair of head-to-head studies with an older three-drug regimen still used to treat newly diagnosed patients. Glaxo's next challenger to Gilead's lead in the HIV space combines dolutegravir with lamivudine (which suppressed the virus after 48 weeks), as well as dolutegravir, tenofovir disoproxil fumarate, and emtricitabine for patients new to treatment.
In the third quarter, GlaxoSmithKline will present 96-week results for its two-drug candidate. Gilead investors will want to keep an eye open for the results to see how the potential competitor stacks up to Biktarvy.
2. Selonsertib for NASH
Nonalcoholic steatohepatitis (NASH) is a progressive condition that describes an immune system persistently attacking fatty liver tissue. Around one-third of American adults have livers with dangerous fat levels, or nonalcoholic fatty liver disease (NAFLD), but few realize it unless they become one of an estimated 20 million in the U.S. with the persistent inflammation that defines NASH.
NASH progresses so slowly that the Food and Drug Administration is willing to grant accelerated approval of treatments for advanced-stage patients with liver tissue already scarred and stiffened by inflammation. Specifically, it wants to see drugs that stop the inflammation without fibrosis worsening, or reduce fibrosis without inflammation worsening.
In the first half of the year, Gilead will present top-line data from pivotal studies with selonsertib as a treatment for patients with bridging fibrosis, and another for patients with compensated cirrhosis caused by NASH. If Gilead's NASH candidate performs in line with earlier observations, it could carve out a niche among severely affected NASH patients capable of driving annual sales past $1 billion in a few short years. During a mid-stage study, selonsertib helped 43% of patients achieve a fibrosis score improvement compared with just 2 out of 10 patients given a placebo.
Selonsertib's mid-stage data was positive but difficult to interpret because of the small groups. That means anything can happen when Gilead reads out the results.
3. Filgotinib for rheumatoid arthritis
The world's top-selling drug, Humira, hauled in around $20 billion last year as an anti-inflammatory injection for people with rheumatoid arthritis (RA), psoriasis, and inflammatory bowel disease. Gilead's filgotinib is an easy-to-swallow tablet in late-stage pivotal trials for the treatment of RA, which puts it far behind a couple other similar candidates ready to break into this space.
Last year, Eli Lilly (NYSE: LLY) launched a new, easy-to-swallow tablet for rheumatoid arthritis called Olumiant, but the FDA restricted the dosage to a level that probably won't be very effective. The agency was troubled by a very small number of patients who experienced life-threatening blood clots during studies with Olumiant. AbbVie (NYSE: ABBV) is waiting for the FDA to review an application submitted late last year for upadacitinib, another oral RA therapy with a safety record besmirched by a small number of lethal clots during phase 3 trials.
During the Finch-2 study with filgotinib, RA patients who didn't respond well to Humira, or other injectables, achieved improvements after 12 weeks that suggest filgotinib can stand up to Olumiant and upadacitinib. Moreover, it hasn't been associated with dangerous blood clots yet.
Investigators will present data from two more Finch studies before the end of the first quarter. If Gilead's RA hopeful can maintain a squeaky-clean safety profile, there's a good chance it will also become the best-selling new rheumatoid arthritis treatment, with potential expansions to inflammatory bowel disease down the road.
A bargain now?
Gilead's diminished hepatitis C franchise contributes just 16% of total revenue now. That means continued commercial success with Biktarvy might be enough to return the company's sagging top line to growth on its own.
Shares of the biotech have fallen to just 10.2 times forward earnings expectations. That looks like a bargain compared with the average S&P 500 stock, which currently trades at around 15.7 times estimates.
Gilead also offers a nice 3.3% dividend yield at recent prices, and HIV sales generate plenty of cash to make the payments and keep raising them each year. It's hard to predict what's going to happen with filgotinib and selonsertib, but those quarterly payouts are yours to keep.
10 stocks we like better than Gilead Sciences
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Gilead Sciences wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of November 14, 2018
Cory Renauer owns shares of Gilead Sciences. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie (NYSE: ABBV) is waiting for the FDA to review an application submitted late last year for upadacitinib, another oral RA therapy with a safety record besmirched by a small number of lethal clots during phase 3 trials. Gilead Sciences investors want to keep an eye on a two-drug combination from GlaxoSmithKline (NYSE: GSK) that's in a pair of head-to-head studies with an older three-drug regimen still used to treat newly diagnosed patients. If Gilead's RA hopeful can maintain a squeaky-clean safety profile, there's a good chance it will also become the best-selling new rheumatoid arthritis treatment, with potential expansions to inflammatory bowel disease down the road. | AbbVie (NYSE: ABBV) is waiting for the FDA to review an application submitted late last year for upadacitinib, another oral RA therapy with a safety record besmirched by a small number of lethal clots during phase 3 trials. Filgotinib for rheumatoid arthritis The world's top-selling drug, Humira, hauled in around $20 billion last year as an anti-inflammatory injection for people with rheumatoid arthritis (RA), psoriasis, and inflammatory bowel disease. Gilead's filgotinib is an easy-to-swallow tablet in late-stage pivotal trials for the treatment of RA, which puts it far behind a couple other similar candidates ready to break into this space. | AbbVie (NYSE: ABBV) is waiting for the FDA to review an application submitted late last year for upadacitinib, another oral RA therapy with a safety record besmirched by a small number of lethal clots during phase 3 trials. Gilead Sciences investors want to keep an eye on a two-drug combination from GlaxoSmithKline (NYSE: GSK) that's in a pair of head-to-head studies with an older three-drug regimen still used to treat newly diagnosed patients. In the first half of the year, Gilead will present top-line data from pivotal studies with selonsertib as a treatment for patients with bridging fibrosis, and another for patients with compensated cirrhosis caused by NASH. | AbbVie (NYSE: ABBV) is waiting for the FDA to review an application submitted late last year for upadacitinib, another oral RA therapy with a safety record besmirched by a small number of lethal clots during phase 3 trials. Of course, this biotech stock isn't going anywhere if ongoing clinical trials don't produce the right results. Glaxo's new two-drug HIV combo Last February, Gilead introduced Biktarvy, a single-pill regimen for HIV that's already the company's lead growth driver. |
25154.0 | 2019-01-22 00:00:00 UTC | 5 Amazing Earnings Charts | ABBV | https://www.nasdaq.com/articles/5-amazing-earnings-charts-2019-01-22 | nan | nan | We're off!
This is week two o f earnings season with just over 250 companies expected to report on an MLK Day shortened trading week.
How does a company stand out from the crowd? You have an excellen t earnings surprise track record.
Beating every quarter, or nearly every quarter, isn't as easy as it sounds. These five companies have managed to do it the last 5 years even amidst incredible odds.
What does it take to succeed during earnings season?
Good management that communicates with the analysts, transparency, and a business that doesn't have roller coaster revenue.
These 5 companies are all in different industries, but they have managed to put together outstanding earnings surprise track records.
5 Amazing Earnings Charts You Must See
1. Lam Research LRCX has the best earnings track record this week, with a perfect record of beating for over 5 years. But that hasn't stopped the shares from declining in 2018 as the semiconductor industry started to hit its down cycle. Will another beat this quarter matter to the stock?
2. Tal Education TAL has only missed once since 2015. That's a great record for this Chinese tutoring company. But shares took a beating in 2018, falling 12% by the end of the year as investor fled Chinese stocks on fears of an economic slowdown. But was the selling overdone?
3. Intuitive Surgical ISRG has a great looking chart. Not only hasn't it missed since Zacks data began in 2015 but shares have rebounded off the December lows. Will another earnings beat send its shares back to new highs?
4. Starbucks SBUX has missed only once in the last 5 years. They finally broke out to new multi-year highs in 2018 only to have the shares sell off in December. Will another beat push the shares out to a new breakout?
5. AbbVie ABBV has only missed one time since 2014. Shares surged in 2017 but the drug stocks were out of favor in 2018 which pushed the shares lower. They fell 6.3% in 2018. With a forward P/E of just 10.3, is AbbVie a hidden gem?
[In full disclosure, Tracey owns shares of SBUX in her personal portfolio.]
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
TAL Education Group (TAL): Free Stock Analysis Report
AbbVie Inc. (ABBV): Get Free Report
Intuitive Surgical, Inc. (ISRG): Get Free Report
Starbucks Corporation (SBUX): Get Free Report
Lam Research Corporation (LRCX): Get Free Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie ABBV has only missed one time since 2014. With a forward P/E of just 10.3, is AbbVie a hidden gem? Click to get this free report TAL Education Group (TAL): Free Stock Analysis Report AbbVie Inc. (ABBV): Get Free Report Intuitive Surgical, Inc. (ISRG): Get Free Report Starbucks Corporation (SBUX): Get Free Report Lam Research Corporation (LRCX): Get Free Report To read this article on Zacks.com click here. | Click to get this free report TAL Education Group (TAL): Free Stock Analysis Report AbbVie Inc. (ABBV): Get Free Report Intuitive Surgical, Inc. (ISRG): Get Free Report Starbucks Corporation (SBUX): Get Free Report Lam Research Corporation (LRCX): Get Free Report To read this article on Zacks.com click here. AbbVie ABBV has only missed one time since 2014. With a forward P/E of just 10.3, is AbbVie a hidden gem? | Click to get this free report TAL Education Group (TAL): Free Stock Analysis Report AbbVie Inc. (ABBV): Get Free Report Intuitive Surgical, Inc. (ISRG): Get Free Report Starbucks Corporation (SBUX): Get Free Report Lam Research Corporation (LRCX): Get Free Report To read this article on Zacks.com click here. AbbVie ABBV has only missed one time since 2014. With a forward P/E of just 10.3, is AbbVie a hidden gem? | AbbVie ABBV has only missed one time since 2014. With a forward P/E of just 10.3, is AbbVie a hidden gem? Click to get this free report TAL Education Group (TAL): Free Stock Analysis Report AbbVie Inc. (ABBV): Get Free Report Intuitive Surgical, Inc. (ISRG): Get Free Report Starbucks Corporation (SBUX): Get Free Report Lam Research Corporation (LRCX): Get Free Report To read this article on Zacks.com click here. |
25155.0 | 2019-01-22 00:00:00 UTC | J&J's (JNJ) Q4 Earnings Beat, 2019 Sales Forecast Soft | ABBV | https://www.nasdaq.com/articles/jjs-jnj-q4-earnings-beat-2019-sales-forecast-soft-2019-01-22 | nan | nan | Johnson & Johnson 's JNJ fourth-quarter 2018 earnings came in at $1.97 per share, which beat the Zacks Consensus Estimate of $1.95 and increased 13.2% from the year-ago period driven by higher revenues and better operating margins.
Adjusted earnings excluded after-tax intangible amortization expense and some special items. Including these items, J&J reported fourth-quarter earnings of $1.12 per share against loss of $3.99 per share in the year-ago quarter.
Sales came in at $20.39 billion, beating the Zacks Consensus Estimate of $20.1 billion. Sales increased 1% from the year-ago quarter, reflecting an operational increase of 3.3% and an unfavorable currency impact of 2.3%.
Organically, excluding the impact of acquisitions and divestitures, sales increased 5.3% on an operational basis, less than 6.1% increase seen in the previous quarter. Continued growth in the Pharmaceutical segment offset a softer performance in the Consumer and Medical Devices units.
Fourth-quarter sales grew 1.5% in the domestic market to $10.63 billion and 0.4% in international markets to $9.77 billion, reflecting 5.1% operational growth and 4.7% negative currency impact.
Segment Details
J&J's Pharma segment continued to perform well despite the impact of biosimilars on Remicade sales.
Pharmaceutical segment sales rose 5.3% year over year to $10.19 billion, reflecting 7.2% operational growth and 1.9% negative currency impact as sales rose in both domestic and international markets. Sales in the domestic market rose 2.8% to $5.94 billion. International sales grew 8.9% to $4.25 billion (operational increase of 13.7%). Excluding the impact of all acquisitions and divestitures, on an operational basis, worldwide sales increased 7.2%, less than 8.2% in the previous quarter.
The strong performance was led by the company's oncology portfolio. Worldwide sales of J&J's cancer drugs rose 22.1% in the quarter.
J&J's cancer drugs like Imbruvica and Darzalex continued to perform well. Core products like Stelara and Invega Sustenna also contributed to growth. However, sales of some other key drugs like Simponi/Simponi Aria and Xarelto declined in the quarter. Sales of Zytiga slowed down significantly from the previous quarter.
Imbruvica sales rose 34.7% to $703 million in the quarter. Please note that J&J markets Imbruvica in partnership with AbbVie, Inc. ABBV . Darzalex sales rose 57.4% to $584 million in the quarter. Stelara sales rose 33.6% to $1.44 billion in the quarter. Invega Sustenna sales rose 10.1% to $763 million in the quarter.
In the quarter, J&J recorded pulmonary arterial hypertension (PAH) revenues of $667 million, up 9.3% year over year.
Simponi/Simponi Aria sales declined 1.6% to $482 million in the quarter.
Zytiga sales rose 4.1% to $786 million in the quarter. Sales of Invokana/Invokamet declined 14.6% to $228 million. Xarelto sales declined 14.4% in the quarter to $608 million.
Sales of Procrit/Eprex declined 4.7% to $221 million in the quarter.
Sales of Remicade were down 15.6% in the quarter to $1.24 billion due to competition from biosimilars. While U.S. sales declined 21.4%, U.S. exports went down 21.7%. Remicade sales rose 9.7% in international markets. Please note that J&Jmarkets Remicade in partnership with Merck MRK .
Newly launched Tremfya recorded sales of $175 million in the quarter compared with $171 million in the third quarter.
Medical Devices segment sales came in at $6.67 billion, down 4.4% from the year-ago period. It included an operational decrease of 2.2% and negative currency movement of 2.2%.
Excluding the impact of all acquisitions and divestitures, on an operational basis, worldwide sales increased 3.3%, better than 2.9% in the previous quarter.
Domestic market sales declined 3% year over year to $3.2 billion. International market sales decreased 5.6% (operational decrease of 1.4%) year over year to $3.45 billion.
The Consumer segment recorded revenues of $3.54 billion in the reported quarter, almost flat year over year. Moreover, on an operational basis, Consumer segment sales increased 3.3%, which was offset by unfavorable foreign currency movement of 3.4%.
Excluding the impact of acquisitions and divestitures, adjusted operational sales growth was 3.8% worldwide, a significant deceleration from 6.1% the previous quarter.
Sales in the domestic market rose 7.3% from the year-ago period to $1.48 billion. Meanwhile, the international segment recorded a decline of 4.8% to $2.06 billion. The operational increase of 0.8% was offset by negative currency impact of 5.6% in the quarter.
2018 Results
Full-year 2018 sales rose 6.7% to $81.58 billion, beating the Zacks Consensus Estimate of $81.36 billion and came ahead of the guided range of $81 to $81.4 billion
Adjusted earnings for 2018 were $8.18 per share, exceeding the Zacks Consensus Estimate of $8.16 and up 12.1% year over year. Earnings were at the higher end of the guided range of $8.13 - $8.18 per share.
Forecast for 2019
J&J issued earnings and sales guidance for 2019.
J&J expects 2019 adjusted earnings per share in the range of $8.50 - $8.65. The guidance range reflects an operational growth rate between 5.7% and 7.6%. The Zacks Consensus Estimate for 2019 is $8.64.
Revenues are expected in the range of $80.4 to $81.2 billion, which falls short of the Zacks Consensus Estimate for revenues of $82.61 billion.
The sales guidance reflects operational constant currency sales growth in the range of 0% to 1%. Organically, excluding the impact of acquisitions and divestitures, sales growth is expected to be in the range of 2% to 3% on an operational basis.
Our Take
J&J beat estimates for both earnings and sales in the fourth quarter of 2018, pushing its shares up 1% in pre-market trading . The sales guidance for 2019 was however below expectations.
J&J's Pharma segment performed better than the market in 2018 despite the impact of biosimilars on Remicade sales. We believe that new products in all segments, successful label expansion of cancer drugs like Imbruvica and Darzalex and contribution from acquisitions will continue to drive the top line in 2019.
The stock has depreciated 11.8% in the past year compared with a decrease of 0.8% recorded by the industry .
J&J is fighting thousands of lawsuits alleging that its talc/baby powders contain asbestos, which causes users to develop ovarian cancer. J&J, in a statement, called the reports by Reuters "one-sided, false, and inflammatory". J&J said that independent tests by regulators, academic institutions and leading labs have proven that its talc-based products never contained asbestos.
J&J currently has a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
A better-ranked large-cap pharma stock is Eli Lilly & Company LLY , holding a Zacks Rank #2 (Buy).
Lilly's earnings estimates have increased 1.4% for 2019 over the past 60 days. The company's shares have surged 36.5% in the past year.
Johnson & Johnson Price, Consensus and EPS Surprise
Johnson & Johnson Price, Consensus and EPS Surprise | Johnson & Johnson Quote
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Merck & Co., Inc. (MRK): Free Stock Analysis Report
Eli Lilly and Company (LLY): Free Stock Analysis Report
AbbVie Inc. (ABBV): Get Free Report
Johnson & Johnson (JNJ): Get Free Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Please note that J&J markets Imbruvica in partnership with AbbVie, Inc. ABBV . Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report AbbVie Inc. (ABBV): Get Free Report Johnson & Johnson (JNJ): Get Free Report To read this article on Zacks.com click here. Excluding the impact of acquisitions and divestitures, adjusted operational sales growth was 3.8% worldwide, a significant deceleration from 6.1% the previous quarter. | Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report AbbVie Inc. (ABBV): Get Free Report Johnson & Johnson (JNJ): Get Free Report To read this article on Zacks.com click here. Please note that J&J markets Imbruvica in partnership with AbbVie, Inc. ABBV . Pharmaceutical segment sales rose 5.3% year over year to $10.19 billion, reflecting 7.2% operational growth and 1.9% negative currency impact as sales rose in both domestic and international markets. | Please note that J&J markets Imbruvica in partnership with AbbVie, Inc. ABBV . Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report AbbVie Inc. (ABBV): Get Free Report Johnson & Johnson (JNJ): Get Free Report To read this article on Zacks.com click here. Fourth-quarter sales grew 1.5% in the domestic market to $10.63 billion and 0.4% in international markets to $9.77 billion, reflecting 5.1% operational growth and 4.7% negative currency impact. | Please note that J&J markets Imbruvica in partnership with AbbVie, Inc. ABBV . Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report AbbVie Inc. (ABBV): Get Free Report Johnson & Johnson (JNJ): Get Free Report To read this article on Zacks.com click here. Pharmaceutical segment sales rose 5.3% year over year to $10.19 billion, reflecting 7.2% operational growth and 1.9% negative currency impact as sales rose in both domestic and international markets. |
25156.0 | 2019-01-22 00:00:00 UTC | Bet on These 5 Low Leverage Stocks to Secure Returns | ABBV | https://www.nasdaq.com/articles/bet-on-these-5-low-leverage-stocks-to-secure-returns-2019-01-22 | nan | nan | Leverage refers to the investment strategy of using borrowed money -the use of borrowed capital - to run a business smoothly. In the complex world of investment, understanding the amount of financial leverage a company bears is crucial.
Although there remains an option to choose equity for borrowing capital, debt is the more popular one due to its cheap and easy availability over equity financing. Moreover, in case of equity financing, a shareholder not only becomes a partial owner of the company but also has a direct claim on the company's future profits. So, debt financing remains more dearer for corporates.
Yet, debt financing has its share of drawbacks. The problem arises when leverage, referred to as the amount of debt a company bears, becomes exorbitant. A high degree of financial leverage means high interest payments, which affect the company's bottom line.
Of course, this does not mean that corporations should totally avoid debt financing. In fact, it has been an inherent instrument for corporations to grow their earnings.
Nevertheless, to be on the safe side, investors try to avoid stocks that bear large debt loads. Empirically, several leverage ratios have been constructed to measure the exact amount of debt risk a company bears in order to safeguard investors from debt traps.
Debt-to-equity ratio is one such measure, perhaps the most popular one, which has been used to evaluate a company's credit worthiness, for potential equity investments.
Analyzing Debt/Equity
Debt-to-Equity Ratio = Total Liabilities/Shareholders' Equity
This metric is a liquidity ratio that indicates the amount of financial risk a company bears. A company with a lower debt-to-equity ratio indicates improved solvency for a company.
With the Q4 earnings season knocking on the doors, investors must be targeting companies with solid earnings growth projections. But, in the uncertain world of investment, markets can falter anytime, particularly affecting companies with a higher degree of financial leverage. Therefore, blindly investing in stocks displaying solid earnings growth without considering their debt level is not a wise move.
The Winning Strategy
Considering the aforementioned factors, it is wise to choose stocks with a low debt-to-equity ratio to ensure safe returns.
However, an investment strategy based solely on debt-to-equity ratio might not fetch the desired outcome. To choose stocks that have the potential to give you steady returns, we have expanded our screening criteria to include some other factors.
Here are the other parameters:
Debt/Equity less than X-Industry Median : Stocks that are less leveraged than their industry peers.
Current Price greater than or equal to 10 : The stocks must be trading at a minimum of $10 or above.
Average 20-day Volume greater than or equal to 50000 : A substantial trading volume ensures that the stock is easily tradable.
Percentage Change in EPS F(0)/F(-1) greater than X-Industry Median : Earnings growth adds to optimism, leading to a stock's price appreciation.
VGM Score of A or B : Our research shows that stocks with a VGM Score of A or B when combined with a Zacks Rank #1 (Strong Buy) or 2 (Buy) offer the best upside potential.
Estimated One-Year EPS Growth F(1)/F(0) greater than 5 : This shows earnings growth expectation
Zacks Rank #1 or 2 : Irrespective of market conditions, stocks with a Zacks Rank #1 (Strong Buy) or 2 (Buy) have a proven history of success.
Excluding stocks that have a negative or a zero debt-to-equity ratio, here are five of the 31 stocks that made it through the screen.
AbbVie Inc.ABBV : It is a research-based biopharmaceutical company. The company generated an average positive earnings surprise of 3.54% in the last four quarters and currently carries a Zacks Rank #2.
HCA Healthcare, Inc.HCA : It is the largest non-governmental operator of acute care hospitals in the United States. The company currently holds a Zacks Rank of 2 and delivered average positive earnings surprise of 11.22% over the trailing four quarters.
Steelcase Inc.SCS : It offers a range of architecture, furniture and technology products and services designed to create high-performance work environments. The company came up with average positive earnings surprise of 21.87% in the preceding four quarters and sports a Zacks Rank #1 at present. You can see the complete list of today's Zacks #1 Rank stocks here .
The Michaels Companies, Inc.MIK : It is one of the leading arts and crafts specialty retailer in North America on the basis of store count. Currently, the company carries a Zacks Rank #2. It came up with average positive earnings surprise of 6.36% in the preceding four quarters.
The Boeing CompanyBA : The company is a premier jet aircraft manufacturer and one of the largest defense contractors in the United States. It currently flaunts a Zacks Rank #1 and delivered average positive earnings surprise of 28.01% in the last four quarters.
Get the rest of the stocks on the list and start putting this and other ideas to the test. It can all be done with the Research Wizard stock picking and back testing software.
The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out.
Click here to sign up for a free trial to the Research Wizard today .
Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.
Disclosure: Performance information for Zacks' portfolios and strategies are available at: https://www.zacks.com/performance .
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Get Free Report
The Boeing Company (BA): Get Free Report
Steelcase Inc. (SCS): Get Free Report
HCA Healthcare, Inc. (HCA): Get Free Report
The Michaels Companies, Inc. (MIK): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie Inc.ABBV : It is a research-based biopharmaceutical company. Click to get this free report AbbVie Inc. (ABBV): Get Free Report The Boeing Company (BA): Get Free Report Steelcase Inc. (SCS): Get Free Report HCA Healthcare, Inc. (HCA): Get Free Report The Michaels Companies, Inc. (MIK): Free Stock Analysis Report To read this article on Zacks.com click here. The Winning Strategy Considering the aforementioned factors, it is wise to choose stocks with a low debt-to-equity ratio to ensure safe returns. | Click to get this free report AbbVie Inc. (ABBV): Get Free Report The Boeing Company (BA): Get Free Report Steelcase Inc. (SCS): Get Free Report HCA Healthcare, Inc. (HCA): Get Free Report The Michaels Companies, Inc. (MIK): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc.ABBV : It is a research-based biopharmaceutical company. Estimated One-Year EPS Growth F(1)/F(0) greater than 5 : This shows earnings growth expectation Zacks Rank #1 or 2 : Irrespective of market conditions, stocks with a Zacks Rank #1 (Strong Buy) or 2 (Buy) have a proven history of success. | Click to get this free report AbbVie Inc. (ABBV): Get Free Report The Boeing Company (BA): Get Free Report Steelcase Inc. (SCS): Get Free Report HCA Healthcare, Inc. (HCA): Get Free Report The Michaels Companies, Inc. (MIK): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc.ABBV : It is a research-based biopharmaceutical company. Estimated One-Year EPS Growth F(1)/F(0) greater than 5 : This shows earnings growth expectation Zacks Rank #1 or 2 : Irrespective of market conditions, stocks with a Zacks Rank #1 (Strong Buy) or 2 (Buy) have a proven history of success. | AbbVie Inc.ABBV : It is a research-based biopharmaceutical company. Click to get this free report AbbVie Inc. (ABBV): Get Free Report The Boeing Company (BA): Get Free Report Steelcase Inc. (SCS): Get Free Report HCA Healthcare, Inc. (HCA): Get Free Report The Michaels Companies, Inc. (MIK): Free Stock Analysis Report To read this article on Zacks.com click here. Although there remains an option to choose equity for borrowing capital, debt is the more popular one due to its cheap and easy availability over equity financing. |
25157.0 | 2019-01-22 00:00:00 UTC | Better Buy: Pfizer vs. AbbVie | ABBV | https://www.nasdaq.com/articles/better-buy-pfizer-vs-abbvie-2019-01-22 | nan | nan | If you've been looking for big pharma stocks with juicy dividend yields, you've probably noticed Pfizer (NYSE: PFE) , and AbbVie (NYSE: ABBV) recently. AbbVie currently offers a better dividend yield, but smart investors want to know which one can deliver the largest payout bumps in the years to come.
Pfizer's top line has been stagnating for years while AbbVie's has surged, but the tables might turn in the years ahead. Let's see what that will do to their dividend programs to figure out which is the better stock right now.
Nice offers
On the surface, AbbVie looks like a clear winner. At recent prices, its shares offer a giant 4.8% dividend yield, compared to a 3.4% yield you'd receive from Pfizer. Based on recent raises, AbbVie wins again. Since 2015, its payout has grown 118%, while Pfizer's grew just 29% over the same time frame.
Both dividend programs are well funded. Pfizer's profitable operations produced a whopping $15.7 billion in free cash flow over the past year, and the company needed just 50.6% of that profit to cover its dividend obligation. AbbVie's dividend program chewed through just 43.3% of an impressive $11.9 billion in free cash flow generated over the past year.
Going down
Right now, AbbVie's top-selling drug, Humira, is losing ground to biosimilar competition that launched throughout the European Union in October. AbbVie relies on Humira for 61% of total sales now, and investors are right to be nervous about its impending losses.
International Humira sales reached $4.9 billion during the first nine months of 2018, and most of that revenue comes from the EU. With at least three lower-priced biosimilar versions competing for market share, those sales could dry up in a couple of years.
In June, Pfizer will lose exclusivity for Lyrica in the U.S., and that's the last major patent loss that Pfizer needs to worry about until 2026. Pfizer depends on the nerve-pain medication for just 9% of total sales, so its losses will only sting a little.
Going up
Pfizer shareholders have a lot to look forward to in 2019 and beyond. In July, the Food and Drug Administration is expected to make a decision regarding tafamidis, a treatment for patients with progressive heart damage caused by the buildup of a misfolded protein. Taking tafamidis for 30 months reduced patients' chance of death from any cause by 30% and improved important quality of life measurements compared to a placebo.
Cardiomyopathy caused by transthyretin mediated amyloidosis is rare, but it often goes undiagnosed. If approved, annual sales of tafamidis could reach more than $1 billion after a few years and much further down the road if the availability of new treatments brings more patients out of the woodwork.
Pfizer's share of Xtandi revenue is about to soar as well. The prostate cancer capsules are already popular among castration-resistant patients with tumors that have already spread. Last year, they became available for patients without metastatic disease who tend to stay on treatment longer. In 2019, another approval to treat patients who still respond to hormonal treatments could make Xtandi available for just about anyone with prostate cancer.
Humira's still protected by a fortress of U.S. patents that will keep biosimilars from the U.S. market until 2023. During the first nine months of 2018, U.S. Humira sales rose 11.3% to $10.1 billion and will probably continue marching upwards through the end of 2022.
By the time total Humira sales begin sliding downhill, AbbVie could have a stable of blockbuster drugs working together to push the needle forward again. Tomorrow's growth drivers include Orlissa, the first new treatment for endometriosis pain in over a decade. Endometriosis affects around one in 10 women of reproductive age, and roughly three quarters of women will be affected by uterine fibroids, another hormone driven growth that causes a great deal of discomfort. In early 2020, Orlissa could earn an approval to treat women affected by uterine fibroids, driving annual sales up to $2 billion by 2025.
AbbVie's experimental psoriasis treatment, risankizumab, should receive an FDA approval decision in April. An approval for risankizumab could lead to $5 billion in annual sales by 2025, and a new rheumatoid arthritis candidate called upadacitinib is expected to do just as well.
The better buy
AbbVie does offer a bigger dividend yield off the bat, but the company's top line could stall later this year. Orlissa, risankizumab, and upadacitinib need to succeed and fast, or AbbVie's dividend isn't going anywhere very fast.
Pfizer's on the edge of a long stretch of double-digit growth beginning in 2020, that should stretch through at least 2026. That should allow the company to make steady dividend raises that will probably overtake AbbVie's down the road.
10 stocks we like better than Pfizer
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Pfizer wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of November 14, 2018
Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | By the time total Humira sales begin sliding downhill, AbbVie could have a stable of blockbuster drugs working together to push the needle forward again. If you've been looking for big pharma stocks with juicy dividend yields, you've probably noticed Pfizer (NYSE: PFE) , and AbbVie (NYSE: ABBV) recently. AbbVie currently offers a better dividend yield, but smart investors want to know which one can deliver the largest payout bumps in the years to come. | By the time total Humira sales begin sliding downhill, AbbVie could have a stable of blockbuster drugs working together to push the needle forward again. If you've been looking for big pharma stocks with juicy dividend yields, you've probably noticed Pfizer (NYSE: PFE) , and AbbVie (NYSE: ABBV) recently. AbbVie currently offers a better dividend yield, but smart investors want to know which one can deliver the largest payout bumps in the years to come. | If you've been looking for big pharma stocks with juicy dividend yields, you've probably noticed Pfizer (NYSE: PFE) , and AbbVie (NYSE: ABBV) recently. AbbVie currently offers a better dividend yield, but smart investors want to know which one can deliver the largest payout bumps in the years to come. Pfizer's top line has been stagnating for years while AbbVie's has surged, but the tables might turn in the years ahead. | The better buy AbbVie does offer a bigger dividend yield off the bat, but the company's top line could stall later this year. If you've been looking for big pharma stocks with juicy dividend yields, you've probably noticed Pfizer (NYSE: PFE) , and AbbVie (NYSE: ABBV) recently. AbbVie currently offers a better dividend yield, but smart investors want to know which one can deliver the largest payout bumps in the years to come. |
25158.0 | 2019-01-21 00:00:00 UTC | What's in Store for Bristol-Myers (BMY) in Q4 Earnings? | ABBV | https://www.nasdaq.com/articles/whats-in-store-for-bristol-myers-bmy-in-q4-earnings-2019-01-21 | nan | nan | Bristol-Myers Squibb CompanyBMY is expected to report fourth-quarter 2018 results on Jan 24, before market opens.
Bristol-Myers' shares have decreased 8.9% in the past six months, against the industry 's growth of 7.1%.
Bristol-Myers has an excellent track record. The company delivered positive earnings surprise in all the four quarters. Average positive earnings surprise in the last four quarters is 12%. In the las t report ed quarter, Bristol-Myers delivered a positive surprise of 19.8%.
Let's see how things are shaping up for this quarter.
What Will Drive Growth in Q4?
Bristol-Myers' key immuno-oncology drug, Opdivo is expected to be the primary revenue driver in the fourth quarter, with several line extensions in the past year. Earlier in 2018, Opdivo was approved as a monotherapy for the treatment of metastatic small cell lung cancer (SCLC) in third-line setting in patients who have received platinum-based chemotherapy and at least one other line of therapy. The drug also received approval for treating microsatellite instability high or mismatch repair deficient metastatic colorectal cancer, in combination with Yervoy in second-line setting in the United States.
The European Commission recently approved the combination of Opdivo plus Yervoy for the first-line treatment of patients with intermediate- and poor-risk advanced renal cell carcinoma (RCC). Opdivo has already captured 30% share of new patients in the first-line RCC market.
The drug, which is approved for multiple indications, has generated sales of $1.8 billion in the third quarter and $4.9 billion in the first nine months of 2018, increasing 42% and 37%, respectively, from the year-ago period.
Yervoy's line extension in pediatric patients aged 12 years or older with unresectable or metastatic melanoma was approved in Europe. The FDA approved the drug in combination with Opdivo for first-line treatment of RCC. Label expansion of the drug should further boost sales.
Oncology drug, Sprycel is also maintaining momentum. The European Commission approved a line extension of Sprycel in pediatric patients with Ph+ chronic myeloid leukemia. The FDA also approved the drug for the treatment of pediatric patients aged one year or older, with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL), in combination with chemotherapy. We expect the recent label expansion of the drug to boost sales. Cardiovascular drug, Eliquis also showed strong performance in the first nine months of 2018, with sales growing 35% from the year-ago quarter. In fact, robust sales are expected in the fourth quarter too, driven by expansion in market share.
However, the Hepatitis C and HIV businesses continue to face competitive pressure. Sales for the franchise are expected to decline.
Investors will also focus on further updates on the company's recent announcement of acquiring Celgene Corporation CELG for $74 billion. The impending acquisition will result in a specialty biopharma company with a strong oncology portfolio and diverse pipeline in the therapeutic areas of inflammatory, immunologic and cardiovascular diseases. Bristol-Myers was pursuing an acquisition for quite some time now to bolster its portfolio. While its blockbuster immuno-oncology drug, Opdivo continues to perform well on the back of label expansions, pricing concerns and stiff competition in the immuno-oncology space have limited market share gains.
The Zacks Consensus Estimate for fourth-quarter sales and earnings is pegged at $5.98 billion and 85 cents, respectively.
Earnings Whispers
Our proven model does not conclusively show that Bristol-Myers will bea t earnings estimates this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen.
Earnings ESP : The company's Earnings ESP is -0.12%. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter .
Zacks Rank : Bristol-Myers has a Zacks Rank #3, which is favorable. However, the company's negative Earnings ESP makes surprise prediction difficult.
Conversely, we caution against the Sell-rated stocks (#4 or 5) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Bristol-Myers Squibb Company Price, Consensus and EPS Surprise
Bristol-Myers Squibb Company Price, Consensus and EPS Surprise | Bristol-Myers Squibb Company Quote
Stocks to Consider
Here are some stocks you might want to consider as our model shows that these have the right combination of elements to post an earnings beat this quarter.
AbbVie Inc. ABBV is scheduled to release its results on Jan 25. The company has an Earnings ESP of +2.65% and a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here .
Amgen, Inc. AMGN is scheduled to release its results on Jan 29. The company has an Earnings ESP of +0.25% and a Zacks Rank #2.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year?
Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.
See Latest Stocks Today >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bristol-Myers Squibb Company (BMY): Get Free Report
AbbVie Inc. (ABBV): Get Free Report
Amgen Inc. (AMGN): Free Stock Analysis Report
Celgene Corporation (CELG): Get Free Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie Inc. ABBV is scheduled to release its results on Jan 25. Click to get this free report Bristol-Myers Squibb Company (BMY): Get Free Report AbbVie Inc. (ABBV): Get Free Report Amgen Inc. (AMGN): Free Stock Analysis Report Celgene Corporation (CELG): Get Free Report To read this article on Zacks.com click here. Earlier in 2018, Opdivo was approved as a monotherapy for the treatment of metastatic small cell lung cancer (SCLC) in third-line setting in patients who have received platinum-based chemotherapy and at least one other line of therapy. | Click to get this free report Bristol-Myers Squibb Company (BMY): Get Free Report AbbVie Inc. (ABBV): Get Free Report Amgen Inc. (AMGN): Free Stock Analysis Report Celgene Corporation (CELG): Get Free Report To read this article on Zacks.com click here. AbbVie Inc. ABBV is scheduled to release its results on Jan 25. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. | Click to get this free report Bristol-Myers Squibb Company (BMY): Get Free Report AbbVie Inc. (ABBV): Get Free Report Amgen Inc. (AMGN): Free Stock Analysis Report Celgene Corporation (CELG): Get Free Report To read this article on Zacks.com click here. AbbVie Inc. ABBV is scheduled to release its results on Jan 25. Bristol-Myers' key immuno-oncology drug, Opdivo is expected to be the primary revenue driver in the fourth quarter, with several line extensions in the past year. | AbbVie Inc. ABBV is scheduled to release its results on Jan 25. Click to get this free report Bristol-Myers Squibb Company (BMY): Get Free Report AbbVie Inc. (ABBV): Get Free Report Amgen Inc. (AMGN): Free Stock Analysis Report Celgene Corporation (CELG): Get Free Report To read this article on Zacks.com click here. Bristol-Myers Squibb CompanyBMY is expected to report fourth-quarter 2018 results on Jan 24, before market opens. |
25159.0 | 2019-01-21 00:00:00 UTC | AbbVie's Imbruvica Fails in Phase III Pancreatic Cancer Study | ABBV | https://www.nasdaq.com/articles/abbvies-imbruvica-fails-in-phase-iii-pancreatic-cancer-study-2019-01-21 | nan | nan | AbbVie Inc.ABBV announced that a combination regimen of its blockbuster cancer drug, Imbruvica (ibrutinib), failed in a phase III study, evaluating it for the treatment of metastatic pancreatic adenocarcinoma, one of the most aggressive and deadliest forms of cancer. The study was unable to meet its primary endpoint of improving progression-free survival (PFS) or overall survival (OS) benefit amid the given patient population.
The phase III RESOLVE study investigated the efficacy of Imbruvica in combination with chemotherapy agents nab-paclitaxel and gemcitabine compared with placebo in combination with these chemotherapy agents for first-line treatment of patients suffering metastatic pancreatic cancer. The study did not show a statistically-significant PFS or OS benefit in the Imbruvica combo arm as compared to the placebo one.
Complete data from the study will be submitted for presentation at a future medical conference.
Shares of AbbVie have declined 16% in the past year, wider than the industry's dip of 0.8%.
Notably, Imbruvica has been jointly developed and marketed by AbbVie and Janssen Biotech, a unit of Johnson & Johnson JNJ .
Currently approved for nine cancer indications, Imbruvica has multi-billion-dollar potential and AbbVie is exploring the potential to expand Imbruvica's label into solid tumors and autoimmune diseases.
In the first nine months of 2018, Imbruvica generated sales of $2.58 billion, reflecting a surge of 38.7% year over year. AbbVie expects Imbruvica's peak sales to be more than $7 billion and revenues of about $5 billion in 2020. However, study failure like that of RESOLVE will cause a hindrance to AbbVie/J&J's expansion plans for Imbruvica.
Another important cancer drug in AbbVie's oncology portfolio is Venclexta. Regulatory applications seeking an approval for Venclexta plus Roche's RHHBY Rituxan for relapse/refractory chronic lymphocytic leukemia (based on MURANO study data) were lent with a nod in the United States, last June and in the EU, last October. Visibly, label expansion for this indication has increased the patient population for Venclexta significantly, which will further boost its commercial potential.
Also, last November, AbbVie gained an FDA approval for Venclexta for first-line acute myeloid leukemia (AML) while outcomes from the phase III program on multiple myeloma are awaited in the first half of 2019. AbbVie/Roche also plans to soon file for approving Venclexta +Gazyva in first-line CLL setting.
Zacks Rank & Another Key Pick
AbbVie currently carries a Zacks Rank #2 (Buy). Another top-ranked stock in large cap pharma sector is H Lundbeck A/S HLUYY , which sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
H Lundbeck's earnings estimates have moved 5.2% north for 2019 over the past 60 days.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year?
Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.
See Latest Stocks Today >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Roche Holding AG (RHHBY): Free Stock Analysis Report
Johnson & Johnson (JNJ): Get Free Report
H Lundbeck A/S (HLUYY): Free Stock Analysis Report
AbbVie Inc. (ABBV): Get Free Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Also, last November, AbbVie gained an FDA approval for Venclexta for first-line acute myeloid leukemia (AML) while outcomes from the phase III program on multiple myeloma are awaited in the first half of 2019. AbbVie Inc.ABBV announced that a combination regimen of its blockbuster cancer drug, Imbruvica (ibrutinib), failed in a phase III study, evaluating it for the treatment of metastatic pancreatic adenocarcinoma, one of the most aggressive and deadliest forms of cancer. Shares of AbbVie have declined 16% in the past year, wider than the industry's dip of 0.8%. | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Johnson & Johnson (JNJ): Get Free Report H Lundbeck A/S (HLUYY): Free Stock Analysis Report AbbVie Inc. (ABBV): Get Free Report To read this article on Zacks.com click here. AbbVie Inc.ABBV announced that a combination regimen of its blockbuster cancer drug, Imbruvica (ibrutinib), failed in a phase III study, evaluating it for the treatment of metastatic pancreatic adenocarcinoma, one of the most aggressive and deadliest forms of cancer. Shares of AbbVie have declined 16% in the past year, wider than the industry's dip of 0.8%. | AbbVie Inc.ABBV announced that a combination regimen of its blockbuster cancer drug, Imbruvica (ibrutinib), failed in a phase III study, evaluating it for the treatment of metastatic pancreatic adenocarcinoma, one of the most aggressive and deadliest forms of cancer. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Johnson & Johnson (JNJ): Get Free Report H Lundbeck A/S (HLUYY): Free Stock Analysis Report AbbVie Inc. (ABBV): Get Free Report To read this article on Zacks.com click here. Shares of AbbVie have declined 16% in the past year, wider than the industry's dip of 0.8%. | AbbVie Inc.ABBV announced that a combination regimen of its blockbuster cancer drug, Imbruvica (ibrutinib), failed in a phase III study, evaluating it for the treatment of metastatic pancreatic adenocarcinoma, one of the most aggressive and deadliest forms of cancer. Shares of AbbVie have declined 16% in the past year, wider than the industry's dip of 0.8%. Notably, Imbruvica has been jointly developed and marketed by AbbVie and Janssen Biotech, a unit of Johnson & Johnson JNJ . |
25160.0 | 2019-01-20 00:00:00 UTC | Better Buy: AbbVie vs. Johnson & Johnson | ABBV | https://www.nasdaq.com/articles/better-buy-abbvie-vs-johnson-johnson-2019-01-20 | nan | nan | AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) partner on one of the hottest cancer drugs on the market, Imbruvica. But the two big drugmakers are rivals on several other fronts.
Both stocks have been popular with investors, especially those seeking solid dividends. AbbVie has outperformed J&J, delivering a total return nearly double that of J&J over the last five years. But which of these two stocks is the better buy now?
The case for AbbVie
Let's start with AbbVie's exceptionally attractive dividend. Its yield currently stands at 4.85%. AbbVie has increased its dividend payout by 168% since being spun off from parent Abbott Labs in 2013.
What enables AbbVie to deliver such a strong dividend? The company claims the world's top-selling drug with Humira. It co-markets blockbuster cancer drug Imbruvica with J&J in the U.S. and has exclusive rights to the drug outside of the U.S. AbbVie is also a leader in the hepatitis C market with Mavyret.
The big pharma company also has a couple of rising stars in its current lineup. Venclexta has already won Food and Drug Administration approvals in treating chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). Orilissa is approved in managing pain associated with endometriosis. AbbVie hopes to secure additional indications for both drugs.
AbbVie's pipeline provides even more reasons to like the stock. Immunology drugs risankizumab and upadacitinib especially stand out. The drugs await FDA approval as treatments for psoriasis and rheumatoid arthritis, respectively. AbbVie thinks that risankizumab and upadacitinib will combine to generate peak annual sales of more than $10 billion.
With its strong current lineup and promising pipeline, AbbVie should deliver double-digi t earnings growth over the next several years. But the stock is relatively cheap, with shares trading at less than 10 times expected earnings. This attractive valuation is due primarily to investors' concerns about AbbVie's reliance on Humira, which faces competition from biosimilars in Europe already and will see biosimilar entrants in the U.S. market in 2023.
However, AbbVie isn't worried about the threats to Humira. The company expects its other drugs and pipeline candidates will keep it in growth mode well into the next decade.
The case for Johnson & Johnson
Johnson & Johnson's dividend yield of 2.81% is also quite appealing. Even better, the company has increased its dividend for 56 consecutive years and is likely to keep that streak going.
"Healthcare giant" is probably the best way to describe Johnson & Johnson. The company claims the largest market cap among healthcare stocks. J&J isn't just a huge drugmaker; it also is a major consumer healthcare company and one of the world's largest medical device makers.
This broad scope of operations gives J&J significant competitive advantages. For example, it can bundle products and services from its various businesses to win new customers and keep existing customers.
Johnson & Johnson's primary growth driver is its pharmaceutical unit. Although sales for its top-selling drug Remicade are falling due to biosimilar competition, several of J&J's other products -- especially multiple myeloma drug Darzalex and Imbruvica -- continue to enjoy strong growth.
J&J's consumer segment also appears to be returning to solid growth . CEO Alex Gorsky said in October that the company is seeing "accelerated momentum" for its consumer healthcare business. In particular, J&J has enjoyed strong demand in the U.S. for its over-the-counter medications, beauty products, and baby care products.
While Johnson & Johnson might not deliver spectacularly high growth, the company should be able to continue to provide solid total returns to investors over the long run. J&J has also shown that it's willing to use its strong cash flow to make strategic acquisitions to fuel future growth.
Better buy
In my view, Johnson & Johnson is one of a select group of stocks that you can buy and hold practically forever. J&J was successful 100 years ago and will likely be successful 100 years from now and beyond. It's a solid stock for almost any portfolio.
Having said that, though, I think AbbVie is the better stock to buy right now. AbbVie has a higher dividend yield than J&J. It has stronger growth prospects. And it's valued more attractively. Buying either of these two stocks is a good idea, but if I could only buy one, I'd go with AbbVie.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of November 14, 2018
Keith Speights owns shares of AbbVie. The Motley Fool owns shares of Johnson & Johnson and has the following options: short January 2019 $140 calls on Johnson & Johnson. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | With its strong current lineup and promising pipeline, AbbVie should deliver double-digi t earnings growth over the next several years. AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) partner on one of the hottest cancer drugs on the market, Imbruvica. AbbVie has outperformed J&J, delivering a total return nearly double that of J&J over the last five years. | With its strong current lineup and promising pipeline, AbbVie should deliver double-digi t earnings growth over the next several years. AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) partner on one of the hottest cancer drugs on the market, Imbruvica. AbbVie has outperformed J&J, delivering a total return nearly double that of J&J over the last five years. | AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) partner on one of the hottest cancer drugs on the market, Imbruvica. AbbVie has outperformed J&J, delivering a total return nearly double that of J&J over the last five years. The case for AbbVie Let's start with AbbVie's exceptionally attractive dividend. | With its strong current lineup and promising pipeline, AbbVie should deliver double-digi t earnings growth over the next several years. Having said that, though, I think AbbVie is the better stock to buy right now. AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) partner on one of the hottest cancer drugs on the market, Imbruvica. |
25161.0 | 2019-01-18 00:00:00 UTC | Can AbbVie (ABBV) Keep the Earnings Surprise Streak Alive? | ABBV | https://www.nasdaq.com/articles/can-abbvie-abbv-keep-the-earnings-surprise-streak-alive-2019-01-18 | nan | nan | Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering AbbVie (ABBV), which belongs to the Zacks Large Cap Pharmaceuticals industry.
This drugmaker has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 3.74%.
For the most recent quarter, AbbVie was expected to pos t earnings of $2.01 per share, but i t report ed $2.14 per share instead, representing a surprise of 6.47%. For the previous quarter, the consensus estimate was $1.98 per share, while it actually produced $2 per share, a surprise of 1.01%.
Price and EPS Surprise
For AbbVie, estimates have been trending higher, thanks in part to this earnings surprise history. And when you look at the stock's positive Zacks Earnings ESP (Expected Surprise Prediction), it's a great indicator of a future earnings beat, especially when combined with its solid Zacks Rank.
Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank #3 (Hold) or better produce a positive surprise nearly 70% of the time . In other words, if you have 10 stocks with this combination, the number of stocks that beat the consensus estimate could be as high as seven.
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
AbbVie currently has an Earnings ESP of +0.22%, which suggests that analysts have recently become bullish on the company's earnings prospects. This positive Earnings ESP when combined with the stock's Zacks Rank #2 (Buy) indicates that another beat is possibly around the corner. We expect the company's nex t earnings report to be released on January 25, 2019.
Investors should note, however, that a negative Earnings ESP reading is not indicative of an earnings miss, but a negative value does reduce the predictive power of this metric.
Many companies end up beating the consensus EPS estimate, but that may not be the sole basis for their stocks moving higher. On the other hand, some stocks may hold their ground even if they end up missing the consensus estimate.
Because of this, it's really important to check a company's Earnings ESP ahead of its quarterly release to increase the odds of success. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Get Free Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | It is worth considering AbbVie (ABBV), which belongs to the Zacks Large Cap Pharmaceuticals industry. For the most recent quarter, AbbVie was expected to pos t earnings of $2.01 per share, but i t report ed $2.14 per share instead, representing a surprise of 6.47%. Price and EPS Surprise For AbbVie, estimates have been trending higher, thanks in part to this earnings surprise history. | It is worth considering AbbVie (ABBV), which belongs to the Zacks Large Cap Pharmaceuticals industry. For the most recent quarter, AbbVie was expected to pos t earnings of $2.01 per share, but i t report ed $2.14 per share instead, representing a surprise of 6.47%. Price and EPS Surprise For AbbVie, estimates have been trending higher, thanks in part to this earnings surprise history. | It is worth considering AbbVie (ABBV), which belongs to the Zacks Large Cap Pharmaceuticals industry. For the most recent quarter, AbbVie was expected to pos t earnings of $2.01 per share, but i t report ed $2.14 per share instead, representing a surprise of 6.47%. Price and EPS Surprise For AbbVie, estimates have been trending higher, thanks in part to this earnings surprise history. | It is worth considering AbbVie (ABBV), which belongs to the Zacks Large Cap Pharmaceuticals industry. For the most recent quarter, AbbVie was expected to pos t earnings of $2.01 per share, but i t report ed $2.14 per share instead, representing a surprise of 6.47%. Price and EPS Surprise For AbbVie, estimates have been trending higher, thanks in part to this earnings surprise history. |
25162.0 | 2019-01-18 00:00:00 UTC | AbbVie's Imbruvica fails to meet main goal in pancreatic cancer study | ABBV | https://www.nasdaq.com/articles/abbvies-imbruvica-fails-meet-main-goal-pancreatic-cancer-study-2019-01-18 | nan | nan | Jan 18 (Reuters) - AbbVie Inc said on Friday its blockbuster cancer treatment in combination with chemotherapy agents failed to meet the main goal in a late-stage study of patients with a form of pancreatic cancer.
The treatment, Imbruvica, failed to show statistically significant improvement in progression-free survival (PFS) or overall survival in metastatic pancreatic cancer patients, compared with the combination of placebo and two chemotherapy agents.
The American Cancer society estimates that pancreatic cancer accounts for about 3 percent of all cancers in the United States and about 7 percent of all cancer deaths, and expects that 56,770 people will be diagnosed with pancreatic cancer in 2019.
The drug improved survival in blood cancer patients in a separate late-stage study in December.
Imbruvica, which brought in revenue of $2.57 billion for AbbVie in 2017, was first approved in November 2013 and is used to treat several forms of cancer, including mantle cell lymphoma and chronic lymphocytic leukemia.
The drug is currently approved by the U.S. Food and Drug Administration in six disease areas with nine treatment indications, AbbVie said.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Imbruvica, which brought in revenue of $2.57 billion for AbbVie in 2017, was first approved in November 2013 and is used to treat several forms of cancer, including mantle cell lymphoma and chronic lymphocytic leukemia. Jan 18 (Reuters) - AbbVie Inc said on Friday its blockbuster cancer treatment in combination with chemotherapy agents failed to meet the main goal in a late-stage study of patients with a form of pancreatic cancer. The drug is currently approved by the U.S. Food and Drug Administration in six disease areas with nine treatment indications, AbbVie said. | Jan 18 (Reuters) - AbbVie Inc said on Friday its blockbuster cancer treatment in combination with chemotherapy agents failed to meet the main goal in a late-stage study of patients with a form of pancreatic cancer. Imbruvica, which brought in revenue of $2.57 billion for AbbVie in 2017, was first approved in November 2013 and is used to treat several forms of cancer, including mantle cell lymphoma and chronic lymphocytic leukemia. The drug is currently approved by the U.S. Food and Drug Administration in six disease areas with nine treatment indications, AbbVie said. | Jan 18 (Reuters) - AbbVie Inc said on Friday its blockbuster cancer treatment in combination with chemotherapy agents failed to meet the main goal in a late-stage study of patients with a form of pancreatic cancer. Imbruvica, which brought in revenue of $2.57 billion for AbbVie in 2017, was first approved in November 2013 and is used to treat several forms of cancer, including mantle cell lymphoma and chronic lymphocytic leukemia. The drug is currently approved by the U.S. Food and Drug Administration in six disease areas with nine treatment indications, AbbVie said. | Imbruvica, which brought in revenue of $2.57 billion for AbbVie in 2017, was first approved in November 2013 and is used to treat several forms of cancer, including mantle cell lymphoma and chronic lymphocytic leukemia. Jan 18 (Reuters) - AbbVie Inc said on Friday its blockbuster cancer treatment in combination with chemotherapy agents failed to meet the main goal in a late-stage study of patients with a form of pancreatic cancer. The drug is currently approved by the U.S. Food and Drug Administration in six disease areas with nine treatment indications, AbbVie said. |
25163.0 | 2019-01-18 00:00:00 UTC | AbbVie's cancer drug fails to meet main goal in late-stage study | ABBV | https://www.nasdaq.com/articles/abbvies-cancer-drug-fails-meet-main-goal-late-stage-study-2019-01-18 | nan | nan | Jan 18 (Reuters) - AbbVie Inc said on Friday its cancer treatment in combination with chemotherapy agents failed to meet the main goal in a late-stage study of patients with a form of pancreatic cancer.
The treatment, ibrutinib, failed to show statistically significant improvement, compared to placebo, in progression-free survival (PFS) or overall survival in metastatic pancreatic cancer patients.
OCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
Jan 18 (Reuters) - AbbVie Inc said on Friday its cancer treatment in combination with chemotherapy agents failed to meet the main goal in a late-stage study of patients with a form of pancreatic cancer.
The treatment, ibrutinib, failed to show statistically significant improvement, compared to placebo, in progression-free survival (PFS) or overall survival in metastatic pancreatic cancer patients.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Jan 18 (Reuters) - AbbVie Inc said on Friday its cancer treatment in combination with chemotherapy agents failed to meet the main goal in a late-stage study of patients with a form of pancreatic cancer. OCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd"> Jan 18 (Reuters) - AbbVie Inc said on Friday its cancer treatment in combination with chemotherapy agents failed to meet the main goal in a late-stage study of patients with a form of pancreatic cancer. The treatment, ibrutinib, failed to show statistically significant improvement, compared to placebo, in progression-free survival (PFS) or overall survival in metastatic pancreatic cancer patients. | Jan 18 (Reuters) - AbbVie Inc said on Friday its cancer treatment in combination with chemotherapy agents failed to meet the main goal in a late-stage study of patients with a form of pancreatic cancer. The treatment, ibrutinib, failed to show statistically significant improvement, compared to placebo, in progression-free survival (PFS) or overall survival in metastatic pancreatic cancer patients. OCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd"> Jan 18 (Reuters) - AbbVie Inc said on Friday its cancer treatment in combination with chemotherapy agents failed to meet the main goal in a late-stage study of patients with a form of pancreatic cancer. | Jan 18 (Reuters) - AbbVie Inc said on Friday its cancer treatment in combination with chemotherapy agents failed to meet the main goal in a late-stage study of patients with a form of pancreatic cancer. OCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd"> Jan 18 (Reuters) - AbbVie Inc said on Friday its cancer treatment in combination with chemotherapy agents failed to meet the main goal in a late-stage study of patients with a form of pancreatic cancer. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Jan 18 (Reuters) - AbbVie Inc said on Friday its cancer treatment in combination with chemotherapy agents failed to meet the main goal in a late-stage study of patients with a form of pancreatic cancer. OCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd"> Jan 18 (Reuters) - AbbVie Inc said on Friday its cancer treatment in combination with chemotherapy agents failed to meet the main goal in a late-stage study of patients with a form of pancreatic cancer. The treatment, ibrutinib, failed to show statistically significant improvement, compared to placebo, in progression-free survival (PFS) or overall survival in metastatic pancreatic cancer patients. |
25164.0 | 2019-01-18 00:00:00 UTC | AbbVie (ABBV) Reports Next Week: Wall Street Expects Earnings Growth | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-reports-next-week%3A-wall-street-expects-earnings-growth-2019-01-18 | nan | nan | The market expects AbbVie (ABBV) to deliver a year-over-year increase in earnings on higher revenues when i t report s results for the quarter ended December 2018. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.
The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on January 25. On the other hand, if they miss, the stock may move lower.
While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.
Zacks Consensus Estimate
This drugmaker is expected to pos t quarterly earnings of $1.92 per share in its upcoming report, which represents a year-over-year change of +29.7%.
Revenues are expected to be $8.38 billion, up 8.3% from the year-ago quarter.
Estimate Revisions Trend
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.
Price, Consensus and EPS Surprise
Earnings Whisper
Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is subject to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time , and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for AbbVie?
For AbbVie, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +0.22%.
On the other hand, the stock currently carries a Zacks Rank of #2.
So, this combination indicates that AbbVie will most likely beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?
While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that AbbVie would pos t earnings of $2.01 per share when it actually produced earnings of $2.14, delivering a surprise of +6.47%.
Over the last four quarters, the company has beaten consensus EPS estimates four times.
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
AbbVie appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Get Free Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The market expects AbbVie (ABBV) to deliver a year-over-year increase in earnings on higher revenues when i t report s results for the quarter ended December 2018. How Have the Numbers Shaped Up for AbbVie? For AbbVie, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. | The market expects AbbVie (ABBV) to deliver a year-over-year increase in earnings on higher revenues when i t report s results for the quarter ended December 2018. How Have the Numbers Shaped Up for AbbVie? For AbbVie, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. | The market expects AbbVie (ABBV) to deliver a year-over-year increase in earnings on higher revenues when i t report s results for the quarter ended December 2018. How Have the Numbers Shaped Up for AbbVie? For AbbVie, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. | For the last reported quarter, it was expected that AbbVie would pos t earnings of $2.01 per share when it actually produced earnings of $2.14, delivering a surprise of +6.47%. The market expects AbbVie (ABBV) to deliver a year-over-year increase in earnings on higher revenues when i t report s results for the quarter ended December 2018. How Have the Numbers Shaped Up for AbbVie? |
25165.0 | 2019-01-17 00:00:00 UTC | Zacks Market Edge Highlights: Occidental, Gilead, AbbVie, AT&T and Verizon | ABBV | https://www.nasdaq.com/articles/zacks-market-edge-highlights%3A-occidental-gilead-abbvie-att-and-verizon-2019-01-17 | nan | nan | For Immediate Release
Chicago, IL - January 17, 2018 - Zacks Market Edge is a podcast hosted weekly by cks Stock Strategist Tracey Ryniec. Every week, Tracey will be joined by guests to discuss the hottest investing topics in stocks, bonds and ETFs and how it impacts your life. To listen to the podcast, click here:
Please use the Soundcloud link from this URL for the PR. Thanks: https://www.zacks.com/stock/news/347850/will-dividend-stocks-be-the-hot-stocks-of-2019? )
Will Dividend Stocks Be the Hot Stocks for 2019?
Welcome to Episode #163 of the Zacks Market Edge Podcast.
Every week, host and Zacks stock strategist, Tracey Ryniec, will be joined by guests to discuss the hottest investing topics in stocks, bonds and ETFs and how it impacts your life.
In this episode, Tracey is joined by Ryan McQueeney, Editor of Zacks Income Investor newsletter to discuss what is going on with dividend stocks in 2019.
After several years of investors diving into all the growth stocks, it seems like 2019 could see a change.
For the first time in a while, the FAANG stocks aren't dominating the conversation. Some investors are starting to ask about income generating stocks.
But will dividend stocks really be hot in 2019?
Where to Look for High Yields
The beaten down sectors are always a place to start to search for yield.
Many of the big energy stocks are now paying juicy dividends including Occidental (OXY) which is yielding 4.7%. But it's also a Zacks Rank #5 (Strong Sell) stock as its estimates have been cut following the oil price plunge.
The drug stocks are also on the "outs" with Wall Street.
Gilead (GILD) is yielding 3.4% while AbbVie (ABBV) is at 4.9%. Both are down 16% over the last year, however.
Telecoms have always been a popular place for yields. AT&T (T) is paying a 6.7% yield while Verizon (VZ) is yielding 4.2%.
But yield isn't everything. AT&T shares were down 17% over the last year while Verizon has rallied 12% over the same time.
Where else should you be looking for yield in 2019?
Tune into this week's podcast to find out.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com/performance
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Get Free Report
AT&T Inc. (T): Free Stock Analysis Report
Verizon Communications Inc. (VZ): Free Stock Analysis Report
Gilead Sciences, Inc. (GILD): Get Free Report
Occidental Petroleum Corporation (OXY): Get Free Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Gilead (GILD) is yielding 3.4% while AbbVie (ABBV) is at 4.9%. Click to get this free report AbbVie Inc. (ABBV): Get Free Report AT&T Inc. (T): Free Stock Analysis Report Verizon Communications Inc. (VZ): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Get Free Report Occidental Petroleum Corporation (OXY): Get Free Report To read this article on Zacks.com click here. For Immediate Release Chicago, IL - January 17, 2018 - Zacks Market Edge is a podcast hosted weekly by cks Stock Strategist Tracey Ryniec. | Click to get this free report AbbVie Inc. (ABBV): Get Free Report AT&T Inc. (T): Free Stock Analysis Report Verizon Communications Inc. (VZ): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Get Free Report Occidental Petroleum Corporation (OXY): Get Free Report To read this article on Zacks.com click here. Gilead (GILD) is yielding 3.4% while AbbVie (ABBV) is at 4.9%. Every week, Tracey will be joined by guests to discuss the hottest investing topics in stocks, bonds and ETFs and how it impacts your life. | Click to get this free report AbbVie Inc. (ABBV): Get Free Report AT&T Inc. (T): Free Stock Analysis Report Verizon Communications Inc. (VZ): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Get Free Report Occidental Petroleum Corporation (OXY): Get Free Report To read this article on Zacks.com click here. Gilead (GILD) is yielding 3.4% while AbbVie (ABBV) is at 4.9%. Every week, host and Zacks stock strategist, Tracey Ryniec, will be joined by guests to discuss the hottest investing topics in stocks, bonds and ETFs and how it impacts your life. | Gilead (GILD) is yielding 3.4% while AbbVie (ABBV) is at 4.9%. Click to get this free report AbbVie Inc. (ABBV): Get Free Report AT&T Inc. (T): Free Stock Analysis Report Verizon Communications Inc. (VZ): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Get Free Report Occidental Petroleum Corporation (OXY): Get Free Report To read this article on Zacks.com click here. In this episode, Tracey is joined by Ryan McQueeney, Editor of Zacks Income Investor newsletter to discuss what is going on with dividend stocks in 2019. |
25166.0 | 2019-01-17 00:00:00 UTC | 1 Chart That Shows Why Celgene Has Been Bought Out and Gilead Hasn't (Yet) | ABBV | https://www.nasdaq.com/articles/1-chart-shows-why-celgene-has-been-bought-out-and-gilead-hasnt-yet-2019-01-17 | nan | nan | At the start of the year, Gilead Sciences (NASDAQ: GILD) and Celgene (NASDAQ: CELG) were arguably the biggest value plays in the biotech industry. Gilead was off 48% from its all-time high in July 2015, while Celgene was down 56% from its high-water mark set in September 2017.
Celgene found a suitor in Bristol-Myers Squibb (NYSE: BMY) willing to pay a 54% premium.
Gilead hasn't. Yet.
The reasons for their declines, and therefore their attractiveness as potential takeout targets, couldn't be different. This chart pretty much sums it up.
Revenue data by YCharts .
For the last five years, Celgene's revenue has been steadily marching higher. Gilead, on the other hand, peaked a few years ago as competition from AbbVie (NYSE: ABBV) ate into its hepatitis C franchise. Through the first three quarters of 2018, Gilead's sales are down 19% year over year; Celgene's are up 18% over the same time period.
While past growth looks great, the decline of Celgene's stock price was predicated on future expectations. Investors were worried that the company wasn't going to be able to make up for the loss of sales from top-selling Revlimid, which will start seeing limited generic competition in 2022, escalating until full competition starts in early 2026.
Some of the worry is certainly warranted; the launch trajectory of anti-inflammatory Otezla has been lumpy , and there was a delay with the filing for approval of multiple sclerosis drug ozanimod. But management insists that five pipeline drugs, including ozanimod, will be able to make up for all of the lost Revlimid sales.
Bristol-Myers Squibb appears to have agreed -- with the caveat that $9 per share of the potential payout would be tied to a contingent value right that only gets paid upon the approval of three of those drugs (ozanimod, liso-cel, and bb2121) by certain prearranged dates.
What it would take for Gilead to follow suit
First and foremost, Gilead needs to stabilize its revenue and get back to growing. It's really hard for potential acquirers to value declining assets when a competitor exists that could result in a pricing war, so any suitor is likely to factor in a large margin of safety that would result in a minuscule premium. Management has said that 2019 will be a return to growth with less volatility in the hepatitis C market, so perhaps this year will mark the turnaround.
Just as importantly, a potential suitor would need to see impending growth from Gilead's pipeline. The 2017 acquisition of Kite Pharma added a pipeline of CAR-T therapies , but the most important near-term pipeline news will come from results of two late-stage trials testing selonsertib for nonalcoholic steatohepatitis (NASH) that are due out in the first half of this year. There's also a late-stage study of filgotinib for rheumatoid arthritis, which is expected to read out this quarter, but rheumatoid arthritis is a competitive market, so the data will have to be outstanding to unseat the entrenched competitors.
NASH, on the other hand, is wide open. Based on the number of patients, it's easy to see Gilead making a few billion selling NASH drugs, especially if it's able to find a cocktail of drugs that work together like it has for HIV and hepatitis C.
Finally, to make itself more valuable -- whether that results in an acquisition or just an increase in investor-assigned valuation -- Gilead will have to make smart use of its cash. For all the problems the biotech has had keeping its revenue high, Gilead still throws off a lot of free cash flow, which new CEO Daniel O'Day will have to put to work wisely, balancing share repurchases with acquisitions of its own to boost its pipeline and future revenue.
10 stocks we like better than Gilead Sciences
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Gilead Sciences wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of November 14, 2018
Brian Orelli has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Celgene and Gilead Sciences. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Gilead, on the other hand, peaked a few years ago as competition from AbbVie (NYSE: ABBV) ate into its hepatitis C franchise. Some of the worry is certainly warranted; the launch trajectory of anti-inflammatory Otezla has been lumpy , and there was a delay with the filing for approval of multiple sclerosis drug ozanimod. Bristol-Myers Squibb appears to have agreed -- with the caveat that $9 per share of the potential payout would be tied to a contingent value right that only gets paid upon the approval of three of those drugs (ozanimod, liso-cel, and bb2121) by certain prearranged dates. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Gilead, on the other hand, peaked a few years ago as competition from AbbVie (NYSE: ABBV) ate into its hepatitis C franchise. At the start of the year, Gilead Sciences (NASDAQ: GILD) and Celgene (NASDAQ: CELG) were arguably the biggest value plays in the biotech industry. | Gilead, on the other hand, peaked a few years ago as competition from AbbVie (NYSE: ABBV) ate into its hepatitis C franchise. At the start of the year, Gilead Sciences (NASDAQ: GILD) and Celgene (NASDAQ: CELG) were arguably the biggest value plays in the biotech industry. Based on the number of patients, it's easy to see Gilead making a few billion selling NASH drugs, especially if it's able to find a cocktail of drugs that work together like it has for HIV and hepatitis C. Finally, to make itself more valuable -- whether that results in an acquisition or just an increase in investor-assigned valuation -- Gilead will have to make smart use of its cash. | Gilead, on the other hand, peaked a few years ago as competition from AbbVie (NYSE: ABBV) ate into its hepatitis C franchise. Revenue data by YCharts . But management insists that five pipeline drugs, including ozanimod, will be able to make up for all of the lost Revlimid sales. |
25167.0 | 2019-01-17 00:00:00 UTC | Pacira's Study on Exparel Label Expansion Meets Endpoints | ABBV | https://www.nasdaq.com/articles/paciras-study-exparel-label-expansion-meets-endpoints-2019-01-17 | nan | nan | Shares of Pacira Pharmaceuticals, Inc.PCRX went up 2.62% after the company announced that the phase IV study on its lead drug Exparel in patients undergoing Cesarean section (C-section) achieved its primary endpoint, with a statistically significant reduction in total postsurgical opioid consumption through 72 hours (P≤0.05).
Exparel also achieved statistical significance for reduction in pain intensity through 72 hours. Shares of the company have declined 4.9% in the past year compared with the industry 's decline of 19.8%.
We remind investors that Exparel is a liposome injection of bupivacaine, which is indicated for single-dose administration into the surgical site to produce postsurgical analgesia. In June 2018, the FDA also approved Exparel label to include administration via nerve block for prolonged regional analgesia. With this approval, Exparel is the first long-acting, single-dose nerve block available for patients undergoing upper extremity surgeries, such as total shoulder arthroplasty or rotator cuff repair.
The study also achieved statistical significance for relevant additional endpoints pre-specified in the statistical analysis plan to better characterize the clinical benefit of the opioid reduction, includingtotal opioid consumption at one and two weeks, following C-section and percentage of opioid-spared patients, which was the composite endpoint.
In the study, patients undergoing elective C-section and given spinal anesthesia were randomized to receive Exparel or the active comparator bupivacaine HCl. Patients in the Exparel arm were administered a transversus abdominis plane (TAP) field block with 10 mL Exparel admixed with 10 mL 0.25% bupivacaine HCl and 10 mL normal sterile saline injected bilaterally. Patients in the active comparator arm received a TAP field block with 10 mL 0.25% bupivacaine HCl admixed with 20 mL normal sterile saline injected bilaterally.
The study showed that when added to the standard of care, an Exparel TAP block provided a superior long-acting field block that not only adequately controlled patients' pain following C-section, but also greatly reduced their need for opioids.
The company is also conducting a phase IV study of Exparel in spinal fusion surgery. The company is also launching a series of phase IV studies in soft tissue procedures. These studies will assess Exparel as part of its multimodal protocol for colon cancer and breast reconstruction surgery.
The company's efforts to expand Exparel's label to boost sales are encouraging.
Exparel sales were $82.2 million in the third quarter of 2018, rising 23% year over year.
Pacira Pharmaceuticals, Inc. Price
Pacira Pharmaceuticals, Inc. Price | Pacira Pharmaceuticals, Inc. Quote
Zacks Rank and Stocks to Consider
Pacira currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks worth considering are Merck & Co., Inc. MRK , AbbVie Inc. ABBV and Eli Lilly and Co. LLY . While Merck sports a Zacks Rank #1 (Strong Buy), AbbVie and Lilly carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
Merck's earnings per share estimates have increased from $4.28 to $4.33 for 2018 and from $4.65 to $4.69 for 2019 over the past 90 days. The company delivered a positive earnings surprise in all the trailing four quarters, with average of 3.96%.
AbbVie's earnings per share estimates have increased from $7.86 to $7.93 for 2018 and over the past 90 days. The company delivered a positive earnings surprise in all the trailing four quarters, with average of 3.54%.
Lilly's earnings per share estimates have increased from $5.47 to $5.58 for 2018 and from $5.78 to $5.87 for 2019 over the past 90 days. The company delivered a positive earnings surprise in all the trailing four quarters, with average of 10.03%.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6% and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Get Free Report
Merck & Co., Inc. (MRK): Free Stock Analysis Report
Eli Lilly and Company (LLY): Get Free Report
Pacira Pharmaceuticals, Inc. (PCRX): Get Free Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks worth considering are Merck & Co., Inc. MRK , AbbVie Inc. ABBV and Eli Lilly and Co. LLY . While Merck sports a Zacks Rank #1 (Strong Buy), AbbVie and Lilly carry a Zacks Rank #2 (Buy). AbbVie's earnings per share estimates have increased from $7.86 to $7.93 for 2018 and over the past 90 days. | Click to get this free report AbbVie Inc. (ABBV): Get Free Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Eli Lilly and Company (LLY): Get Free Report Pacira Pharmaceuticals, Inc. (PCRX): Get Free Report To read this article on Zacks.com click here. Some better-ranked stocks worth considering are Merck & Co., Inc. MRK , AbbVie Inc. ABBV and Eli Lilly and Co. LLY . While Merck sports a Zacks Rank #1 (Strong Buy), AbbVie and Lilly carry a Zacks Rank #2 (Buy). | Click to get this free report AbbVie Inc. (ABBV): Get Free Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Eli Lilly and Company (LLY): Get Free Report Pacira Pharmaceuticals, Inc. (PCRX): Get Free Report To read this article on Zacks.com click here. Some better-ranked stocks worth considering are Merck & Co., Inc. MRK , AbbVie Inc. ABBV and Eli Lilly and Co. LLY . While Merck sports a Zacks Rank #1 (Strong Buy), AbbVie and Lilly carry a Zacks Rank #2 (Buy). | Some better-ranked stocks worth considering are Merck & Co., Inc. MRK , AbbVie Inc. ABBV and Eli Lilly and Co. LLY . While Merck sports a Zacks Rank #1 (Strong Buy), AbbVie and Lilly carry a Zacks Rank #2 (Buy). AbbVie's earnings per share estimates have increased from $7.86 to $7.93 for 2018 and over the past 90 days. |
25168.0 | 2019-01-16 00:00:00 UTC | Will Dividend Stocks be the Hot Stocks of 2019? | ABBV | https://www.nasdaq.com/articles/will-dividend-stocks-be-hot-stocks-2019-2019-01-16 | nan | nan | (0:30) - Is Income Investing Becoming More of A Trend?
(2:45) - Where To Find Good Dividend Paying Stocks
(7:15) - MLP's and Banking Stocks To Watch
(13:50) - Big Pharma's Paying Large Dividend Yields
(16:30) - Are Retail Stocks Dividend Yield Traps?
(20:20) - Telecommunications and REITs
(26:30) - Episode Roundup: T, BP, OXY, MPLX, GILD, VZ, ABBV, LB, CHCT
Welcome to Episode #163 of the Zacks Market Edge Podcast.
Every week, host and Zacks stock strategist, Tracey Ryniec, will be joined by guests to discuss the hottest investing topics in stocks, bonds and ETFs and how it impacts your life.
In this episode, Tracey is joined by Ryan McQueeney, Editor of Zacks Income Investor newsletter to discuss what is going on with dividend stocks in 2019.
After several years of investors diving into all the growth stocks, it seems like 2019 could see a change.
For the first time in a while, the FAANG stocks aren't dominating the conversation. Some investors are starting to ask about income generating stocks.
But will dividend stocks really be hot in 2019?
Where to Look for High Yields
The beaten down sectors are always a place to start to search for yield.
Many of the big energy stocks are now paying juicy dividends including Occidental OXY which is yielding 4.7%. But it's also a Zacks Rank #5 (Strong Sell) stock as its estimates have been cut following the oil price plunge.
The drug stocks are also on the "outs" with Wall Street.
Gilead GILD is yielding 3.4% while AbbVie ABBV is at 4.9%. Both are down 16% over the last year, however.
Telecoms have always been a popular place for yields. AT&T T is paying a 6.7% yield while Verizon VZ is yielding 4.2%.
But yield isn't everything. AT&T shares were down 17% over the last year while Verizon has rallied 12% over the same time.
Where else should you be looking for yield in 2019?
Tune into this week's podcast to find out.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (20:20) - Telecommunications and REITs (26:30) - Episode Roundup: T, BP, OXY, MPLX, GILD, VZ, ABBV, LB, CHCT Welcome to Episode #163 of the Zacks Market Edge Podcast. Gilead GILD is yielding 3.4% while AbbVie ABBV is at 4.9%. In this episode, Tracey is joined by Ryan McQueeney, Editor of Zacks Income Investor newsletter to discuss what is going on with dividend stocks in 2019. | (20:20) - Telecommunications and REITs (26:30) - Episode Roundup: T, BP, OXY, MPLX, GILD, VZ, ABBV, LB, CHCT Welcome to Episode #163 of the Zacks Market Edge Podcast. Gilead GILD is yielding 3.4% while AbbVie ABBV is at 4.9%. (2:45) - Where To Find Good Dividend Paying Stocks (7:15) - MLP's and Banking Stocks To Watch (13:50) - Big Pharma's Paying Large Dividend Yields (16:30) - Are Retail Stocks Dividend Yield Traps? | (20:20) - Telecommunications and REITs (26:30) - Episode Roundup: T, BP, OXY, MPLX, GILD, VZ, ABBV, LB, CHCT Welcome to Episode #163 of the Zacks Market Edge Podcast. Gilead GILD is yielding 3.4% while AbbVie ABBV is at 4.9%. (2:45) - Where To Find Good Dividend Paying Stocks (7:15) - MLP's and Banking Stocks To Watch (13:50) - Big Pharma's Paying Large Dividend Yields (16:30) - Are Retail Stocks Dividend Yield Traps? | (20:20) - Telecommunications and REITs (26:30) - Episode Roundup: T, BP, OXY, MPLX, GILD, VZ, ABBV, LB, CHCT Welcome to Episode #163 of the Zacks Market Edge Podcast. Gilead GILD is yielding 3.4% while AbbVie ABBV is at 4.9%. In this episode, Tracey is joined by Ryan McQueeney, Editor of Zacks Income Investor newsletter to discuss what is going on with dividend stocks in 2019. |
25169.0 | 2019-01-16 00:00:00 UTC | Noteworthy ETF Outflows: IUSG, NEE, ABBV, ISRG | ABBV | https://www.nasdaq.com/articles/noteworthy-etf-outflows-iusg-nee-abbv-isrg-2019-01-16 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Core S&P U.S. Growth ETF (Symbol: IUSG) where we have detected an approximate $148.3 million dollar outflow -- that's a 2.6% decrease week over week (from 104,150,000 to 101,450,000). Among the largest underlying components of IUSG, in trading today NextEra Energy Inc (Symbol: NEE) is down about 0.3%, AbbVie Inc (Symbol: ABBV) is up about 0.6%, and Intuitive Surgical Inc (Symbol: ISRG) is higher by about 1.1%. For a complete list of holdings, visit the IUSG Holdings page » The chart below shows the one year price performance of IUSG, versus its 200 day moving average:
Looking at the chart above, IUSG's low point in its 52 week range is $49.14 per share, with $62.57 as the 52 week high point - that compares with a last trade of $55.07. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IUSG, in trading today NextEra Energy Inc (Symbol: NEE) is down about 0.3%, AbbVie Inc (Symbol: ABBV) is up about 0.6%, and Intuitive Surgical Inc (Symbol: ISRG) is higher by about 1.1%. For a complete list of holdings, visit the IUSG Holdings page » The chart below shows the one year price performance of IUSG, versus its 200 day moving average: Looking at the chart above, IUSG's low point in its 52 week range is $49.14 per share, with $62.57 as the 52 week high point - that compares with a last trade of $55.07. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of IUSG, in trading today NextEra Energy Inc (Symbol: NEE) is down about 0.3%, AbbVie Inc (Symbol: ABBV) is up about 0.6%, and Intuitive Surgical Inc (Symbol: ISRG) is higher by about 1.1%. For a complete list of holdings, visit the IUSG Holdings page » The chart below shows the one year price performance of IUSG, versus its 200 day moving average: Looking at the chart above, IUSG's low point in its 52 week range is $49.14 per share, with $62.57 as the 52 week high point - that compares with a last trade of $55.07. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of IUSG, in trading today NextEra Energy Inc (Symbol: NEE) is down about 0.3%, AbbVie Inc (Symbol: ABBV) is up about 0.6%, and Intuitive Surgical Inc (Symbol: ISRG) is higher by about 1.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Core S&P U.S. Growth ETF (Symbol: IUSG) where we have detected an approximate $148.3 million dollar outflow -- that's a 2.6% decrease week over week (from 104,150,000 to 101,450,000). For a complete list of holdings, visit the IUSG Holdings page » The chart below shows the one year price performance of IUSG, versus its 200 day moving average: Looking at the chart above, IUSG's low point in its 52 week range is $49.14 per share, with $62.57 as the 52 week high point - that compares with a last trade of $55.07. | Among the largest underlying components of IUSG, in trading today NextEra Energy Inc (Symbol: NEE) is down about 0.3%, AbbVie Inc (Symbol: ABBV) is up about 0.6%, and Intuitive Surgical Inc (Symbol: ISRG) is higher by about 1.1%. For a complete list of holdings, visit the IUSG Holdings page » The chart below shows the one year price performance of IUSG, versus its 200 day moving average: Looking at the chart above, IUSG's low point in its 52 week range is $49.14 per share, with $62.57 as the 52 week high point - that compares with a last trade of $55.07. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). |
25170.0 | 2019-01-16 00:00:00 UTC | 3 Healthcare Stocks That Will Keep Your Portfolio Healthy | ABBV | https://www.nasdaq.com/articles/3-healthcare-stocks-will-keep-your-portfolio-healthy-2019-01-16 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Healthcare stocks cover a wide range of equities. Pharmaceuticals, equipment providers, insurers, pharmacies, technology, and even healthcare-related real estate investment trusts (REIT) can all fall under this category.
However, these companies all benefit from the same trends. The share of healthcare in the overall U.S. economy continues to grow. The Centers for Medicare and Medicaid Services (CMS) estimates that healthcare encompasses about 17.9% of the U.S. economy . Moreover, with an estimated 10,000 baby boomers aging into Medicare a day, the pressure on limited healthcare resources continues to mount.
7 Oversold Small-Cap Stocks With Massive Profit Growth
While this can mean pain for the healthcare consumer, it can also bring benefit to those who invest in healthcare. With more of the baby boom generation on Medicare, a larger percentage of the population benefits from a healthcare subsidy. This gives a noticeable boost to healthcare stocks. Here are three that could help you benefit from this trend.
AbbVie (ABBV)
Source: Shutterstock
Few healthcare stocks find themselves in a better position for both income and growth potential than AbbVie (NYSE: ABBV ). Abbott Laboratories (NYSE: ABT ) created AbbVie when it spun off its pharmaceutical division in 2013. After a growth spurt in 2017, ABBV fell as concerns about patent expirations on its blockbuster drug Humira weighed on the stock. Today it trades at about 30% below its 52-week high.
However, ABBV stock also looks well-positioned to make a comeback. The Humira-driven swoon in ABBV has taken the forward P/E ratio to around 9.8. This comes in well below the average P/E of 18.2 over the last five years. Moreover, Evaluate Pharma ranks AbbVie's drug pipeline as second-best in the industry for value creation. Also, the company has time to transition to its next high-revenue drug. It will hold a patent on Humira in the U.S. until at least 2022. Analysts also do not seem worried as they predict profit growth of almost 10% per year through at least 2021.
Furthermore, Wall Street considers AbbVie a dividend aristocrat due to its previous ties to Abbott. As a result, the company faces tremendous pressure to increase its dividend annually. AbbVie increased its payout from $3.59 per share to $4.28 per share this year. Hence, despite a generous yield of almost 4.9%, investors can probably expect annual increases in future years.
Also, I see this massive dividend increase as a vote of confidence in itself. Couple that with the low P/E and the high ratings that AbbVie's drug pipeline has received, and ABBV should be one of the few healthcare stocks which will outperform in both the growth and income categories.
Teladoc Health (TDOC)
Source: MayApps207 via WikiMedia
Buying Teladoc Health (NYSE: TDOC ) amounts to buying into the future of healthcare. Without a doubt, the 17.9% of the economy that healthcare now consumes weighs heavily on family budgets. Teladoc allows patients to see a licensed doctor at any time via a PC or mobile device, reducing the need to take time off from work. It also saves money as visits can run as low as $40.
Telehealth has only begun to realize its potential. Analysts estimate telehealth can handle about one-third of the 1.25 billion office visits that take place each year in the U.S. With Teladoc handling an estimated two million visits in 2018, the company still covers less than 1% of its potential market.
Teladoc also shows that it can acquire the right partners to improve its quality and reach more patients. It widened its competitive moat by investing in diagnostic capabilities with a takeover of Best Doctors. It also partnered with CVS Health (NYSE: CVS ) to provide care to its customers. Additionally, it boosted its offshore footprint by buying Advance Medical. Advance Medical was the leading telehealth provider outside the U.S. before TDOC purchased the company.
Investors should note that TDOC remains expensive. Its price in the $55 per share range places it at around 9.3 times sales. Still, it has fallen almost 40% from its October high. Also, revenue grew by 78% in 2018. Although that growth will fall over time, analysts estimate that the company will turn profitable in 2021.
10 Growth Stocks With the Future Written All Over Them
Teladoc remains one of the more speculative healthcare stocks. However, with a $3.8 billion market cap, and a majority market share in a business that has reached less than one percent of its full potential, Teladoc could become one of the best stocks in healthcare.
Dentsply Sirona (XRAY)
Source: Shutterstock
An aging population creates an increasing need for dental care and the equipment provided by Dentsply Sirona (NASDAQ: XRAY ). As the ticker implies, Dentsply manufactures dental imaging equipment as well as consumable supplies and specialty dental products.
Medicare rarely covers dental needs. However, many consumers place a high value on having a beautiful smile and the ability to chew food. Hence, most customers will spend money on services requiring XRAY's supplies and equipment. This also holds true outside of the U.S. Dentsply Sirona conducts business in over 120 countries. These other countries account for about 65% of the company's revenue.
XRAY stock rose steadily between 2009 and 2018. However, in 2018, the stock lost almost half of its value. By late October, it traded as low as $33.93 per share, a level first seen in 2011. The stock sold off for most of the year on lower-than-expected sales. An impairment charge on goodwill and intangible assets in the second quarter hurt earnings. The stock fell by nearly 20% on August 7 following this announcement.
However, management responded with a restructuring plan. While that breeds uncertainty, the forecasts indicate an opportunity for buyers. The forward P/E ratio stands at around 18, well below the five-year average of 28.1. Furthermore, analysts predict 11.2% consensus profit growth this year. They also foresee double-digit profit increases through at least 2021.
XRAY faced a great deal of pain in 2018. Still, the need for dental supplies and equipment will only rise in the coming years. For this reason, the lower multiple and the predicted profit growth should bring about a recovery in Dentsply Sirona.
As of this writing, Will Healy is long TDOC stock. You canfollow Will on Twitterat @HealyWriting.
More From InvestorPlace
2 Toxic Pot Stocks You Should Avoid
Top 10 Global Stock Ideas for 2019 From RBC Capital
10 A-Rated Stocks the Smart Money Is Piling Into
5 Best Bank ETFs for This Week's Earnings Avalanche
Compare Brokers
The post 3 Healthcare Stocks That Will Keep Your Portfolio Healthy appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | After a growth spurt in 2017, ABBV fell as concerns about patent expirations on its blockbuster drug Humira weighed on the stock. Couple that with the low P/E and the high ratings that AbbVie's drug pipeline has received, and ABBV should be one of the few healthcare stocks which will outperform in both the growth and income categories. AbbVie (ABBV) Source: Shutterstock Few healthcare stocks find themselves in a better position for both income and growth potential than AbbVie (NYSE: ABBV ). | AbbVie (ABBV) Source: Shutterstock Few healthcare stocks find themselves in a better position for both income and growth potential than AbbVie (NYSE: ABBV ). Abbott Laboratories (NYSE: ABT ) created AbbVie when it spun off its pharmaceutical division in 2013. After a growth spurt in 2017, ABBV fell as concerns about patent expirations on its blockbuster drug Humira weighed on the stock. | AbbVie (ABBV) Source: Shutterstock Few healthcare stocks find themselves in a better position for both income and growth potential than AbbVie (NYSE: ABBV ). Abbott Laboratories (NYSE: ABT ) created AbbVie when it spun off its pharmaceutical division in 2013. After a growth spurt in 2017, ABBV fell as concerns about patent expirations on its blockbuster drug Humira weighed on the stock. | AbbVie (ABBV) Source: Shutterstock Few healthcare stocks find themselves in a better position for both income and growth potential than AbbVie (NYSE: ABBV ). Abbott Laboratories (NYSE: ABT ) created AbbVie when it spun off its pharmaceutical division in 2013. After a growth spurt in 2017, ABBV fell as concerns about patent expirations on its blockbuster drug Humira weighed on the stock. |
25171.0 | 2019-01-15 00:00:00 UTC | 3 of the Top Big Pharma Stocks to Buy Now | ABBV | https://www.nasdaq.com/articles/3-top-big-pharma-stocks-buy-now-2019-01-15 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
The JPMorgan (NYSE: JPM ) healthcare conference has brought greater awareness to the positive developments ahead for pharmaceutical stocks. Sure enough, the healthcare sector is up 1.3% Tuesday, with pharmaceutical stocks gaining a 1%.
And although Big Pharma stocks are up because of the event, aided by a broad market rebound, there are still undervalued stocks in wider healthcare space.
10 Growth Stocks With the Future Written All Over Them
So what are the best stocks in Big Pharma that investors should pick up? The following pharmaceutical companies all have a track record of strong management, high-value product portfolios, and are on pace for continued growth in 2019.
Source: Shutterstock
AbbVie (ABBV)
AbbVie Inc. (NYSE: ABBV ) recapped its many achievements since becoming a public company in 2013. In that time, the company followed through on its mission to create an innovation-driven, patient-focused biotech company. Its revenue growth, which accelerated last year, is proof of its outstanding execution of delivering on new medicines.
2018 Achievements and Outlook: AbbVie expects to deliver on strong growth again this year. Even with biosimilars bringing more competition to its more than $6 billion HUMIRA business, it will ramp up its HCV business in 2018 and will make big investments this year to support new product launches. Imbruvica and Venclexta are two leading mechanisms in the biosimilars that will drive AbbVie's future growth. These investments, or operating costs as seen on the income statement, will pay off as it supports growth over the next decade.
Growth Products: AbbVie's hematology and oncology franchise is already annualizing over $4 billion and is growing in the double-digit rates. Upadacitinib and risankizumab, if approved, will come to market later this year and add to revenue. Management affirmed its confidence in the business by authorizing a $5 billion share buyback. Investors interested in ABBV stock should note the upcoming $1.07 dividend. The stock trades ex-dividend on Jan. 14.
Source: Shutterstock
Regeneron Pharmaceuticals (REGN)
Regeneron Pharmaceuticals (NASDAQ: REGN ) is trending near 52-week highs for good reason. Its atopic dermatitis drug, Dupixent, has a strong prescription growth rate. Patients, despite the costs, are staying with the medication. Eyelea is another source of revenue. And Regeneron is now developing CAR-T therapies.
CAR-T Science: Regeneron is effectively disconnecting the CAR-T cell from the CD28 system. In doing so, it will allow its scientists to mix and match them. By having combinatorial specificity, it is possible to get better targeting and higher efficacy for treatments. In the non-small cell lung cancer space, where Keytruda failed, Regeneron hopes its agent is at least as effective as Merck's (NYSE: MRK ).
10 A-Rated Stocks the Smart Money Is Piling Into
Core Drivers: Regeneron's core revenue drivers continue to give investors confidence. As mentioned, Dupixent is working out very well for patients. In its last quarter, the drug's global sales were $260 million, or nearly $1 billion annualized. The drug will also treat asthma. Plus, the company has positive data in eosinophilic asthma for reductions in the exacerbations for pulmonary function tests. Given the market size for patients suffering from asthma, Regeneron's revenues are likely to grow at a faster pace than the market expects.
Source: Shutterstock
Amgen (AMGN)
Amgen Inc. (NASDAQ: AMGN ) highlighted its double-digit earnings per share growth targets at the JPMorgan conference. It will get there by improving its operating margin from 38% to 52%-54%. Saving $1.5 billion will give it the room it needs to raise its return on capital to its shareholders while continuing on its transformation.
Growth Drivers: Amgen will launch nine new products in two therapeutic areas. It already increased its global presence from 50 countries (in 2011) to over 100 at the end of last year. Its high R&D investments include those in the genetics space. In particular, deCODE Genetics in Iceland is impressive because it has 1 million people outside of Iceland who are part of the effort. It also ended the year with 500,000 patients in the U.S. who are available to study genotypically and phenotypically.
Products: Amgen has six cancer medicines that are in the early stages of product development. Drugs in this space make $4 billion in revenues for Amgen and grew in the double-digit rates in the last twelve months. Looking ahead, Amgen expects to have a strong portfolio of first-in-class molecules. With biospecifics, small molecules, large molecules, its BiTE platform and CAR-Ts, Amgen has the potential to exceed its own growth goals.
As of this writing, Chris Lau did not hold a position in any of the aforementioned securities.
More From InvestorPlace
2 Toxic Pot Stocks You Should Avoid
10 Companies That Could Post Decelerating Profits
10 A-Rated Stocks the Smart Money Is Piling Into
Mizuho: 7 Long-Term Value Stocks to Buy Now
Compare Brokers
The post 3 of the Top Big Pharma Stocks to Buy Now appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Source: Shutterstock AbbVie (ABBV) AbbVie Inc. (NYSE: ABBV ) recapped its many achievements since becoming a public company in 2013. 2018 Achievements and Outlook: AbbVie expects to deliver on strong growth again this year. Imbruvica and Venclexta are two leading mechanisms in the biosimilars that will drive AbbVie's future growth. | Source: Shutterstock AbbVie (ABBV) AbbVie Inc. (NYSE: ABBV ) recapped its many achievements since becoming a public company in 2013. 2018 Achievements and Outlook: AbbVie expects to deliver on strong growth again this year. Imbruvica and Venclexta are two leading mechanisms in the biosimilars that will drive AbbVie's future growth. | Source: Shutterstock AbbVie (ABBV) AbbVie Inc. (NYSE: ABBV ) recapped its many achievements since becoming a public company in 2013. 2018 Achievements and Outlook: AbbVie expects to deliver on strong growth again this year. Imbruvica and Venclexta are two leading mechanisms in the biosimilars that will drive AbbVie's future growth. | Source: Shutterstock AbbVie (ABBV) AbbVie Inc. (NYSE: ABBV ) recapped its many achievements since becoming a public company in 2013. 2018 Achievements and Outlook: AbbVie expects to deliver on strong growth again this year. Imbruvica and Venclexta are two leading mechanisms in the biosimilars that will drive AbbVie's future growth. |
25172.0 | 2019-01-14 00:00:00 UTC | U.S. lawmaker launches investigation into pharma drug pricing | ABBV | https://www.nasdaq.com/articles/us-lawmaker-launches-investigation-pharma-drug-pricing-2019-01-14 | nan | nan | By Yasmeen Abutaleb
WASHINGTON, Jan 14 () - A top U.S. lawmaker launched an investigation into pharmaceutical industry pricing practices on Monday, less than a week after he and fellow Democrats introduced legislation aimed at lowering medicine prices.
Representative Elijah Cummings, who chairs the House Oversight Committee, sent letters to 12 drugmakers seeking information on price increases, investment in research and development, and corporate strategies to preserve market share and pricing power, his office said in a statement.
Novo Nordisk, Amgen, Celgene, and Novartis said they were reviewing the request. The other drug companies did not immediately respond to requests for comment.
Cummings' letters focused on drugs that are the costliest to Medicare Part D, a program that helps beneficiaries of the federal health insurance program for the elderly and disabled pay for self-administered medicines like those purchased at drugstores, as well as drugs that have had the largest price increases over a five-year period.
They include AbbVie's Humira, the world's top-selling medicine that had a price increase at the start of the year, Johnson & Johnson's blockbuster cancer drug Imbruvica and several diabetes medications.
President Donald Trump made high prescription drug prices a top issue in the 2016 U.S. presidential campaign and said that drug companies were "getting away with murder." The U.S. Department of Health and Human Services (HHS) last year rolled out a plan to lower drug prices and has introduced several modest proposals to curb medicine costs, but Democrats have said Trump and his administration are not doing enough.
Several pharmaceutical companies temporarily froze prices on select drugs last year after being criticized by Trump on Twitter. But drugmakers raised prices on more than 250 prescription drugs to begin 2019.
Cummings, along with U.S. Senator Bernie Sanders, an independent who caucuses with Democrats, introduced three bills last week aimed at lowering drug prices.
That legislation would peg U.S. prescription drug prices to the median price from five countries - Canada, Britain, France, Germany and Japan - where drug costs are typically far lower because of government price controls. It would also allow Americans to import medication from Canada and other countries, as well as allow the HHS secretary to negotiate prices in Medicare Part D.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | They include AbbVie's Humira, the world's top-selling medicine that had a price increase at the start of the year, Johnson & Johnson's blockbuster cancer drug Imbruvica and several diabetes medications. Cummings' letters focused on drugs that are the costliest to Medicare Part D, a program that helps beneficiaries of the federal health insurance program for the elderly and disabled pay for self-administered medicines like those purchased at drugstores, as well as drugs that have had the largest price increases over a five-year period. The U.S. Department of Health and Human Services (HHS) last year rolled out a plan to lower drug prices and has introduced several modest proposals to curb medicine costs, but Democrats have said Trump and his administration are not doing enough. | They include AbbVie's Humira, the world's top-selling medicine that had a price increase at the start of the year, Johnson & Johnson's blockbuster cancer drug Imbruvica and several diabetes medications. By Yasmeen Abutaleb WASHINGTON, Jan 14 () - A top U.S. lawmaker launched an investigation into pharmaceutical industry pricing practices on Monday, less than a week after he and fellow Democrats introduced legislation aimed at lowering medicine prices. Senator Bernie Sanders, an independent who caucuses with Democrats, introduced three bills last week aimed at lowering drug prices. | They include AbbVie's Humira, the world's top-selling medicine that had a price increase at the start of the year, Johnson & Johnson's blockbuster cancer drug Imbruvica and several diabetes medications. Cummings' letters focused on drugs that are the costliest to Medicare Part D, a program that helps beneficiaries of the federal health insurance program for the elderly and disabled pay for self-administered medicines like those purchased at drugstores, as well as drugs that have had the largest price increases over a five-year period. President Donald Trump made high prescription drug prices a top issue in the 2016 U.S. presidential campaign and said that drug companies were "getting away with murder." | They include AbbVie's Humira, the world's top-selling medicine that had a price increase at the start of the year, Johnson & Johnson's blockbuster cancer drug Imbruvica and several diabetes medications. Novo Nordisk, Amgen, Celgene, and Novartis said they were reviewing the request. Cummings, along with U.S. |
25173.0 | 2019-01-13 00:00:00 UTC | 3 Top Dividend Stocks Selling at a Discount Right Now | ABBV | https://www.nasdaq.com/articles/3-top-dividend-stocks-selling-discount-right-now-2019-01-13 | nan | nan | There's at least one positive result from the stock market correction over the past few months. Great dividend stocks can be bought at great discounts. Even better, dividend yields are higher because share prices fell.
But what are the best bargains? I like AbbVie (NYSE: ABBV) , Bristol-Myers Squibb (NYSE: BMY) , and Enterprise Products Partners (NYSE: EPD) . Here's what makes these three top discounted dividend stocks look especially attractive.
1. AbbVie
AbbVie claims one of the bes t dividends in healthcare. Its yield currently stands at 4.8%. The drugmaker has increased its dividend by 168% since being spun off from parent Abbott Labs in 2013. And AbbVie's executives reiterated the company's commitment to maintaining a strong dividend at the recent J.P. Morgan Healthcare Conference .
You won't find too many healthcare stocks more attractively priced than AbbVie, either. Shares trade at only 10 times expected earnings. This low valuation is even more appealing because of AbbVie's solid growth prospects.
Although the company faces biosimilar competition in Europe for its top-selling drug, Humira, AbbVie isn't worried about hitting its growth targets. The drugmaker's current lineup includes a fast-growing hematology franchise featuring Imbruvica and Venclexta, as well as a rising star with endometriosis drug Orilissa.
In addition, AbbVie expects to launch a couple of new blockbuster immunology drugs later this year. Risankizumab could win FDA approval for treating psoriasis in April, while AbbVie thinks upadacitinib will win approval later in 2019. The two drugs could combine for annual sales of more than $10 billion by 2025.
2. Bristol-Myers Squibb
Bristol-Myers Squibb (BMS) is another big pharma with a big dividend. Its dividend yields nearly 3.3%. Although BMS's track record of dividend increases isn't as impressive as AbbVie's is, the company has still boosted its dividend in each of the past 10 years.
The overall market correction took a toll on BMS, contributing a 25% decline in its share price since October. However, the stock looks like a bargain now, with a forward earnings multiple of 11.4.
BMS should be able to generate solid earnings growth thanks to powerhouse cancer drug Opdivo and blockbuster blood thinner Eliquis, both of which are projected to rank in the top five best-selling drugs in the world by 2024 . These drugs, along with immunology drug Orencia, chemotherapy Sprycel, and immunotherapy Yervoy, should more than offset headwinds from declining sales of the company's older drugs.
Growth could also be turbocharged if shareholders and regulators approve BMS's proposed acquisition of Celgene . Celgene's Revlimid is already one of the world's top-selling drugs. The biotech's current portfolio also includes big winners with Otezla, Pomalyst, and Abraxane. But Celgene's pipeline is the real crown jewel, with at least half a dozen potential blockbusters on the way.
3. Enterprise Products Partners
Unlike AbbVie and Bristol-Myers Squibb, Enterprise Products Partners isn't in the healthcare business. The company is a midstream oil and gas company, which means it owns assets such as pipelines and storage facilities involved in the transportation of oil and natural gas. But Enterprise's dividend yield of 7.1% and 21 consecutive years of dividend increases make it a top dividend stock to consider.
Back in October, my Motley Fool colleague Gregg Brewer wrote that Enterprise Products Partners was a steal . It's even more of a steal now, with shares trading at 13.7 times expected earnings.
Enterprise isn't a monopoly, but it does dominate in several markets where it operates. There are huge barriers to entry in the midstream business, especially the sheer cost of building pipelines and other key assets required to compete.
Another plus for Enterprise Products Partners is that it's largely insulated from volatility in oil and gas prices. The company charges fixed fees for its transportation and processing services instead of other financial arrangements tied to commodity prices. That means Enterprise can depend on relatively steady revenue -- something that dividend-seeking investors should love.
Best pick
If your top priority is high yield, Enterprise Products Partners is a great stock to buy. The company's yield might not stay this high for too much longer as its share price rebounds, so locking in now might be a good idea.
On the other hand, if you want the whole package -- a high yield, strong growth, and a bargain valuation -- I think AbbVie wins. Even though the drugmaker faces competition for Humira, AbbVie appears to have a solid plan in place to generate double-digit percenta ge earnings growth while continuing to boost its dividend payout.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of November 14, 2018
Keith Speights owns shares of AbbVie and Celgene. The Motley Fool owns shares of and recommends Celgene. The Motley Fool recommends Enterprise Products Partners. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Although the company faces biosimilar competition in Europe for its top-selling drug, Humira, AbbVie isn't worried about hitting its growth targets. Even though the drugmaker faces competition for Humira, AbbVie appears to have a solid plan in place to generate double-digit percenta ge earnings growth while continuing to boost its dividend payout. I like AbbVie (NYSE: ABBV) , Bristol-Myers Squibb (NYSE: BMY) , and Enterprise Products Partners (NYSE: EPD) . | I like AbbVie (NYSE: ABBV) , Bristol-Myers Squibb (NYSE: BMY) , and Enterprise Products Partners (NYSE: EPD) . Enterprise Products Partners Unlike AbbVie and Bristol-Myers Squibb, Enterprise Products Partners isn't in the healthcare business. AbbVie AbbVie claims one of the bes t dividends in healthcare. | Although BMS's track record of dividend increases isn't as impressive as AbbVie's is, the company has still boosted its dividend in each of the past 10 years. Enterprise Products Partners Unlike AbbVie and Bristol-Myers Squibb, Enterprise Products Partners isn't in the healthcare business. I like AbbVie (NYSE: ABBV) , Bristol-Myers Squibb (NYSE: BMY) , and Enterprise Products Partners (NYSE: EPD) . | On the other hand, if you want the whole package -- a high yield, strong growth, and a bargain valuation -- I think AbbVie wins. I like AbbVie (NYSE: ABBV) , Bristol-Myers Squibb (NYSE: BMY) , and Enterprise Products Partners (NYSE: EPD) . AbbVie AbbVie claims one of the bes t dividends in healthcare. |
25174.0 | 2019-01-11 00:00:00 UTC | 5 Reasons Why Investors Should Buy Novo Nordisk (NVO) in 2019 | ABBV | https://www.nasdaq.com/articles/5-reasons-why-investors-should-buy-novo-nordisk-nvo-in-2019-2019-01-11 | nan | nan | Novo Nordisk A/SNVO is not only a leader in the worldwide diabetes market, but also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.
Here are five reasons to invest in the stock.
Favorable Rank, Rising Share Price and Estimates: Novo Nordisk has a Zacks Rank #2 (Buy).
Novo Nordisk's shares have outperformed the large-cap pharma industry in the past three months. The stock has returned 14.1% in the said time frame compared with the industry 's rise of 1.1%. The company's outperformance was backed by decent quarterly results, positive news flow and regulatory updates.
Strong Foothold in the Diabetes Market: Novo Nordisk has a strong presence in the Diabetes care market with a global value market share of 28%. Also, the company has strong presence in the total insulin market, and modern and new-generation insulin market with a global value market share of 46% and 45%, respectively. The company has one of the broadest diabetes portfolios in the industry. A solid performance from Tresiba, Victoza, Saxenda and NovoRapid boosted sales performance in the first nine months of 2018.
Per the International Diabetes Federation, nearly 592 million people are expected to be diagnosed with diabetes by 2035. We expect the company's diabetes products to continue performing well and contribute to growth.
Diabetes Products Doing Well: Novo Nordisk's top line is driven by strong performance of products like Victoza (liraglutide). Victoza is currently the market leader in the GLP-1 segment with a 53% share. Going forward, we expect Victoza to continue being a significant contributor to the company's top line.
The FDA approved Ozempic (semaglutide) once-daily pre-filled pen to improve glycaemic control in type II diabetes patients in December 2017. It is also approved in Europe, Japan and Canda for the same indication.
Following the FDA's approval of the drug, Novo Nordisk engaged in a constructive dialogue with the FDA, focusing on minimizing the need for additional large cardiovascular outcomes trials (CVOTs) to obtain a cardiovascular (CV) indication for Ozempic as well as the overall number of large cardiovascular outcomes trials necessary for the semaglutide molecule in different formulations. Thus, Novo Nordisk agreed with the FDA that a bridging strategy between Ozempic and oral semaglutide could be utilized to pursue a CV indication.
Acquisitions: In August 2018, Novo Nordisk acquired all the shares of Ziylo Ltd. Ziylo is a University of Bristol spin-out company, based at Unit DX science incubator in the United Kingdom. The acquisition gives Novo Nordisk full rights to Ziylo's glucose binding molecule platform to develop glucose responsive insulins (GRIs). Novo Nordisk is focused on this technology to develop this next generation of insulin, which would lead to a safer and more effective insulin therapy.
In October 2018, Novo Nordisk announced the expansion of its biopharm business, with an agreement to acquire the U.S. and Canadian rights to Macrilen (macimorelin), the first and only FDA-approved oral growth hormone receptor indicated for the diagnosis of Adult Growth Hormone Deficiency (AGHD), which is a rare endocrine disorder, from Strongbridge Biopharma Plc. The acquisition of Macrilen is in line with Novo Nordisk's strategy for its biopharm business, with growth being driven by both organic and bolt-on initiatives.
Restructuring Initiatives: The company announced plans to restructure the R&D organization to speed up the expansion and diversification of its pipeline, and enable increased investment in transformational biological and technological innovations. Thus, the total workforce was reduced by approximately 1,300 employees before the end of 2018. Majority of these reductions were implemented as of Nov 1, 2018.
Novo Nordisk faces its share of challenges in the form of genericization of key drugs, and patent expiry on some of the products.
Novo Nordisk A/S Price
Novo Nordisk A/S Price | Novo Nordisk A/S Quote
Zacks Rank and Other Stocks to Consider
Novo Nordisk currently carries a Zacks Rank #2 (Buy).
Some top-ranked stocks worth considering are AbbVie Inc. ABBV , Eli Lilly and Co. LLY and Merck & Co., Inc. MRK . All of them sport a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
AbbVie's earnings per share estimates have increased from $7.93 to $7.94 for 2018 and from $8.70 to $8.71 for 2019 over the past 60 days. The company delivered a positive earnings surprise in all the trailing four quarters, with average of 3.54%.
Lilly's earnings per share estimates have increased from $5.55 to $5.59 for 2018 and from $5.81 to $5.92 for 2019 over the past 60 days. The company delivered a positive earnings surprise in all the trailing four quarters, with average of 10.03%.
Merck's earnings per share estimates have increased from $4.71 to $4.72 for 2019 over the past 60 days. The company delivered a positive earnings surprise in all the trailing four quarters, with average of 3.96%.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Eli Lilly and Company (LLY): Free Stock Analysis Report
Novo Nordisk A/S (NVO): Free Stock Analysis Report
Merck & Co., Inc. (MRK): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some top-ranked stocks worth considering are AbbVie Inc. ABBV , Eli Lilly and Co. LLY and Merck & Co., Inc. MRK . AbbVie's earnings per share estimates have increased from $7.93 to $7.94 for 2018 and from $8.70 to $8.71 for 2019 over the past 60 days. Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report Novo Nordisk A/S (NVO): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report Novo Nordisk A/S (NVO): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Some top-ranked stocks worth considering are AbbVie Inc. ABBV , Eli Lilly and Co. LLY and Merck & Co., Inc. MRK . AbbVie's earnings per share estimates have increased from $7.93 to $7.94 for 2018 and from $8.70 to $8.71 for 2019 over the past 60 days. | Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report Novo Nordisk A/S (NVO): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Some top-ranked stocks worth considering are AbbVie Inc. ABBV , Eli Lilly and Co. LLY and Merck & Co., Inc. MRK . AbbVie's earnings per share estimates have increased from $7.93 to $7.94 for 2018 and from $8.70 to $8.71 for 2019 over the past 60 days. | Some top-ranked stocks worth considering are AbbVie Inc. ABBV , Eli Lilly and Co. LLY and Merck & Co., Inc. MRK . AbbVie's earnings per share estimates have increased from $7.93 to $7.94 for 2018 and from $8.70 to $8.71 for 2019 over the past 60 days. Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report Novo Nordisk A/S (NVO): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. |
25175.0 | 2019-01-11 00:00:00 UTC | Top Ranked Momentum Stocks to Buy for January 11th | ABBV | https://www.nasdaq.com/articles/top-ranked-momentum-stocks-to-buy-for-january-11th-2019-01-11 | nan | nan | Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, January 11th:
Asbury Automotive Group, Inc. (ABG): This automotive retailer has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 2.5% over the last 60 days.
Asbury Automotive Group, Inc. Price and Consensus
Asbury Automotive Group, Inc. price-consensus-chart | Asbury Automotive Group, Inc. Quote
Asbury Automotive Group's shares gained 7.9% over the last one month more than S&P 500's loss of -1.5%. The company possesses a Momentum Score of A.
Asbury Automotive Group, Inc. Price
Asbury Automotive Group, Inc. price | Asbury Automotive Group, Inc. Quote
AbbVie Inc. (ABBV): This developer and manufacturer of pharmaceutical products has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 0.1% over the last 60 days.
AbbVie Inc. Price and Consensus
AbbVie Inc. price-consensus-chart | AbbVie Inc. Quote
AbbVie's shares gained 0.2% over the last one month. The company possesses a Momentum Score of B.
AbbVie Inc. Price
AbbVie Inc. price | AbbVie Inc. Quote
Sibanye Gold Limited ( SBGL): This precious metals mining company has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 13.9% over the last 60 days.
Sibanye Gold Limited Price and Consensus
Sibanye Gold Limited price-consensus-chart | Sibanye Gold Limited Quote
Sibanye Gold's shares gained 14.9% over the last one month. The company possesses a Momentum Score of A.
Sibanye Gold Limited Price
Sibanye Gold Limited price | Sibanye Gold Limited Quote
See the full list of top ranked stocks here
Learn more about the Momentum score and how it is calculated here .
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Sibanye Gold Limited (SBGL): Free Stock Analysis Report
Asbury Automotive Group, Inc. (ABG): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The company possesses a Momentum Score of A. Asbury Automotive Group, Inc. Price Asbury Automotive Group, Inc. price | Asbury Automotive Group, Inc. Quote AbbVie Inc. (ABBV): This developer and manufacturer of pharmaceutical products has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 0.1% over the last 60 days. AbbVie Inc. Price and Consensus AbbVie Inc. price-consensus-chart | AbbVie Inc. Quote AbbVie's shares gained 0.2% over the last one month. The company possesses a Momentum Score of B. AbbVie Inc. Price AbbVie Inc. price | AbbVie Inc. Quote Sibanye Gold Limited ( SBGL): This precious metals mining company has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 13.9% over the last 60 days. | The company possesses a Momentum Score of A. Asbury Automotive Group, Inc. Price Asbury Automotive Group, Inc. price | Asbury Automotive Group, Inc. Quote AbbVie Inc. (ABBV): This developer and manufacturer of pharmaceutical products has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 0.1% over the last 60 days. Click to get this free report Sibanye Gold Limited (SBGL): Free Stock Analysis Report Asbury Automotive Group, Inc. (ABG): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc. Price and Consensus AbbVie Inc. price-consensus-chart | AbbVie Inc. Quote AbbVie's shares gained 0.2% over the last one month. | The company possesses a Momentum Score of A. Asbury Automotive Group, Inc. Price Asbury Automotive Group, Inc. price | Asbury Automotive Group, Inc. Quote AbbVie Inc. (ABBV): This developer and manufacturer of pharmaceutical products has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 0.1% over the last 60 days. The company possesses a Momentum Score of B. AbbVie Inc. Price AbbVie Inc. price | AbbVie Inc. Quote Sibanye Gold Limited ( SBGL): This precious metals mining company has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 13.9% over the last 60 days. Click to get this free report Sibanye Gold Limited (SBGL): Free Stock Analysis Report Asbury Automotive Group, Inc. (ABG): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report Sibanye Gold Limited (SBGL): Free Stock Analysis Report Asbury Automotive Group, Inc. (ABG): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. The company possesses a Momentum Score of A. Asbury Automotive Group, Inc. Price Asbury Automotive Group, Inc. price | Asbury Automotive Group, Inc. Quote AbbVie Inc. (ABBV): This developer and manufacturer of pharmaceutical products has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 0.1% over the last 60 days. AbbVie Inc. Price and Consensus AbbVie Inc. price-consensus-chart | AbbVie Inc. Quote AbbVie's shares gained 0.2% over the last one month. |
25176.0 | 2019-01-11 00:00:00 UTC | AbbVie Inc. (ABBV) Ex-Dividend Date Scheduled for January 14, 2019 | ABBV | https://www.nasdaq.com/articles/abbvie-inc-abbv-ex-dividend-date-scheduled-january-14-2019-2019-01-11 | nan | nan | AbbVie Inc. ( ABBV ) will begin trading ex-dividend on January 14, 2019. A cash dividend payment of $1.07 per share is scheduled to be paid on February 15, 2019. Shareholders who purchased ABBV prior to the ex-dividend date are eligible for the cash dividend payment. This represents an 11.46% increase over prior dividend payment.
The previous trading day's last sale of ABBV was $88.2, representing a -29.92% decrease from the 52 week high of $125.86 and a 13.81% increase over the 52 week low of $77.50.
ABBV is a part of the Health Care sector, which includes companies such as Johnson & Johnson ( JNJ ) and Pfizer, Inc. ( PFE ). ABBV's current earnings per share, an indicator of a company's profitability, is $4.84. Zacks Investment Research reports ABBV's forecasted earnings growth in 2018 as 41.71%, compared to an industry average of 9.4%.
For more information on the declaration, record and payment dates, visit the ABBV Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to ABBV through an Exchange Traded Fund [ETF]?
The following ETF(s) have ABBV as a top-10 holding:
Invesco Dynamic Pharmaceuticals ETF ( PJP )
VanEck Vectors Pharmaceutical ETF ( PPH )
Inspire 100 ETF ( BIBL )
AdvisorShares Vice ETF ( ACT )
ALPS Sector Dividend Dogs ETF ( SDOG ).
The top-performing ETF of this group is PPH with an decrease of -8.64% over the last 100 days. PJP has the highest percent weighting of ABBV at 5.12%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shareholders who purchased ABBV prior to the ex-dividend date are eligible for the cash dividend payment. Zacks Investment Research reports ABBV's forecasted earnings growth in 2018 as 41.71%, compared to an industry average of 9.4%. For more information on the declaration, record and payment dates, visit the ABBV Dividend History page. | The following ETF(s) have ABBV as a top-10 holding: Invesco Dynamic Pharmaceuticals ETF ( PJP ) VanEck Vectors Pharmaceutical ETF ( PPH ) Inspire 100 ETF ( BIBL ) AdvisorShares Vice ETF ( ACT ) ALPS Sector Dividend Dogs ETF ( SDOG ). The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. AbbVie Inc. ( ABBV ) will begin trading ex-dividend on January 14, 2019. | Shareholders who purchased ABBV prior to the ex-dividend date are eligible for the cash dividend payment. For more information on the declaration, record and payment dates, visit the ABBV Dividend History page. The following ETF(s) have ABBV as a top-10 holding: Invesco Dynamic Pharmaceuticals ETF ( PJP ) VanEck Vectors Pharmaceutical ETF ( PPH ) Inspire 100 ETF ( BIBL ) AdvisorShares Vice ETF ( ACT ) ALPS Sector Dividend Dogs ETF ( SDOG ). | Shareholders who purchased ABBV prior to the ex-dividend date are eligible for the cash dividend payment. The following ETF(s) have ABBV as a top-10 holding: Invesco Dynamic Pharmaceuticals ETF ( PJP ) VanEck Vectors Pharmaceutical ETF ( PPH ) Inspire 100 ETF ( BIBL ) AdvisorShares Vice ETF ( ACT ) ALPS Sector Dividend Dogs ETF ( SDOG ). AbbVie Inc. ( ABBV ) will begin trading ex-dividend on January 14, 2019. |
25177.0 | 2019-01-11 00:00:00 UTC | The Implied Analyst 12-Month Target For FTC | ABBV | https://www.nasdaq.com/articles/implied-analyst-12-month-target-ftc-2019-01-11 | nan | nan | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel , we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Large Cap Growth AlphaDEX Fund ETF (Symbol: FTC), we found that the implied analyst target price for the ETF based upon its underlying holdings is $68.70 per unit.
With FTC trading at a recent price near $60.05 per unit, that means that analysts see 14.41% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of FTC's underlying holdings with notable upside to their analyst target prices are Cadence Design Systems Inc (Symbol: CDNS), Salesforce.com Inc (Symbol: CRM), and AbbVie Inc (Symbol: ABBV). Although CDNS has traded at a recent price of $44.32/share, the average analyst target is 15.82% higher at $51.33/share. Similarly, CRM has 15.61% upside from the recent share price of $147.04 if the average analyst target price of $170.00/share is reached, and analysts on average are expecting ABBV to reach a target price of $101.09/share, which is 14.61% above the recent price of $88.20. Below is a twelve month price history chart comparing the stock performance of CDNS, CRM, and ABBV:
Below is a summary table of the current analyst target prices discussed above:
Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.
10 ETFs With Most Upside To Analyst Targets »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is a twelve month price history chart comparing the stock performance of CDNS, CRM, and ABBV: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of FTC's underlying holdings with notable upside to their analyst target prices are Cadence Design Systems Inc (Symbol: CDNS), Salesforce.com Inc (Symbol: CRM), and AbbVie Inc (Symbol: ABBV). Similarly, CRM has 15.61% upside from the recent share price of $147.04 if the average analyst target price of $170.00/share is reached, and analysts on average are expecting ABBV to reach a target price of $101.09/share, which is 14.61% above the recent price of $88.20. | Similarly, CRM has 15.61% upside from the recent share price of $147.04 if the average analyst target price of $170.00/share is reached, and analysts on average are expecting ABBV to reach a target price of $101.09/share, which is 14.61% above the recent price of $88.20. Three of FTC's underlying holdings with notable upside to their analyst target prices are Cadence Design Systems Inc (Symbol: CDNS), Salesforce.com Inc (Symbol: CRM), and AbbVie Inc (Symbol: ABBV). Below is a twelve month price history chart comparing the stock performance of CDNS, CRM, and ABBV: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? | Similarly, CRM has 15.61% upside from the recent share price of $147.04 if the average analyst target price of $170.00/share is reached, and analysts on average are expecting ABBV to reach a target price of $101.09/share, which is 14.61% above the recent price of $88.20. Below is a twelve month price history chart comparing the stock performance of CDNS, CRM, and ABBV: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of FTC's underlying holdings with notable upside to their analyst target prices are Cadence Design Systems Inc (Symbol: CDNS), Salesforce.com Inc (Symbol: CRM), and AbbVie Inc (Symbol: ABBV). | Below is a twelve month price history chart comparing the stock performance of CDNS, CRM, and ABBV: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of FTC's underlying holdings with notable upside to their analyst target prices are Cadence Design Systems Inc (Symbol: CDNS), Salesforce.com Inc (Symbol: CRM), and AbbVie Inc (Symbol: ABBV). Similarly, CRM has 15.61% upside from the recent share price of $147.04 if the average analyst target price of $170.00/share is reached, and analysts on average are expecting ABBV to reach a target price of $101.09/share, which is 14.61% above the recent price of $88.20. |
25178.0 | 2019-01-11 00:00:00 UTC | 3 Back-of-the-Shelf Consumer Stocks With Growth and Income | ABBV | https://www.nasdaq.com/articles/3-back-shelf-consumer-stocks-growth-and-income-2019-01-11 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Many tend to ignore consumer stocks not oriented toward the latest technology. Consumers and investors tend to focus on companies that produce new gadgets or bring the next wave of tech innovation. Many "boring" consumer stocks that have less of a tech focus, however, offer an impressive track record with dividends . This serves as an advantage over a tech industry, which tends to lag the S&P 500 when it comes to offering dividend stocks.
Due in large part to dividends and a loyal customer base, consumer stocks tend to offer stability lacking in some of these more exciting stocks. Also, contrary to popular belief, many of these companies have become innovation leaders.
Although the press may not always report it, these firms often pioneer new products that place them on the cutting edge in their industries.
10 A-Rated Stocks to Buy That The Smart Money Is Piling Into
The following three companies lead this innovation. They also offer growth rates, valuations and dividend yields that should draw the attention of stock buyers.
Source: Shutterstock
AbbVie (ABBV)
Admittedly, AbbVie (NYSE: ABBV ) has made a few of my stock lists. I had hoped not to write about ABBV for that reason. However, when an equity offers an almost single-digit forward price-to-earnings (P/E) ratio, double-digit profit growth and the third-highest dividend yield among dividend aristocrats, I cannot leave it off in good conscience.
ABBV stock trades a perfect storm for buyers. The patent on Humira faces patent expirations across the world. This has inspired a wave of selling in AbbVie. Despite this, analysts believe the company's drug pipeline will keep profits growing at double-digit rates. This has led to a forward PE ratio that stands at about 10.1.
This perfect storm also applies to the firm's payouts. Due to its previous history as part of Abbott Laboratories (NYSE: ABT ), ABBV holds dividend aristocrat status. When a stock hikes its payout for 46 years as AbbVie has, the stock price depends heavily on keeping this streak alive.
Even better, ABBV has not made not offered a token hike in the payout merely to maintain the dividend aristocrat status. AbbVie went further, taking the payout from $2.56 per share in 2017 to $3.59 per share in 2018 to $4.28 per share this year. Approving such hikes when they face intense pressure to raise the payout every year shows a strong belief in its own future.
Considering the low P/E ratio, the profit levels, and the dividend growth amounts, ABBV becomes one of the more obvious choices among consumer stocks.
Source: Peyri Herrera via Flickr (Modified)
Altria Group (MO)
Few consumer stocks reflect resilience better than Altria (NYSE: MO ). This year will mark 55 years since the U.S. Surgeon General released their report warning on the dangers of smoking. Amid anti-smoking campaigns, increasing tobacco taxes, and multi-billion dollar legal settlements, MO stock should have sunk into obscurity. Instead, Altria has become an unlikely success story.
Despite the hostile environment for tobacco, the company continues to find opportunity. Currently, it invests in both smokeless tobacco and alcohol. It currently holds a 10.2% stake in Anheuser Busch-InBev (NYSE: BUD ), for example. Also, despite legal barriers, it has also turned to the emerging marijuana sector. In late 2018, Altria purchased a 45% stake in Cronos (NASDAQ: CRON ) for $1.8 billion.
Even with the hostile business environment, MO stock manages to maintain a generous dividend. The current dividend of $3.20 per share yields almost 6.6%. Although MO does not hold dividend aristocrat status, the payout has increased in most years.
As a result, MO stock has long remained a dividend powerhouse. Those who bought the equity in 2000 and reinvested the dividends receive their original investment back every year in dividends alone. The same holds true for those who bought in 1985 and spent or invested the payouts elsewhere.
The company also looks attractive from a valuation and growth perspective. The forward P/E stands at 11.3. Moreover, analysts predict a 7.5% profit growth rate this year. Also, they expect those profit increases to remain in the high-single-digits for years to come. With its successes in related business, and its ability to maintain growth despite strong anti-tobacco sentiment, Altria should continue to stand out among consumer stocks.
Source: Shutterstock
General Mills (GIS)
Despite producing recession-proof products, General Mills (NYSE: GIS ) and its direct peers have endured years of struggle. An increasing interest in fresh and organic foods has diminished demand for the packaged foods General Mills has produced. As a result, it has seen both revenue and profits steadily fall over the last few years. This has taken GIS stock to levels first seen in 2012.
However, a turnaround could occur soon. General Mills has begun to pivot to reflect consumer tastes. The company owns brands such as Cascadian Farm, Larabar, and Muir Glen that produce certified organic foods.
Such products have helped revenues and profits turns around. After years of falling numbers, analysts predict a 5.5% increase in profits next year. Revenues have already begun to improve as Wall Street expects a 7.7% increase in sales growth for this year.
Also, due to the years of decline, GIS stock trades at 12.7 forward earnings. Although this would not impress investors in a shrinking business, it begins to appear reasonable with growth returning. Also, with a five-year average P/E of 20.6, investors will likely enjoy a nice gain by waiting for the multiple to return to its long-term average.
Even better for income-oriented investors, the $1.96 per share dividend yields around 4.75%. Since they have achieved a 15-year streak of dividend increases, another payout hike will likely come this year.
Both consumers and investors have waited a long time for packaged food companies to embrace more natural foods. General Mills has finally made that move. With its attractive valuations and dividend yields, GIS stock should find a place among the more attractive high-dividend consumer stocks.
As of this writing, Will Healy did not hold a position in any of the aforementioned stocks. You canfollow Will on Twitterat @HealyWriting.
More From InvestorPlace
2 Toxic Pot Stocks You Should Avoid
10 Stocks You Can Set and Forget (Even In This Market)
10 Virtual Assistants for the Future of Smart Homes
7 5G Stocks to Buy as the Race for Spectrum Tightens
Compare Brokers
The post 3 Back-of-the-Shelf Consumer Stocks With Growth and Income appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Due to its previous history as part of Abbott Laboratories (NYSE: ABT ), ABBV holds dividend aristocrat status. Source: Shutterstock AbbVie (ABBV) Admittedly, AbbVie (NYSE: ABBV ) has made a few of my stock lists. I had hoped not to write about ABBV for that reason. | Source: Shutterstock AbbVie (ABBV) Admittedly, AbbVie (NYSE: ABBV ) has made a few of my stock lists. I had hoped not to write about ABBV for that reason. ABBV stock trades a perfect storm for buyers. | Source: Shutterstock AbbVie (ABBV) Admittedly, AbbVie (NYSE: ABBV ) has made a few of my stock lists. I had hoped not to write about ABBV for that reason. ABBV stock trades a perfect storm for buyers. | Source: Shutterstock AbbVie (ABBV) Admittedly, AbbVie (NYSE: ABBV ) has made a few of my stock lists. I had hoped not to write about ABBV for that reason. ABBV stock trades a perfect storm for buyers. |
25179.0 | 2019-01-10 00:00:00 UTC | Sen. Sanders, Rep. Cummings introduce bill to lower U.S. drug prices | ABBV | https://www.nasdaq.com/articles/sen-sanders-rep-cummings-introduce-bill-lower-us-drug-prices-2019-01-10 | nan | nan | By Yasmeen Abutaleb
WASHINGTON, Jan 10 () - U.S. Senator Bernie Sanders and Representative Elijah Cummings introduced legislation on Thursday aimed at lowering the cost of prescription drugs for American consumers, critiquing President Donald Trump administration's efforts to curb medicine prices.
Democrats have been critical of efforts by the Trump administration to bring down drug prices after Trump, a Republican, promised to do so during his 2016 campaign and since being elected. They have said administration proposals let big drugmakers off the hook and did not do enough to help Americans.
"Americans want government to help them. And this is something you can do to help all Americans," Cummings said, addressing Trump.
The proposed legislation, which has several co-sponsors among Democrats in the House of Representatives and in the Republican-led Senate, is comprised of three bills that aim to curb drug costs.
The U.S. Department of Health and Human Services last year rolled out a plan to lower drug prices and has introduced several modest proposals to curb medicine costs, but Trump has expressed frustration over continued price hikes by drugmakers.
Several pharmaceutical companies temporarily froze prices on select drugs last year. But drugmakers raised prices on more than 250 prescription drugs, including the world's top-selling medicine, AbbVie Inc's Humira, to begin 2019.
In response to increased pressure, however, most drugmakers ended their practice of annual double-digit percentage increases of list prices, keeping most under 10 percent.
The Sanders and Cummings bill would peg U.S. prescription drug prices to the median price from five countries - Canada, Britain, France, Germany and Japan - where drug costs are typically far lower because of government price controls.
That is similar to a proposal the Trump administration said it plans to put forth in the coming months that would create an "international pricing index" to help the cost of prescription drugs to Medicare more closely align with other countries. The government health insurance program covers more than 40 million older and disabled Americans.
The bill would also allow the U.S. Secretary for Health and Human Services (HHS) to negotiate prices in Medicare Part D, a program that helps Medicare beneficiaries pay for self-administered medicines like those purchased at drugstores.
The proposal would also end a ban that keeps Americans from buying medicines at lower prices from Canada and other countries.
Drugmakers opposed Sanders' and Cummings' legislation, arguing that it was not the right way to address prescription drug affordability. Pharmaceutical companies have long argued that price controls in the United States would stifle innovation and that importing drugs from other countries is unsafe.
"The proposals from Senator Sanders would wreak havoc on the U.S. health care system," the Pharmaceutical Research and Manufacturers of America (PhRMA), the industry's top U.S. lobbying group, said in a statement.
"They would interfere with patient access to medicine, while also undermining the U.S. intellectual property system, replicating the flawed policies of foreign governments and circumventing the U.S. Food and Drug Administration's robust safety standards," the group said.
They also say that rebates and discounts they must pay to insurers and pharmacy benefit managers (PBMs) to ensure patient access to their products - and that are not passed on to consumers - forces them to keep list prices high. Trump administration proposals have singled out so-called middlemen like PBMs as a big part of the problem.
"While Americans cannot afford the prescription drugs they desperately need, the pharmaceutical industry year after year makes huge profits and pays an outrageous level of compensation to their CEOs," Sanders, an Independent who caucuses with Democrats, said Thursday at a news conference.
Health and Human Services Secretary Alex Azar has been defending the administration's efforts to lower drug prices.
"(Trump) and I will not stop our work until list prices go down," Azar wrote on Twitter on Wednesday.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | But drugmakers raised prices on more than 250 prescription drugs, including the world's top-selling medicine, AbbVie Inc's Humira, to begin 2019. Senator Bernie Sanders and Representative Elijah Cummings introduced legislation on Thursday aimed at lowering the cost of prescription drugs for American consumers, critiquing President Donald Trump administration's efforts to curb medicine prices. That is similar to a proposal the Trump administration said it plans to put forth in the coming months that would create an "international pricing index" to help the cost of prescription drugs to Medicare more closely align with other countries. | But drugmakers raised prices on more than 250 prescription drugs, including the world's top-selling medicine, AbbVie Inc's Humira, to begin 2019. Senator Bernie Sanders and Representative Elijah Cummings introduced legislation on Thursday aimed at lowering the cost of prescription drugs for American consumers, critiquing President Donald Trump administration's efforts to curb medicine prices. The U.S. Department of Health and Human Services last year rolled out a plan to lower drug prices and has introduced several modest proposals to curb medicine costs, but Trump has expressed frustration over continued price hikes by drugmakers. | But drugmakers raised prices on more than 250 prescription drugs, including the world's top-selling medicine, AbbVie Inc's Humira, to begin 2019. Senator Bernie Sanders and Representative Elijah Cummings introduced legislation on Thursday aimed at lowering the cost of prescription drugs for American consumers, critiquing President Donald Trump administration's efforts to curb medicine prices. The U.S. Department of Health and Human Services last year rolled out a plan to lower drug prices and has introduced several modest proposals to curb medicine costs, but Trump has expressed frustration over continued price hikes by drugmakers. | But drugmakers raised prices on more than 250 prescription drugs, including the world's top-selling medicine, AbbVie Inc's Humira, to begin 2019. Senator Bernie Sanders and Representative Elijah Cummings introduced legislation on Thursday aimed at lowering the cost of prescription drugs for American consumers, critiquing President Donald Trump administration's efforts to curb medicine prices. "Americans want government to help them. |
25180.0 | 2019-01-10 00:00:00 UTC | Ex-Dividend Reminder: Publix Super Markets, AbbVie and Quest Diagnostics | ABBV | https://www.nasdaq.com/articles/ex-dividend-reminder-publix-super-markets-abbvie-and-quest-diagnostics-2019-01-10 | nan | nan | Looking at the universe of stocks we cover at Dividend Channel , on 1/14/19, Publix Super Markets Inc (Symbol: PUSH), AbbVie Inc (Symbol: ABBV), and Quest Diagnostics, Inc. (Symbol: DGX) will all trade ex-dividend for their respective upcoming dividends. Publix Super Markets Inc will pay its quarterly dividend of $0.26 on 2/1/19, AbbVie Inc will pay its quarterly dividend of $1.07 on 2/15/19, and Quest Diagnostics, Inc. will pay its quarterly dividend of $0.53 on 1/30/19. As a percentage of PUSH's recent stock price of $40.00, this dividend works out to approximately 0.65%, so look for shares of Publix Super Markets Inc to trade 0.65% lower - all else being equal - when PUSH shares open for trading on 1/14/19. Similarly, investors should look for ABBV to open 1.22% lower in price and for DGX to open 0.63% lower, all else being equal.
Below are dividend history charts for PUSH, ABBV, and DGX, showing historical dividends prior to the most recent ones declared.
Publix Super Markets Inc (Symbol: PUSH) :
AbbVie Inc (Symbol: ABBV) :
Quest Diagnostics, Inc. (Symbol: DGX) :
In general, dividends are not always predictable, following the ups and downs of company profits over time. Therefore, a good first due diligence step in forming an expectation of annual yield going forward, is looking at the history above, for a sense of stability over time. This can help in judging whether the most recen t dividends from these companies are likely to continue. If they do continue, the current estimated yields on annualized basis would be 2.60% for Publix Super Markets Inc, 4.86% for AbbVie Inc, and 2.51% for Quest Diagnostics, Inc..
In Thursday trading, Publix Super Markets Inc shares are currently trading flat, AbbVie Inc shares are up about 0.3%, and Quest Diagnostics, Inc. shares are down about 0.1% on the day.
Click here to learn which 25 S.A.F.E. dividend stocks should be on your radar screen »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | If they do continue, the current estimated yields on annualized basis would be 2.60% for Publix Super Markets Inc, 4.86% for AbbVie Inc, and 2.51% for Quest Diagnostics, Inc.. Looking at the universe of stocks we cover at Dividend Channel , on 1/14/19, Publix Super Markets Inc (Symbol: PUSH), AbbVie Inc (Symbol: ABBV), and Quest Diagnostics, Inc. (Symbol: DGX) will all trade ex-dividend for their respective upcoming dividends. Publix Super Markets Inc will pay its quarterly dividend of $0.26 on 2/1/19, AbbVie Inc will pay its quarterly dividend of $1.07 on 2/15/19, and Quest Diagnostics, Inc. will pay its quarterly dividend of $0.53 on 1/30/19. | Looking at the universe of stocks we cover at Dividend Channel , on 1/14/19, Publix Super Markets Inc (Symbol: PUSH), AbbVie Inc (Symbol: ABBV), and Quest Diagnostics, Inc. (Symbol: DGX) will all trade ex-dividend for their respective upcoming dividends. Publix Super Markets Inc will pay its quarterly dividend of $0.26 on 2/1/19, AbbVie Inc will pay its quarterly dividend of $1.07 on 2/15/19, and Quest Diagnostics, Inc. will pay its quarterly dividend of $0.53 on 1/30/19. Publix Super Markets Inc (Symbol: PUSH) : AbbVie Inc (Symbol: ABBV) : Quest Diagnostics, Inc. (Symbol: DGX) : In general, dividends are not always predictable, following the ups and downs of company profits over time. | Looking at the universe of stocks we cover at Dividend Channel , on 1/14/19, Publix Super Markets Inc (Symbol: PUSH), AbbVie Inc (Symbol: ABBV), and Quest Diagnostics, Inc. (Symbol: DGX) will all trade ex-dividend for their respective upcoming dividends. Publix Super Markets Inc will pay its quarterly dividend of $0.26 on 2/1/19, AbbVie Inc will pay its quarterly dividend of $1.07 on 2/15/19, and Quest Diagnostics, Inc. will pay its quarterly dividend of $0.53 on 1/30/19. Publix Super Markets Inc (Symbol: PUSH) : AbbVie Inc (Symbol: ABBV) : Quest Diagnostics, Inc. (Symbol: DGX) : In general, dividends are not always predictable, following the ups and downs of company profits over time. | Looking at the universe of stocks we cover at Dividend Channel , on 1/14/19, Publix Super Markets Inc (Symbol: PUSH), AbbVie Inc (Symbol: ABBV), and Quest Diagnostics, Inc. (Symbol: DGX) will all trade ex-dividend for their respective upcoming dividends. If they do continue, the current estimated yields on annualized basis would be 2.60% for Publix Super Markets Inc, 4.86% for AbbVie Inc, and 2.51% for Quest Diagnostics, Inc.. Publix Super Markets Inc will pay its quarterly dividend of $0.26 on 2/1/19, AbbVie Inc will pay its quarterly dividend of $1.07 on 2/15/19, and Quest Diagnostics, Inc. will pay its quarterly dividend of $0.53 on 1/30/19. |
25181.0 | 2019-01-10 00:00:00 UTC | 3 Dividend Stocks That Pay You Better Than Coca-Cola Does | ABBV | https://www.nasdaq.com/articles/3-dividend-stocks-pay-you-better-coca-cola-does-2019-01-10 | nan | nan | Coca-Cola (NYSE: KO) has long been a favorite name among dividend investors and for a number of outstanding reasons. Not only has this iconic beverage company raised its dividend payout for 56 consecutive years, but its current yield of 3.28% is among the richest within the entire consumer goods space.
However, there are a few top stocks that offer even richer yields than this Dividend King. Hanesbrands (NYSE: HBI) , Target (NYSE: TGT) , and AbbVie (NYSE: ABBV) , for instance, all sport substantially higher yields than Coca-Cola. Should income investors add these three dividend stocks to their portfolios right now? Read on to find out.
Big yield at a big discount
Keith Noonan (Hanesbrands): Clothing and apparel company Hanesbrands had a challenging year in 2018. Despite momentum for the company's Champion brand and progress expanding its international business and direct-to-consumer imprint, slowdown for socks and underwear and signs of increased threats from private-label , retailer-specific brands created dynamics that sent the stock tumbling. Uninspiring earnings results and Target's decision not to renew its contract with Hanesbrands for an exclusive athleisure clothing line helped push the stock down nearly 40% over the last year, and shares now trade at less than 7.5 times this year's expected earnings and pack a 4.6% dividend yield.
Hanesbrands dividend yield is higher than it's ever been, and recent movement on the stock suggests that the prevailing view on the company is that it will continue to decline in the highly competitive clothing industry due to commoditization and threats from private-label retail brands and e-commerce. Like any business, Hanesbrands will have to adapt to challenges and shifts in its industry, but the current read on the stock appears overly pessimistic. Total sales for the Champion brand climbed 30% year over year last quarter, direct-to-consumer sales rose 15%, and the company is continuing to reduce operating expenses.
It's worth pointing out that Hanesbrands hasn't raised its payout since 2016, choosing instead to use cash flows to pay down debts from its recent acquisitions push, but the company has tripled its dividend over the last five years and its payout ratio suggests that investors shouldn't be concerned about a payout cut or suspension. Amid the challenges, there's some positive momentum at the company, and its low earnings multiples and big yield should make it a candidate for value- and income-focused investors.
A reliable retailer
Jeremy Bowman (Target): Coca-Cola is hard to beat as a dividend stock. The company has been paying increasing dividends for 56 years, making it a rare Dividend King, and is a global giant with a number of timeless brands, including its namesake soft drink. Today, Coca-Cola offers a solid dividend yield at 3.3%, but another reliable, consumer-focused dividend payer investors may want to consider is Target.
Like Coca-Cola, Target is a Dividend Aristocrat , having raised its dividend payout every year for the last 44 years, and it offers a better yield today than Coke, at 4%. Target is also cheaper than Coke, at a P/E of just 11.6, compared to 22.9 for the beverage giant, and Target appears to have better growth prospects as the company is investing in new, small-format stores and e-commerce. It's also benefiting from the bankruptcy of rivals like Toys R Us, Sears, and Bon-Ton Stores.
Target is also making the most from the strong momentum in the booming consumer economy and its own strategic initiatives , with comparable sales jumping 5.3% in its most recent quarter.
Retailers are generally trading at a discount today as the market is skeptical of their future given the upheaval from the threat of e-commerce, but Target is increasingly looking like it will be a winner from the industry transformation as its own e-commerce business is growing quickly -- up 49% in the third quarter -- thanks in part to its acquisition of Shipt a year ago and a store footprint that helps it enable fast delivery and multiple pickup options.
Finally, dividend investors can take comfort in knowing that Target's payout ratio is much lower than Coca-Cola's -- at 49% compared to 76% -- which means the retailer has plenty of room to raise its payout even if profit growth is slow.
A cheap, high-yield dividend
George Budwell (AbbVie): Not many companies can stand toe-to-toe with Coca-Cola from a dividend standpoint. But AbbVie, a large-cap biopharma, may have what it takes. After all, AbbVie offers a far richer yield than Coca-Cola (4.51% vs. 3.28%) at current levels, as well as a considerably more attractive payout ratio (67.8% vs. 210%). AbbVie's total return on capital has also markedly outperformed that of Coca-Cola's since the company became an independent entity in 2013.
ABBV total return price data by YCharts .
However, AbbVie's stock is clearly more risky than Coca-Cola's. Turning to the specifics, this blue chip is currently dealing with the loss of exclusivity for its megablockbuster arthritis medicine Humira over in Europe , as well as the failure of its high-value cancer therapy known as Rova-T. Fortunately, the drugmaker has taken a number of steps to move beyond Humira's loss of exclusivity in key geographies and soften the impact of Rova-T's unexpected clinical setback.
AbbVie, for instance, has successfully built out a high-growth blood cancer franchise that already sports two top drugs in the field: Imbruvica and Venclexta. The drugmaker should also be able to offset a good chunk of Humira's declines with the successful development of its next-generation immunology medicines, such as upadacitinib and risankizumab. AbbVie thus has the pieces in place to not only survive these two key headwinds, but to keep delivering top-notch growth and shareholder rewards as well.
In all, AbbVie's stock has an outstanding dividend program in place that compares well to even the best in the business. The company's biggest risk factors also appear to be under control, thanks to its robust and highly diverse clinical pipeline.
10 stocks we like better than Coca-Cola
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Coca-Cola wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of November 14, 2018
George Budwell owns shares of AbbVie. Jeremy Bowman has no position in any of the stocks mentioned. Keith Noonan owns shares of Hanesbrands. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Hanesbrands (NYSE: HBI) , Target (NYSE: TGT) , and AbbVie (NYSE: ABBV) , for instance, all sport substantially higher yields than Coca-Cola. A cheap, high-yield dividend George Budwell (AbbVie): Not many companies can stand toe-to-toe with Coca-Cola from a dividend standpoint. But AbbVie, a large-cap biopharma, may have what it takes. | Hanesbrands (NYSE: HBI) , Target (NYSE: TGT) , and AbbVie (NYSE: ABBV) , for instance, all sport substantially higher yields than Coca-Cola. A cheap, high-yield dividend George Budwell (AbbVie): Not many companies can stand toe-to-toe with Coca-Cola from a dividend standpoint. But AbbVie, a large-cap biopharma, may have what it takes. | Hanesbrands (NYSE: HBI) , Target (NYSE: TGT) , and AbbVie (NYSE: ABBV) , for instance, all sport substantially higher yields than Coca-Cola. A cheap, high-yield dividend George Budwell (AbbVie): Not many companies can stand toe-to-toe with Coca-Cola from a dividend standpoint. But AbbVie, a large-cap biopharma, may have what it takes. | Hanesbrands (NYSE: HBI) , Target (NYSE: TGT) , and AbbVie (NYSE: ABBV) , for instance, all sport substantially higher yields than Coca-Cola. A cheap, high-yield dividend George Budwell (AbbVie): Not many companies can stand toe-to-toe with Coca-Cola from a dividend standpoint. But AbbVie, a large-cap biopharma, may have what it takes. |
25182.0 | 2019-01-10 00:00:00 UTC | 3 Big Reasons Why AbbVie Isn't Worried About Humira | ABBV | https://www.nasdaq.com/articles/3-big-reasons-why-abbvie-isnt-worried-about-humira-2019-01-10 | nan | nan | AbbVie (NYSE: ABBV) raised some eyebrows -- and some concerns -- in its Q3 conference call discussion of the early days of European biosimilar competition for Humira. CEO Rick Gonzalez said at the time that discounting for Humira biosimilars was steeper than the company expected. The obvious implication is that Humira sales outside of the U.S. could decline more quickly than projected.
The threat to Humira came up during AbbVie's presentation and question-and-answer session on Wednesday at the J.P. Morgan Healthcare Conference . But Gonzalez and AbbVie President Michael Severino expressed confidence that the big pharma company would continue to grow for years to come despite challenges for its top-selling drug. Here are three big reasons AbbVie isn't worried about Humira.
1. A strong lineup beyond Humira
Michael Severino addressed the threat to Humira head-on in his presentation at the J.P. Morgan conference. His first response to the impact of biosimilar competition was to point out the strong growth and future prospects for two other AbbVie drugs, Imbruvica and Venclexta.
Severino noted that the two hematology drugs currently represent a $4 billion franchise with double-digit percentage sales growth. He said that AbbVie expects Imbruvica and Venclexta combined will generate over $9 billion of risk-adjusted incremental annual sales by 2025.
In addition, Severino singled out a couple of other current products, Orilissa (elagolix) and Mavyret. Orilissa was approved by the FDA last year for the treatment of endometriosis, an indication for which no new treatment has been introduced in decades. AbbVie plans to file for approval of the drug in treating uterine fibroids later this year. The company thinks that Orilissa will contribute upwards of $2 billion in incremental annual risk-adjusted sales by 2025.
Rick Gonzalez acknowledged that Mavyret won't be "a big growth vehicle" in the years ahead. However, he said the hepatitis C virus (HCV) drug would nonetheless generate strong cash flow for years to come.
2. Blockbuster pipeline candidates
Another key reason behind AbbVie's confidence is its pipeline, especially in the area of immunology. Severino stated that AbbVie will "evolve from a single product to a portfolio of therapies" in immunology over the next few years.
The first immunology product likely to join Humira is risankizumab. An FDA approval decision for the drug as a treatment for psoriasis is expected by late April 2019. Risankizumab could soon be followed by upadacitinib. AbbVie expects an FDA decision on the drug as a treatment for rheumatoid arthritis in the second half of the year.
AbbVie is also pursuing additional indications for both drugs. The company thinks that risankizumab and upadacitinib will be best-in-class therapies that together generate $10 billion or more in incremental annual sales by 2025.
In addition, Severino said that the company's neuroscience pipeline candidates should begin contributing to growth by the middle of the next decade. AbbVie's pipeline includes a late-stage candidate targeting Parkinson's disease as well as experimental Alzheimer's disease and multiple sclerosis drugs in earlier-stage clinical studies.
3. Time is on its side
It's also important to remember that Humira isn't going away anytime soon. Severino stated that AbbVie expects the drug to remain at the top of the immunology market through 2022. That's in line with the thinking from market research company EvaluatePharma, which projects that Humira will remain the top-selling drug in the world through 2024 .
Although Humira is being challenged by biosimilars in Europe, AbbVie continues to state that there probably won't be direct biosimilar competition in the U.S. until 2023. That gives the company plenty of time for its other drugs and pipeline candidates to ramp up.
Gonzalez also said that Humira's sales should continue to grow in the U.S., although he acknowledged that the growth rates have moderated and will continue to do so. He stated that Humira has been "a phenomenal story" and will "continue to be an important growth story" for AbbVie.
The magic number
There's one number that investors will want to pay special attention to: $35 billion. That's the minimum level of risk-adjusted sales that AbbVie projects it will generate from drugs other than Humira by 2025. By comparison, AbbVie's total revenue in 2017 including Humira was $28.2 billion.
Some might question whether AbbVie can achieve that goal. Skepticism certainly is higher now than in the past after cancer drug Rova-T flopped in clinical studies .
But the prospects for AbbVie's other drugs and pipeline candidates discussed by Gonzalez and Severino don't seem to be just pie in the sky. AbbVie should be able to continue doing what it's been doing since being spun off in 2013: deliver revenue growth, deliver earnings growth, and deliver a steadily increasing dividend.
10 stocks we like better than AbbVie
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and AbbVie wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of November 14, 2018
Keith Speights owns shares of AbbVie. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie (NYSE: ABBV) raised some eyebrows -- and some concerns -- in its Q3 conference call discussion of the early days of European biosimilar competition for Humira. But Gonzalez and AbbVie President Michael Severino expressed confidence that the big pharma company would continue to grow for years to come despite challenges for its top-selling drug. His first response to the impact of biosimilar competition was to point out the strong growth and future prospects for two other AbbVie drugs, Imbruvica and Venclexta. | But Gonzalez and AbbVie President Michael Severino expressed confidence that the big pharma company would continue to grow for years to come despite challenges for its top-selling drug. He said that AbbVie expects Imbruvica and Venclexta combined will generate over $9 billion of risk-adjusted incremental annual sales by 2025. AbbVie (NYSE: ABBV) raised some eyebrows -- and some concerns -- in its Q3 conference call discussion of the early days of European biosimilar competition for Humira. | But Gonzalez and AbbVie President Michael Severino expressed confidence that the big pharma company would continue to grow for years to come despite challenges for its top-selling drug. That's the minimum level of risk-adjusted sales that AbbVie projects it will generate from drugs other than Humira by 2025. But the prospects for AbbVie's other drugs and pipeline candidates discussed by Gonzalez and Severino don't seem to be just pie in the sky. | AbbVie's pipeline includes a late-stage candidate targeting Parkinson's disease as well as experimental Alzheimer's disease and multiple sclerosis drugs in earlier-stage clinical studies. That's the minimum level of risk-adjusted sales that AbbVie projects it will generate from drugs other than Humira by 2025. AbbVie (NYSE: ABBV) raised some eyebrows -- and some concerns -- in its Q3 conference call discussion of the early days of European biosimilar competition for Humira. |
25183.0 | 2019-01-10 00:00:00 UTC | Top Ranked Momentum Stocks to Buy for January 10th | ABBV | https://www.nasdaq.com/articles/top-ranked-momentum-stocks-to-buy-for-january-10th-2019-01-10 | nan | nan | Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, January 10th:
China Information Technology, Inc. (TAOP): This cloud-based platform provider company has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing more than 100% over the last 60 days.
China Information Technology, Inc. Price and Consensus
China Information Technology, Inc. price-consensus-chart | China Information Technology, Inc. Quote
China Information Technology's shares gained 6.2% over the last one month more than S&P 500's loss of -2.0%. The company possesses a Momentum Score of A.
China Information Technology, Inc. Price
China Information Technology, Inc. price | China Information Technology, Inc. Quote
AbbVie Inc. (ABBV): This developer and manufacturer of pharmaceutical products has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 0.1% over the last 60 days.
AbbVie Inc. Price and Consensus
AbbVie Inc. price-consensus-chart | AbbVie Inc. Quote
AbbVie's shares gained 0.2% over the last one month. The company possesses a Momentum Score of A.
AbbVie Inc. Price
AbbVie Inc. price | AbbVie Inc. Quote
COUPA SOFTWARE (COUP): This is a cloud-based spend management platform provider has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing more than 100% over the last 60 days.
COUPA SOFTWARE Price and Consensus
COUPA SOFTWARE price-consensus-chart | COUPA SOFTWARE Quote
COUPA's shares gained 1.7% over the last one month. The company possesses a Momentum Score of B.
COUPA SOFTWARE Price
COUPA SOFTWARE price | COUPA SOFTWARE Quote
See the full list of top ranked stocks here
Learn more about the Momentum score and how it is calculated here .
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
China Information Technology, Inc. (TAOP): Free Stock Analysis Report
COUPA SOFTWARE (COUP): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | China Information Technology, Inc. Price China Information Technology, Inc. price | China Information Technology, Inc. Quote AbbVie Inc. (ABBV): This developer and manufacturer of pharmaceutical products has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 0.1% over the last 60 days. AbbVie Inc. Price and Consensus AbbVie Inc. price-consensus-chart | AbbVie Inc. Quote AbbVie's shares gained 0.2% over the last one month. The company possesses a Momentum Score of A. AbbVie Inc. Price AbbVie Inc. price | AbbVie Inc. Quote COUPA SOFTWARE (COUP): This is a cloud-based spend management platform provider has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing more than 100% over the last 60 days. | The company possesses a Momentum Score of A. AbbVie Inc. Price AbbVie Inc. price | AbbVie Inc. Quote COUPA SOFTWARE (COUP): This is a cloud-based spend management platform provider has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing more than 100% over the last 60 days. Click to get this free report China Information Technology, Inc. (TAOP): Free Stock Analysis Report COUPA SOFTWARE (COUP): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. China Information Technology, Inc. Price China Information Technology, Inc. price | China Information Technology, Inc. Quote AbbVie Inc. (ABBV): This developer and manufacturer of pharmaceutical products has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 0.1% over the last 60 days. | China Information Technology, Inc. Price China Information Technology, Inc. price | China Information Technology, Inc. Quote AbbVie Inc. (ABBV): This developer and manufacturer of pharmaceutical products has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 0.1% over the last 60 days. The company possesses a Momentum Score of A. AbbVie Inc. Price AbbVie Inc. price | AbbVie Inc. Quote COUPA SOFTWARE (COUP): This is a cloud-based spend management platform provider has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing more than 100% over the last 60 days. Click to get this free report China Information Technology, Inc. (TAOP): Free Stock Analysis Report COUPA SOFTWARE (COUP): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. | The company possesses a Momentum Score of A. AbbVie Inc. Price AbbVie Inc. price | AbbVie Inc. Quote COUPA SOFTWARE (COUP): This is a cloud-based spend management platform provider has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing more than 100% over the last 60 days. China Information Technology, Inc. Price China Information Technology, Inc. price | China Information Technology, Inc. Quote AbbVie Inc. (ABBV): This developer and manufacturer of pharmaceutical products has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 0.1% over the last 60 days. AbbVie Inc. Price and Consensus AbbVie Inc. price-consensus-chart | AbbVie Inc. Quote AbbVie's shares gained 0.2% over the last one month. |
25184.0 | 2019-01-10 00:00:00 UTC | Sen. Sanders, Rep. Cummings to introduce bill to lower U.S. drug prices | ABBV | https://www.nasdaq.com/articles/sen-sanders-rep-cummings-introduce-bill-lower-us-drug-prices-2019-01-10-0 | nan | nan | By Yasmeen Abutaleb
WASHINGTON, Jan 10 () - U.S. Senator Bernie Sanders and Representative Elijah Cummings plan to introduce legislation on Thursday aimed at lowering the cost of prescription drugs for U.S. consumers.
Democrats have been critical of efforts by the Trump administration to bring down drug prices after President Donald Trump promised to do so during his campaign and since being elected. They have said proposals by the administration let big drugmakers off the hook and did not do enough to help Americans.
"The United States pays by far the highest prices in the world for prescription drugs," Sanders said in a statement.
"If the pharmaceutical industry will not end its greed, which is literally killing Americans, then we will end it for them," said Sanders, an Independent who caucuses with Democrats.
The U.S. Department of Health and Human Services last year rolled out a plan to lower drug prices and has introduced several modest proposals to curb medicine costs, but Trump has expressed frustration over continued price hikes by drugmakers.
Several pharmaceutical companies temporarily froze prices on select drugs last year. But drugmakers raised prices on more than 250 prescription drugs, including the world's top-selling medicine, AbbVie's Humira, to begin 2019.
In response to increased pressure, however, most drugmakers ended their practice of annual double-digit percentage increases of list prices, keeping most under 10 percent.
The Sanders and Cummings bill would peg U.S. prescription drug prices to the median price from five countries - Canada, Britain, France, Germany and Japan - where drug costs are typically far lower because of government price controls.
That is similar to a proposal the Trump administration said it plans to put forth in the coming months that would create an "international pricing index" to help the cost of prescription drugs to Medicare more closely align with other countries. The government health insurance program covers more than 40 million older and disabled Americans.
The bill would also allow the U.S. Secretary for Health and Human Services (HHS) to negotiate prices in Medicare Part D, a program that helps Medicare beneficiaries pay for self-administered medicines like those purchased at drugstores.
The proposal would also end a ban that keeps Americans from buying medicines at lower prices from Canada and other countries.
Drugmakers have long argued that price controls in the United States would stifle innovation and that importing drugs from other countries is unsafe.
They also say that rebates and discounts they must pay to insurers and pharmacy benefit managers (PBMs) to ensure patient access to their products - and that are not passed on to consumers - forces them to keep list prices high. Trump administration proposals have singled out so-called middlemen like PBMs as a big part of the problem.
HHS Services Secretary Alex Azar has been defending the administration's efforts to lower drug prices.
"(Trump) and I will not stop our work until list prices go down," Azar wrote on Twitter on Wednesday.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | But drugmakers raised prices on more than 250 prescription drugs, including the world's top-selling medicine, AbbVie's Humira, to begin 2019. Senator Bernie Sanders and Representative Elijah Cummings plan to introduce legislation on Thursday aimed at lowering the cost of prescription drugs for U.S. consumers. That is similar to a proposal the Trump administration said it plans to put forth in the coming months that would create an "international pricing index" to help the cost of prescription drugs to Medicare more closely align with other countries. | But drugmakers raised prices on more than 250 prescription drugs, including the world's top-selling medicine, AbbVie's Humira, to begin 2019. The U.S. Department of Health and Human Services last year rolled out a plan to lower drug prices and has introduced several modest proposals to curb medicine costs, but Trump has expressed frustration over continued price hikes by drugmakers. The Sanders and Cummings bill would peg U.S. prescription drug prices to the median price from five countries - Canada, Britain, France, Germany and Japan - where drug costs are typically far lower because of government price controls. | But drugmakers raised prices on more than 250 prescription drugs, including the world's top-selling medicine, AbbVie's Humira, to begin 2019. The U.S. Department of Health and Human Services last year rolled out a plan to lower drug prices and has introduced several modest proposals to curb medicine costs, but Trump has expressed frustration over continued price hikes by drugmakers. The Sanders and Cummings bill would peg U.S. prescription drug prices to the median price from five countries - Canada, Britain, France, Germany and Japan - where drug costs are typically far lower because of government price controls. | But drugmakers raised prices on more than 250 prescription drugs, including the world's top-selling medicine, AbbVie's Humira, to begin 2019. The Sanders and Cummings bill would peg U.S. prescription drug prices to the median price from five countries - Canada, Britain, France, Germany and Japan - where drug costs are typically far lower because of government price controls. The proposal would also end a ban that keeps Americans from buying medicines at lower prices from Canada and other countries. |
25185.0 | 2019-01-09 00:00:00 UTC | Is AbbVie (ABBV) a Great Value Stock Right Now? | ABBV | https://www.nasdaq.com/articles/is-abbvie-abbv-a-great-value-stock-right-now-2019-01-09 | nan | nan | While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.
Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors use fundamental analysis and traditional valuation metrics to find stocks that they believe are being undervalued by the market at large.
On top of the Zacks Rank, investors can also look at our innovative Style Scores system to find stocks with specific traits. For example, value investors will want to focus on the "Value" category. Stocks with high Zacks Ranks and "A" grades for Value will be some of the highest-quality value stocks on the market today.
One company value investors might notice is AbbVie (ABBV). ABBV is currently sporting a Zacks Rank of #2 (Buy) and an A for Value. The stock is trading with a P/E ratio of 10.36, which compares to its industry's average of 14.69. Over the last 12 months, ABBV's Forward P/E has been as high as 18.44 and as low as 9.10, with a median of 11.51.
ABBV is also sporting a PEG ratio of 0.75. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. ABBV's PEG compares to its industry's average PEG of 1.77. Over the last 12 months, ABBV's PEG has been as high as 1.41 and as low as 0.67, with a median of 0.83.
These are only a few of the key metrics included in AbbVie's strong Value grade, but they help show that the stock is likely undervalued right now. When factoring in the strength of its earnings outlook, ABBV looks like an impressive value stock at the moment.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | These are only a few of the key metrics included in AbbVie's strong Value grade, but they help show that the stock is likely undervalued right now. One company value investors might notice is AbbVie (ABBV). ABBV is currently sporting a Zacks Rank of #2 (Buy) and an A for Value. | ABBV's PEG compares to its industry's average PEG of 1.77. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. One company value investors might notice is AbbVie (ABBV). | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. One company value investors might notice is AbbVie (ABBV). ABBV is currently sporting a Zacks Rank of #2 (Buy) and an A for Value. | One company value investors might notice is AbbVie (ABBV). ABBV is currently sporting a Zacks Rank of #2 (Buy) and an A for Value. Over the last 12 months, ABBV's Forward P/E has been as high as 18.44 and as low as 9.10, with a median of 11.51. |
25186.0 | 2019-01-09 00:00:00 UTC | Novartis' Crizanlizumab Gets Breakthrough Therapy Status | ABBV | https://www.nasdaq.com/articles/novartis-crizanlizumab-gets-breakthrough-therapy-status-2019-01-09 | nan | nan | Novartis AGNVS announced that the FDA has granted crizanlizumab (SEG101) Breakthrough Therapy designation for the prevention of vaso-occlusive crises (VOCs) in patients of all genotypes with sickle cell disease (SCD).
Shares of Novartis have increased 4% in the past year compared with the industry 's growth of 5.6%.
We note that the Breakthrough Therapy designation from the FDA is expected to speed up the development and review of drugs intended to treat serious or life-threatening diseases.
Crizanlizumab, a monthly infusion, is a humanized anti-P-selectin monoclonal antibody that reduces VOCs by binding to a molecule called P-selectin on the surface of platelets and endothelium in the blood vessels. It has been shown to inhibit interactions between endothelial cells, platelets, red blood cells, sickled red blood cells and leukocytes, causing a blockade and thereby preventing these cells from being able to bind to P-selectin.
Breakthrough Therapy designation was based on positive results of the phase II SUSTAIN study, which compared crizanlizumab with placebo in patients with SCD. The study showed that crizanlizumab reduced the median annual rate of VOCs, leading to reduction in health care visits by 45.3%, compared with placebo in patients with or without hydroxyurea therapy. The study also found that crizanlizumab significantly increased the percentage of patients who did not experience any VOCs versus placebo during treatment.
The incidence of treatment-emergent adverse events was 86.4% for patients in the crizanlizumab treatment arm compared to 88.7% for patients in the placebo group, and serious adverse events occurred in 25.8% and 27.4% of patients, respectively. Patients receiving crizanlizumab experienced a low 3% incidence of discontinuations due to adverse events.
Novartis expects to file a new drug application (NDA) for crizanlizumab in the first half of 2019.
The approval of new drugs should boost revenues of the company.
Novartis AG Price
Novartis AG Price | Novartis AG Quote
Zacks Rank and Other Stocks to Consider
Novartis currently carries a Zacks Rank #2 (Buy).
Other top-ranked stocks worth considering are AbbVie Inc. ABBV , Eli Lilly and Company LLY and Merck & Co., Inc. MRK . All of them sport a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
AbbVie's earnings per share estimates have increased from $7.93 to $7.94 for 2018 and from $8.67 to $8.71 for 2019 over the past 60 days. The company delivered a positive earnings surprise in all the trailing four quarters, with average of 3.54%.
Lilly's earnings per share estimates have increased from $5.53 to $5.59 for 2018 and from $5.81 to $5.92 for 2019 over the past 60 days. The company delivered a positive earnings surprise in all the trailing four quarters, with average of 10.03%.
Merck's earnings per share estimates have increased from $4.71 to $4.72 for 2019 over the past 60 days. The company delivered a positive earnings surprise in all the trailing four quarters, with average of 3.96%.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Merck & Co., Inc. (MRK): Free Stock Analysis Report
Eli Lilly and Company (LLY): Free Stock Analysis Report
Novartis AG (NVS): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Other top-ranked stocks worth considering are AbbVie Inc. ABBV , Eli Lilly and Company LLY and Merck & Co., Inc. MRK . AbbVie's earnings per share estimates have increased from $7.93 to $7.94 for 2018 and from $8.67 to $8.71 for 2019 over the past 60 days. Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Other top-ranked stocks worth considering are AbbVie Inc. ABBV , Eli Lilly and Company LLY and Merck & Co., Inc. MRK . AbbVie's earnings per share estimates have increased from $7.93 to $7.94 for 2018 and from $8.67 to $8.71 for 2019 over the past 60 days. | Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Other top-ranked stocks worth considering are AbbVie Inc. ABBV , Eli Lilly and Company LLY and Merck & Co., Inc. MRK . AbbVie's earnings per share estimates have increased from $7.93 to $7.94 for 2018 and from $8.67 to $8.71 for 2019 over the past 60 days. | Other top-ranked stocks worth considering are AbbVie Inc. ABBV , Eli Lilly and Company LLY and Merck & Co., Inc. MRK . AbbVie's earnings per share estimates have increased from $7.93 to $7.94 for 2018 and from $8.67 to $8.71 for 2019 over the past 60 days. Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. |
25187.0 | 2019-01-07 00:00:00 UTC | Neurocrine Gives Ingrezza Sales View, Updates on Pipeline | ABBV | https://www.nasdaq.com/articles/neurocrine-gives-ingrezza-sales-view-updates-on-pipeline-2019-01-07 | nan | nan | Neurocrine Biosciences, Inc.NBIX provided preliminary sales guidance for Ingrezza pertaining to the fourth quarter of 2018 and the full year along with an update on its pipeline candidates.
2018 Preliminary Results
Based on unaudited financial results, Neurocrine expects Ingrezza sales for the full year to be approximately $409 million, reflecting a staggering increase of 250.8% from the prior-year level. The company estimates Ingrezza for the final quarter to be approximately $130 million, which is also significantly higher than the year-earlier level. The company guided preliminary total prescriptions for Ingrezza to be approximately 22,900 and 71,500 for the fourth quarter and full year, respectively.
Ingrezza is Neurocrine's only marketed drug, which received an FDA approval in 2017. It is the first medicine approved in the United States for treating adults with tardive dyskinesia (TD). The drug is also being investigated for Tourette syndrome and has been granted an Orphan Drug Designation by the FDA for the same.
Shares of Neurocrine have lost 4% in the past year, narrower than the industry's decline of 17.8%.
Expected Product and Pipeline Progress in 2019
The company remains on track to accomplish several clinical milestones in 2019.
Neurocrine has a collaboration with AbbVie Inc. ABBV for Orilissa (elagolix). Last July, the FDA approved Orilissa for managing moderate to severe endometriosis pain in women. It is marketed by AbbVie. The drug is also approved in Canada.
Elagolix is also being evaluated for the treatment of uterine fibroids in women. Last August, Neurocrine and AbbVie announced positive top-line results from a study, which showed a majority of women with uterine fibroids having achieved clinical response. Data from the study will support a new drug application (NDA) for elagolix, expected to be filed this year to address uterine fibroids.
Neurocrine is in the process of submitting an NDA for opicapone during the second quarter of 2019 and plans a commercial launch of the same in 2020.
Another candidate in Neurocrine's portfolio is NBI-74788, which is being evaluated in mid-stage studies for the treatment of congenital adrenal hyperplasia (CAH). The company plans to present data from a phase IIa study on NBI-74788 for treating CAH in adult patients during the first quarter of 2019. Neurocrine plans to initiate a phase IIa study on NBI-74788 for treating CAH in pediatric patients later this year.
The company intends to begin a pivotal phase IIa program on NBI-74788 for attending CAH afflicted adult patients during the second half of 2019, which will back a regulatory submission for the candidate.
Neurocrine also aims to file an investigational new drug submission on a newly discovered candidate and subsequently start a phase I study on the same.
Zacks Rank & Stocks to Consider
Neurocrine currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the same sector include BioSpecifics Technologies Corp BSTC and Hikma Pharmaceuticals Plc HKMPF , both sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
BioSpecifics' earnings estimates have been revised 16.8% upward for 2019 over the past 60 days. The stock has soared 45.3% in the past year.
Hikma's earnings estimates have moved 6.9% north for 2019 over the past 60 days. The stock has surged 41.7% in a year.
3 Medical Stocks to Buy Now
The greatest discovery in this century of biology is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating revenue, and cures for a variety of deadly diseases are in the pipeline.
So are big potential profits for early investors. Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it.
See them today for free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Neurocrine Biosciences, Inc. (NBIX): Free Stock Analysis Report
BioSpecifics Technologies Corp (BSTC): Free Stock Analysis Report
Hikma Pharmaceuticals Plc (HKMPF): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Last August, Neurocrine and AbbVie announced positive top-line results from a study, which showed a majority of women with uterine fibroids having achieved clinical response. Neurocrine has a collaboration with AbbVie Inc. ABBV for Orilissa (elagolix). It is marketed by AbbVie. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Neurocrine Biosciences, Inc. (NBIX): Free Stock Analysis Report BioSpecifics Technologies Corp (BSTC): Free Stock Analysis Report Hikma Pharmaceuticals Plc (HKMPF): Free Stock Analysis Report To read this article on Zacks.com click here. Neurocrine has a collaboration with AbbVie Inc. ABBV for Orilissa (elagolix). It is marketed by AbbVie. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Neurocrine Biosciences, Inc. (NBIX): Free Stock Analysis Report BioSpecifics Technologies Corp (BSTC): Free Stock Analysis Report Hikma Pharmaceuticals Plc (HKMPF): Free Stock Analysis Report To read this article on Zacks.com click here. Neurocrine has a collaboration with AbbVie Inc. ABBV for Orilissa (elagolix). It is marketed by AbbVie. | Neurocrine has a collaboration with AbbVie Inc. ABBV for Orilissa (elagolix). It is marketed by AbbVie. Last August, Neurocrine and AbbVie announced positive top-line results from a study, which showed a majority of women with uterine fibroids having achieved clinical response. |
25188.0 | 2019-01-07 00:00:00 UTC | Notable ETF Inflow Detected - SDY, T, O, ABBV | ABBV | https://www.nasdaq.com/articles/notable-etf-inflow-detected-sdy-t-o-abbv-2019-01-07 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR S&P Dividend ETF (Symbol: SDY) where we have detected an approximate $426.7 million dollar inflow -- that's a 2.7% increase week over week in outstanding units (from 178,050,000 to 182,800,000). Among the largest underlying components of SDY, in trading today AT&T Inc (Symbol: T) is up about 1.5%, Realty Income Corp (Symbol: O) is trading flat, and AbbVie Inc (Symbol: ABBV) is higher by about 0.8%. For a complete list of holdings, visit the SDY Holdings page » The chart below shows the one year price performance of SDY, versus its 200 day moving average:
Looking at the chart above, SDY's low point in its 52 week range is $84.28 per share, with $100.07 as the 52 week high point - that compares with a last trade of $89.92. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of SDY, in trading today AT&T Inc (Symbol: T) is up about 1.5%, Realty Income Corp (Symbol: O) is trading flat, and AbbVie Inc (Symbol: ABBV) is higher by about 0.8%. For a complete list of holdings, visit the SDY Holdings page » The chart below shows the one year price performance of SDY, versus its 200 day moving average: Looking at the chart above, SDY's low point in its 52 week range is $84.28 per share, with $100.07 as the 52 week high point - that compares with a last trade of $89.92. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of SDY, in trading today AT&T Inc (Symbol: T) is up about 1.5%, Realty Income Corp (Symbol: O) is trading flat, and AbbVie Inc (Symbol: ABBV) is higher by about 0.8%. For a complete list of holdings, visit the SDY Holdings page » The chart below shows the one year price performance of SDY, versus its 200 day moving average: Looking at the chart above, SDY's low point in its 52 week range is $84.28 per share, with $100.07 as the 52 week high point - that compares with a last trade of $89.92. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of SDY, in trading today AT&T Inc (Symbol: T) is up about 1.5%, Realty Income Corp (Symbol: O) is trading flat, and AbbVie Inc (Symbol: ABBV) is higher by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR S&P Dividend ETF (Symbol: SDY) where we have detected an approximate $426.7 million dollar inflow -- that's a 2.7% increase week over week in outstanding units (from 178,050,000 to 182,800,000). For a complete list of holdings, visit the SDY Holdings page » The chart below shows the one year price performance of SDY, versus its 200 day moving average: Looking at the chart above, SDY's low point in its 52 week range is $84.28 per share, with $100.07 as the 52 week high point - that compares with a last trade of $89.92. | Among the largest underlying components of SDY, in trading today AT&T Inc (Symbol: T) is up about 1.5%, Realty Income Corp (Symbol: O) is trading flat, and AbbVie Inc (Symbol: ABBV) is higher by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR S&P Dividend ETF (Symbol: SDY) where we have detected an approximate $426.7 million dollar inflow -- that's a 2.7% increase week over week in outstanding units (from 178,050,000 to 182,800,000). For a complete list of holdings, visit the SDY Holdings page » The chart below shows the one year price performance of SDY, versus its 200 day moving average: Looking at the chart above, SDY's low point in its 52 week range is $84.28 per share, with $100.07 as the 52 week high point - that compares with a last trade of $89.92. |
25189.0 | 2019-01-07 00:00:00 UTC | Gilead (GILD) Collaborates With Yuhan for NASH Candidates | ABBV | https://www.nasdaq.com/articles/gilead-gild-collaborates-with-yuhan-for-nash-candidates-2019-01-07 | nan | nan | Gilead Sciences, Inc . GILD announced that it entered into a licensing and collaboration agreement with South Korea-based Yuhan Corporation.
Both the companies have entered into a licensing and collaboration agreement to co-develop novel therapeutic candidates for the treatment of patients suffering from advanced fibrosis due to non-alcoholic steatohepatitis (NASH).
Per the agreement, Gilead will acquire global rights to develop and commercialize novel small molecules against two undisclosed targets in all countries, except for Republic of Korea where Yuhan will retain certain commercialization rights. While both the companies will jointly conduct preclinical research, Gilead will be responsible for global clinical development. This agreement builds on the companies' existing commercial collaboration to support the promotion of Gilead's drugs in Korea.
Gilead will pay Yuhan an upfront fee of $15 million. Yuhan is also entitled to receive milestone payments of $770 million.
Gilead was once a market outperformer, with its strong HCV franchise boasting a number of blockbuster drugs. However, the HCV franchise has been under pressure since the last three-four years due to competitive pressure from the likes of AbbbVie, Inc. ABBV .
Consequently, Gilead had shifted focus to its HIV franchise and newer avenues like CAR-T therapy and NASH.
Gilead already has a late-stage candidate, selonsertib, and a mid-stage candidate, investigational, selective, non-steroidal farnesoid X receptor (FXR) agonist, GS-9674.
The market for NASH promises potential. A chronic liver disease, NASH is caused by excessive fat accumulation in the liver, which, in turn, is known as steatosis. NASH is known to affect up to 15 million people in the United States and could lead to inflammation, hepatocellular injury, progressive fibrosis and cirrhosis. It is expected to become the leading cause for liver transplantation by 2020.
Patients living with NASH have limited treatment options. Hence, the successful development of its candidates will significantly boost Gilead.
Gilead's stock has lost 9.5% in the past six months compared with the industry' s decline of 17.6%.
Given the prospects of the NASH market, quite a few companies are developing candidates for the same. Intercept Pharmaceuticals, Inc. ICPT is presently evaluating lead drug Ocaliva in non-cirrhotic NASH patients with liver fibrosis. Merck MRK recently exercised its option to license NGM313, an investigational monoclonal antibody agonist of the β-Klotho/FGFR1c receptor complex that is currently being evaluated for the treatment of NASH and type 2 diabetes.
Zacks Rank
Gilead currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
3 Medical Stocks to Buy Now
The greatest discovery in this century of biology is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating revenue, and cures for a variety of deadly diseases are in the pipeline.
So are big potential profits for early investors. Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it.
See them today for free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Merck & Co., Inc. (MRK): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Gilead Sciences, Inc. (GILD): Free Stock Analysis Report
Intercept Pharmaceuticals, Inc. (ICPT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | However, the HCV franchise has been under pressure since the last three-four years due to competitive pressure from the likes of AbbbVie, Inc. ABBV . Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Intercept Pharmaceuticals, Inc. (ICPT): Free Stock Analysis Report To read this article on Zacks.com click here. Both the companies have entered into a licensing and collaboration agreement to co-develop novel therapeutic candidates for the treatment of patients suffering from advanced fibrosis due to non-alcoholic steatohepatitis (NASH). | Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Intercept Pharmaceuticals, Inc. (ICPT): Free Stock Analysis Report To read this article on Zacks.com click here. However, the HCV franchise has been under pressure since the last three-four years due to competitive pressure from the likes of AbbbVie, Inc. ABBV . Intercept Pharmaceuticals, Inc. ICPT is presently evaluating lead drug Ocaliva in non-cirrhotic NASH patients with liver fibrosis. | Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Intercept Pharmaceuticals, Inc. (ICPT): Free Stock Analysis Report To read this article on Zacks.com click here. However, the HCV franchise has been under pressure since the last three-four years due to competitive pressure from the likes of AbbbVie, Inc. ABBV . Both the companies have entered into a licensing and collaboration agreement to co-develop novel therapeutic candidates for the treatment of patients suffering from advanced fibrosis due to non-alcoholic steatohepatitis (NASH). | However, the HCV franchise has been under pressure since the last three-four years due to competitive pressure from the likes of AbbbVie, Inc. ABBV . Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Intercept Pharmaceuticals, Inc. (ICPT): Free Stock Analysis Report To read this article on Zacks.com click here. Intercept Pharmaceuticals, Inc. ICPT is presently evaluating lead drug Ocaliva in non-cirrhotic NASH patients with liver fibrosis. |
25190.0 | 2019-01-07 00:00:00 UTC | Neurocrine Biosciences Is a Pharma Stock to Watch | ABBV | https://www.nasdaq.com/articles/neurocrine-biosciences-pharma-stock-watch-2019-01-07 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Neurocrine Biosciences (NASDAQ: NBIX ) has been around since 1992 and went public in 2003, though it still isn't exactly on the tip of investors' tongues. But that's already starting to change.
In the past year, the stock was up more than 50% at one point, but then got hit with the market woes as well as the fact that one of its drugs in the pipeline for Tourette's syndrome didn't get the results it had hoped to achieve.
As with most biotech and pharma firms, a setback on a drug can set back the stock as well. And while NBIX has a market cap of more than $6 billion and has development agreements with major pharma companies, it's going to get hit harder than bigger stocks simply because it has fewer drugs in the pipeline than other companies. The setback on one drug could make it harder to keep its burn rate - the amount of money the company is spending on developing and testing its drugs - manageable.
This news and the secular downturn has certainly laid NBIX stock low - it's off 33% in the past three months and 9% for the past year. At this point, it's a C-rated stock in my Portfolio Grader … but it's one worth watching.
Why You Should Watch NBIX Stock
When a stock hits a C rating, it could be because it's falling apart and trying to stay competitive and relevant. Or, it could be it's been oversold in a tough market and has what it takes to make it back, but it may take a while.
For NBIX, the latter is closer to the truth.
10 Top Stock Picks From the Street's Best Analysts
Its TS study was bad news for its current drug Ingrezza, but Ingrezza is already doing better than expected in its current category. And the fact that Neurocrine simply pulled the drug from further TS studies shows that it's not too proud to move that money along to other projects that have more promise.
Plus, its pipeline has other promising drugs in it and interested partners. The company's focus on neurology and endocrinology drugs makes it attractive because it's a niche that few are in. And its success in these sectors also makes it an attractive partner.
Most of its drugs on the market have competitors, NBIX generally has competitive advantages, either in pricing or in dosing. And being able to get these drugs to market with a strong partner like AbbVie (NYSE: ABBV ) - partners on Orilissa, a drug for uterine fibroids - means that it can leave the heavy lifting on the marketing side to a powerful, experienced partner.
When you have big partners, it means you can negotiate better deals with pharmacy benefit management companies and you all get to access their field reps so you get your drug into the hands of more doctors.
But this market is still jumpy, sostock newsis also dictated by market and sector news at this point. This is a long-term pick because it has drugs ready to roll out for the next couple of years and collectively they could spell big opportunities.
There's also the possibility that a big pharma may want to snap up NBIX stock to add to its portfolio. It's worth keeping an eye on.
Louis Navellier is a renowned growth investor. He is the editor of four investing newsletters: Growth Investor , Breakthrough Stocks , Accelerated Profits and Platinum Growth . His most popular service, Growth Investor, has a track record of beating the market 3:1 over the last 14 years. He uses a combination of quantitative and fundamental analysis to identify market-beating stocks. Mr. Navellier has made his proven formula accessible to investors via his free, online stock rating tool, PortfolioGrader.com . Louis Navellier may hold some of the aforementioned securities in one or more of his newsletters.
More From InvestorPlace
2 Toxic Pot Stocks You Should Avoid
7 Downtrodden Stocks to Fish From the Bottom
8 Cheap Value Stocks That Just Got More Enticing
5 Apple Suppliers Hurt by the Guidance Cut
Compare Brokers
The post Neurocrine Biosciences Is a Pharma Stock to Watch appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | And being able to get these drugs to market with a strong partner like AbbVie (NYSE: ABBV ) - partners on Orilissa, a drug for uterine fibroids - means that it can leave the heavy lifting on the marketing side to a powerful, experienced partner. In the past year, the stock was up more than 50% at one point, but then got hit with the market woes as well as the fact that one of its drugs in the pipeline for Tourette's syndrome didn't get the results it had hoped to achieve. And the fact that Neurocrine simply pulled the drug from further TS studies shows that it's not too proud to move that money along to other projects that have more promise. | And being able to get these drugs to market with a strong partner like AbbVie (NYSE: ABBV ) - partners on Orilissa, a drug for uterine fibroids - means that it can leave the heavy lifting on the marketing side to a powerful, experienced partner. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Neurocrine Biosciences (NASDAQ: NBIX ) has been around since 1992 and went public in 2003, though it still isn't exactly on the tip of investors' tongues. 10 Top Stock Picks From the Street's Best Analysts Its TS study was bad news for its current drug Ingrezza, but Ingrezza is already doing better than expected in its current category. | And being able to get these drugs to market with a strong partner like AbbVie (NYSE: ABBV ) - partners on Orilissa, a drug for uterine fibroids - means that it can leave the heavy lifting on the marketing side to a powerful, experienced partner. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Neurocrine Biosciences (NASDAQ: NBIX ) has been around since 1992 and went public in 2003, though it still isn't exactly on the tip of investors' tongues. And while NBIX has a market cap of more than $6 billion and has development agreements with major pharma companies, it's going to get hit harder than bigger stocks simply because it has fewer drugs in the pipeline than other companies. | And being able to get these drugs to market with a strong partner like AbbVie (NYSE: ABBV ) - partners on Orilissa, a drug for uterine fibroids - means that it can leave the heavy lifting on the marketing side to a powerful, experienced partner. At this point, it's a C-rated stock in my Portfolio Grader … but it's one worth watching. Why You Should Watch NBIX Stock When a stock hits a C rating, it could be because it's falling apart and trying to stay competitive and relevant. |
25191.0 | 2019-01-07 00:00:00 UTC | AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-outpaces-stock-market-gains%3A-what-you-should-know-2019-01-07 | nan | nan | AbbVie (ABBV) closed at $90.40 in the latest trading session, marking a +1.49% move from the prior day. This change outpaced the S&P 500's 0.7% gain on the day. Meanwhile, the Dow gained 0.42%, and the Nasdaq, a tech-heavy index, added 1.26%.
Heading into today, shares of the drugmaker had lost 1.39% over the past month, outpacing the Medical sector's loss of 6.76% and the S&P 500's loss of 6.13% in that time.
Wall Street will be looking for positivity from ABBV as it approaches its nex t earnings report date. This is expected to be January 25, 2019. On that day, ABBV is projected to report earnings of $1.92 per share, which would represent year-over-year growth of 29.73%. Meanwhile, our latest consensus estimate is calling for revenue of $8.36 billion, up 8.07% from the prior-year quarter.
Any recent changes to analyst estimates for ABBV should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.06% higher. ABBV currently has a Zacks Rank of #3 (Hold).
Looking at its valuation, ABBV is holding a Forward P/E ratio of 10.23. This represents a discount compared to its industry's average Forward P/E of 14.41.
Meanwhile, ABBV's PEG ratio is currently 0.76. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Large Cap Pharmaceuticals was holding an average PEG ratio of 1.9 at yesterday's closing price.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 106, which puts it in the top 42% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie (ABBV) closed at $90.40 in the latest trading session, marking a +1.49% move from the prior day. Wall Street will be looking for positivity from ABBV as it approaches its nex t earnings report date. On that day, ABBV is projected to report earnings of $1.92 per share, which would represent year-over-year growth of 29.73%. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie (ABBV) closed at $90.40 in the latest trading session, marking a +1.49% move from the prior day. Wall Street will be looking for positivity from ABBV as it approaches its nex t earnings report date. | AbbVie (ABBV) closed at $90.40 in the latest trading session, marking a +1.49% move from the prior day. Wall Street will be looking for positivity from ABBV as it approaches its nex t earnings report date. On that day, ABBV is projected to report earnings of $1.92 per share, which would represent year-over-year growth of 29.73%. | ABBV currently has a Zacks Rank of #3 (Hold). AbbVie (ABBV) closed at $90.40 in the latest trading session, marking a +1.49% move from the prior day. Wall Street will be looking for positivity from ABBV as it approaches its nex t earnings report date. |
25192.0 | 2019-01-07 00:00:00 UTC | The Zacks Analyst Blog Highlights: Bristol-Myers, Celgene, Merck, Pfizer and AbbVie | ABBV | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-bristol-myers-celgene-merck-pfizer-and-abbvie-2019-01 | nan | nan | For Immediate Release
Chicago, IL - January 7, 2019 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Bristol-Myers BMY , Celgene Corporation CELG , Merck MRK , Pfizer PFE and AbbVie ABBV .
Here are highlights from Friday's Analyst Blog:
Pharma Stock Roundup: BMY/CELG Deal & More
The pharma sector was relatively lying low this week with some news grabbing attention only towards the end. Top stories this week were Bristol-Myers' offer to buy cancer giant Celgene Corporation in a cash and stock deal worth $74 billion and Merck's decision to exercise the option to in-license a NASH candidate from partner NGM Biopharmaceuticals.
Recap of the Week's Most Important Headlines
Bristol-Myers to Acquire Celgene for $74B: Bristol-Myers began the year announcing one of the largest merger deals in the biotech/pharma sector. The company is acquiring cancer drug specialist Celgene in a cash-stock deal valued at $74 billion. Per the transaction, each Celgene shareholder will receive a consideration of $102.43, comprising one share of Bristol-Myers (valued at $52.43 on Jan 2, 2019) and $50 per share in cash. The deal makes strategic sense as the combination will create a premier innovative biopharma giant with leading franchises in oncology, immunology and inflammation and cardiovascular disease. The combined entity with have nine products generating more than $1 billion in sales and is expected to launch six products in the near term. Moreover, the consolidated company will have a deep and diverse early and late-stage pipeline. Following the transaction, Bristol-Myers is expected to realize cost synergies of approximately $2.5 billion by 2022. The company also separately issued adjusted earnings guidance for 2019 in the range of $4.10-$4.20. While shares of Bristol-Myers decline, that of Celgene were up on announcement of the news.
Meanwhile, Bristol-Myers tyrosine kinase inhibitor, Sprycel, gained an FDA nod for its use in pediatric patients in combination with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Sprycel is also approved for Ph+ chronic myeloid leukemia in chronic phase in pediatric patients.
Merck In-Licenses NASH Candidate, Keytruda Gets 5 Approvals in Japan: Merck exercised its option to in-license a NASH and type II diabetes candidate, NGM313, now renamed as MK-3655 from NGM Biopharmaceuticals, Inc. for $20 million. With this deal, Merck gets exclusive global rights to develop, manufacture and commercialize NGM313, a once-monthly insulin sensitizer. Merck's one-time option was triggered as NGM completed a phase Ib proof-of-concept study on the candidate. Data from the study presented last November showed that a single dose of the medicine led to a statistically significant reduction in liver fat content (LFC) and improvements in multiple metabolic parameters after five weeks of treatment. Merck plans to initiate a phase IIb study on the candidate while NGM Biopharmaceuticals retains the option to take a 50% cost and profit-sharing partnership for NGM313 once the candidate enters late-stage development.
Meanwhile, the company's PD-1 inhibitor Keytruda clinched five new label expansion approvals in Japan. These included three approvals as a first-line treatment option for advanced non-small cell lung cancer (NSCLC) and the other two as an adjuvant therapy for melanoma and in advanced microsatellite instability-high (MSI-H) tumors.
Pfizer Starts Pivotal Study on Alopecia Areata Candidate: Pfizer initiated a global pivotal phase IIb/III study on its oral JAK3 inhibitor candidate, PF-06651600, for the treatment of moderate to severe alopecia areata. Alopecia areata is a chronic autoimmune skin disease causing hair loss - often patchy - on the scalp, face or body. Top-line data from a phase IIa study on PF-06651600 was presented in September 2018. The study met the primary endpoint of improving hair re-growth on the scalp as compared to baseline over 24 weeks' regimen.
AbbVie Inks New Immunotherapy Deal: AbbVie signed a strategic collaboration with private cancer biotech, Tizona Therapeutics, to develop and commercialize immunotherapies targeting the CD39-enzyme including pre-clinical candidate TTX-030. AbbVie plans to begin clinical studies on TTX-030 in the first quarter of 2019. The company made an upfront payment of $105 million to Tizona for the license to its CD39 program while also buying an equity stake in the company.
The NYSE ARCA Pharmaceutical Index declined 1.4% in the last four trading sessions.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss . This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Merck & Co., Inc. (MRK): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Pfizer Inc. (PFE): Free Stock Analysis Report
Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report
Celgene Corporation (CELG): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks recently featured in the blog include: Bristol-Myers BMY , Celgene Corporation CELG , Merck MRK , Pfizer PFE and AbbVie ABBV . AbbVie Inks New Immunotherapy Deal: AbbVie signed a strategic collaboration with private cancer biotech, Tizona Therapeutics, to develop and commercialize immunotherapies targeting the CD39-enzyme including pre-clinical candidate TTX-030. AbbVie plans to begin clinical studies on TTX-030 in the first quarter of 2019. | Stocks recently featured in the blog include: Bristol-Myers BMY , Celgene Corporation CELG , Merck MRK , Pfizer PFE and AbbVie ABBV . Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inks New Immunotherapy Deal: AbbVie signed a strategic collaboration with private cancer biotech, Tizona Therapeutics, to develop and commercialize immunotherapies targeting the CD39-enzyme including pre-clinical candidate TTX-030. | Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks recently featured in the blog include: Bristol-Myers BMY , Celgene Corporation CELG , Merck MRK , Pfizer PFE and AbbVie ABBV . AbbVie Inks New Immunotherapy Deal: AbbVie signed a strategic collaboration with private cancer biotech, Tizona Therapeutics, to develop and commercialize immunotherapies targeting the CD39-enzyme including pre-clinical candidate TTX-030. | Stocks recently featured in the blog include: Bristol-Myers BMY , Celgene Corporation CELG , Merck MRK , Pfizer PFE and AbbVie ABBV . AbbVie Inks New Immunotherapy Deal: AbbVie signed a strategic collaboration with private cancer biotech, Tizona Therapeutics, to develop and commercialize immunotherapies targeting the CD39-enzyme including pre-clinical candidate TTX-030. AbbVie plans to begin clinical studies on TTX-030 in the first quarter of 2019. |
25193.0 | 2019-01-04 00:00:00 UTC | Pharma Stock Roundup: BMY to Buy CELG for $74B, MRK Gets Rights to NASH Candidate | ABBV | https://www.nasdaq.com/articles/pharma-stock-roundup%3A-bmy-to-buy-celg-for-%2474b-mrk-gets-rights-to-nash-candidate-2019-01 | nan | nan | The pharma sector was relatively lying low this week with some news grabbing attention only towards the end. Top stories this week were Bristol-Myers' BMY offer to buy cancer giant Celgene Corporation CELG in a cash and stock deal worth $74 billion and Merck's MRK decision to exercise the option to in-license a NASH candidate from partner NGM Biopharmaceuticals.
Recap of the Week's Most Important Headlines
Bristol-Myers to Acquire Celgene for $74B: Bristol-Myers began the year announcing one of the largest merger deals in the biotech/pharma sector. The company is acquiring cancer drug specialist Celgene in a cash-stock deal valued at $74 billion. Per the transaction, each Celgene shareholder will receive a consideration of $102.43, comprising one share of Bristol-Myers (valued at $52.43 on Jan 2, 2019) and $50 per share in cash. The deal makes strategic sense as the combination will create a premier innovative biopharma giant with leading franchises in oncology, immunology and inflammation and cardiovascular disease. The combined entity with have nine products generating more than $1 billion in sales and is expected to launch six products in the near term. Moreover, the consolidated company will have a deep and diverse early and late-stage pipeline. Following the transaction, Bristol-Myers is expected to realize cost synergies of approximately $2.5 billion by 2022. The company also separately issued adjusted earnings guidance for 2019 in the range of $4.10-$4.20. While shares of Bristol-Myers decline, that of Celgene were up on announcement of the news.
Meanwhile, Bristol-Myers tyrosine kinase inhibitor, Sprycel, gained an FDA nod for its use in pediatric patients in combination with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Sprycel is also approved for Ph+ chronic myeloid leukemia in chronic phase in pediatric patients.
Merck In-Licenses NASH Candidate, Keytruda Gets 5 Approvals in Japan: Merck exercised its option to in-license a NASH and type II diabetes candidate, NGM313, now renamed as MK-3655 from NGM Biopharmaceuticals, Inc. for $20 million. With this deal, Merck gets exclusive global rights to develop, manufacture and commercialize NGM313, a once-monthly insulin sensitizer. Merck's one-time option was triggered as NGM completed a phase Ib proof-of-concept study on the candidate. Data from the study presented last November showed that a single dose of the medicine led to a statistically significant reduction in liver fat content (LFC) and improvements in multiple metabolic parameters after five weeks of treatment. Merck plans to initiate a phase IIb study on the candidate while NGM Biopharmaceuticals retains the option to take a 50% cost and profit-sharing partnership for NGM313 once the candidate enters late-stage development.
Meanwhile, the company's PD-1 inhibitor Keytruda clinched five new label expansion approvals in Japan. These included three approvals as a first-line treatment option for advanced non-small cell lung cancer (NSCLC) and the other two as an adjuvant therapy for melanoma and in advanced microsatellite instability-high (MSI-H) tumors.
Pfizer Starts Pivotal Study on Alopecia Areata Candidate: Pfizer PFE initiated a global pivotal phase IIb/III study on its oral JAK3 inhibitor candidate, PF-06651600, for the treatment of moderate to severe alopecia areata. Alopecia areata is a chronic autoimmune skin disease causing hair loss - often patchy - on the scalp, face or body. Top-line data from a phase IIa study on PF-06651600 was presented in September 2018. The study met the primary endpoint of improving hair re-growth on the scalp as compared to baseline over 24 weeks' regimen.
AbbVie Inks New Immunotherapy Deal: AbbVie ABBV signed a strategic collaboration with private cancer biotech, Tizona Therapeutics, to develop and commercialize immunotherapies targeting the CD39-enzyme including pre-clinical candidate TTX-030. AbbVie plans to begin clinical studies on TTX-030 in the first quarter of 2019. The company made an upfront payment of $105 million to Tizona for the license to its CD39 program while also buying an equity stake in the company.
The NYSE ARCA Pharmaceutical Index declined 1.4% in the last four trading sessions.
Large Cap Pharmaceuticals Industry 5YR % Return
Large Cap Pharmaceuticals Industry 5YR % Return
Here is how the seven major stocks performed in the last four trading sessions:
All the stocks except AstraZeneca AZN were in the red in the last four trading sessions with Bristol-Myers declining the most (10.5%). AstraZeneca rose 2.8% in the same period.
In the past six months, Lilly LLY has been the biggest gainer (28.5%) while Bristol-Myers declined the most (19.2%).
(See the last pharma stock roundup here: GSK, PFE Ink Consumer Health JV, JNJ Hit by Talc Allegations )
What's Next in the Pharma World?
Watch out for pipeline and regulatory updates next week.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce ""the world's first trillionaires,"" but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report
Merck & Co., Inc. (MRK): Free Stock Analysis Report
Eli Lilly and Company (LLY): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Pfizer Inc. (PFE): Free Stock Analysis Report
AstraZeneca PLC (AZN): Free Stock Analysis Report
Celgene Corporation (CELG): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie Inks New Immunotherapy Deal: AbbVie ABBV signed a strategic collaboration with private cancer biotech, Tizona Therapeutics, to develop and commercialize immunotherapies targeting the CD39-enzyme including pre-clinical candidate TTX-030. AbbVie plans to begin clinical studies on TTX-030 in the first quarter of 2019. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report AstraZeneca PLC (AZN): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report AstraZeneca PLC (AZN): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inks New Immunotherapy Deal: AbbVie ABBV signed a strategic collaboration with private cancer biotech, Tizona Therapeutics, to develop and commercialize immunotherapies targeting the CD39-enzyme including pre-clinical candidate TTX-030. AbbVie plans to begin clinical studies on TTX-030 in the first quarter of 2019. | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report AstraZeneca PLC (AZN): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inks New Immunotherapy Deal: AbbVie ABBV signed a strategic collaboration with private cancer biotech, Tizona Therapeutics, to develop and commercialize immunotherapies targeting the CD39-enzyme including pre-clinical candidate TTX-030. AbbVie plans to begin clinical studies on TTX-030 in the first quarter of 2019. | AbbVie Inks New Immunotherapy Deal: AbbVie ABBV signed a strategic collaboration with private cancer biotech, Tizona Therapeutics, to develop and commercialize immunotherapies targeting the CD39-enzyme including pre-clinical candidate TTX-030. AbbVie plans to begin clinical studies on TTX-030 in the first quarter of 2019. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report AstraZeneca PLC (AZN): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report To read this article on Zacks.com click here. |
25194.0 | 2019-01-04 00:00:00 UTC | Pfizer Begins Pivotal Study on Alopecia Areata Candidate | ABBV | https://www.nasdaq.com/articles/pfizer-begins-pivotal-study-on-alopecia-areata-candidate-2019-01-04 | nan | nan | Pfizer Inc.PFE announced that it has initiated a pivotal phase IIb/III clinical study to evaluate its oral JAK3 inhibitor candidate, PF-06651600, for treating moderate to severe alopecia areata ("AA").
Alopecia areata is an autoimmune dermatologic condition that results in patchy non-scarring hair loss, usually affecting the scalp. There is no FDA approved drug presently available to treat this condition, which can lead to high levels of depression and anxiety in patients.
The study will evaluate the safety and effectiveness of the candidate in nearly 660 patients, including adults and adolescents with 50% or greater scalp hair loss. Currently, PF-06651600 enjoys breakthrough therapy designation, which was granted based on positive data from the successfully completed phase IIa study.
In September 2018, Pfizer announced data from the phase IIa study, which demonstrated that the candidate improved hair re-growth on the scalp compared to the baseline after 24 weeks of treatment.
Apart from AA, PF-06651600 is being developed for rheumatoid arthritis ("RA"), Crohn's disease and ulcerative colitis ("UC").
A glimpse of Pfizer's price trend reveals that it has outperformed the industry in the past six months. The stock has gained 14% compared with the industry 's 6.9% growth.
Among approved kinase inhibitors, Xeljanz is a successful product in Pfizer's portfolio. In the first nine months of 2018, Xeljanz garnered approximately $1.2 billion.
The company also has biosimilar products of other drugs generating tens of billions of dollars, which are indicated for inflammatory diseases in its portfolio. Pfizer already markets biosimilar version of Merck MRK /J&J's JNJ Remicade, while biosimilar of AbbVie's ABBV Humira is in late stage development.
Successful development of kinase inhibitors and Humira biosimilar along with approved drugs, will create a strong portfolio of inflammatory drugs going forward.
Pfizer Inc. Price
Pfizer Inc. Price | Pfizer Inc. Quote
Zacks Rank
Pfizer has a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Merck & Co., Inc. (MRK): Free Stock Analysis Report
Pfizer Inc. (PFE): Free Stock Analysis Report
Johnson & Johnson (JNJ): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Pfizer already markets biosimilar version of Merck MRK /J&J's JNJ Remicade, while biosimilar of AbbVie's ABBV Humira is in late stage development. Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Pfizer Inc.PFE announced that it has initiated a pivotal phase IIb/III clinical study to evaluate its oral JAK3 inhibitor candidate, PF-06651600, for treating moderate to severe alopecia areata ("AA"). | Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Pfizer already markets biosimilar version of Merck MRK /J&J's JNJ Remicade, while biosimilar of AbbVie's ABBV Humira is in late stage development. Successful development of kinase inhibitors and Humira biosimilar along with approved drugs, will create a strong portfolio of inflammatory drugs going forward. | Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Pfizer already markets biosimilar version of Merck MRK /J&J's JNJ Remicade, while biosimilar of AbbVie's ABBV Humira is in late stage development. Successful development of kinase inhibitors and Humira biosimilar along with approved drugs, will create a strong portfolio of inflammatory drugs going forward. | Pfizer already markets biosimilar version of Merck MRK /J&J's JNJ Remicade, while biosimilar of AbbVie's ABBV Humira is in late stage development. Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. In September 2018, Pfizer announced data from the phase IIa study, which demonstrated that the candidate improved hair re-growth on the scalp compared to the baseline after 24 weeks of treatment. |
25195.0 | 2019-01-04 00:00:00 UTC | AbbVie (ABBV) Inks Immunotherapy Deal with Private Biotech | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-inks-immunotherapy-deal-with-private-biotech-2019-01-04 | nan | nan | AbbVieABBV and Tizona Therapeutics, Inc. ("Tizona"), entered into a strategic collaboration to develop and commercialize CD39-targeted therapeutics, including pre-clinical candidate TTX-030. Per the agreement, Tizona received an upfront payment of $105 million for the exclusive option to license the CD39 program while also buying an equity stake in the company.
CD39 is the enzyme, which helps in converting immune stimulatory extracellular ATP to immune suppressive adenosine in the tumor microenvironment (TME). Inhibition of CD39 with TTX-030 represents a unique way to target this pathway. Preclinical research shows that inhibiting CD39 may be helpful in restoring and bolstering immune responses against tumors.
Share price of AbbVie has declined 9.8% in the past year, against the industry 's growth of 3.3%.
Tizona will take care of clinical development until the completion of phase Ib studies, after which AbbVie will have an exclusive option to conduct global development and commercial activities. Tizona has retained the option to co-develop and market the candidate in the United States and is also entitled to future development, commercial milestone payments and tiered royalties on net sales.
An investigational new drug application for TTX-030 has been accepted by the FDA. Initiation of clinical studies with TTX-030 is targeted in the first quarter of 2019.
AbbVie has been actively pursuing partnership deals and collaborations for candidates across several therapeutic areas, including oncology, immunology, neuroscience and infectious diseases. Some of AbbVie's partners include Roche RHHBY , J&J JNJ , Bristol-Myers BMY and Boehringer Ingelheim, among others. We believe the company will continue pursuing such deals to enhance its pipeline.
AbbVie Inc. Price
AbbVie Inc. Price | AbbVie Inc. Quote
Zacks Rank
AbbVie currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Johnson & Johnson (JNJ): Free Stock Analysis Report
Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Roche Holding AG (RHHBY): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie has been actively pursuing partnership deals and collaborations for candidates across several therapeutic areas, including oncology, immunology, neuroscience and infectious diseases. AbbVieABBV and Tizona Therapeutics, Inc. ("Tizona"), entered into a strategic collaboration to develop and commercialize CD39-targeted therapeutics, including pre-clinical candidate TTX-030. Share price of AbbVie has declined 9.8% in the past year, against the industry 's growth of 3.3%. | AbbVie Inc. Price AbbVie Inc. Price | AbbVie Inc. Quote Zacks Rank AbbVie currently carries a Zacks Rank #3 (Hold). Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVieABBV and Tizona Therapeutics, Inc. ("Tizona"), entered into a strategic collaboration to develop and commercialize CD39-targeted therapeutics, including pre-clinical candidate TTX-030. | Tizona will take care of clinical development until the completion of phase Ib studies, after which AbbVie will have an exclusive option to conduct global development and commercial activities. AbbVie Inc. Price AbbVie Inc. Price | AbbVie Inc. Quote Zacks Rank AbbVie currently carries a Zacks Rank #3 (Hold). Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report To read this article on Zacks.com click here. | Tizona will take care of clinical development until the completion of phase Ib studies, after which AbbVie will have an exclusive option to conduct global development and commercial activities. AbbVieABBV and Tizona Therapeutics, Inc. ("Tizona"), entered into a strategic collaboration to develop and commercialize CD39-targeted therapeutics, including pre-clinical candidate TTX-030. Share price of AbbVie has declined 9.8% in the past year, against the industry 's growth of 3.3%. |
25196.0 | 2019-01-04 00:00:00 UTC | Abbvie to record $4 bln impairment charges on Stemcentrx assets | ABBV | https://www.nasdaq.com/articles/abbvie-record-4-bln-impairment-charges-stemcentrx-assets-2019-01-04 | nan | nan | Jan 4 - Abbvie Inc on Friday it will record an estimated $4 billion in impairment charges related to the scrapping of its development program of Rova-T, an investigational cancer therapy (graphic).
The drugmaker acquired Rova-T through its $5.8 billion acquisition of Stemcentrx in 2016, as it aimed to enter the broad and lucrative arena of solid tumors and lessen dependence on its blockbuster arthritis treatment Humira.
In December, Abbvie halted enrollment for a late-stage trial of Rova-T as a second-line therapy for advanced small-cell lung cancer, following recommendations made by an independent data monitoring committee.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Jan 4 - Abbvie Inc on Friday it will record an estimated $4 billion in impairment charges related to the scrapping of its development program of Rova-T, an investigational cancer therapy (graphic). In December, Abbvie halted enrollment for a late-stage trial of Rova-T as a second-line therapy for advanced small-cell lung cancer, following recommendations made by an independent data monitoring committee. The drugmaker acquired Rova-T through its $5.8 billion acquisition of Stemcentrx in 2016, as it aimed to enter the broad and lucrative arena of solid tumors and lessen dependence on its blockbuster arthritis treatment Humira. | Jan 4 - Abbvie Inc on Friday it will record an estimated $4 billion in impairment charges related to the scrapping of its development program of Rova-T, an investigational cancer therapy (graphic). In December, Abbvie halted enrollment for a late-stage trial of Rova-T as a second-line therapy for advanced small-cell lung cancer, following recommendations made by an independent data monitoring committee. The drugmaker acquired Rova-T through its $5.8 billion acquisition of Stemcentrx in 2016, as it aimed to enter the broad and lucrative arena of solid tumors and lessen dependence on its blockbuster arthritis treatment Humira. | Jan 4 - Abbvie Inc on Friday it will record an estimated $4 billion in impairment charges related to the scrapping of its development program of Rova-T, an investigational cancer therapy (graphic). In December, Abbvie halted enrollment for a late-stage trial of Rova-T as a second-line therapy for advanced small-cell lung cancer, following recommendations made by an independent data monitoring committee. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Jan 4 - Abbvie Inc on Friday it will record an estimated $4 billion in impairment charges related to the scrapping of its development program of Rova-T, an investigational cancer therapy (graphic). In December, Abbvie halted enrollment for a late-stage trial of Rova-T as a second-line therapy for advanced small-cell lung cancer, following recommendations made by an independent data monitoring committee. The drugmaker acquired Rova-T through its $5.8 billion acquisition of Stemcentrx in 2016, as it aimed to enter the broad and lucrative arena of solid tumors and lessen dependence on its blockbuster arthritis treatment Humira. |
25197.0 | 2019-01-03 00:00:00 UTC | 3 Biopharma Stocks to Buy for Their Robust Dividend Yields | ABBV | https://www.nasdaq.com/articles/3-biopharma-stocks-buy-their-robust-dividend-yields-2019-01-03 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
I expect 2019 to be a good year for many biopharma stocks, including GlaxoSmithKline (NYSE: GSK ), AbbVie (NYSE: ABBV ) and Gilead Sciences (NASDAQ: GILD ).
Many U.S. stocks, as well as many British American Depositary Receipts (ADRs) listed in U.S. exchanges, are cheaper than they were several months ago. This "discount" has given long-term investors relatively good entry points into many strong stocks to buy.
Despite competitive pressures from other big pharma and biotech companies, all three of these biopharma stocks to buy have strong balance sheets, proactive management and several important drugs in the pipeline that are likely to keep them ahead of the competition. Furthermore, all three companies offer healthy dividend yields that will provide strong support for their respective stock prices in the months ahead.
10 Top Stock Picks From the Street's Best Analysts
With all of that said, let's take a closer look at these high-yield, discounted stocks to buy.
GlaxoSmithKline (GSK)
Source: Shutterstock
Of all three of the stocks to buy on this list, I am most bullish on GSK stock. When major indices come under stress, more than ever I look for companies that offer fundamental value and growth potential, as well as proven stability. Overall, GSK shares fit the criteria well.
Despite management's efforts to boost the company's financial strength, since 2014, the GlaxoSmithKline shares have not done much for investors. The lackluster performance was mostly because its pharmaceutical business lagged other big pharma rivals in offering blockbuster drugs.
However, GSK management has been focusing on developing strong assets for its pipeline. For example, "immune system," which gives the company pricing power, is now getting a higher share of its R&D budget. The company is also a global leader in respiratory diseases.
Furthermore, I am excited about the recent merger announcement between GSK and Pfizer (NYSE: PFE ), which will create a leader in over-the-counter (OTC) products. The two companies will spinoff their consumer healthcare brands in a new venture of which GSK will own 68% and contribute with its top brands, including Theraflu, Sensodyne and Voltaren. I expect this new company to be a winner for the investors.
Over the past two years, the political discourse in the U.K. on Brexit - the country's decision to leave the European Union (E.U.) - has increased the volatility of British companies and their stock prices. Although a potential no-deal Brexit could affect GSK with a broader sell-off, I believe that in a few weeks we will witness a trade deal between the U.K. and the E.U. that will calm the nerves and offer visibility for businesses. Going forward, Brexit is not likely to have a major negative impact on GlaxoSmithKline's business model or the GSK share price.
GSK's latest earnings release on Oct. 31 showed a strong balance sheet and a positive outlook for 2019. Due to its rock-solid dividend, which stands at over 5%, and its solid growth potential, GlaxoSmithKline belongs in any balanced portfolio of healthcare stocks.
AbbVie (ABBV)
Source: Shutterstock
Through 2023, Illinois-based AbbVie owns the U.S. patent protection for Humira, the world's bestselling drug that treats rheumatoid arthritis and Crohn's disease. Many analysts on Wall Street have been concerned with the concentration risk on the high level of earnings from a single drug. But other analysts are optimistic that management will continue to grow earnings in double digits through different successful drugs in the pipeline, including Venclexta, Risankizumab and Orilissa.
ABBV's earnings release on Nov. 2 showed robust top-line growth, a strong pipeline of existing and new drugs and gave a positive outlook for early 2019. Humira, as well as Imbruvica, another blockbuster drug in the lymphoma/leukemia segment, saw double-digit growth and exceeded revenue expectations.
Top 10 Stock Market Predictions for 2019
AbbVie also offers investors a healthy dividend yield at about 5%. Since its spin-off from Abbott Laboratories (NYSE: ABT ) in 2013, ABBV has increased dividends every year - a tend that is likely to continue. During early 2019, I expect ABBV stock to trade between $85 - $95.
Gilead Sciences (GILD)
Source: Shutterstock
The second half of 2018 has been difficult for GILD investors. However, as per the discussion by my InvestorPlace colleague Josh Enomoto, I also believe the GILD stock price has been punished for too long and that its best days are yet to come.
Under the leadership of the incoming CEO Daniel O'Day, I expect the company pipeline to expand considerably. For example, in recent weeks the company entered into an agreement with Scholar Rock Holding Corporation (NASDAQ: SRRK ) for holding the option to license three fibrosis-inhibiting candidates. GILD management is determined to find a blockbuster non-alcoholic steatohepatitis (NASH) drug for the treatment of fibrotic diseases. NASH is a chronic, inflammatory and fibrotic disease of the liver, which can lead to liver cirrhosis and even to cancer. About 10% of the U.S. adult population suffers from NASH.
Therefore, GILD regards the treatment of NASH an extremely important area for the company . The deal with SRRK does not put Gilead Sciences into a lot of financial or R&D risk, yet gives it the option to develop and market a potential winner drug.
The healthcare stock is expected to report earnings on Feb. 5 after the close. Wall Street is looking for earnings-per-share to be $1.70 on revenues of $5.5 billion; its dividend yield stands at over 3.5%. If you are still worried about general market volatility and how the upcoming managerial guidance will be, you may want to wait to make an investment decision after GILD stock reports next month.
What Could Derail These Biopharma Stocks?
Source: Shutterstock
2019 started with the acquisition announcement of Celgene (NASDAQ: CELG ) by Bristol-Myers Squibb (NYSE: BMY ). I expect the sector to have more exciting news, both in terms of R & D, marketing of new drugs, and further M&A activity. As dividend and potential growth plays, GSK, ABBV and GILD stock deserve further due diligence from potential investors.
However, investment risk and return go together, and any of these stocks may suffer a setback in 2019, too. In addition to potential company-specific issues, one industry concern is that the U.S. government may increase its drug pricing regulations. Both President Trump and other politicians on both sides of the aisle have openly criticized healthcare companies for the ever growing prescription prices and the effect on Medicare budget.
7 Reasons Tesla Stock Will Win in 2019
Therefore, if the U.S. political discourse turns against the sector more, these stocks may experience further volatility. Nonetheless, at this point, I would be ready to invest in any of the three companies.
As of this writing, Tezcan Gecgil did not hold a position in any of the aforementioned securities.
More From InvestorPlace
2 Toxic Pot Stocks You Should Avoid
10 Stocks to Pull From the Bear Market Bargain Bin
7 Reasons Tesla Stock Will Win in 2019
7 Bargain-Bin ETFs For Frugal Investors
Compare Brokers
The post 3 Biopharma Stocks to Buy for Their Robust Dividend Yields appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABBV's earnings release on Nov. 2 showed robust top-line growth, a strong pipeline of existing and new drugs and gave a positive outlook for early 2019. InvestorPlace - Stock Market News, Stock Advice & Trading Tips I expect 2019 to be a good year for many biopharma stocks, including GlaxoSmithKline (NYSE: GSK ), AbbVie (NYSE: ABBV ) and Gilead Sciences (NASDAQ: GILD ). AbbVie (ABBV) Source: Shutterstock Through 2023, Illinois-based AbbVie owns the U.S. patent protection for Humira, the world's bestselling drug that treats rheumatoid arthritis and Crohn's disease. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips I expect 2019 to be a good year for many biopharma stocks, including GlaxoSmithKline (NYSE: GSK ), AbbVie (NYSE: ABBV ) and Gilead Sciences (NASDAQ: GILD ). Top 10 Stock Market Predictions for 2019 AbbVie also offers investors a healthy dividend yield at about 5%. AbbVie (ABBV) Source: Shutterstock Through 2023, Illinois-based AbbVie owns the U.S. patent protection for Humira, the world's bestselling drug that treats rheumatoid arthritis and Crohn's disease. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips I expect 2019 to be a good year for many biopharma stocks, including GlaxoSmithKline (NYSE: GSK ), AbbVie (NYSE: ABBV ) and Gilead Sciences (NASDAQ: GILD ). AbbVie (ABBV) Source: Shutterstock Through 2023, Illinois-based AbbVie owns the U.S. patent protection for Humira, the world's bestselling drug that treats rheumatoid arthritis and Crohn's disease. ABBV's earnings release on Nov. 2 showed robust top-line growth, a strong pipeline of existing and new drugs and gave a positive outlook for early 2019. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips I expect 2019 to be a good year for many biopharma stocks, including GlaxoSmithKline (NYSE: GSK ), AbbVie (NYSE: ABBV ) and Gilead Sciences (NASDAQ: GILD ). AbbVie (ABBV) Source: Shutterstock Through 2023, Illinois-based AbbVie owns the U.S. patent protection for Humira, the world's bestselling drug that treats rheumatoid arthritis and Crohn's disease. ABBV's earnings release on Nov. 2 showed robust top-line growth, a strong pipeline of existing and new drugs and gave a positive outlook for early 2019. |
25198.0 | 2019-01-03 00:00:00 UTC | Will Pfizer's (PFE) Stock Keep Up the Momentum in 2019? | ABBV | https://www.nasdaq.com/articles/will-pfizers-pfe-stock-keep-up-the-momentum-in-2019-2019-01-03 | nan | nan | Pfizer, Inc .'s PFE shares rallied 20.5% in 2018 compared with the industry 's 4.7% increase. Pfizer's outperformance was backed by decent quarterly results, positive news flow and regulatory updates.
Higher sales of key products like Ibrance Eliquis, Prevnar and other drugs, cost-cutting efforts, a lower tax rate and share buybacks supported Pfizer's bottom line - a trend expected to continue in 2019.
Pfizer gained FDA approval for four new cancer medicines last year, which can boost its oncology sales in 2019. These include Daurismo (glasdegib) for previously untreated AML, Lorbrena (lorlatinib) for second line non-small-cell lung cancer, Vizimpro (dacomitinib) for advanced NSCLC with EGFR activating mutations and Talzenna (talazoparib), an orally-available PARP inhibitor for advanced breast cancer.
Pfizer also boasts a strong pipeline and looks well positioned to deliver several potential new breakthrough innovative medicines in the next five years. These medicines have the potential to drive long-term growth. Pfizer expects approximately 25 to 30 drug approvals through 2022, including approval for 15 products that have blockbuster potential. These include line extensions for Xtandi, Ibrance & Xeljanz/XR. Half of these potential blockbusters are expected to receive approval by 2020. Bavencio, though approved for two small indications currently, is being considered a key long-term growth driver for Pfizer if it can gain approval for label expansion.
In 2018, Pfizer made significant progress with its biosimilar portfolio. In the United States, a biosimilar of Amgen's AMGN Neupogen was launched in late September 2018 while a biosimilar version of Epogen was approved in May 2018. Biosimilar versions of Roche's cancer drugs, Rituxan, Avastin and Herceptin are under review in the United States with FDA decisions expected in 2019.
Pfizer is evaluating 13 biosimilar molecules in various stages of development including that of AbbVie's ABBV Humira in late-stage development. Pfizer hopes to launch five biosimilars in the next two years, which will bring in additional sales.
Pfizer has also been working on strengthening its product portfolio through acquisitions and licensing deals. In October 2018, Pfizer formed a collaboration agreement with Novartis NVS to research on combination therapies of their early-stage investigational candidates for the treatment of non-alcoholic steatohepatitis (NASH), a fatty liver disease with no approved treatments at present. In the same month, it also announced the creation of a new biotech, Cerevel Therapeutics in partnership with private equity firm Bain Capital, LP. The biotech will focus on developing drugs to treat central nervous system (CNS) disorders, including Parkinson's and Alzheimer's disease.
Importantly, it resolved a long pending issue in 2018 by announcing an agreement to merge its consumer healthcare unit with Glaxo's unit. The new joint venture (JV) will be the world's largest consumer healthcare business. While Glaxo will own a controlling stake of 68% in the JV, Pfizer will own 32%. The JV will operate under the GSK Consumer Healthcare name. The separation of its consumer health unit will allow it to better concentrate on its core pharmaceutical unit in 2019.
Conclusion
Pfizer faces its share of challenges in the form of loss of exclusivity for some key drugs, supply challenges in the legacy Hospira portfolio, lower sales of legacy Established Products in developed markets, pricing pressure and rising competition. However, we believe that Pfizer will be able to overcome these headwinds, as it did in 2018.
Pfizer currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
More Stock News: This Is Bigger than the iPhone !
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
Pfizer Inc. (PFE): Free Stock Analysis Report
Novartis AG (NVS): Free Stock Analysis Report
Amgen Inc. (AMGN): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Pfizer is evaluating 13 biosimilar molecules in various stages of development including that of AbbVie's ABBV Humira in late-stage development. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. Higher sales of key products like Ibrance Eliquis, Prevnar and other drugs, cost-cutting efforts, a lower tax rate and share buybacks supported Pfizer's bottom line - a trend expected to continue in 2019. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. Pfizer is evaluating 13 biosimilar molecules in various stages of development including that of AbbVie's ABBV Humira in late-stage development. Conclusion Pfizer faces its share of challenges in the form of loss of exclusivity for some key drugs, supply challenges in the legacy Hospira portfolio, lower sales of legacy Established Products in developed markets, pricing pressure and rising competition. | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. Pfizer is evaluating 13 biosimilar molecules in various stages of development including that of AbbVie's ABBV Humira in late-stage development. Pfizer expects approximately 25 to 30 drug approvals through 2022, including approval for 15 products that have blockbuster potential. | Pfizer is evaluating 13 biosimilar molecules in various stages of development including that of AbbVie's ABBV Humira in late-stage development. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. Pfizer, Inc . |
25199.0 | 2019-01-02 00:00:00 UTC | Drug companies greet 2019 with U.S. price hikes | ABBV | https://www.nasdaq.com/articles/drug-companies-greet-2019-us-price-hikes-2019-01-02 | nan | nan | By Michael Erman
NEW YORK, Jan 2 () - Drugmakers kicked off 2019 with price increases in the United States on more than 250 prescription drugs, including the world's top-selling medicine, Humira, although the pace of price hikes was slower than last year.
The industry has been under pressure by the U.S. President Donald Trump to hold their prices level as his administration works on plans aimed at lowering the costs of medications for consumers in the world's most expensive pharmaceutical market.
The overall number of price increases was down by around a third from last year, when drugmakers raised prices on more than 400 medicines, according to data provided by Rx Savings Solutions, which helps health plans and employers seek lower cost prescription medicines.
Allergan Plc was particularly aggressive. It raised list prices on more than 50 drugs, and more than half of those by 9.5 percent, according to the Rx Savings data
AbbVie Inc increased by 6.2 percent the list price of its blockbuster rheumatoid arthritis treatment Humira, which is on pace to record about $20 billion in sales in 2018.
Allergan said in a statement that its average list price increase across its portfolio is around 3.8 percent this year. It said it does not expect to realize any net benefit from the increases this year because of higher rebates and discounts it expects to make to payers.
AbbVie did not immediately respond to request for comment.
More price increases are expected this month. reported late last year that nearly 30 drugmakers had notified California agencies they plan to raise list prices of their drugs. Not all of those increases have been announced yet.
The United States, which leaves drug pricing to market competition, has higher prices than in other countries where governments directly or indirectly control the costs, making it the world's most lucrative market for manufacturers.
HHS has proposed policy changes aimed at lowering drug prices and passing more of the discounts negotiated by health insurers on to patients. Those measures are not expected to provide relief to consumers in the short-term, however, and fall short of giving government health agencies direct authority to negotiate or regulate drug prices.
"It's business as usual" for drugmakers, said Rx Savings Solutions Chief Executive Michael Rea, who said he believes there has to be meaningful changes to the marketplace, rather than new regulations in order for drug prices to drop.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | It raised list prices on more than 50 drugs, and more than half of those by 9.5 percent, according to the Rx Savings data AbbVie Inc increased by 6.2 percent the list price of its blockbuster rheumatoid arthritis treatment Humira, which is on pace to record about $20 billion in sales in 2018. AbbVie did not immediately respond to request for comment. The industry has been under pressure by the U.S. President Donald Trump to hold their prices level as his administration works on plans aimed at lowering the costs of medications for consumers in the world's most expensive pharmaceutical market. | It raised list prices on more than 50 drugs, and more than half of those by 9.5 percent, according to the Rx Savings data AbbVie Inc increased by 6.2 percent the list price of its blockbuster rheumatoid arthritis treatment Humira, which is on pace to record about $20 billion in sales in 2018. AbbVie did not immediately respond to request for comment. By Michael Erman NEW YORK, Jan 2 () - Drugmakers kicked off 2019 with price increases in the United States on more than 250 prescription drugs, including the world's top-selling medicine, Humira, although the pace of price hikes was slower than last year. | It raised list prices on more than 50 drugs, and more than half of those by 9.5 percent, according to the Rx Savings data AbbVie Inc increased by 6.2 percent the list price of its blockbuster rheumatoid arthritis treatment Humira, which is on pace to record about $20 billion in sales in 2018. AbbVie did not immediately respond to request for comment. By Michael Erman NEW YORK, Jan 2 () - Drugmakers kicked off 2019 with price increases in the United States on more than 250 prescription drugs, including the world's top-selling medicine, Humira, although the pace of price hikes was slower than last year. | It raised list prices on more than 50 drugs, and more than half of those by 9.5 percent, according to the Rx Savings data AbbVie Inc increased by 6.2 percent the list price of its blockbuster rheumatoid arthritis treatment Humira, which is on pace to record about $20 billion in sales in 2018. AbbVie did not immediately respond to request for comment. The overall number of price increases was down by around a third from last year, when drugmakers raised prices on more than 400 medicines, according to data provided by Rx Savings Solutions, which helps health plans and employers seek lower cost prescription medicines. |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.